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PREFACE 
Latent herpesvirus infections are of great importance in animal produc­
tion and the phenomena of Latency, reactivation and re-excretion of latent 
viruses impede their control. 
Animals react to these infections by an immune response that can prevent 
not only the deleterious effects of an eventual reinfection but, sometimes, 
also, viral re-excretion and consequently dissemination. 
Immunity to herpesviruses is therefore of primary importance and the 
comprehension of the underlying phenomena is the key to rational prophylaxis. 
This book contains the reports given during a CEC Agricultural Research 
seminar held in Brussels on the 4th and 5th December, 1984. The seminar had 
as a central theme the immunology of herpesvirus infections. Sessions 1 to 
4 are on the different features of the immune response to herpesvirus infec­
tions in general. Sessions 5 to 7 deal with some peculiar aspects of the 
immune response to specific herpesvirus infections of domestic animals. The 
last session gives a summary of the problems exposed during the seminar and 
forcasts further research. 
We are greatly indebted to the Commission of the European Communities, 
for giving us the opportunity to organize this seminar in the Berlaymont 
building in Brussels. 
We would also like to express our gratitude to all the people who helped 
us to make the seminar a success, to Prof. Y. BECKER of the Hebrew University 
of Israel for his help in drawing up the final programme and to all the 
staff of the Department of Virology-Immunology, Faculty of Veterinary Medicine, 








MOLECULAR ASPECTS OF HERPESVIRUSES 
Chairman ι J . H . SUBAK-SHARPE 
Co-chairman : G. DARAI 
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Immunogenic components of herpesviruses 
Hanns Ludwig and Georg Pauli 
Institute of Virology, Free University of Berl in, Nordufer 20 (Robert Koch-Institut), 1000 
Berlin 65 
Detailed information on immunogenic components of herpesviruses would certainly f i l l an 
additional symposium and most probably even discussing the components of only one animal 
herpesvirus wi l l need so in the next future. 
During herpesvirus infection a variety of virus specific proteins can give rise to an immune 
response. T hese proteins are presented in the right way one might even raise antibodies against 
the majority of the more than 50 herpesvirus-specific proteins. Therefore we would like to 
concentrate on the major immunogenic components and neglect all immune reactions dealing 
with cellular immunity, recognized by the humoral Immune response. 
Antibodies produced under natural infections or obtained from hyperimmunized animals, and 
nowadays monoclonal antibodies, are the tools to enravel, what we consider to be major 
immunogenic components. There is no question that antibodies from hyperimmunized animals 
recognize different antigen patterns than antibodies obtained from naturally infected 
convalescent animals 
Usually the major immunogenic components can already be detected by immunodiffusion , 
immunoelectrophoreses or immunoprecipitation assays. More sensitive techniques, like 
radioimmuno-assays and all kinds of blotting techniques, may clarify the picture. They might, 
however, also distract from the real ÍILYJYO, situation. Certainly, the neutralizing capacity of an 
antibody helps to recognize a major immunogenic component. 
Using recombinant DNA analysis it is possible to localize the major immunogenic components of 
a variety of herpesviruses by fine mapping on the genetic material. Most information exists on 
herpes simplex viruses and more and more is gathered recently about, animal herpesviruses. 
Although all viruses have distinct features a high amount of colinearity in the genomes and gene 
functions has been observed ( Roizman and Batterson, 1965; Davison and Wilkie, 1983). 
Obviously internal structures of herpesviruses like those of the nucleocapsid or specific 
enzymes, which are not under a strong immune pressure (as it is the case with the envelope and 
membrane-exposed components') seem to be more conserved. Only a few herpesviruses as 
ν nown so far possess conserved sites on their envelope proteins. Major immunogenic 
components are associated with membrane structures and are therefore recognized by the 
immune system early in infection. This makes sense since the organism has to eliminate infected 
cells and activate the defense mechanisms against such structures. There is general agreement 
that the major immunogenic components are comprised in glycoprotein structures. Profound 
knowledge exists already about the human herpesviruses types 1 and - 2 . Here, gB andgD make 
up major immunogenic components. Their essential role in neutralization and protection is out 
of question. They are also involved in fusion of cells (for review see Spear, 1965). Their 
expression on the cell surface during the infectious cycle has not fully been clarified. 
However, there is evidence, that a lot of the gD epitopes are recognized by neutralizaing 
antibodies. Using infected cells the anti-gD antibodies can much easier be absorbed out from 
convalescent sera than those antibodies directed against gB (Pauli and Ludwig, 1977). Batteries 
of monoclonal antibodies against these glycoprotein complexes are now in use to identify the 
epitopes of these membrane inserted proteins and determine-their functional role (Pel letetal . , 
1985). 
In the animal herpesvirus systems, knowledge about the major antigens is st i l l premature. For 
bovine herpesvirus type I (BHV-1 ), glycoproteins in a molecular weight range of 75 K seem to 
be involved in neutralization. Monoclonal antibodies and the use of convalescent as well as 
monoprecipiting antibodies show that several proteins in molecular weight ranges between 50 K 
and 150 K are either in close steric neighbourhood on the virion or become closely associated 
during the detergent extraction, when the tertiary structure might be altered (Collins et al., 
1984; Øregersen, 1983, Gregersen et al.. 1965; Letchworth et al., personal communication; 
Van Drumen Little-Van den Hurk étal , 1984) 
A similar situation is observed with the antigens and major immunogenic components of 
Pseudorabies viruses Here a 90-95 Κ glycoprotein gives rise to neutralizing antibodies and is 
regarded to be the major immunogenic component, although strong neutralization has also been 
observed with antibodies recognizing a 50 Κ glycoprotein (Bund, 1983; Hampl et al., 1984, 
Wathen and Wathen, 1984). 
To simplify the picture one can argue that not all of theapprox. 10 glycoproteins found in human 
or animal herpesviruses give rise to the seme strong humoral immune response, but there are 
one or two (and often not more) single glycoproteins or glycoprotein complexes initiating the 
bulk, of neutralizing antibodies. The fine structure of these complexes has st i l l tobeenravelled. 
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A unique situation extending the strong cross-reactivtiy of the major immunogenic components of 
HSV-1 and - 2 hes been elucidated with HSV, BHM virus and Β virus (Ludwig, 1983), were 
undoubtedly several conserved antigenic determinants are present on gB, , when looked at all 
three viruses and on gO comparing HSV and Β virus (Ludwig et al., 1983). Detailed studies on 
conserved structures in these two glycoproteins wi l l soon show where evolutionary retained and 
where variable epitopes can be expected. Preliminary data indicate for example that on the 
glycoprotein "tree" of gB (HSV), modelled by Pelletetal. ( 1985) at least \0% of the epitopes 
are shared with those of the BHM virus glycoprotein. These are absent in the gD of these viruses 
end cannot be found in EB virus when the same panel of gB monblonals to HSV gB was used for 
comparative studies ( Ludwig et al., manuscript in preparation). 
Modern tools, like monxlonal antibodies and the sequencing data of herpesvirus DNAs which 
enable to construct synthetic polypeptides, wi l l soon allow deeper insights into conserved and 
variable structures of the major immunogenic components. 
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SESSION 2 
THE IMMUNE SYSTEM I N THE DEFENSE 
AGAINST HERPESVIRUSES 
Chairman : Β.T. ROUSE 
Co-chairman : C. STOKES 

IMMUNOBIOLOGY OF HERPESVIRUS INFECTIONS 
Barry T. Rouse 
C o l l e g e of V e t e r i n a r y M e d i c i n e 
U n i v e r s i t y of T e n n e s s e e 
K n o x v i l l e , TN 3 7 9 9 6 - 0 8 4 5 
ABSTRACT 
This review surveys some major immunobiological features of herpes­
virus infections that must be considered in the design of immunological 
control measures. An overview is presented of the pathogenesis of various 
groups of herpesviruses. This is followed by a discussion of the mechan­
isms of defense which serve to impart resistance. Against initial infec­
tion, natural defense mechanisms predominate with natural killer cells, 
macrophages and interferons being the most important components involved. 
Adaptive immune responses are discussed with regard to their role in re­
covery from infection. Emphasis is directed at aspects of Τ lymphocyte 
mediated responses since such mechanisms appear to play dominant roles in 
immunity. Finally, the circumstances in which host responsiveness against 
herpesviruses can be immunopathological is briefly discussed. 
INTRODUCTION 
Herpesvirus are prevalent infectious agents in almost all species and 
with few exceptions have not been successfully controlled by vaccination 
schemes. Indeed, for many herpesviruses acceptable vaccines are unavail­
able and the agents are gaining in importance. Thus, there is some urgen­
cy to develop successful control measures either immunological or other­
wise. The principal reason for our failure to develop successful immuno­
logic control cannot be explained by the viruses' poor immunogenic it y. 
Rather, it is because a state of latency is established after primary in­
fection. In some instances, latent or chronic infection can involve com­
ponents of the immune system itself and can lead to immune dysfunction. 
Despite intensive effort, we neither understand the molecular biology of 
latency nor know how to achieve its termination. The biological signifi­
cance of latency is that it serves as a nidus of infection for reactivated 
disease in the infected host and as a source of virus to be spread to 
others. Thus immunological control measures must emphasize approaches to 
prevent initial infection and the establishment of latency or modulate 
immune responsiveness such that reactivated virus is inconsequential both 
as regards disease and dissemination to cohorts. In this article some 
immunobiological features of herpesvirus infections are discussed and the 
relevance of such observations to possible control measures are mentioned. 
11 
the treatment is by necessity cursory and selective and for more detailed 
discussion several recent reviews should be consulted (Shore and Nahmias, 
1982; Kirchner, 1982, 1984; Rouse, 1984a, b, c; Lopez 1984a, b; Rouse and 
Horohov, 1984). Where possible references are made to appropriate reviews 
rather than to the original authors. 
PATHOGENESIS OF HERPESVIRUS INFECTIONS 
The members of the alphavirinae family of herpesviruses all cause 
acute infections which if not lethal are followed by clinical recovery 
with the virus remaining latent at some site in the nervous tissue. Of 
far more interest from an immunobiological perspective are viruses in the 
gammavirinae family which characteristically interact in a variety of ways 
with cells of the immune system. Examples include Epstein-Barr virus 
(EBV) of man and Marek's disease virus of chickens. Our comments will be 
confined to the former. EBV infection of young children is an unnotice-
able event and entails an inapparent infection of Β cells and cells in the 
oropharaynx (Epstein and Morgan, 1983). In contrast, primary infection of 
adolescents results in infectious mononucleosis in 50% of cases. The 
essential lesion is a polyclonal activation of Β cells. The Β lymphocytes 
undergo proliferation and activation which results in raised levels of 
antibody, including autoantibodies. One consequence is that immune com­
plex disease can occur. Under normal circumstances, polyclonal Β cell 
activation is terminated by an HLA restricted cytotoxic Τ cell and natural 
killer (NK) cell response. Ordinarily clinical and hematological recovery 
occurs, but there are exceptions. Most prominent among these are sit­
uations where individuals receive prolonged immunosuppressive therapy or 
suffer from an inherited X- linked immunoproliferative disorder (XLP) 
(Purtilo, 1980). In both instances, EBV infection can be fatal. With the 
XLP syndrome, which results from a primary Τ cell immunoregulatory defect, 
a variety of EBV induced diseases result from the uncontrolled Β cell pro­
liferation. These include space-occupying lesions, infarctions and hyper-
gammaglobulinema. Occasionally monoclonal lymphomas occur. These seem to 
result from a cytogenetic error such as an 8:14 translocation similar to 
that which occurs in Burkitt's lymphoma (Manolov and Manolova, 1972). 
Viruses of the beta herpesvirinae family may also establish a complex 
immunobiological relationship with their host. Best studied is the human 
cytomegalovirus (HCMV) (reviewed by Kirchner, 1984). Normally, HCMV is 
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not a cause of disease. However, if immunosuppression occurs through 
iatrogenic measures, other diseases or immune incompetence, then HCMV in­
fection may lead to disease. Particularly prone to infection are the 
unborn and newborn, transplant recipients and those with secondary immuno­
suppressive diseases such as the acquired immunodeficiency syndrome. In 
such circumstances, HCMV may cause a variety of effects of which inter­
stitial pneumonia, mononucleosis and hepatitis are major signs. Following 
HCMV infection, further immunosuppression occurs perhaps because of im­
pairment of macrophage (M0) function. The consequences of such immuno­
suppression is superinfection with a range of low grade pathogens of which 
Pneumocystis and Aspergillus are the usual culprits. Frequently the out­
come is fatal. 
RESISTANCE TO INITIAL INFECTION 
Upon initial exposure to virus many natural defense mechanisms are 
available that can limit and curtail infection. The most comprehensive 
investigations on this topic have been with herpes simplex viruses (HSV) 
and the subject was lucidly reviewed by Lopez (1984a, b). Since the 
severity of initial herpetic infections is often a harbinger of recru­
descent disease, natural immunity may have indirect effects on the latter 
and serve to limit the extent of latency. Adaptive immunity, which takes 
some time to develop, assumes more importance in facilitating recovery and 
enhancing resistance to reinfection (Rouse, 1984b). 
A number of approaches have been used to identify natural defense 
mechanisms involved in resistance to herpetic infections. These include: 
(A) observations of naturally-occurring immune deficiencies to determine 
if enhanced susceptibility correlates with impaired activity of some de­
fense mechanism; (B) measurement of effect on immunity of treatment to 
enhance or suppress some defense parameter; (C) observations of severity 
of infection in animal models of genetic resistance and finally (D) recon­
stitution experiments. None of these approaches prove ideal since rarely 
if ever is the activity of a single natural immune mechanism being mea­
sured. Thus, for example, the observation that herpetic infections are 
usually more severe when NK function is impaired as in the Wiscott-Aldrich 
syndrome of man (Lopez et al., 1983) and the beige gene mutation in mice 
(Shellam et al., 1981) has been taken as evidence for a crucial role of NK 
cells in resistance. However, since other cell types, such as polymorpho-
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nuclear n e u t r o p h i l s (PMN) and M0 are a lso impaired in funct ion, the con-
c lu s ions remain equ ivoca l . The observat ion that newborns are more s u s -
c e p t i b l e to he rpe t i c in fec t ions was explained by immature M0 function 
(Johnson, 1964) and, in f ac t , r e s i s t a n c e could be increased by adoptive 
t r a n s f e r of adult M0 (Hirsch et a l . , 1970). However, newborns have more 
than j u s t an immaturity in M0 function and the adopt ively t rans fe red c e l l s 
were not exc lus ive ly M0s. 
Problems of a lack of s e l e c t i v i t y a lso befoul the i n t e r p r e t a t i o n of 
experiments in which animals are t r ea t ed so as to augment or suppress some 
na tu r a l defense mechanism for the purpose of determining the effect on 
subsequent i n f e c t i o n . Many groups have used t h i s approach to ind ica te a 
c r u c i a l ro le for M0 in na tu ra l r e s i s t a n c e (reviewed by Morahan, 1984; 
Lopez, 1984a, b ) . Thus treatment with M0 poisons such as s i l i c a and c a r -
rageenan increased s u s c e p t i b i l i t y . Unfor tunate ly , the function of PMN, NK 
c e l l s and perhaps other c e l l types involved in r e s i s t a n c e are a lso af-
fec ted . Observat ions that r e s i s t a n c e is increased following the use of M0 
immunopotentiators has a lso been used to i nd i ca t e an e s s e n t i a l ro le of M0. 
Thus, C_. parvum admin is t ra t ion to mice increases t h e i r r e s i s t a n c e to 
i n t r a p e r i t o n e a l in fec t ion with HSV, although i n t e r e s t i n g l y not to the more 
phys io log ica l local routes of i n f ec t ion (McGeorge and Morahan, 1978). C. 
parvum a c t i v a t e s M0 but a lso causes i n t e r f e ron induct ion which, in ad-
d i t i o n to i t s ro le as a M0 a c t i v a t o r , has i nd i r ec t a n t i v i r a l e f fec t s and 
increases the a c t i v i t y of NK c e l l s by a v a r i e t y of mechanisms (Roy, 1984; 
Herberman et a l . , 1979). Consequently, the lack of s e l e c t i v i t y provides a 
dilemma. 
Two other r e s u l t s worthy of comment in which treatment with s e l e c t i v e 
reagents was used to imply mechanisms of na tu r a l r e s i s t a n c e agains t he r -
pesvirus i n fec t ions were those which showed that the in vivo admin i s t ra -
t i on of a n t i i n t e r f e r o n ( a n t i - I F ) (Gresser et a l . , 1976) and a n t i - a s i a l o 
GMj serum (Bukowski et a l . , 1983) both increased s u s c e p t i b i l i t y . The 
l a t t e r serum is claimed to a f fec t only NK c e l l funct ion , although i t i s 
well known that the a s i a l o GMj marker i s expressed on many other c e l l 
types including PMN and M0 (Herberman and Or ta ldo , 1981). The observa-
t i o n s with a n t i - I F serum s t rong ly ind i ca t e a ro le for IF in r e s i s t a n c e but 
s ince IF plays mu l t i p l e ro l e s in immunobiology, i t i s not poss ib le from 
such experiments to conclude which aspect of immunity was being a f fec ted . 
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Some of the more persuasive arguments which indicate the mechanistic 
role of a natural defense component have come from studies of animal 
models of genetic resistance (reviewed by Lopez, 1984a, b ) . In such sys­
tems, in vitro and in vivo correlates of resistance can be evaluated in 
crosses and backcrosses of resistant and susceptible mice to determine 
whether functions in question segregate with resistance or independently. 
Another advantage is that these models use genetically homogeneous mice. 
Consequently, cell transfer experiments can be performed. Using the 
genetic model of resistance of HSV, Lopez (1984a) and Mogensen (1977), 
examined several mouse strains and showed that resistance was dominant and 
governed by two independently segregating, nonsex-1inked, non H-2- linked 
loci. The pattern of resistance was true for all HSV strains investi­
gated, whether the route of challenge was intraperitoneal, intravaginal or 
intraocular. 
The results of several studies indicated that the host's hemato­
poietic defense system was responsible for genetic resistance and that 
resistance served to inhibit virus from reaching the central nervous 
system which appears to be the target organ in the mouse. The use of 
chimeras constructed from lethally irradiated susceptible mice recon­
stituted with bone marrow from resistant (Fj) mice was one line of 
evidence used. In addition, treatment of resistant mice with the bone 
seeking isotope strontium-89 abrogated genetic resistance as did prolonged 
treatment with oestradiol. 
In analyzing the mechanisms involved in genetic resistance, most evi­
dence pointed towards NK cells although some favor the M0 (Morahan, 1984) 
or the early interferon response (Engler et al., 1981) as the chief 
mechanism of resistance. Arguing principlely against M0 were experiments 
showing that MØ's ability to resist virus replication did not segregate 
with genetic resistance in Fj and F2 populations (Lopez, 1984b). The 
extent of NK cell activity correlated with the resistant state and NK cell 
responsiveness segregated with resistance in crosses and backcrosses. 
However, exceptions have been made noted by less enthusiastic advocates of 
NK cells (Kirchner, 1984). Nevertheless, the case for NK cells becomes 
even stronger when full realization of their heterogeneity is taken into 
account (Lopez, 1984b). The most likely alternatiye explanation is that 
the interferon response provides the direct defense mechanism. Both NK 
and interferons are now known to be highly heterogenous and interact with 
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each other intimately (Herberman and Ortaldo, 1981). Thus, interferons 
may serve to activate NK cells, recruit pre-NK cells, increase rate of NK 
cell recycling and render virus infected target cells more susceptible to 
NK cell lysis (Herberman et al., 1979). Certainly, in vitro examples can 
be found where the lytic function of NK cells is independent of interferon 
activity, but in the normal in vivo environment the two components serve 
parallel supportive roles to diminish the significance of herpetic infec-
t ions. 
In conclusion, natural resistance mechanisms constitute a significant 
barrier to herpesvirus infections. The proper functioning of these mech­
anisms is required by the host to survive their numerous encounters with 
the pathogens. With a thorough understanding of the effector cells in­
volved and their interactions, it should be possible to develop ways of 
manipulating these to the advantage of the host. This topic has been dis­
cussed in detail elsewhere (Rouse and Lopez, 1984). 
RECOVERY FROM INFECTION 
There seems little doubt that whereas natural defense mechanisms play 
a crucial role in preventing or limiting initial infection, once infection 
has occurred resolution depends largely on the adaptive immune response 
(reviewed by Shore and Nahmias, 1982; Rouse, 1984a). Accordingly, if 
adaptive immunity is impaired, infections are more severe, often lethal, 
and are more likely to desseminate to critical organs such as the brain. 
Severe and lethal infections are commonly observed in the very young, the 
immunosuppressed such as renal transplant patients and in some models of 
primary Τ cell deficiency. In studies of both immunodeficient humans and 
immunosuppressed animals, the capacity to generate an antibody response 
can be normal in the face of a severe virus infection (Meyers et al., 
1980; Lopez et al., 1974). In such individuals, cell mediated immunity 
(CMI) is often suppressed. Such observations, along with the knowledge 
that herpesviruses can disseminate in tissue culture in the presence of 
neutralizing antibody, are arguments commonly taken in support of a prin­
cipal role for CMI in resolving infection. The fact that Τ lymphocytes 
seem designed to recognize virus infected cells (Zinkernagel and Doherty, 
1979) (the principal target of recovery responses rather than free virus) 
and that the Τ cell response better correlates with lesion resolution than 
do antibody responses also supports a major role for Τ cell mediated 
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immune mechanisms. Nevertheless, the scenario is complex and it seems 
highly likely that the many mechanisms of Τ cell immunity interact posi­
tively and negatively with other aspects of immunity. The outcome with 
herpesvirus infections is usually rapid recovery, although examples of 
immunopathology have been noted (Rouse, 1984c) and, as is well known, 
immunity is never total since persistent or latent infection usually 
occurs. Since humoral immunity will be dealt with in the chapter by Dr. 
Norrild further mention will not be made of this aspect of adaptive immun­
ity. Our discussion will emphasize Τ cell mediated mechanism and will be 
selective and incomplete because of space limitation. However, several 
more comprehensive reviews have been published recently (Shore and 
Nahmias, Rouse, 1984a, b; Kirchner, 1982, 1984; Rouse and Horohov, 1984). 
Several approaches have been used to assess the role of adaptive 
immunity in herpetic infections, but perhaps the most analytical has in­
volved observations of the course of infection in normal or compromised 
animals following passive transfer of antibody and adoptive transfer of 
defined Τ cell populations (reviewed by Rouse, 1984b). With such systems, 
evidence was obtained that several different mechanisms played a role in 
recovery (including antibody). Aspects of CMI appear as the principal 
mechanism of recovery, but whether delayed type hypersensitivity (DTH) or 
some other function of Τ cells such as cytotoxicity plays the dominant 
role remains debatable. In the mouse ear model, rapid elimination of 
infective virus from the ear of an acutely infected animal correlates with 
the appearance of DTH and this protection can be transferred to infected 
recipients with Lytl+2- Τ cells, the only Τ cell subset known to mediate 
DTH against HSV in the mouse (Nash and Gell, 1981). However, by means of 
adoptive transfers of immune lymphocytes, others have shown that Lyt 1-2 + 
cytotoxic Τ lymphocytes (CTL) populations can also clear virus (Larsen et 
al., 1984). Moreover, it is known that animals rendered tolerant for DTH 
still recover from infection. Such observations indicate that several Τ 
cell systems serve similar overlapping functions of clearing virus from 
tissues. Removal of replicating virus from epidermal or mucocutaneous 
surfaces is usually achieved without tissue damage (reviewed by Rouse, 
1984c). However, there are instances where prolonged responses result in 
immunopathological reactions. Some of these are discussed subsequently. 
IMMUNOBIOLOGICAL ASPECTS OF ANTI-HERPES Τ CELL IMMUNITY 
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Herpesvirus specific Τ cell responsiveness can be measured in a 
variety of ways. The most usual, but analytically least helpful, has been 
to measure antigen induced proliferation in peripheral blood leukocyte or 
lymphoid cell suspensions. Several functional cell types of Τ cells can 
be induced to proliferate and under some circumstances herpesvirus anti­
gens may even act as Β cell mitogens (Kirchner, 1982). Moreover, pro­
liferation is dependent on the presence of appropriate antigen presenting 
cells and the elaboration of proliferation factors such as interleukin 2 
(IL-2) (Rouse, 1984a). The response of cell mixtures is also subject to 
inhibition and regulation by antigen specific suppressor cells. Conse­
quently, unless efforts are made to separate lymphocyte subsets prior to 
stimulation it is difficult to relate levels of lymphocyte proliferation 
to any functional parameter of Τ cell immunity. A discussion of how lym-
phoproliferation correlates with viral pathogenesis and in particular with 
the onset of recrudescent herpetic disease was published elsewhere 
(Horohov et al., 1984). 
Several in vitro assays of Τ cell reactivity to herpetic antigens 
correlate more closely with probable in vivo function. These include 
assays for CTL and their precursors (CTL-P), assays for helper lymphocytes 
(HTL) and their precursors (HTL-P) and finally assays of suppressor lym­
phocyte (STL) activity. It is clear from work done in several systems, 
including those involving herpesvirus antigens (Rouse, 1984a), that these 
activities are usually expressed by different lymphocyte subsets and that 
the series of events which lead to their activation are quite different. 
Thus, all 3 functional lymphocyte subsets precursors must be activated by 
viral antigen in the membrane of an antigen presenting cell (APC), usually 
a M0. It is becoming increasingly evident that different APC serve to 
activate the various subsets of lymphocytes (Unanue, 1984). Thus, HTL-P 
are activated by IA positive APC, CTL-P by IA negative (as well as perhaps 
positive) APC and STL by IJ positive APC. Presumably, subtypes of APC are 
differentially represented at various locations in the body. This could 
well provide an explanation for the observation that different routes of 
infection may affect the type of Τ cell immune response that occurs (dis­
cussed subsequently). 
The delayed type hypersensitivity (DTH) response is the paradigm of 
an in vivo Τ cell mediated CMI response. This response has been carefully 
investigated in regard to HSV in the mouse and has been reviewed (Nash and 
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Gell, 1984). Particular attention was paid to determining the cell types 
involved in the response, its regulation, the antigens and routes of 
immunization required for DTH induction and the role of DTH as a protec­
tive or immunopathological reaction. Anti-herpesvirus DTH was established 
following local infection, but not after exposure via the intravenous 
route. In this latter circumstance, suppressor cells were induced which 
served to inhibit DTH at both afferent and efferent levels (Schrier et 
al., 1983). It is instructive to emphasize some observations made with 
viruses other than herpes since similar effects could also occur with 
herpesviruses in nonmurine systems. In influenza, for example, following 
infection with replicating virus, two subsets of DTH mediating Τ cells 
were induced r one restricted by class I and the other by class II (IA) 
major histocompatible antigens (Ada et al., 1981). After exposure to non-
replicating virus, only the IA restricted cells were induced. Moreover, 
such cells were involved in immunopathological reactions rather than pro­
tective immunity. Upon exposure to live virus, the induced response was 
protective. This occurred because the class I mediated DTH cell provided 
protection and in addition, immunopathological reactions were prevented by 
a concomitant induction of suppressor cells (Liew and Russell, 1983). 
Clearly the nature of antigens used in vaccines is important since certain 
forms of non-infective antigen preparations could set the stage for 
imraunopathology when subsequently exposed to replicating virus. 
IMMUNOPATHOLOGICAL REACTIONS INVOLVING HERPESVIRUS INFECTIONS 
In the majority of circumstances the outcome of an adaptive immune 
response to herpesvirus infection is protection. However, sometimes sig­
nificant tissue damage occurs. Such immunopathological reactions vary 
widely in mechanism and include chronic Τ cell mediated responses to per­
sistent antigen, toxic immune complexes and perhaps reactions mediated by 
IgE. The general topic of the role of immunopathological reactions in 
herpesvirus infections was reviewed recently (Rouse, 1984c). 
There are several sporadic examples of immunopathology such as immune 
complex lesions in skin and the glomerulus after infection under certain 
circumstances. Perhaps the best candidate syndrome involving herpes­
viruses in which the mechanism of pathogenesis is essentially immunopatho­
logical is that of disciform keratitis. This inflammatory reaction of the 
corneal stroma occurs following HSV recrudescence in the eye (Kaufman, 
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1978). Frequently the reaction can become more marked with each recru­
descence and corneal blindness may result. In fact HSV infection is a 
common cause of corneal blindness in the USA. Epithelial keratitis 
results directly from virus replication in epithelial cells and responds 
very well to treatment with antivirale. Indeed it was in the treatment of 
epithelial keratitis that antiviral drug treatment was first found to be 
clinically useful (Kaufman et al., 1962). However, keratitis affecting 
the stroma responds less well to antiviral drugs and needs judicious 
treatment with corticosteroids for successful management. It is usually 
not possible to demonstrate infectious virus in the stroma, but from work 
done on clinical material and in animal models, viral antigens can often 
be detected in keratocytes which are surrounded by inflammatory lympho­
cytes. (Metcalf and Reichert, 1979). 
The mechanism of herpetic keratitis has been studied in both rabbits 
and mouse models. It remains unclear as to the exact immunopathological 
sequence of events that causes the reaction but evidence has been mar­
shalled to support a role for immune complex lesions as well as a chronic 
Τ cell response mediated by more than one subset of Τ cells (Russell et 
al., 1984). It is important to be aware of the possibility of inducing or 
sensitizing for subsequent immunopathological reactions in designing fu­
ture vaccines for use against herpesviruses. 
CONCLUSIONS AND SPECULATIONS 
In the development of new vaccination approaches for use against 
herpesviruses some immunobiological aspects should be taken into account. 
Of principal relevance are the influences that route of vaccination and 
nature of vaccine can have on the type of immune response induced. For 
example, whereas infection via the subcutaneous or intramuscular routes 
induces a positive response, oral, intravenous (i/v), or ocular infection 
favors the generation of suppressor cell responses (Rubin et al., 1984; 
Nash and Gell, 1981; Whittum et al., 1984). The target cells for such 
suppression may vary. With i/v infection, APC as well as lymphocyte pre­
cursors and effectors that mediate DTH act as the targets (Schrier et al., 
1983). Conditions have also been established in which suppressor cells 
are induced which regulate the activity of herpesvirus specific CTL 
(Horohov et al., 1984b). The reasons why a given route of infection pre­
ferentially induces suppression needs to be established. However, the 
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most l i k e l y explana t ion is tha t APC involved in induct ion of the d i f f e ren t 
types of responses are d i f f e r e n t i a l l y represented in each l o c a t i o n . 
I t is c l e a r l y evident tha t the na ture of antigen can markedly affect 
the type of immune response induced. However, we know l i t t l e about the 
na ture of herpesv i rus an t igens involved in Τ c e l l induct ion or t a r g e t c e l l 
r e c o g n i t i o n . For CTL induct ion and recogn i t ion agains t HSV they seem to 
be g lycopro te ins (Rouse, 1984a). In c o n t r a s t agains t CMV, nons t ruc tu ra l 
e a r ly p ro t e in s appear to be the ant igens involved (Reddehase et a l . , 
1984). I t could be that determinant groups involved in CTL and HTL i n ­
duct ion d i f f e r from those involved in suppress ion . This i s the case with 
less complex ant igens such as lysozymes (Adorini et a l . , 1979). Hope­
f u l l y , t h i s topic w i l l become c l a r i f i e d once more becomes known about the 
immune response to h e r p e s v i r u s - s p e c i f i c syn the t i c p e p t i d e s . 
With h e r p e s v i r u s e s , our experience has been tha t n o n - r e p l i c a t i n g 
v i r u s e s and i so l a t ed v i r a l g lycopro te ins represen t very weak ant igens in 
regards to the in vivo induct ion of CTL and he lper Τ c e l l s involved in CMI 
responses (Rouse, 1984a). For i n s t a n c e , we have developed highly s e n s i ­
t i v e l i m i t i n g d i l u t i o n assays to q u a n t i t a t e numbers of CTL, CTL-P and IL-2 
producing HTL precursors in lymphoid t i s s u e s of mice following exposure to 
HSV (Rouse and Wagner, 1984; Prymowicz e t a l . , 1984). Our e s t ima tes of 
numbers of both CTL-P and HTL-P f a l l in the range of 1/3000 - 1/8000 af ter 
recent exposure to in fec t ious v i r u s and 1/15000 in long term memory pop­
u l a t i o n s . I n t e r e s t i n g l y , exposure to n o n r e p l i c a t i n g v i rus and glyco­
p r o t e i n an t igens may f a i l to induce any IL-2 producing HTL-P, although 
he lpe r Τ c e l l s involved in antibody product ion are e l i c i t e d . In c o n t r a s t , 
CTL-P are induced although the memory CTL-P are markedly reduced. Our 
r e s u l t s demonstrate the ine f fec t iveness of i nac t i va t ed vaccines at s t im­
u l a t i n g appropr i a t e an t i - he rpe s v i r u s immunity and also i n d i c a t e tha t to 
induce a broadly r e a c t i v e balanced Τ c e l l response , r e p l i c a t i n g vaccines 
are r equ i r ed . However, i t i s l i k e l y tha t with more careful ana lys i s of 
ant igen p r e s e n t a t i o n requirements and the use of ad juvants , i s o l a t e d v i r a l 
p r o t e i n s and pept ides wi l l prove to be s u i t a b l e immunogens agains t he rpes ­
v i r u s e s . There could also be a place for a n t i - i d i o t y p e vaccines (Rouse, 
1984c). 
I t is important to continue research in the f ie ld of iramunoregulation 
with with respec t to v i r a l i n f e c t i o n s . The c l i n i c a l a p p l i c a t i o n of our 
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knowledge is that eventually it may prove feasible to tailor the type of 
immune response obtained. For example, if recovery is found to correlate 
best with the HTL response, we need to use immunogens and routes of vac­
cination which best stimulate this type of response. In cases of herpes­
virus immunopathology, such as corneal stromal keratitis, ways must be 
found to induce regulatory suppressor cells. In situations of recru­
descence, which some have suggested results from the overactivity of 
suppressor Τ cells (Sheridan et al., 1982), we need to find modes of im­
munization that will inhibit such suppression and so limit the severity of 
recrudescence. Recently, basic studies on the nature of suppression have 
indicated that some forms may be overcome by the administration of addi­
tional IL-2 (Green et al., 1983). In our own studies on HSV specific CTL 
suppression, we have also observed such effects, and have also shown that 
the in vivo supplementation of IL-2 may markedly facilitate recovery from 
infection (Rouse et al., 1984b). Such studies lead us to anticipate that 
IL-2 administration could minimize the severity of recrudescent disease, a 
topic currently under further investigation in our laboratory. 
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ABSTRACT. 
One of the lajor features of herpesvirus infections of minis is latency. Fro· tiie to tiie detectable 
episodes of virus shedding lay occur, both apparently spontaneously and as a result of certain endogenous 
and exogenous stiiuli, A nuiber of experimental systets have been investigated to study the phenomenon of 
latency and recrudescence, lainly using herpes siiplex virus infection in the louse eodel. Honever, there 
are a nuiber of other aniial species that can be studied «here the herpesvirus is in its owi natural 
host-virus systei. Tuo such exaiples, the cat and pigeon herpesviruses, are described here. Both of these 
produce a latent infection in their hosts, and can be reactivated under «ell-defined conditions either as a 
result of natural, physiological stresses, or fro· lore artificial stiiuli. As a result of these 
observations, sote conclusions are drawn about the biological role of latency. 
INTRODUCTION. 
One o-f t h e m a j o r - f e a t u r e s o-f h e r p e s v i r u s i n f e c t i o n s o-f 
a n i m a l s i s t h e phenomenon o-f l a t e n c y . L a t e n c y may be d e f i n e d a s 
t h e masked p e r s i s t e n c e o-f v i r u s i n t h e h o s t , so t h a t i t c a n n o t 
be d e t e c t e d b y c o n v e n t i o n a l v i r o l o g i c a l t e c h n i q u e s . From t i m e 
t o t i m e , h o w e v e r , d e t e c t a b l e e p i s o d e s o-f v i r u s s h e d d i n g 
( r e — e x c r e t i o n ) may o c c u r , b o t h a p p a r e n t l y s p o n t a n e o u s l y and a s 
a r e s u l t o-f c e r t a i n e n d o g e n o u s o r e x o g e n o u s s t i m u l i , and w h i c h 
may o r may n o t be a c c o m p a n i e d by c l i n i c a l s i g n s 
( r e c r u d e s c e n c e ) . T h u s i n p e o p l e , h e r p e s s i m p l e x v i r u s (HSV) 
r e c r u d e s c e n c e t e n d s t o o c c u r a f t e r p h y s i o l o g i c a l s t r e s s e s s u c h 
a s m e n s t r u a t i o n o r p y r e x i a ( R o i z m a n , 1 9 6 5 ) , and i n a n i m a l 
h e r p e s v i r u s i n f e c t i o n s s t r e s s e s s u c h a s a c h a n g e o f h o u s i n g o r 
t h e r e p r o d u c t i v e p e r i o d may i n d u c e v i r u s r e — e x c r e t i o n ( G a s k e l l 
and P o v e y , 1 9 7 7 , 1 9 8 2 ; M c F e r r a n e t a l . , 1 9 8 4 ; V i n d e v o g e l e t 
a l . , 1 9 B 5 ) . R e - e x c r e t i o n may a l s o be s t i m u l a t e d i n many s p e c i e s 
by means o f c o r t i c o s t e r o i d o r o t h e r i m m u n o — s u p p r e s s i v e 
t r e a t m e n t ( S h e f f y and D a v i e s , 1 9 7 2 ; G a s k e l l and P o v e y , 1 9 7 3 ; 
V i n d e v o g e l e t a l . , 1 9 8 0 b ; W i t t m a n n n e t a l . , 1 9 8 2 ) , t h o u g h t h e 
e x a c t mechan ism o f t h i s i s u n k n o w n . 
A number o f e x p e r i m e n t a l s y s t e m s h a v e b e e n i n v e s t i g a t e d i n 
o r d e r t o s t u d y t h e phenomenon o f l a t e n c y and r e c r u d e s c e n c e . T h e 
m a j o r i t y h a v e c o n c e n t r a t e d on human HSV i n f e c t i o n i n t h e mouse 
m o d e l , t h e mouse b e i n g c h o s e n n o t o n l y b e c a u s e o f c o n v e n i e n c e 
and o u r i m m u n o l o g i c a l k n o w l e d g e o f t h e h o s t , b u t a l s o b e c a u s e 
o f i t s l o w b a c k g r o u n d l e v e l o f s p o n t a n e o u s r e a c t i v a t i o n 
c o m p a r e d t o some o t h e r l a b o r a t o r y s p e c i e s ( S e k i z a w a e t a l . , 
1 9 8 0 ; Openshaw, 1 9 8 4 ) . A v a r i e t y o f m e t h o d s h a v e b e e n u s e d i n 
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the mouse to induce re-excretion, including corticosteroid 
treatment (Underwood and Weed, 1974), cyclophosphamide (Kurata 
et al., 1978), skin trauma (Hill et al., 1978) and ultraviolet 
light (Blyth et al., 1976). Possible mechanisms for the 
establishment, maintenance and control of HSV latency, 
particularly with respect to experi menata l findings on the mouse 
model, have been discussed by Blyth and Hill (1984). 
However, there are a number of other animal species that 
may be studied where the herpesvirus is in its own natural 
host-virus system. Studying latency in the proper animal 
species reduces errors that may arise as a result of 
experimental contrivance, for the same herpesvirus infection 
may give different results both within and between species. In 
veterinary medicine compared to human medicine however, virus 
re-excretion or shedding ("reactivation" in the mouse model) is 
considered more important than recrudescent disease, for it is 
the epidemiological implications of the re—excreting animal in 
a herd or group that are important, rather than recrudescent 
disease in the individual. 
This paper describes two herpesvirus infections of 
animals; Felid herpesvirus 1 (FHV 1) and Pigeon herpesvirus 1 
(PHV 1). Both of these produce a latent infection in their hosts, 
and can be reactivated under well-defined conditions either as 
a result of natural, physiological stresses, or from more 
artificial stimuli. As a result of these observations, some 
conclusions are drawn about the biological role of latency. 
EELID_HERPESyiRyS_l_iFHV_l!. 
FHV 1 is an alphaherpesvirus of cats. It is a respiratory 
pathogen producing a disease known as feline viral 
rhinotracheitis. In contrast to the broader host range of some 
other herpesviruses such as ADV or HSV, the virus only affects 
domestic cats and other Felidae (Povey, 1979). All isolates so 
far examined from many parts of the world show antigenic 
homogeneity on the basis of conventional serological 
cross-neutralisation tests (Crandell et al., I960; Bittle et 
al., 1960; Johnson and Thomas, 1966), although more refined 
serological techniques have not been used. Recent work using 
restriction enzyme analysis of the viral DNA has confirmed this 
high degree of similarity between strains which in general is 
reflected in the relatively uniform'biological behaviour of 
isolates (Hermann et al., 1984). However strains of modified 
virulence do exist, having been produced in recent years for 
vaccines (Slater and York, 1976; Davies and Beckenhauer, 1976; 
Bittle and Rubic, 1975). 
No serological relationship has been demonstrated between 
FHV 1 and a second feline herpesvirus associated with 
urolithiasis (Fabricant and Gillespie, 1971), nor with several 
other alphaherpesvirus of other species (Povey, 1979). 
FHV 1 is highly infectious to susceptible cats, infection 
occurring via the intranasal, oral or conjunctival routes. In 
the acute phase of the disease, the major sites of virus 
replication are in the nasal septum, turbinates, nasopharynx 
and tonsils; conjunctivae, mandibular lymph nodes and trachea 
are also often involved (Crandell et al., 1961; Gaskell and 
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Povey, 1979a). A viraemia has only rarely been reported. A 
possible genital tropism has been investigated experimentally, 
but is not thought to be of significance under natural 
conditions (Bittle and Peckham, 1971; Hoover and Griesemer, 
1971). 
The virus is a comparatively labile virus, surviving under 
typical external environment conditions for less than a day 
(Povey and Johnson, 1970) and susceptible to all common 
disinfectants (Scott, 1980). As an aerosol, it is relatively 
unstable at midrange and higher relative humidities (Donaldson 
and Ferris, 1976). 
Xnçidençe_and_çiÍQÍçal_si.gnsi 
FHV 1 is a highly successful virus in cats. It is 
widespread throughout the world (Crandell, 1973) and together 
with feline calicivirus, accounts for the majority of cases of 
feline respiratory disease (Kahn and Hoover, 1976; Gaskell and 
Wardley, 1978). Clinically it is the most significant of the 
feline respiratory pathogens. Serological surveys prior to 
vaccination demonstrated FHV 1 serum neutralising antibody 
titres in 26-70X of cats, depending on the nature of the sample 
population (Studdert and Martin, 1970; Povey and Johnson, 1971; 
Ellis, 1981). In general infection is less common in isolated 
household pets than in colony animals. However, the household 
pet is artificially separated from other cats by man; an open 
colony situation being a truer reflection of how virus and host 
evolved together. Once the virus has gained access to a 
susceptible colony, often by means of a clinically normal 
carrier, the disease rapidly becomes endemic, its presence 
being noted by the existence of chronically affected animals 
with recurrent or persistent signs. Outbreaks of acute disease 
may also occur, particularly in young kittens when they lose 
their passive immunity. 
Acute infection with FHV 1 is characterised by depression, 
sneezing and ocular and nasal discharges (Crandell et al., 
1961; Gaskell and Povey, 1979a). There is usually a fever and 
loss of appetite. Conjunctivitis, hypersalivation, and 
sometimes dyspnoea and coughing may develop and there may be a 
recurrence of the pyrexia. A leucocytosis with a left shift is 
present throughout the course of the disease. Other, rarer 
manifestations have been reviewed by Gaskell and Wardley (1978) 
and Povey (1979). Mortality may be high in young or debilitated 
cats and virus generalisation may occasionally occur. The 
majority of clinical signs have usually resolved in 10-20 days, 
but some animals may be left with chronic sequelae such as 
conjunctivitis, rhinitis, or sinusitis. These are probably 
mainly due to severe mucosal damage and secondary bacterial 
infection, but may also occur as a result of viral 
recrudescence. 
Ex.Eerimental_in£e^tiçm_and_indyc:tiçxi_of_re^exç 
The most common route of infection used experimentally is 
intranasal, although several other routes have been 
investigated (Povey, 1979). The incubation period is 2—7 days, 
though it may be longer and has been shown to be dose-related 
(Gaskell and Povey, 1979a). Virus is shed in oropharyngeal, 
nasal and conjunctival secretions for a period of one to three 
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weeks, titres of up to 10*··a (mean 10*) TCIDno per ml. o-f 
secretion being reached (Gaskell, 1975). 
Experimentally it has been shown that the majority of FHV 
1 recovered animals are latently infected virus carriers 
(Gaskell and Povey, 1973, 1977). Re-excretion may occur 
spontaneously, but is most likely to occur following stress. 
Under experimental conditions it has been shown that a change 
of housing may induce virus shedding in 187. of 22 FHV 1 
recovered cats on 157. occasions, and corticosteroid in 697. of 
32 cats on 54"/. occasions (Gaskell and Povey, 1973, 1977). 
Climatic stress appeared to be ineffective in inducing 
re—excretion. The apparently spontaneous shedding rate was 0.97. 
on any one day. In these studies, a total of 827. of FHV 1 
recovered cats shed endogenous virus on at least one occasion 
and 457. shed virus spontaneously or under "natural" stress 
conditions and thus could be considered epidemiological 1 y 
important. Similar findings have been reported by Ellis (1981) 
and Goddard (1984). 
A lag period occurred before onset of virus shedding of 
from 4—11 days (mean 7.2) after corticosteroid treatment, and 
from 4-10 days (mean 7.2) after re-housing (Gaskell and Povey, 
1973, 1977). The duration of virus shedding ranged from 1-13 
days (mean 6.5) after corticosteroid and 4—7 days (mean 7.2) 
after re-housing. Titres of virus shed were generally lower (p 
less than 0.01) than in the acute stage of the disease, 
although amounts of up to 10°-α (mean 103-1) TCID H O per ml. of 
secretion were recorded (Gaskell, 1975). In some cases (727. 
following corticosteroid stress, 307. following re-housing) 
shedding was accompanied by recrudescence of mild clinical 
signs, though occasionally signs were seen in carriers 
unassociated with detectable episodes of re—excretion. 
It appeared that there was a refractory period following 
an episode of corticosteroid induced re—excretion during which 
further administration of corticosteroid was less effective 
(Gaskell and Povey, 1977). Cats which did re-excrete as a 
result of treatment had last shed virus on an average of 16 
weeks before, whereas cats which did not re-excrete had 
experienced their last episode of virus shedding on an average 
of only eight weeks before (p less than 0.01). Considerable 
variation was apparent however, both within and between 
individuals. 
The site or sites of latency have not been completely 
elucidated for FHV 1. Despite several unsuccessful attempts in 
the past to isolate virus from the trigeminal ganglia and a 
number of other tissues of latently infected cats (Plummer et 
al., 1973; Gaskell and Povey, 1979b; Ellis, 1982), recently 
virus has been isolated using a tissue fragment culture 
technique from the trigeminal ganglia of a small proportion, 3 
(187.) of 17 recovered animals (Gaskell and Goddard, 1984; 
Gaskell et al., 198 5). However, it remains to be seen if this 
is the major or only site of viral persistence in this species. 
Natural _transiiiissign_gf_the_diseaseI_ 
The major method of spread of FHV 1 is by direct 
cat—to—cat contact, either from animals in the acute stage of 
the disease, or from shedding carriers. There is no evidence of 
vertical transmission. Indirect transmission may also occur, 
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but probably less frequently, and only within the close 
confines of a cattery. Carrier cats are of considerable 
epidemiological significance: they are widespread in the 
population, and in an endemic cattery, constitute the majority 
of recovered animals. In the field situation, surveys of 
clinical normal cats have shown an apparently spontaneous 
shedding rate of 1-27. (Wardley et al., 1974; Ellis, 1981), and 
Gaskell (1975) recorded FHV 1 re-excretion in 3 of 75 cats 9-12 
days after entering a boarding cattery. It seems probable, 
therefore, extrapolating from the experimental studies, that 
other stresses, such as going to stud, to a cat show, or 
entering a new cat colony, may also induce similar episodes of 
re—excretion. 
Although carriers are undoubtedly a source of infectious 
virus and can initiate outbreaks of disease, it seems that 
cross-infection is less easily achieved from a shedding carrier 
than from an acutely infected animal (Gaskell and Povey, 1982). 
Thus under experimental conditions, fairly intimate contact of 
several days' duration is necessary before successful 
transmission may occur. This is presumably because discharges 
are usually more copious and in slightly higher titre in 
acutely infected animals than in carriers. 
Under more natural conditions, however, it is likely that 
the greatest importance of the carrier lies in its ability to 
transmit the virus within the close contact of family groups, 
thus enabling it to perpetuate the host—virus relationship into 
the next generation. In studies on the possible transmission of 
FHV 1 from carrier queens to their kittens, the shedding rate 
from queens in the 10 week post—partum period did appear to be 
marginally increased above the spontaneous rate: four of ten 
queens re-excreted virus and four kittens from three litters 
developed a contact infection (Gaskell and Povey, 1982). None 
showed clinical signs and were presumably infected under cover 
of passive immunity. Two shed virus for one day only and did 
not become carriers, and two shed virus for two to three weeks 
and were subsequently shown to have become carriers: their SN 
antibody titres rising from less than 1 in 4 and 1 in 8 prior 
to re-excretion, to 1 in 96 and 1 in 128 after. The 
establishment of a latent carrier state under cover of passive 
immunity in animals which then became sero-negative, has also 
been shown for HSV infection in mice (Sekizawa et al., 1980). 
From other studies it appears that there are many cases 
where carrier queens shed virus either when their own or other 
kittens in close contact are unprotected by maternal antibody, 
and cases of acute disease result (Povey and Johnson, 1967; 
Crandell, 1971). Although such cases will aid viral 
dissemination in the short term, in many ways it is not a good 
method for the virus to perpetuate itself in its host as 
mortality and also chronic sequelae in young kittens can be 
high. The findings outlined above, however, show that on some 
occasions at least, the cat has an ideal method of perpetuating 
a balanced virus—host relationship which does not depend on the 
development of clinical disease. This then leads to the 
establishment in the next generation of the latent carrier 
state, so the cycle is complete. 
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I«eyne_çontrgl_gf_re—excretigQi -
Immunity to re-infection following primary infection with 
FHV 1 is not very complete or persistent; an animal may be 
re-infected within six months of a primary infection, although 
such cats show only mild clinical signs and a reduced period of 
virus shedding (Walton and Gillespie, 1970). A number of 
vaccines have been developed for use in controlling the 
disease, including live attenuated vaccines given intranasal 1 y 
or systemically, and inactivated vaccines given systemically. 
These have been reviewed elsewhere (Gaskell, 1981). All 
vaccines protect to a large extent against clinical signs 
following challenge, though the intranasal route may be 
marginally more effective. However it has been shown that 
following systemic vaccination, cats generally replicate virus 
for several days after challenge and may subsequently become 
latent field virus carriers (Orr et al-, 1978). Following 
intranasal vaccination, however, with a cold—adapted strain of 
FHV 1, virus replication after challenge appeared to be 
minimal, and in the short term at least, no animals appeared to 
have become carriers (Orr et al., 1980; Cocker et al., 19B4). 
Thus some vaccinated animals, whilst themselves protected from 
clinical disease, may still be a source to others of infectious 
field virus. 
Whether or not repeated vaccination helps control viral 
re—excretion episodes is not known. There appears to be a 
natural refractory period after an episode of re-excretion (see 
earlier) and so it seems possible that externally administered 
antigen may also help control re-excretion. 
PIGEON HERPESVIRUS 1 <PHV 1). 
PHV 1 is predominantly a respiratory pathogen of pigeons, 
although it also occurs in budgerigars and is antigenically 
indistinguishable from falcon or owl herpesviruses (Mare and 
Graham, 1973; Purchase et al., 1972). However it is probable 
that pigeons are the predominant natural host of PHV 1, and 
that infection in budgerigars, and possibly other species, is 
an epidemiological dead-end. Thus, although a spectrum of 
clinical signs may be seen in infected pigeons, in budgerigars, 
PHV 1 provokes, both naturally and experimentally, a fatal 
hepatitis (Vindevogel and Duchatel, 1977; Vindevogel et al., 
197B, 19B0C). 
A similar situation exists with Aujeszky's disease virus 
(ADV) (Suid herpesvirus 1) where pigs are the main host, and 
infection in other species, such as cattle, dogs and cats, is 
of no epidemiological significance (Aguilai—Setién et al., 
1979a, 1979b). 
Xnçidence_and_cl_iniçal_si.gnsí. 
PHV 1 infection is widespread in domestic pigeon 
populations. In Belgium, specific antibodies have been detected 
in the sera of 847. of clinically normal pigeons and 637. of 
pigeons affected with acute respiratory illness. PHV 1 has been 
isolated in 607. of dove-cots permanently affected with 
respiratory disease and from 825C of pigeons affected with acute 
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respiratory troubles (Vindevagel et al., 1981; Vindevogel and 
Duchatel, 1978). A similar situation has been described in 
Germany and France (Heffels et al., 1981; Landre et al., 1982). 
Virus has also been isolated from pigeons coming from dove-cots 
where all birds are devoid of detectable specific antibodies 
(Landre et al., 1982). 
Under natural conditions, clinical disease is 
predominantly seen in primary infection of young pigeons 
derived from parents free of the infection, or in carriers of 
the virus with the help of debilitating factors (Vindevogel et 
al., 1980a, 19B1). Experimental disease may be reliably 
produced in squabs born from virus—free parents (Vindevogel and 
Pastoret, 1981). 
Classical signs of PHV 1 infection in pigeons are 
conjunctivitis, rhinitis, and focal necrosis, in the mouth, 
pharynx and larynx. In some cases, particularly in pigeons 
weakened by debilitating factors such as parasitic disorders or 
secondary bacterial invaders, viral dissemination may also 
occur and lesions may be observed in liver, spleen, kidney and 
pancreas (Cornwell and Wright, 1970; Boyle and Binnington, 
1973; Vindevogel et al., 1975; Vindevogel and Pastoret, 1981). 
ExEectfSeDtai-iOÍeEÊigD-stía-iDdyEÈÍgO-gf-re^exçretigni 
After inoculation with PHV 1 by pharyngeal painting, 
susceptible squabs excrete virus for a minimum of 7 to 10 days 
(Vindevogel et al., 1980b). The typical lesions appear 1 to 3 
days after infection when the viral excretion reaches its 
highest titre. Virus usually remains confined near the site of 
inoculation, although viraemia may occur. 
Mild episodes of recurrence, without clinical signs, occur 
spontaneously (Vindevogel et al., 1980b). High titres of 
specific antibodies do not prevent these recurrences, and 
conversely, recurrent episodes do not occur more frequently 
when the animals are nearly devoid of specific antibodies. 
PHV 1 re-excretion can be provoked experimentally by 
cyclophosphamide (Cy) treatment, and this period of 
re—excretion may be accompanied by lesions of varying severity 
and some birds may die (Vindevogel et al., 1980b; Vindevogel 
and Pastoret, 1981). In one group, all birds re-excreted 
infectious virus starting 2 to 5 days after the first injection 
of Cy for between 1 to 10 days: amounts of virus shed were 
similar to those seen in the acute phase of the disease. The 
mechanism by which Cy initiates viral re-excretion is not 
known. It may be due to a direct cytotoxic effect on latently 
infected cells or indirectly through the effects, of Cy on B and 
T lymphocytes (Coignoul and Vindevogel, 1980). This effect of 
Cy on the immune system may account for the more severe 
clinical syndrome and higher mortality seen in Cy treated birds 
(Vindevogel et al., 1980b; Vindevagel and Pastaret, 1981). 
Natural _transmissi_gn_gf_the_diseasei As far as is known, egg transmission of the disease does 
not occur. No genital form of the disease has been detected and 
neither virus nor its antigen could be demonstratred in cell 
cultures derived from embryos from infected parents (Vindevogel 
and Pastoret, 1980, 1981). 
Although virus may be spread horizontally from acutely 
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infected birds, infection is mainly perpetuated by means of 
carriers. Thus in a flock of pigeons infected with PHV 1, 
virtually all the mature birds are asymptomatic carriers of the 
virus and are thus a potential source of infection to their 
offspring, and to any susceptible in-coming birds. Apparently 
spontaneous episodes of re—excretion may occur, and since 
significant amounts of virus are shed, such birds presumably 
may transmit the infection (Vindevogel et al., 1980b). However 
there is some evidence that these spontaneous episodes are not 
as long-lasting as Cy-induced or natural stress-induced 
episodes of re-excretion, and thus they may not be of such 
epidemiological significance. 
Studies have shown however, that virtually all pigeons 
will experience an asymptomatic re-excretion episode of 
reasonable duration during the reproductive period. Most of 
them re—excrete virus soon after the hatching period, when they 
regurgitate "milk" for their squabs (Vindevogel et al., 19B5). 
After weaning (12th week after hatching) all parents cease 
shedding virus. The squabs become infected but are protected 
from the disease by passive immunity of parental origin, 
conferred to the squabs through the egg yolk. Most of the 
squabs themselves then become asymptomatic carriers after this 
initial infection, though they are very soon devoid of 
detectable antibodies. However, infection may be unmasked by Cy 
treatment, and presumably such squabs may themselves be capable 
subsequently of transmitting the virus to the next generation. 
Under natural conditions therefore, there is a 
sophisticated equilibrium between the virus and its host that 
prevents the occurrence of disease. Nearly all the birds are 
infected and the infection can be perpetuated with a small 
number of infected birds, without exogenous introduction of 
wild virus. 
Xmmune_çgntrgl._gf _re-excretigni 
Primary infection of pigeons with a pathogenic strain of 
PHV 1 (Vindevogel et al-, 1982) prevents recurrence of the 
disease after re-infection. The protection is sufficient to 
inhibit viral multiplication in some birds. Both attenuated and 
oi1-adjuvanted inactivated vaccines have been developed and are 
effective in reducing primary viral excretion and symptoms 
after challenge (Vindevogel et al., 1982a and b ) . Nevertheless 
neither vaccine was able to prevent the appearance of carriers 
since most of the pigeons subsequently re-excreted virus after 
Cy treatment. However vaccination helps to prevent spontaneous 
viral re-excretion and therefore helps to control viral 
dissemination. If animals are vaccinated with an inactivated 
vaccine after challenge with a virulent strain, experimental 
re-excretion is also reduced. 
Nevertheless, vaccination is not the complete answer for 
the control of PHV infection, since young pigeons are often 
infected shortly after hatching and vaccination does not 
prevent the development of a carrier state or subsequent 
episodes of re-excretion. 
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DISCUSSION. 
These animal-herpesvirus systems demonstrate the 
phenomenon of latency in the natural host. In each system, 
well—defined re—excretion episodes may be provoked by means of 
artificial stimuli such as corticosteroid or cyclophosphamide. 
In addition, re-excretion episodes may also be stimulated by 
means of natural stresses such as reproduction or a change of 
housing. 
There are several advantages to using natural host—virus 
systems to study the phenomenon of herpesvirus latency. 
Firstly, since virus and host probably evolved together over a 
considerable period, the biological and epidemiological 
significance of spontaneous and natural shedding episodes may 
be assessed. In addition, observations on the mechanism of 
establishing, maintaining reactivating, and controlling latency 
are probably more valid since they also relate to a naturally 
evolved relationship. In contrast, laboratory models such as 
the mouse—HSV system are easier and cheaper to maintain and are 
better defined genetically and immunologically. 
To be a successful parasite, a virus needs to be able to 
ensure its transmission to as many animals as possible in each 
generation. Herpesviruses are in general relatively fragile 
outside their host, and therefore they cannot rely on external 
survival for their long—term persistence. In general, they have 
no reservoir or alternative hosts. Transmission by direct 
contact spread from acutely infected to susceptible animals 
certainly occurs, but requires a sufficient number of 
susceptible animals in the population and sufficient 
opportunities for contact between them or the virus will die 
out. Herpesviruses have there evolved the highly successful 
method of perpetuating themselves in a population by means of 
latently-infected carriers. Such carriers are only of 
biological significance, however, if shedding episodes coincide 
with the presence of susceptible individuals in close enough 
contact for transmission to occur. 
In a population where the disease is endemic, the time 
when this is most likely to occur is just before or during 
weaning when the parent and young are still in very close 
contact but the young have become susceptible to the virus due 
to the waning of passive antibody. 
Studies on the cat and pigeons have shown however that the 
timing of the shedding episode during this post—partum period 
is crucial. If it is too soon, only transient infection will 
occur and the offspring might not themselves become carriers. 
If it is too late, i.e. when maternal antibody has completely 
waned, then the clinical disease may be too severe and the 
host's survival compromised. Ideally the shedding, episode 
should occur whilst the offspring are still protected from 
clinical disease, but not from virus shedding and the 
subsequent development of a latent carrier state. In the pigeon 
particularly, but to a lesser extent also in the cat, such a 
balanced virus-host relationship does occur, ensuring survival 
of the virus in as many animals as possible in the next 
generation, so that the cycle is complete. Indeed it may be 
that even in the cat, under more natural conditions, shedding 
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may occur in more animals during the post-partum period than 
was apparent from these studies: the cats used in this work had 
previously been induced to shed artificially on a number of 
occasions, and this may have induced a relative "refractory 
period", making them less likely to shed after parturition. 
In a herd or family group, where the young are of similar 
age and are in reasonably close contact, not all the parents 
need to re-excrete to ensure virus transmission to all the 
offspring. Once one clinical case has occurred, virus 
dissemination will be greatly increased. Nevertheless, such a 
system, which tends to be seen particularly in cat colonies, is 
not ideal, since the timing of shedding in relation to the 
presence or absence of maternal antibody may be less than 
perfect. Severe clinical disease may then ensue and mortality 
and chronic sequelae may be significant, thus jeopardizing the 
host's and therefore the virus's survival into the next 
generation. 
Another useful tool for the virus epidemiologically is the 
increased likelihood of shedding after a change in living 
conditions, a situation which has been demonstrated 
particularly in cats. Thus if an animal is driven from its 
territory or family group, then it is likely to re-excrete 
virus in its new surroundings and may therefore infect another 
population. By this means the virus has a mechanism for 
increasing its chances of horizontal spread. 
In conclusion, observations on natural host-virus systems 
may tell us more about the biological significance of latency, 
and indeed, more about the host-virus relationship in general. 
Perhaps if most natural infections occur in young animals when 
they are losing their passive immunity, this should be the age 
at which both the mechanisms for establishing and controlling 
latency should be examined. It should be interesting to compare 
the frequency of recrudescent disease in people or animals that 
have experienced asymptomatic primary infection at an early age 
under cover of passive immunity, with those who experienced 
later symptomatic infections. Finally perhaps hormone 
influences on re-excretion rates and recrudescent disease 
should be examined in more detail. 
REFERENCES. 
AGUILAR-SETIEN Α., PASTORET P.-P., TOMA Β., JOUBERT L., MICHAUX 
C. and SCHOENAERS F. (1979a). 
Réponse immunitaire de type anamnestique envers le virus de 
la rhinotrachéite infectieuse bovine (Bgvi_d_hergesvi_rus_ 1 ) 
chez des bovins, après exposition à des antigènes du virus 
de la maladie d'Aujeszky (Sus_hergesyirus_l.) . 
Ann. Méd. Vét., 123, 429-434. 
- 34 -
AGUILAR-SETΙΕΝ Α., VANDEPUTTE J., PASTORET P.-P., MICHAUX C., 
PENSAERT M.B. and SCHOENAERS F. (1979b). 
Présence concomitante chez les bovins et les porcs 
d'anticorps neutralisant le virus de la rhinotrachéite 
infectieuse bovine (Bgvi_d_hergesvi_rus_ 1, BHV 1) et celui de 
la maladie d'Aujeszky (Sus her ges v i_rus_l, SHV 1), après 
contact avec le virus homologue. 
Ann. Méd. Vét-, 123, 275-2B4. 
BITTLE J.L. and PECKHAM J.C. (1971). 
Comments: genital infection induced by feline viral 
rhinotracheitis virus and effects on newborn kittens. 
J. Am. vet. Med. Ass., 158, 927-928. 
BITTLE J.L. and RUBIC W.J. (1975). 
Immunogenic and protective effects of 
feline viral rhinotracheitis virus. 
Am. J. Vet. Res-, 36, 89-91. 
the F2 strain of 
BITTLE J.L., YORK C.J., NEWBERNE J.W. and MARTIN M. (1960). 
Serologic relationship of new feline cytopathogenic 
viruses. 
Am. J. Vet. Res., 21, 547-550. 
BLYTH W.A. and HILL T.J. (1984). 
Establishment, maintenance and control of herpes simplex 
virus (HSV) latency. In: Immunobiology of herpes simplex 
virus infection. Eds. Rouse B.T. and Lopez C. 
C.R.C. Press Inc., Florida, pp 9-32. 
BLYTH W.A., HILL T.J., FIELD H.J. 
Reactivation of herpes 
ultraviolet light and 
prostaglandins. 
J. gen. Virol., 33, 547-549. 
and HARBOUR D.A. (1976). 
simplex virus infection by 
possible involvement of 
BOYLE D.B. and BINNINGTON J.A. (1973). 
Isolation of a herpesvirus from a pigeon. 
Austr. Vet. J., 4?, 54. 
COCKER F., GASKELL R.M., NEWBY T.J., GASKELL C.J., STOKES C. 
and BOURNE F.J. (1984). 
Efficacy of early (48 and 96 hr) protection against feline 
viral rhinotracheitis following intranasal vaccination with 
a temperature sensitive mutant. 
Vet. R e e , 114, 353-354. 
CORNWELL H.J.C, and WRIGHT N.G. (1970) 
Herpesvirus infection of pigeons, 
isolation. 
J. Comp. Path., 80, 221-227. 
Pathology and virus 
CRANDELL R.A. (1971). 
Virologie and immunologic aspects of 
rhinotracheitis virus. 
J. Am. vet. Med. Ass., 158, 922-926. 
fel ine viral 
35 
CRANDELL R.A. (1973). 
Feline viral rhinotracheitis (FVR). 
Adv. vet. Sci. comp. Med., 17, 201­224. 
CRANDELL R.A., GANAWAY J.R., NIEMANN W.H. and MAURER F.D. 
(1960). 
Comparative study of three isolates with the original 
feline viral rhinotracheitis virus. 
Am. J. vet. Res­, 21, 504­506. 
CRANDELL R.A., REHKEMPER J.Α., NIEMANN W.H., GANAWAY J.R. and 
MAURER F.D. (1961). 
Experimental feline viral rhinotracheitis. 
J. Am. vet. Med. Ass., 138, 191­196. 
DAVIS E.V. and BECKENHAUER W.H. (1976). 
Studies on the safety and efficacy of an intranasal feline 
rhinotracheitis — cal ici virus vaccine. 
Vet. Med. small Anim. Clin., 71, 1405­1410. 
DONALDSON A.I. and FERRIS N.P. (1976). 
The survival of some ail—borne animal viruses in relation 
to relative humidity. 
Vet. Microbiol., 1, 413­420. 
ELLIS T.M. (1981). 
Feline respiratory virus carriers in clinically healthy 
cats. 
Austr. Vet. J., 57, 115­118. 
ELLIS T.M. (1982). 
Feline viral rhinotracheitis: expiant and cocui ti vati on 
studies on tissues collected from persistently infected 
cats. 
Res. Vet. Sci., 33, 270­274. 
GASKELL R.M. (1975). 
Studies on feline viral rhinotracheitis with particular 
reference to the carrier state. 
PhD. Thesis, University of Bristol. 
GASKELL R.M. (1981). 
A assessment of the use of feline respiratory virus 
vaccines. 
¿n: Veterinary Annual, 21st issue (C.S.G. Grunsell and 
F.W.G. Hill, editors), Wright­Scientech­nica, Bristol, pp. 
267­274. 
GASKELL R.M., DENNIS P.E., GODDARD L.E., COCKER F.M. and WILLS 
J.M. (1985). 
Isolation of felid herpesvirus 1 from the trigeminal 
ganglia of latently infected cats. 
J. gen. Virol. 66, 391­394. 
­ 36 
GASKELL R.M. and GODDARD L.E. (1984). 
The epizootiology of feline virai rhinotracheitis with 
particular reference to the nature and role of the carrier 
state. 
I_n: Latent Herpesvirus Infections in Veterinary Medicine. 
Eds. G. Wittmann, R.M. Gaskell, H.J. Rziha. Martinus 
Nijhoff Publishers, The Hague, pp. 337-349. 
GASKELL R. M. and POVEY R.C. (1973). 
Re-excretion of feline viral rhinotracheitis virus 
following corticosteroid treatment. 
Vet. R e e , 93, 204-205. 
GASKELL R.M. and POVEY R.C. (1977). 
Experimental induction of feline viral rhinotracheitis 
virus re-excretion in FVR-recovered cats. 
Vet. R e e , 100, 128-133. 
GASKELL R.M. and POVEY R.C. (1979a). 
Feline viral rhinotracheitis sites of virus replication and 
persistence in acutely and persistently infected cats. 
Res. Vet. Sci., 27, 167-174. 
GASKELL R.M. and POVEY R.C. (1979b). 
The dose response of cats to experimental infection with 
feline viral rhinotracheitis virus. 
J. Comp. Path., 89, 179-191. 
GASKELL R.M. and POVEY R.C. (1982). 
The transmission of feline viral rhinotracheitis. 
Vet. R e e , 111, 359-362. 
GASKELL R.M. and WARDLEY R.C. (197B). 
Feline viral respiratory disease: a review with particular 
reference to its epizootiology and control. 
J. small Anim. Pract., 19, 1-16. 
GODDARD L.E. (1984). 
PhD Thesis, University of Bristol. 
HEFFELS V., TRITZSCHE K., KALETA E.F. and NEUMANN V. (1981). 
Serologische Untersuchungen zum Nachweis virus bedingter 
Infektionen bei der Taube in der Bundesrepublik 
Deutschland. 
Dtsch. Tierärztl. Wschr., 88, 97-102. 
HERMANN S., GASKELL R.M., EHLERS B. and LUDWIG H. (1984). 
Characterisation of the herpesvirus genome and molecular 
epidemiology of isolates from natural outbreaks and latent 
infections. 
¿n: Latent Herpesvirus Infections in Veterinary Medicine. 
Eds. G. Wittmann, R.M. Gaskell, H.J. Rziha. Martinus 
Nijhoff Publishers, The Hague, pp. 321-336. 
37 
HILL T.J., BLYTH W.A. and HARBOUR D.Α. (1978). 
Trauma to the skin causes recurrence of herpes simplex in 
the mouse. 
J. gen. Virol., 39, 21­28. 
HOOVER E.A. and GRIESEMER R.A. (1971). 
Experimental feline herpesvirus infection in the pregnant 
cat. 
Am. J. Path., 65, 173­1BB. 
JOHNSON R.H. and THOMAS R.G. (1966). 
Feline viral rhinotracheitis in Britain. 
Vet. R e e , 7?, 188­190. 
KAHN D.A. and HOOVER E.A. (1976). 
Infectious respiratory diseases of cats. 
Vet. Clins. Ν. America, 6(3), 399­413. 
KURATA T., KURTATA K. and ΑΟΥAMA Y. (1978). 
Reactivation of herpes simplex virus (type 2) infection in 
trigeminal ganglia and oral lips with cyclophosphamide 
treatment. 
Jap. J. exp. Med., 48, 427­435. 
LANDRE F., VINDEVOGEL H., PASTORET P.­P., SCHWERS Α., THIRY E. 
and ESPINASSE J. (1982). 
Fréquence de l'infection du pigeon par le Pi_9ggQ 
Ü6Cggsyirus_l. et le virus de la maladie de Newcastle dans 
le Nord de la France. 
R e e Méd. Vét., 158, 523­528. 
MARE C. and GRAHAM D.L. (1973). 
Falcon herpesvirus, the etiologic agent of inclusion 
disease of falcons. 
Infect. Immun., 8, 118­126. 
body 
McFERRAN J.B., McCRACKEN R.M. and DOW C. (1984). 
The role of the carrier pig in the epidemiology of 
Aujeszky's disease. 
in: Latent Herpesvirus Infections in Veterinary Medicine. 
Eds. G. Wittmann, R.M. Gaskell, H.J. Rziha. Martinus 
Nijhoff Publishers, The Hague, pp. 403­415. 
OPENSHAW H. (1984). 
A review of HSV latency in experimental animals. 
In: Latent Herpesvirus Infections in Veterinary Medicine. 
Eds. G. Wittmann, R.M. Gaskell, H.J. Rziha. Martinus 
Nijhoff Publishers, The Hague, pp. 33—39. 
ORR C M . , GASKELL C.J. and GASKELL R.M. (1978). 
Interaction of a combined feline viral rhinotracheitis ­
feline calicivirus vaccine and the FVR carrier state. 
Vet. R e e , 103, 200­202. 
­ 38 ­
ORR C.M., GASKELL C.J. and GASKELL R.M. (1980). 
Interaction of an intranasal combined feline viral 
rhinotracheitis, feline calicivirus vaccine and the FVR 
carrier state. 
Vet. R e e , 106, 164-166. 
PLUMMER G. (1973). 
Isolation of herpesviruses from trigeminal ganglia of man, 
monkeys and cats. 
J. Infect. Dis., 128, 345-348. 
POVEY R.C. (1979). 
A review of feline viral rhinotracheitis (feline 
herpesvirus 1 infection). 
Comp. Immun. Microbiol, infect. Dis., 2, 373-3B7. 
POVEY R.C. and JOHNSON R.H. (1967). 
Further observations on feline viral rhinotracheitis. 
Vet. R e e , 81, 686-689. 
POVEY R.C. and JOHNSON R.H. (1970). 
Observations on the epidemiology and control of viral 
respiratory disease in cats. 
J. small Anim. Pract., 11, 485-494. 
POVEY R.C. and JOHNSON R.H. (1971). 
A survey of feline viral rhinotracheitis and feline 
Picornavirus infection in Britain. 
J. small Anim. Pract-, 12, 233-247. 
PURCHASE H.G., MARE C.J. and BURMESTER B.R. (1972). 
Antigenic comparison of avian and mammalian herpesviruses 
and protection tests against Marek's disease. 
Proc. 76th ann. Meet. U.S. Anim. Health Assoc, 4B4-492. 
ROIZMAN B. (1965). 
An inquiry into the mechanisms of recurrent herpes 
infections in man. 
I_n: Perspectives in Virology. Ed. M. Pollard. Harper and 
Row, New York. pp. 283-301. 
SCOTT F.W. (1980). 
Virucidal disinfectants and feline viruses. 
Am. J. vet. Res., 41, 410-414. 
SEKIZAWA T., 0PENSHAW H., WOHLENBERG C. and N0TKINS A.L. 
(1980). 
Latency of herpes simplex virus in absence of neutralising 
antibody: model for reactivation. 
Science, 210, 1026-1028. 
SHEFFY B.E. and DAVIES D.H. (1972). 
Reactivation of a bovine herpes virus after corticosteroid 
treatment. 
Proc. s o e exp. Biol. Med., 140, 974-976. 
- 39 -
SLATER E. and YORK C. (1976). 
Comparative studies on parenteral and intranasal 
inoculation of an attenuated feline herpesvirus. 
Devel. biol. Stand., 33, 410­416. 
STUDDERT M.J. and MARTIN M.C. (1970). 
Virus diseases of the respiratory tract of cats. I. 
Isolation of feline rhinotracheitis virus. 
Austr. vet. J., 46, 99­105. 
UNDERWOOD G.E. and WEED S.D. (1974). 
Recurrent cutaneous herpes simplex in hairless mice. 
Infect. Immun., ÌQ, 471­474. 
VINDEVOGEL H., AGUILAR­SETIEN Α., DAGENAIS L. and PASTORET 
P.­P. (1980a). 
Diagnostic de l'infection herpétique du pigeon. 
Ann. Méd. Vét., 124, 407­418. 
VINDEVOGEL H., DEBRUYNE H. and PASTORET P.­P. (1985) 
Observation of Pigegn_hergesyirus_¿ re—excretion during the 
reproduction period in conventionally reared homing 
pigeons. 
J. Comp. Path., 95, 105­112. 
VINDEVOGEL H. and DUCHATEL J.P. (1977). 
Réceptivité de la perruche au virus herpes du pigeon. 
Ann. Méd. Vét., 121, 193­195. 
VINDEVOGEL H. and DUCHATEL J.P. (1978). 
Contribution à l'étude de l'étiologie du coryza infectieux 
du pigeon. 
Ann. Méd. Vét., 122, 507­513. 
VINDEVOGEL H­, DUCHATEL J.P. and BURT0NB0Y G. (1978). 
Infection herpétique de psittacidés. 
Ann. Méd. Vét., 122, 167­169. 
VINDEVOGEL H­, KAECKENBEECK A. and PASTORET P.­P. (19B1). 
Fréquence de 1'orni those—psittacose et de l'infection 
herpétique chez le pigeon voyageur et les psittacidés en 
Belgi que. 
Rev. Méd. Liège, 36, 693­696. 
VINDEVOGEL H. and PASTORET P.­P. (1980). 
Pigeon herpes infection: natural transmission of the 
disease. 
J. Comp. Path., 90, 409­413. 
VINDEVOGEL H. and PASTORET P.­P. (1981). 
Pathogenesis of pigeon herpesvirus infection. 
J. Comp. Path., 91, 415­426. 
40 
VINDEVOGEL H., PASTORET P.-P. and BURTONBOY G. (19B0b). 
Pigeon herpes infection: excretion and re-excretion of 
virus after experimental infection. 
J. Comp. Path., 90, 401-408. 
VINDEVOGEL H., PASTORET P.-P., BURTONBOY G., GOUFFAUX M. and 
DUCHATEL J.P. (1975). 
Isolement d'un virus herpes dans un élevage de pigeons de 
chair. 
Ann. Rech. Vét., 6, 431-436. 
VINDEVOGEL H., PASTORET P.-P. and LEROY P. (1982a). 
Vaccination trials against pigeon herpesvirus infection 
'EiâëSQ—tiÊCEëSY.iey§_!' -
J. Comp. Path., 92, 483-494. 
VINDEVOGEL H., PASTORET P.-P. and LEROY P. (1982b). 
Comportement d'une souche atténuée du P_igegn_hergesyirus_l 
et de souches pathogènes lors d'infections successives chez 
le pigeon. 
Ann. Rech. Vét. 13, 143-148. 
VINDEVOGEL H., PASTORET P.-P., LEROY P. and COIGNOUL F. (19B0c) 
Comparaison de trois souches de virus herpétique isolées de 
psittacidés avec le virus herpes du pigeon. 
Av. Path., 9, 385-394. 
VINDEVOGEL H-, PASTORET P.-P. and THIRY E. (1984). 
Latency of Pi.gegn_hergesyirus_l. 
Jn: Latent Herpesvirus Infections in Veterinary Medicine. 
Eds. G. Wittmann, R.M. Gaskell, H.J. Rziha. Martinus 
Nijhoff Publishers, The Hague, pp. 489-499. 
WALTON T.E. and GILLESPIE J.H. (1970). 
Feline viruses VII. Immunity to the feline herpesvirus in 
kittens inoculated experimentally by the aerosol method. 
Cornell Vet., 60, 232-239. 
WARDLEY R . C , GASKELL R.M. and POVEY R.C. (1974). 
Feline respiratory viruses: their prevalence in clinically 
healthy cats. 
J. small Anim. Pract., 15, 579-586. 
Wittmann G., RZIHA H.-J. and DOLLER P.C. (1982). 
Occurrence of clinical Aujeszky's disease in 
immunosuppressed latently infected pigs. 
I_n: Aujeszky's disease. Eds. G. Wittmann and S.A. Hall. 
Martinus Nijhoff Publishers, The Hague, pp. 211-214. 
41-

GENETIC RESISTANCE TO HERPES SIMPLEX VIRUS-1 
INFECTIONS AND THE IMMUNE SYSTEM 
Yechiel Becker and Tamir Ben-Hur 
Department of Molecular Virology 
Faculty of Medicine 
The Hebrew University 
Jerusalem, Israel 
ABSTRACT 
C57BL/6 mice are genetically resistant to infection with herpes simplex 
virus type 1 (Lopez, 1975). Mice of this strain eliminate the infecting 
virus from the liver and spleen after intraperitoneal infection. Mice of 
genetically sensitive strains die of the infection. The genetically re­
sistant C57BL/6 mice do not develop a herpesvirus infection when the herpes 
simplex virus-1 is inoculated into the nose and eyes and, at low virus 
doses, also intracerebrally. We suggest that the cell system involved in 
the protection of the C57BL/6 mice against the virulent virus is the 
reticuloendothelial system (RES: Kupffer cells in the liver, dendritic cells 
in the spleen, Langerhans cells in the skin, etc.). These cells are pro­
duced in the bone marrow and migrate to different organs to become specific 
organ-associated macrophages. It is hypothesized that in the genetically 
resistant C57BL/6 mice, the two genes which confer genetic resistance are 
involved in the elimination of the virus. The RES is involved in the 
presentation of antigens to the lymphocytes of the immune system, and thus 
control part of the immune response. Destruction of the RES by a 
herpesvirus might lead to an incomplete immune response. 
In a review of genetic determinants of virus susceptibility, it was 
stated by Brinton and Nathanson (1981) that 
"In focusing on host genetics, it is important to keep in mind that 
the severity of disease is the result of the interaction between 
host resistance genes, virus virulence genes, and host defense systems. 
Both host and viral genes play an important role in maintaining a 
balance which ensures the continued survival of the host and the virus 
under natural conditions"(p. 116, M.A. Brinton and N. Nathanson. 
Genetic determinants of virus susceptibility: epidemiologic implica­
tions of murine models. Epidemiologic Reviews 3^ :115-139, 1981.) 
Herpesviruses which have been isolated from many vertebrate hosts 
follow the balance indicated above, ensuring a virus-host interaction which 
allows survival of the host and virus in most instances. Herpes simplex 
virus (HSV) type 1 infections in humans are rarely fatal, but the virus 
becomes latent in the nervous tissues. Even when the virus is reactivated 
- 43 
it moves with the axonal flow in the neuron in which it is reactivated in 
the direction of the skin, and not in the direction of the central nervous 
system (CNS). Nevertheless, damage to the immune system as a result of a 
genetic disorder or immune suppression by drugs, leads to the uncontrolled 
spread of the virus and to a lethal generalized HSV-1 infection (Nahmias 
et al., 1981). Thus, the balance between a localized HSV-1 infection and 
a disseminated one is dependent on the immune system which is involved in 
the control of the incoming virulent virus. Regarding Epstein-Barr virus 
(EBV), another human herpesvirus pathogen, individuals respond differently 
to infection: a) most individuals are infected during childhood and develop 
a positive immune response; b) seronegative young adults develop infectious 
mononucleosis (IM), resulting in proliferation of Τ cells; and c) in 
certain populations, the virus leads to the development of Burkitt's 
lymphoma (BL) (e.g. Africans in Uganda) and nasopharyngeal carcinoma (NPC) 
(e.g. Chinese in south China, and North Africans). In all EBV-infected 
individuals with IM, BL and NPC, antibodies to viral antigens and enzymes 
are produced by the immune system. Nevertheless, the virus is capable of 
exerting its ill effects on only a few individuals in the EBV-infected 
populations. 
Another known possibility is the transfer of a herpesvirus from a host 
which is resistant to the virus to a highly sensitive host. A good example 
is monkey Β virus, which does not harm the monkey host but is highly 
pathogenic for humans. This example indicates that a herpesvirus infecting 
a sensitive host might have the ability to abrogate the immune defense 
system and, in its absence, the infected host is unable to defend itself. 
Also, injection of EBV into owl monkeys leads to the development of lymphomas, 
suggesting that this monkey is defenseless against this herpesvirus. 
Studies on the sensitivity of various laboratory mouse strains to 
viruses (reviewed by Brinton and Nathanson, 1981) revealed differences in 
their sensitivity to viruses. The inbred strain of black mice (designated 
C67BL/6) is resistant to infection with many viruses: a) to picornaviruses 
which cause diabetes in a sensitive mouse strain SWRJ (Onodera et al., 1978); 
b) to murine leukemia virus (Lilly, 1970; Axelrod and Steeves, 1964; Blank 
et al., 1976); c) to Friend leukemia virus (recovery from splenomegaly), 
while mouse strain Balb/c is highly sensitive (Doig and Chesebro, 1979); 
d) to polyoma virus which causes tumors and runting in the AKR mouse strain 
(Chang and Hildemann, 1964); e) to ectromelia (mousepox) which infects CBA 
mice (Myers et al., 1954); and f) to herpes simplex virus type 1 which 
- 44 
causes encephalitis in many other mouse strains (Lopez, 1975). 
The studies on the genetic resistance of C57BL mice to HSV were re­
viewed by Lopez (1981). Intraperitoneal (i.p.) injection of virulent HSV-1 
into C57BL/6 mice resulted in the disappearance of the virus, namely, the 
host was able to overcome the infecting virus (Lopez, 1975; Kirchner et al., 
1978). This phenomenon was quantitated by Lopez et al. (1980), who reported 
that after i.p. injection of HSV-1 into C57BL/6 mice, the virus was found 
in the liver and spleen at day 1 after infection. At days 3 and 5, no 
virus was detected in livers and spleens of the infected mice. A signifi­
cant further finding reported by Lopez et al. (1980) was the observation 
that when BDF1 mice, which are a cross between C57BL/6 mice and DBA/2 mice, 
were treated with the bone marrow-seeking radionuclide "'Strontium (°"Sr), 
the invading virus was present in the liver and spleen at 1, 3 and 5 days 
post-infection. The virus invaded the spinal cord and the CNS, and the 
mice died of viral encephalitis, whereas nonirradiated mice overcame the 
virus infection. These studies led Lopez et al. (1980) to suggest that 
bone marrow-derived natural killer cells are involved in the ability of 
genetically resistant mice to overcome the virus infection. Kirchner et al. 
(1982) maintain that endogenously produced interferon plays a critical role 
in the genetic resistance to HSV-1 infection in the mouse, and not natural 
killer cells. 
Another cell type that might be involved in genetic resistance is 
marrow-dependent macrophages (Stevens and Cook, 1971). Lopez and Dudas 
(1979) reported that peritoneal macrophages from C57BL/6 mice restrict HSV-1 
replication significantly better than macrophages from susceptible mice. 
However, this function is not directly related to resistance, since macro­
phages from resistant F± mice failed to restrict HSV-1 replication. 
Studies by Lopez (1980) on progeny of the F-2 cross using C57BL/6 χ 
A/J (susceptible) F^ mice suggested that two major loci were responsible for 
resistance. Studies with congenie mice showed that genes within the H-2 
locus did not influence resistance or susceptibility to HSV-1. 
Resistance and sensitivity of mouse strains to HSV-1 
The ability of C57BL/6 mice to restrict HSV-1 infection and the 
mechanism of genetic resistance was studied in our laboratory, with special 
attention to the response of C57BL/6 mice to HSV-1 infection in the nose, 
eyes and CNS. 
Various strains of mice were injected i.p. and intracerebrally (i.e.) 
with HSV-1 (TK+ large plaque NIH strain,isolated in our laboratory; Gordon 
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et al., 1983; Ben-Hur et ài., 1983). Table 1 shows that two of the three 
mouse strains (Sabra and AKR) were highly sensitive, whereas C57BL/6 was 
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a Virus titer (pfu/mouse) leading to death of 50% of the infected mice 
b Total body irradiation of mice 
c Not done 
The same was true when the virus was injected i.e.. Whole body radiation 
(500 rad) resulted in the abrogation of the resistance of C57BL/6 mice to 
HSV-1. Also, C57BL/6 mice younger than four weeks were found to be sen­
sitive to HSV-1 infection. This suggests that "genetic resistance" to HSV-1 
gradually develops during the first four weeks of the mouse life cycle in 
parallel to the development of the immune system. 
Further studies revealed that C57BL/6 mice are resistant to HSV-1 
infection in the nose. This mode of infection enables the virus to pene­
trate the olfactory bulb and migrate to the CNS (Fig. 1). Infection of 
C57BL/6 mice by inoculation of the virus onto the cornea resulted in the 
appearance of the virus in the trigeminal ganglion on day 5 and disappear­
ance of the virus from the ganglia afterwards (T. Ben-Hur and Y. Becker, 
to be published). 
These results have confirmed and extended the studies by Lopez (1975, 
1981) and indicate that the genetic resistance of the C57BL/6 mouse is ex­
pressed not only in the liver and spleen, but also in the eyes, trigeminal 
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Fig. 1 Routes of infection by herpes simplex virus type 1 in the 
mouse. The virus isolates from an N.I.H. strain in our laboratory 
differ in their thymidine kinase (TK) activity and their virulence 
for mice: TK+, active TK gene; TKij, 25% of the TK activity of the TK+ 
strain; TK­, no TK activity (Gordon et al., 1983; Ben­Hur et al.,1983). 
ganglia and CNS. 
Nature of the cell system which miRht be involved in genetic resistance 
Lopez (1981), in discussing the cells which might be involved in the 
genetic resistance to HSV­1 favored the possibility of natural killer cell 
involvement in the restriction of HSV­1 infection, although the role of 
macrophages was also mentioned. The cell system which we favor as having 
a major role in the genetic resistance to HSV­1 is the reticuloendothelial 
system of tissue­specific macrophages that are of bone marrow origin and 
express the la antigen (mouse immune response gene­associated antigen) on 
the cell surface. These cells in the C57BL/6 mouse interact with the in­
vading viruses and, due to their resistance genes, they are able to restrict 
virus replication. These cells also present the foreign (viral) antigens 
to lymphocytes of the immune system which eventually produce specific 
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Table 2. Possible role of tissue-specific reticuloendothelial cells (in liver 
and spleen) in the prevention of herpes simplex virus-1 infection in 
genetically resistant mice 
co 
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(LD50 = 1 pfu) 
Cell types: Members of the reticuloendothelial system which are antiqen presenting 
cells expressing Ia antigen on their cell surface and originate in the bone marrow. 
From C. Lopez, R. Ryshke and M. Bennett, Infection and Immunity 28:1028-1032, 1980. 
immunoglobulins (Schwartz et al., 1978). 
We would like to suggest that Kupffer cells in the liver (Berzofsky 
et al., 1979), Langerhans cells in the skin (Stingi et al., 1978).dendritic 
cells in the spleen (Steinman and Cohen, 1973), and microglea cells in the 
CNS which are of bone marrow origin (Ting et al., 1983) might be involved 
in the defence mechanism (genetic resistance) against HSV­1. Table 2 pre­
sents the hypothesis that reticuloendothelial cells might be involved in 
the genetic resistance to HSV­1. Namely, it is suggested that the two 
genes involved in the genetic resistance are expressed in the macrophages 
of the reticuloendothelial system, and the gene products enhance the 
ability of the Kupffer and dendritic cells to destroy land eliminate the 
virus. This might be the explanation for the results reported by Lopez et 
al. (1975). Kupffer and dendritic cells most probably present the viral 
antigens to the Τ and Β lymphocytes, respectively, for antibody induction. 
Viral antigens associated with such macrophages are far more immunogenic 
than free viral antigens. Thus, Kupffer and dendritic cells most probably 
are able to destroy the infecting virus and are efficient in stimulating 
the immune response. 
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Our present understanding of local immune systems has developed largely 
out of the discovery of IgA (Heremans et al 1959) and the subsequent obser­
vations that it was the predominant immunoglobulin in milk and other exocrine 
secretions (Hanson, 1961; Tornasi et al 1965). These findings formed the 
basis of tne concept of a local immune system mediated by IgA antibody which 
is stimulated by, and which controls events at mucosal surfaces. These ideas 
were strengthened by the discovery that precursor IgA lymphoblasts show 
distinct migratory pathways that are relatively independent of the spleen and 
peripheral lymph nodes (for review see Bienenstock & Befus, 1980). Further 
support for this concept came from the observations of Bienenstock (1974) who 
showed that similar lymphoid follicles could be found at different mucosal 
surfaces and that lymphoblasts isolated from them showed similar homing 
characteristics (Rudzik et al 1975). Although the precise nature of a common 
mucosal immune system has been questioned (Spencer & Hill 1984) there is no 
doubt of the independence of immune mechanisms that operate at mucosal sur­
faces as opposed to those found systemically. 
In general herpesviruses are presented at the mucosal surfaces of the 
respiratory and reproductive tracts. It is therefore appropriate to review 
the immune mechanisms that operate at these sites in an attempt to under­
stand how they might be stimulated to afford protection, 
a) RESPIRATORY TRACT 
Defence mechanisms that operate in the lung are like others, multi­
factorial involving both non-specific and specific acquired elements. In the 
former category one can list anatomical disposition within the respiratory 
tract as results from the anatomy of the tract, the mucociliary apparatus, 
non-specific cellular mechanisms and humoral factors such as lysozymes, 
lactoferrin,surfactants, "normal flora", complement and interferon. Whilst 
a number of these are of no significance against viruses others do provide a 
first line of defence. 
Immunoglobulins, G, A, M and E have all been detected in respiratory 
fluids. Dimeric locally synthesised and secretory IgA, predominates most 
dramatically in the upper tract. Although a number of effector functions 
have been ascribed to IgA including viral neutralization (Ogra et al 1968) 
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opsonic activity (Reynolds et al 1975) antibody dependant cell mediated cyto­
toxicity (Lowell et al 1980) (for review see McDermott et al 1982), it has 
also been suggested that its principal role is anti-inflammatory, preventing 
immunogenic material from either being absorbed across mucosal membranes 
(Stokes et al 1975) or from stimulating other immune mechanisms such as Chemo­
taxis (Van Epps et al 1976) and complement activation (Griffus & Bertram 1977) 
IgG also occurs at relatively high concentrations in pulmonary secre­
tions derived from both local production and serum transudation. The precise 
role of IgG in mucosal secretions is unclear, but in the lower respiratory 
tract where its levels relative to other immunoglobulins are highest, and 
approaches those found in serum (Kaltreider and Chan 1976) it may well have 
a similar virus neutralisation role to that ascribed for serum IgG. 
IgM is present at only low concentrations in respiratory secretions and 
little is known of its significance at this site except in IgA deficient 
individuals where it may take over (Baklier & Brandtzaeg 1976). Bronchio-
alveolar washings have also been shown to contain IgE (Deuschl & Johansson 
1974) but no significance has been attached to it with respect to viral 
immunity. The recent description of high levels of IgB in milk (Olson & 
Leslie 1982; Brandtzaeg 1983) would indicate that this immunoglobulin may 
also have a role in mucosal immunity, at present it remains undetermined. 
The airspaces within the bronchi, bronchioles and alveoli contain sig­
nificant free cell populations. In all species studied the predominant cell 
type isolated from bronchioalveolar washings of healthy lungs are macro -
phages which may comprise up to 95% of the total cell population recovered. 
Polymorphs and lymphocytes may also be present in significant numbers and in 
washing taken from infected lungs the former may take over as the predominant 
cell type. 
The alveolar macrophage is primarily bone marrow derived although there 
is evidence of local proliferation. Whilst their main activity is the non­
specific ingestion of particles in the lung, their phagocytic activity is 
markedly enhanced by the presence of specific antibody. Interestingly viral 
infection may interfere with this activity Jakab et al 1980). The relative 
importance of alveolar macrophages in the interaction and induction of sensi­
tised T-lymphocytes as opposed to those at other respiratory sites (i.e. 
BALT, draining lymph nodes, etc.) remains to be determined. 
Fractionation studies of lymphocytes from bronchioalveolar washings 
indicate T-cells are the major cell type although significant numbers of B-
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and null cells have been found. Of the B-cells, IgA is the predominant sur­
face immunoglobulin (Davis et al 1980), and most cells synthesised this 
immunoglobulin isotype. The T-cell population is heterogenous and includes 
both those capable of eliciting delayed type hypersensitivity reaction and 
specific cytotoxicity. Natural killer (NK) cell activity has also been 
reported within the free cell population in the lung. 
The cells found in bronchioalveolar washings are but a small portion of 
the lymphoid population associated with the lung, that includes the bronchus 
associated lymphoid tissue (BALT) and the palatine and nasopharyngeal tonsils. 
Detailed descriptions of the lymphoepithelium that overlie the lymphoid fol­
licles that together make up BALT have been provided (see McDermott et al 
1982). Functionally they have an important role in uptake of antigen taken 
into the lung, and its presentation to professional immune cells. By 
analogy with the gut associated lymphoid tissue it is likely that such presen­
tation leads to the generation of IgA (+ ? IgG) plasmacyte precursors and 
regulator T-cells, that can migrate and home to both the lung lamina propria 
and other mucosal sites. 
The tonsils are ideally placed and suited for trapping inhaled antigens, 
having an epithelium capable of absorbing antigen. Although theycontain 
both Τ and Β lymphocytes it is not clear how they are involved in immunity. 
Interestingly we have recently shown that following instillation of feline 
viral rhinotracheitis virus into the nose of cats, the virus may be detected 
in the tonsil, and that in immune animals although the virus can apparently 
get into the tonsil it is rapidly killed (Cocker et al 1984). 
b) REPRODUCTIVE TRACT (Female) 
Histologically the reproductive tract is a mucous membrane, however 
unlike the respiratory and gastrointestinal tract it is not exposed to the 
continuous antigenic challenge. Despite this the vagina does have a resident 
microflora although the uterus remains sterile. Like the other mucosal 
surfaces a number of non-specific defence mechanisms operate. These include 
the structure of the cervix, mucus and anti-microbial proteins. 
The immunoglobulins have been detected in the reproductive tract fluids 
of a number of species, although there is considerable variation'between 
species and with the different levels of the tract. In general though folli­
cular fluids tend to be dependent on serum and thus the immunoglobulins 
present reflect their serum concentrations and molecule size. Further down 
the tract in the uterus again IgG tends to predominate, but in a number of 
species this has been shown to be of local origin. Thus there would appear 
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to be a decrease in the dependence upon serum transudation the further the 
tract is descended (Widders et al 1984) in the cow (Corbeil et al 1976) IgA 
predominates in the vagina. 
The importance of cellular elements in the defence of the reproductive 
tract is less well defined. However both lymphocytes and polymorphs can be 
isolated in washings from the tract. 
THE IMMUNE RESPONSE TO LOCAL IMMUNISATION 
It is a generally accepted concept that local application of antigen is 
most effective in stimulating protective immune responses. For example intra­
nasal instillation of influenza virus resulted in ten times as much secretory 
antibody in nasal secretions as was produced following sub-cutaneous immuni­
sation (Fazekas de St. Groth et al 1950). 
Soluble antigens presented to the Bronchus associated lymphoid tissue may 
be taken up into the lymphoepithelium by pinosytosis (Tenner-Racz et al 1979) 
in a manner similar to that shown for M-cells of Peyer's patches (Owen,1977). 
Such antigen may then be transferred to the follicle where there is an abun­
dance of lymphocytes. The response elicited by dead antigens presented to 
mucosal surfaces is highly dose dependant, the greatest responses requiring 
very large doses of antigen (for review see Newby & Stokes 1984). Far 
greater responses may be achieved with the use of live organisms at doses 
sufficiently large to promote multiplication. Whilst early studies ques­
tioned whether secondary response could be elicited by mucosal stimulation, 
it is clear from studies in the gut that an anamnestic can be elicited 
(Andrew & Hall 1982). Iuterestingly there is evidence from influenza virus 
infections that the dose and frequencyof immunization influences whether a 
secondary response occurred (ShVartsman & Zykov, 1976). Further rabbits 
immunised with live Shigella produced a good secretory IgA antibody response 
on challenge 60 days later, whilst those fed the dead antigen showed no 
evidence of memory (Keren et alT9&2)-^_ 
A common feature of antigen presentation at mucosal surface is the 
development of hyporesponsiveness. It has been postulated that these 
mechanisms are important in preventing overreaction (allergy) to food 
antigens (for review see Newby & Stokes 1984). Such events are rarely 
induced to microbial antigens (Stokes et al 1979), but it has been shown that 
whilst oral immunisation of mice with living reovirus stimulates a strong 
delayed type hypersensitivity response whilst using the dead virus produces 
a specific immunologic tolerance to the viral antigens (Rubin et al 1981). 
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Respiratory infection with a variety of viruses produces a local secre­
tory antibody response that is primarily IgA; (Biandford S Heath, 1974) and 
its presence may indicate protection. Little data is available on the 
response to herpesviruses, but by analogy to studies with other viruses it is 
likely that whilst serum antibody may protect in the lower airways, locally 
produced antibody will be protective in the upper respiratory tract (Ramphal 
et al 1979; Biandford & Heath 1974). 
It is possible that cell mediated immune reactions may provide pro­
tection. Like humoral immunity, local CMI may best be stimulated by local 
application of antigen (Nash & Holle, 1973). The importance of cells in the 
respiratory tract has been emphasised by studies of calves infected with 
bovine herpes. Whilst the addition of blood lymphocytes with or without 
serum had a slight inhibition of viral replication (BHV-1) in bovine tissue 
culture cells, cells collected from bronchio-alveolar washings could markedly 
inhibit the virus (Bouffard et al 1982). Similarly nasal leukocytes taken 
from cattle vaccinated intranasally with temperature sensitive mutant IBR 
were able to protect from cytopathological changes whilst those that received 
the virus intramuscularly were not (Gerber et al 1977). The appearance of 
interferon in nasal secretions has also been associated with local immuni­
sation (Todd et al 1972) where its appearance it was suggested coincided 
with protection. 
That mucosal stimulation can be effective in generating protection 
from subsequent infection by a herpesvirus is thus established. For example 
oral vaccination with Herpes simplex type I can enhance the protection 
against intravaginal challenge with Herpes simplex type II (Sturn & 
Schneweis 1978). Whilst much has been written about how protection may be 
afforded systemically (Onions 1982; Rouse & Horoho» 1984) the mechanisms 
that operate against herpesviruses at mucosal surfaces remain unclear. Since 
both local humoral and cellular immune factors operate independently of 
systemic immunity it remains important to determine first how protection is 
afforded and secondly how best it may be stimulated. 
REFERENCES 
Andrew, E. & Hall, J.G. (1982) IgA antibodies in the bile of rats. II 
Evidence for immunological memory in secretory immunity. Immunol.45,177. 
Bienenstock, J. (1974) The physiology of the local immune system and the 
gastrointestinal tract. Prog. Immunol. II, 4, 197. 
Bienenstock, J. & Befus, A.D. (1980) Mucosal Immunity (Review) Immunol.41,249. 
Biandford, G. & Heath, R.B. (1974) Studies on the immune response and patho­
genesis of Sendac virus infection of mice II The immunoglobulin class 
of plasma cell in the bronchial sub-mucosa. Immunol. 26, 667. 
55 
Bouffard, Α., Derbyshire, J.B. S, Wilkie, B.N. (1982) Effect of lymphocytes 
and broncho-alveolar washing cells on the replication of bovine herpes­
virus type I in tracheal organ cultures. Vet. Microbiol. ]_, 241. 
Brandtzaeg, P. (1983) The Secretory Immune system of lactating human mammary 
glands compared with other exocrine organs. IN: The Secretory Immune 
System (J.R. McGhee & J. Mestecky, eds.) Ann. N.Y. Acad. Sei. 409, 353. 
Cocker, F. (1984) Studies on early protection against felid herpesvirus-1 
(FHV-1) following intranasal vaccination with live cold-adapted FHV-1 
strain. (In this Volume). 
Corbeil, L.B., Hall, C E . , Lein, D., Corbeil, R.R. & Duncan, J.D. (1976). 
Immunoglobulin classes in genital secretions of mycoplasma-infected 
and normal heifers. Infect. Immun. 13, 1595. 
Davis, J.K., Maddox, P.A., Thorp, R.B. & Cassei 1, G.H. (1980) Immuno-
fluorescent characterisation of lymphocytes in lungs of rats infected 
with Mycoplasma pulmonis. Infect. Immun. 2_7, 255. 
Deuschl, H. & Johansson, S.G.O. (1974) Immunoglobulin-Ε in I 
secretions. Clin. Exp. Immunol. 16, 401. 
Gerber, J.D., Marrow, A.E. & Kucera, C.J. (1977) Local and syste.. 
lar and antibody immune responses of cattle to infectious bovine 
tracheitis virus vaccines administered intranasally or intramusculari>. 
Am.J.Vet.Res. _39 753. 
Griffis, J.M. & Bertram, M.A. (1977) J. Infect. Dis. 136, 733. 
Fazekas de St. Groth, S. Donnelley, M. & Graham, D.M. (1951) Aust. J. Exp. 
Biol. Med. Sci. 29, 323. 
Hanson, L.A. (1961) Comparative immunological studies of the immune globu­
lins of human milk and of blood serum. Int. Arch. Allergy 18, 241. 
Heremans, J.F., Heremans, M.T. S, Schultze, H.E. (1958) Isolation-and des­
cription of a few properties of the £2A globulin of human secretions. 
Clin. Chim. Acta 4_, 96. 
Jakab, G.J., Warr, G.A. SSannes, P.C. (1980) Alveolar Macrophage ingestion 
and phagosome-lysosome fusion defect associated with virus pneumonia. 
Infect. Immun. 2]_, 960. 
Kaltreider, H.B. & Chan, M.K.C. (1976) The class specific immunoglobulin 
compositon of fluids obtained from various levels of the canine 
respiratory tract. J. Immunol. 116, 423. 
Keren, D.F., Kern ,S.E., Banes, D.H., Scott, P.J. & Porter, P. (1982) Direct 
demonstration in intestinal secretions of an IgA memory response to 
orally administered Shigella flexneri antigens. J. Immunol. 128 475. 
Lowell, G.H., Smith, L.F. , Griffiss, J.M. & Brandt, B.C. (1980) IgA"depen­
dant monocyte mediated anti-bacterial activity. J.Exp.Med. 152 452. 
McDermott, M.R., Befus, A.D. & bienenstock, J. (1982) The structural basis 
for immunity in the respiratory tract. Int. Rev. Exp. Path. 23, 47. 
Nash, D.R. & Holle, Β. (1973) Local & Systemic cellular immune responses in 
guinea pigs given antigen parenterally or directly into the lower 
respiratory tract. Clin. exp. Immunol. J_3_, 575. 
Newby, T.J. & Stokes, C R . (1984) Local Immune Responses of the Intestinal 
tract. CRC Press Inc. 
Ogra, P.L., Karson, D.T., Righthand, F. & McGillivray, M. (1968) Immuno­
globulin response in serum and secretions after immunisation with live 
and inactivated polio vaccine and natural infection. New Engl. J. Med. 
279 893. 
Olson, J.C. & Leslie, G.A. (1982) IgD : A Component of the secretory immune 
system. IN: Immunoglobulin D: Structure & Function (G.J. Thorbecke & 
G.A. Leslie, eds) Ann. N.Y. Acad. Sci. 399, 97. 
Onions, D.E. (1982) The Immune response to Virus Infections. Adv. Vet. 
Immunol. 1982. Developments in Animal Veterinary Science 12, 237. 
56 -
Owen, R.L. (1977) Sequential uptake of horseradish peroxidase by lymphoid 
follicle epithelium of Peyer's patches in the normal unobstructed mouse 
intestine: an ultrastructural study. Gastroenterology 72, 440. 
Ramphal, R. , Cogliano, R . C , Shands, J.W. & Small P.A. (1979J- Serum antibody 
prevents lethal murine influenza pneumonitis but not tracheitis. 
Infect. Immuno. 25, 992. 
Reynolds, H.Y., Atkinson, J.P. , Newball, H.H. & Frank, M.M. (1975) Receptors 
for immunoglobulin and complement on human alveolar macrophages. 
J. Immunol. 114, 1813. 
Rouse, B.T. & HorohoV, D.N. (1984) Cytotoxic T. lymphocyte in Herpesvirus 
infections. Vet. Immunol. & Immunopathol. 6, 35. 
Rubin, D., Weiner, H.L., Fields, B.N. & Creene.^M.I. (1981) Immunologic 
tolerance after oral administration of reovirus: Requirement for two 
viral gene products for tolerance induction. J. Immunol. 127 1697. 
Rudzik, 0., Clancy, R.L., Perey, D.Y.E., Day, R.P. & Bienenstock, J. (1975) 
Repopulation with IgA containing cells of bronchial and intestinal 
lamina propria after transfer of homologous Peyer's patches and bronchial 
lymphocytes. J. Immunol. 114, 1599. 
Shi/artsman, Y.S. & Zykov, M.P. (1976) Secretory Anti-Influenzaimmunity. 
Adv. Immunol. 22, 291. 
Spencer, J. & Hall, J.C (1984) Studies on the lymphocytes of sheep IV 
migration patterns of lung associated lymphocytes efferent from the 
caudal mediastinal lymph node. Immunology 5_2_, 1. 
Stokes, CR., Newby, T.J., Huntley, J.F., Patel, D. & Bourne, F.J. (1979) 
The immune response of mice to bacterial antigens given by mouth. 
Immunology 3fi_, 497. 
Stokes, CR., Soothill, J.F. & Turner M.W. (1975) Immune exclusion is a 
function of IgA. Nature 255, 745. 
Sturn, B. & Schneweis, K.E. (1978) Protective effect of an oral infection 
with herpes simplex virus type I against subsequent genital infection 
with herpes simplex virus type 2. Med. Microbiol. Immunol. 165, 119. 
Tenner-Racz, K., Racz, P., Myruik, Q.N., Ockers, J.R. & Geister, R. (1979) 
Uptake and transport of horseradish peroxidase by lymphoepithelium of 
bronchus associated lymphoid tissue in normal or BCG immunised and 
challenged mice. Lab. Invest. 41, 106. 
Todd, J.D., Volenec, F.J. & Paton, I.M. (1972) Interferon in nasal secretion 
and sera of calves after intranasal administration of avirulent 
infectious bovine rhinotracheitis virus: Association of interferon in 
nasal secretion with early resistance to challenge with virulent virus. 
Infect. Immunity 5 699. 
Tornasi, T.B., Tan, E.MT, Solomon, A. & Prendergast, R.A. (1965) Character­
istics of an immune system common to certain external secretions. 
J. Exp. Med. 121, 101. 
Van Epps, D.E. & Williams, R.C (1976) Suppression of leukocyte Chemotaxis 
by human IgA myeloma components. J. exp. Med. 144 1227. 
Widders, P.R., Stokes, C R . , David, J.S.E. & Bourne, F.J. (1984) Quanti­
tation of the immunoglobulins in reproductive tract secretion of the 
mare. Res. Vet. Sci. (In Press) 
57 -

SUMMARY OF SESSION TWO. 
THE IMMUNE SYSTEM IN THE DEFENCE AGAINST HERPESVIRUSES. 
by B.T. ROUSE and C R . STOKES. 
The session, -for convenience, may be considered in three 
parts, covering the biology of herpesvirus infections, genetic 
resistance and acquired immunity. 
In the first GASKELL describes two herpesvirus infections, 
Fel id herpesvirus 1 (FHV 1 — formerly known as feline viral 
rhinotracheitis (FVR) virus) and Pigeon herpesvirus 1 <PHV-1). 
The advantage of these natural host-virus systems for the study 
of latency and re—activation by natural stimuli were 
emphasized. For example the post-partum shedding of virus from 
carrier queens and the establishment of a latent carrier state 
in the kittens whilst under the cover of passive immunity, was 
used to indicate the biological role of latency. 
BECKER described how certain inbred strains of mice are 
resistant to the effects of virus infection. Such genetic 
resistance being a feature of CH7· black/6 mice which are 
resistant to a number of viruses. Following I.P. injection 
virus could be detected in the liver and spleen on day 1 but by 
day 3-5 it was completely eliminated. Cellular depletion 
studies indicated that the responsible cells are sensitive to 
e"*Strontium, whole body irradiation (500 rads) and are probably 
bone marrow derived. Young mice (less than 4/52) are sensitive. 
Interestingly the route of "infection" with virus is critical, 
whilst mice are resistant to I.P. infection following eye or 
nose infection the virus can be found in the ganglion. 
The importance of route of infection was also illustrated 
by the two other talks. ROUSE emphasized the importance of 
natural defence mechanisms against initial infections and 
indicated the importance of natural killer cells, macrophages 
and interferons in this role. In considering local immunity to 
herpesviruses, STOKES took up this point and describes how 
non-specific defence mechanisms operate at mucosal surfaces 
(mucus, cilia, interferon, macrophages, physical structure) and 
are essential for the handling of viruses at their main sites 
of entry namely the respiratory and reproductive tracts. ROUSE 
focused on T-lymphocyte mediated immunity since such mechanisms 
have been shown to predominate over antibody in systemic 
immunity to herpesviruses. The immuno—pathological lesions 
associated with such responses were also discussed. The immune 
mechanisms that operate at the mucosal surfaces of the 
respiratory and reproductive tracts were illustrated (STOKES). 
The independence of local and systemic immune systems was 
re—emphasized and the importance of local immunity in the 
protection from experimental herpesvirus challenge was 
discussed. Finally the problems associated with the development 
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ABSTRACT 
A formalisation of infectious bovine rhinotracheitis virus (Bovine 
herpesvirus 1)_ latent infection was built by logical analysis. The formal 
description deals essentially with the events that appear after primary 
infection, reactivation or vaccination with inactivated or attenuated 
vaccines, in a virgin animal or a latently infected one. It consists of 
a set of five logical equations defining five functions: V (viral multi­
plication); R (development of reactivation of latent virus); A (develop­
ment of an immune response); G (establishment of the viral genome); 
M (development of a memory of a first immune response). Five internal 
variables (v; r; a; g; m) are associated with the five logical functions. 
In addition, there are four input variables: i (infection with a virulent 
virus); i (infection with an attenuated virus); v. (injection of inac­
tivated virus); d (treatment with dexamethasone or any exogenous or endo­
genous stimulus able to provoke reactivation). Time delays of appearance or 
disappearance are given for each internal variables. 
INTRODUCTION 
The infection of cattle with Bovine herpesvirus 1 (BHV I) provokes 
two major diseases: infectious bovine rhinotracheitis (IBR) and infectious 
pustular vulvovaginitis (IPV) (Gibbs and Rweyemamu, 1977). After recovery 
from primary infection, the virus persists in the animal in a latent form: 
it is no more detectable by means of conventional virological methods. 
Latency, a biological property of great epidemiological importance, 
is shared by the herpesviridae (Honess and Watson, 1977). In latently 
infected animals, the virus is occasionally reactivated; it can be re-excre­
ted without any clinical sign and, by this way, transmitted silently to 
virgin animals. Latency also allows RHV 1 to persist in a restricted 
herd without introduction of exogenous virus. 
BHV 1 latency is well documented and it is a good model for several 
reasons: the phenomenon of latency can be studied in the proper species 
where it appears and in a naturally fixed situation (Pastoret et al., 
1982). In addition, BHV 1 can be experimentally reactivated by the use of 
glucocorticoids (dexamethasone). The re-excretion of BHV 1 is modulated by 
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the level of the specific immunity, and, when this level is above a certain 
threshold, reactivation can occur without re-excretion of virions (Pastoret 
et al. , 1980). 
The aim of this work is not to provide a detailed model of BHV 1 latent 
infection: not enough is known so far about the mechanisms. More modestly, 
we wish to present a formal description of our present view of the system, 
with special emphasis on the conditions of viral re-excretion. 
A first justification is that, as in many other fields, the steady 
accumulation of facts makes it increasingly difficult to have a global view 
of the subject: a formal description may help although it is necessarily 
over-simplified. The main objective, however, is to provide a way to check 
the consistency of the views we may have on such a complex system. Besides 
the essential point of self-consistency, models are usually built to 
account for a small number of selected features of a system, but formal 
analysis almost invariably shows up implications which had not been consi­
dered during the modelling. Some of them will be consistent with already 
known facts. Others are "predictions" which will have to be submitted to 
the test of experience. 
As in many other cases, a quantitative description of the situation 
would only serve to give the impression that we know more on the system 
than we really do. We would be very satisfied with a qualitative, if cohe­
rent, description. This is why we turned to a logical formalisation, i.e. 
a description which uses variables with a limited number of values (typi­
cally, two only: 0 and 1). More specifically, we use the method described 
by Thomas (1973; 1979). It has become clear that the essential dynamical 
aspects of complex systems are preserved by a proper logical description, 
in spite of its apparently caricatural character. 
DESCRIPTION OF BHV 1 LATENT INFECTION 
BHV 1 infection 
The pathology of BHV 1 infection is largely due to respiratory infec­
tion; the virus is usually transmitted by direct contact from animal to 
animal. After a primary infection, virus replicates in epithelial cells of 
the anterior respiratory tract. Thus during a primary infection, when virus 
is replicating intensively, a large amount of virions is present in nasal 
exudates (Pastoret et al., 1979). During this period of intense virus multi­
plication, the animal is highly contagious for its surroundings during 
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several days. The same is true when the animal shows the genital form 
(IPV), but in this case, the transmission is venereal. 
Animals recover within two weeks, except when bacterial superinfection 
occurs (Gibbs and Rweyemamu, 1977). 
The latency of BHV 1 
After recovery from the primary infection, BHV I infectious particles 
are no more detected in nasal mucus or vaginal samples and, moreover, the 
animal is immune. As already mentioned, the virus persists in the host 
in a latent form. The conditions required for the establishment of latency 
are still under investigation: especially, it is not known if the dose of 
virus to which the animal is exposed during primary infection and its 
subsequent multiplication is important for the establishment of latency. 
It is not yet known to which extent the immune stage of the animal follo­
wing a primary infection influences the ability of another strain to 
establish latency in the same animal. 
Nevertheless, the latency of BHV 1 has already been investigated in 
several models: the most extensively studied models involved attenuated 
vaccine strains. In this case, it is established that: (1) attenuated 
strains can remain in a latent state (Pastoret et al., 1980) and, for the 
thermosensitive (ts) strain (Zygraich et al., 1974), even after usual 
vaccination procedure (Nettleton et al., 1984); (2) vaccination by atte­
nuated or inactivated vaccines does not prevent the further installation 
of challenge wild virus in a latent form (Darcel le Q. and Dorward, 1975; 
Nettleton et al., 1984); (3) primary infection with a virulent strain seems 
to prevent latency of a reinfecting attenuated strain (Thiry et al., 1985a). 
All animals then carry in a latent form the virus after primary infection; 
in addition, in spite of vaccination, a superinfect ing virus will induce 
latency if it is virulent. 
BHV 1 reactivation and re-excretion 
Reactivation οΎ BHV 1 can occur by means of several endogenous or exo­
genous stimuli, including the injection of glucocorticoids especially 
dexamethasone (Snowdon, 1965; Sheffy and Davies, 1972). The mechanism of 
BHV I reactivation is still unknown. The reactivation of latent virus may 
be followed by re-excretion of infectious particles (Snowdon, 1965) and 
non-infectious particles (Pastoret et al., 1979). In other words, 
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reactivation without re-excretion of virions is an encountered situation 
(Thiry et al., 1983a). 
In fact, the re-excretion of latent BHV 1 is modulated by the level 
of specific immunity, which, in turn, is dependent on the schedule of 
previous infections, reactivations or vaccinations, and whether the immune 
response was induced by the multiplication of a wild-type or an attenuated 
virus (Straub and Wagner, 1977; Rossi and Kiesel, 1982). 
The sequence of events may be interpreted as follows (Pastoret et al., 
1980, 1984): after a primary infection, the animal is able, by its immune 
system, to prevent the clinical effects of a reinfection with a virulent 
strain but cannot properly control an episode of re-excretion (Davies 
and Carmichael, 1973). The first viral reactivation with or without 
re-excretion produces an increase of the specific immune status and of the 
efficiency of some immune mechanisms. The animal is therefore able to con­
trol a further reactivation better and for a longer time and no re-excre­
tion occurs. 
Animals which, under experimental conditions (e.g. dexamethasone 
treatment), excrete the highest level of virus after reactivation are those 
with the lowest specific immune response. This observation supports the 
view that re-excretion is influenced by the specific immune stage of the 
animal (Pastoret et al., 1979, 1980). 
The occurrence of spontaneous viral reactivation and re-excretion is 
not well documented. It is studied by the detection of re-excretion of 
BHV 1 virions and of a rise in specific antibodies. The spontaneous re-
excretion of field strains of BHV 1 occurs in experimental animals and 
in closed herds at least until one year after infection (Snowdon, 1965; 
Hyland et al., 1975; Bitsch, 1975): this is reported for both the genital 
and the respiratory infections. The spontaneous re-excretion of attenuated 
strains, administered intranasally, is probably a rare event (Thiry et al., 
1983c). 
Reactivation and re-excretion of BHV 1 can be provoked repeatedly 
in the same animal by dexamethasone treatment (Pastoret et al., 1979). 
METHODOLOGY 
Kinetic logic 
The method known as kinetic logic (Thomas, 1973) has been described 
in detail elsewhere (Thomas, 1979; 1984). In short, to each of the elements 
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whose decription seems crucial to us we associate both a logical variable 
(a, b, c, ...) whose value (1 or 0) tells whether the element is or is not 
present at a significant level, and a logical function (A, B, C, ...) 
which tells whether the element is being produced at a significant rate. 
For instance, in a genetic system, the logical value of a variable 
tells whether the gene product is present, the logical value of the corres­
ponding function tells whether the gene is on . More generally, our logical 
variables usually describe concentrations while our functions describe 
rate of production. It must be emphasized that a=0 (product "absent") does 
not mean that the product is completely absent; it means that the product 
is below its threshold level. 
In our context, variable ν (for instance) takes the value I when 
virions are actually present and the corresponding function V takes the 
value 1 when virions are being produced. In a state of regime, ν and V 
have the same value: virions have not been produced (V=0) for a long time 
and there are no more virions present (v=0); or virions have been produced 
(V=l)for some time and are present (v=l). However, when the value of V 
has recently changed, ν and V may have different values: virions are 
being produced but they are not yet present at a detectable level (v=0); 
or virions have stopped being produced (V=0) but they are still present 
(v=l) (figure 1). 
There is thus a rather simple temporal relation between a variable 
and the corresponding function. Let us start from a state of regime in 
which a function and its variable have the same logical value. If a signal 
changes the value of the function (i.e. switches it on or off), the 
variable adopts the new value of the function, but only after a charac­
teristic time delay; if function V has been switched on, one must wait 
from a time t before virions appear; if function V has been switched off, 
one must wait for a time t- before virions disappear. There is no reason 
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why the "on" and "off" delays should be the same; in practice, they are 
often very different. Note that during the transient period in which 
a function and the corresponding variables have different values, the 
logical value of the variable serves as a memory of the preceding value 
of the function. 
As shown in detail elsewhere (Thomas, 1984), we describe a system by 
a set of logical equations which relate the value of each function to the 
values of the relevant variables; more concretely, the logical equations 
tell in what conditions each function is on or off, depending on the 
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Fig. I The logical value of variable ν functions as a memory 
of the preceding value of function V. 
The arrows indicate that a signal has changed the value of V (more 
concretely, switched on or off the synthesis of virions). This 
operates as an order to change the value ν (more concretely, to make 
virions appear or disappear, according to the case). But this order 
is executed only after a suitable delay, t or t- depending on 
whether the function is switched on or off. If a counterorder takes 
place before the order has been executed, we reason as if the order 
had not been given. 
presence or absence of the relevant elements. A logical equation of the 
form η = f (a, b, c, ...) 
means that function A is on (A has the value I) if the values of variables 
a, b, c, ... are such that (a, b, c) = I. We use the classical connectives: 
a.b (or ab) means a AND b (logical product) 
a + b means a OR (inclusive) b (logical sum) 
a means NOT a (logical complement) 
For instance, A = ab + c means that function A has the value I if a (and 
not b) or c, or both, have the value I. These logical equations resemble 
the differential equations used in chemical kinetics in the sense that 
both relate rates of synthesis to concentrations: and this is how the time 
is (implicitely) included in our logical equations. 
From these logical equations, one can build a state table, which 
gives the values of the functions for each combination of values of the 
variables. Note that in addition to the internal variables described 
so far, one has to consider input variables. While, as already mentioned, 
the value of an internal variable is a delayed effect of the value of the 
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corresponding function, the values of input variables can typically be 
changed at will. For instance, one can decide to submit a "virgin" animal 
to infection with BHV 1 Ci), or reactivate the latent virus using an appro­
priate stimulus (d); i and d are input variables. 
From the state tables, one can derive all the sequences of states 
(pathways) of the system. Which sequence(s) is Care) followed depends on 
the relative values of time delays. Which are involved in the choices 
between sequences of states, and how, are determined by a subsequent 
analysis. 
A formal description of the BHV 1 infection 
Various choices of functions and variables are conceivable. Those we 
finally chose are shown in table I. 
TABLE 1 Functions and variables 
Functions : 
V : development of viral 
multiplication 
R : development of reactivation 
of the latent virus 
A : development of an 
immune response 
G : establishment of the 
viral genome 
M : development of a memory 
of a first immune response 
Variables : 
ν : presence of virions 
r : effective reactivation 
of the latent virus 
a : presence of specific active 
immunity 
g : presence and persistence 
of the viral genome 
m : presence of a memory of a 
first immune response 
Now, a few comments on this table. Function V represents viral multiplica­
tion . The associated variable ν refers to the presence of mature virions. 
As regards the immune response we chose to describe it simply by the 
presence (a) or absence Ca) of active specific immunity directed against 
the virus, and by the presence Cm) or absence (m) of a memory of an earlier 
response. The logical functions associated with these variables are repec-
tively, A, which refers to the development or maintenance of the response, 
and M, which refers to the establishment or maintenance of a memory of the 
response. It may be noticed that in this symbolism, primary and secondary 
( or more generally, anamnestic) responses are represented by the same 
variable a. However, the value of m tells us whether one deals with a 
primary (m=0) or a secondary (m=1) response, and depending on the case, 
the time delays are very different (table 2). In other words, instead 
of explicitely using distinct variables and functions to describe the 
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primary and secondary responses, we distinguish between the two situations 
by the values of the time delays (a secondary response develops faster 
and persists longer). 
The reason for introducing variable m is that while value, 0 or 1, 
of variable a tells whether specific immunity is above or below a protec­
tive threshold now, we need a variable whose value tells whether it is or 
has been present. Clearly, if one wrote M = a, function M would take the 
value 1 some time after the appearance of immunity, but it would drop back 
to 0 after immunity has disappeared (see again fig. I for the time depen­
dence between a function and its associated variable). However, if 
M = a + m (its means a or m ) , once m has taken the value 1, both M and m 
will keep this value. More generally, the simple logical structure 
X = ... + χ ensures that once χ has reached the value 1 both X and χ are 
blocked for ever at this value. Similarly, we have to express that once 
an animal has been successfully infected with BHV 1, the viral genome will 
persist indefinitely. This can be written: G = ν + g. Most of the time, 
the virus will then remain latent, but following appropriate treatment, e.g. 
dexamethasone treatment (d), the virus is reactivated. When we write : 
R = gd, we implicitely assume that independently of the above-mentioned 
effect of immunity on viral multiplication, there is a mechanism which 
somehow keeps the established viral genome in a latent state unless proper 
conditions are applied. Once these conditions are fulfilled, R=1 and 
reactivation is effective (r=1) after a delay t . 
r 
Now, we are in a position to propose equations for V and A. 
V = a (i + i + r) means that provided the level of immunity against v a r ' 
the virus is below a threshold (a), virus multiplication can take place 
following infection (i) or reactivation (r). Infection with virulent (i ) 
or with attenuated (i ) virus both result in virus development (V), but 
with different "on" and "off" delays (table 2). 
A = v + v. + r means that the development of specific immunity against the 
virus is induced by a successful multiplication of the virus (v) or by 
the massive injection of inactivated virus or by reactivation (r). 
We thus reach the following provisional description (figure 2): 
V = Π (i + i + r) v a 
R = gd 
A = ν + v. + r 
ι 
G = ν + g 
M = a + m 
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Fig. 2 Logical scheme of the BHV 1 latent infection. 
Note that i , i , v. and d are input variables: whether or not infec-v a l 
tion, injection of inactivated virus or an appropriate reactivation stimu­
lus take place does not depend on the internal state of the system but 
rather on a deliberate decision of the experimenter or on casual external 
circumstances. The other variables (v, r, a, g, m) are internal variables 
whose value depends on earlier values of each other. An essential point 
is that we do not try to mention in the equation of a function all the 
variables which influence the value of this function, but rather those 
variables which (rightly or wrongly) are considered to influence directly 
the function. For instance, variable v influences its own development, 
but only indirectly. This is why v is not seen in the equation of V. 
But v directly influences the development of immunity (and it is thus 
present in the equation of A) and a in turn influences the multiplication 
of the virus (and it is thus present in the equation of V ) . Thus v figures 
in the equation of A and a figures in the equation of V; this describes 
the indirect effect of v on its own later development. 
The values of the time delays are expressed in "units of time delay", 
which correspond roughly to days. They represent the time required, under 
experimental conditions, to switch on or off the variables when the values 
of the corresponding function has changed. It is assumed, for example, 
that the level of neutralising antibodies and of cell-mediated immunity 
has reached a protective threshold ten days after primary infection. We 
therefore chose the value 10 for t .. Other values of time delays have been 
a 1 ' 
arbitrarily chosen: for instance, t- value cannot be deduced from experi-
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tal data and was therefore considered as equal to 1 (table 2). 
TABLE 2 Time delays 
m = 0 











t­ : no value 
9, 
t = 0 πι 
no value 
t = 1 v 
t­ = i; 
v t = 1 r 
t­ = 1 
The delay values are expressed in units of time delay; 
one unit corresponds roughly to one day; 
t : delay of appearance of the variable x; 
t­: delay of disappearance of the variable x. 
From our set of logical equations, one can derive a state table 
(table 3) which provides the values of the functions for each combination 
of values of the variables. Usually, each of the 2 combinations of values 
of the η internal variables occupies a row. In the present case, however, 
instead of writing a big table with 32 rows (corresponding to the combina­
tions of values of the 5 internal variables), we give two five­variable­
sub­tables, one for m=0, one for m=1. This is convenient because in practi­
ce one begins in the sub­table (m=0), and as soon as there has been a 
primary response, one shifts to (and remains in) the sub­table (m=I). 
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Each table (or sub-table) comprises columns corresponding to the va­
rious possible treatments (input variables). Here, we have considered 
columns corresponding to: no present treatment (o); injection of inactiva­
ted virus (v.); infection with a live virus (i); treatment with dexametha­
sone or a similar reactivating stimulus (d). We have not considered columns 
corresponding to simultaneous double or multiple treatments; however, one 
can perfectly go, for example, from column 0 to column/i (infection), back 
to column 0 and then to column d (stimulus of reactivation). 
Note that each logical state of the system can be described by a logi­
cal vector listing the values of the variables and a second logical vector 
listing the corresponding values of the functions. Consider, for instance, 
a virgin animal which has just been vaccinated with inactivated virus. In 
this situation, the state of variables is 00000 (first line of table 3, 
left column), but the state of functions is 00100 (same line, column v . ) , 
indicating that function A (the development of specific immunity apainst 
the virus) is on. One can describe this state of the system by giving the 
vector of variables followed by the vector of functions: 00000/00100. 
However, it is more compact and more convenient to write 00000, in 
which the dash over the value of the third variable indicates that there is 
an order to change its value; indeed, specific immunity is not yet present, 
but it is being developed ( as a result of vaccination). Note that a state 
without any dash is a stable state, as there is no order to change the value 
of any variable. See, for instance, state ]0001 l| in the right part of 
table 3, second row, column 0: this describes a carrier state in which 
there is neither mature virus nor a state of reactivation nor specific immu­
nity, but the viral genome and a memory of an earlier immunisation are 
present. 
It has been found convenient to re-write, after a state table, a "com­
pact" state table in which each state is described by the logical vector 
of the variables, completed by the dashes which indicate which variables 
are asked to commute. In the present case, this gives table 4. 
DYNAMICAL ANALYSIS 
Let us start from |00000| , a stable state of column 0 (table 4) which 
represents a "virgin" animal free of BHV 1 infection and of any previous 
contact with BHV 1 antigen. Infection is seen in our formalism as a shift 
from column 0 to column i. Strictly speaking, the system should remain in 
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this column just for the actual duration of the exposition to exogenous 
virus. This could be decribed by ascribing to the process a specific time 
delay or by introducing an additional variable to memorize the exposition 
to virus. In practice, it appeared more convenient and not too distorting 
to keep the system in a column other than column O just for the time requi­
red to switch one variable; afterwards, the system goes back to the initial 





Fig.3 Pathway followed after infection of a virgin animal 
The system is now in state 10000, in which three variables are asked to 
change their value; the change that will actually take place depends on the 
values of the time delays (table 2). We assume that once the animal is 
successfully infected, the time required to establish the viral genome is 
short and at any rate shorter than the two other time delays, which we 
estimate to 10 units of delay (UD) for the development of an efficient 
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specific immunity and at about 12 UD for the disappearance of mature viral 
particles. With these values of the delays, the pathway is as described in 
figure 4 with as successive steps: permanent establishment of the viral 
genomes (g); establishment of specific immunity (a). The state is now 
TOMO; as soon as specific immunity is developed, m (which serves to remind 
that there has been a primary response) takes the value I and we reach state 
10111 (column 0 i,n the right part of table 4, which corresponds to the situ­
ation m= 1 ). From now, there is only one possible evolution: To I 1 1 -► OOT 1 1 —"· 
|0001 l| , in which the virions and immunity disappear after some days and 
some weeks, respectively. The animal is now in a stable state |Q001 l| in 
which the viral genome is still present (latent state) and there is a memo­
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Fig. 4 Pathway followed after infection of a virgin animal (following) 
Starting from state |000l l| , various stimuli (e.g. treatment with dexa­








Fig. 5 Application of stimulus of reactivation 
The system now goes back to column 0: the stimulus itself has disappeared, 
but the organism keeps for a while (1 UD) a memory of the stimulus, which is 
symbolized by function R (reactivation), but which mechanism is still un-
know. Virus is produced as early as 1 UD after the application of the sti­
mulus, followed by the development of a specific immune response; here, one 
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is dealing with a secondary response (m=1), therefore the "on" delay is 
much shorter (t ., = 7). than the first time and the "off" delay much longer a2 






Fig. 6 Pathway followed after reactivation 
Another possibility would consist in promoting reactivation very soon 
after primary infection, before a specific immune response has developed. 
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Fig. 7 Pathway followed after reactivation induced very soon 
after primary infection 
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A characteristic feature of this scenario is that reactivation provides 
a counterorder to the order to stop virus production and the new order 
to stop this production takes place only after the state of reactivation 
has disappeared. Here we would expect virus to persist 14 to 22 UD in 
contrast with the normal period of 12 UD. Although there are no available 
experiments in which a dexamethasone treatment has been applied soon after 
primary infection, partly similar experiments have been performed in which, 
10 days after primary infection, animals have been infested with Dictuo-
caulus viviparus , which also induces reactivation (Msolla et al., 1983). 
Virions are indeed found up to 3 weeks after primary infection, precisely 
until day 13 after primary infection and also at day 20 (Thiry et al., 
1985b). 
The injection of inactivated virus provokes the immunization of 
the animal, as indicated in the logical equation: A = ν + y. + r. 
This procedure can be used to impede the reexcretion of infectious parti­
cles by cattle in which a latent BHV 1 is reactivated. The pathway follo­
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Fig. 8 Prevention of BHV 1 reexcretion by injection of 
inactivated antigens. 
It can be shown that no re­excretion occurs when the reactivation stimulus 
is applied at least 7 UD after the injection of inactivated antigens. 
Nevertheless, the effect of reactivation on specific immunity is not 
modified and the order of disappearance of variable a is lost during the 
period when r=1. This situation was precisely observed in latently 
infected cattle in which a booster effect was provoked by delayed 
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hypersensitivity test (OHI) (Thiry et al., 1983a). DHT antigen is inacti­
vated BHV 1 virus and, when dht is applied on sensitized animals, it induces 
a booster response (Brochier et al,, 1984): this mimics the situation pro­
voked by v.=l, but only in the case of a booster response, because DHT 
does not induce any primary immune response ( at least the humoral one) 
in virgin animals (Thiry et al., 1983b). 
CONCLUSIONS 
The formalized description gives a coherent, even if simplified, 
picture of the sequences of events which follow BHV 1 infection, reactiva­
tion or vaccination with inactivated antigens. When examining the cases 
described in the dynamical analysis, the description shows that it is in 
accordance with experimental observations. Therefore, the logical descrip­
tion must be essentially considered as a tool in research work and in the 
analysis of epizootiological situations. It makes possible a schematic 
representation of an experimental schedule and helps to choose the most 
appropriate schedule. It gives a prevision of the evolution of the inter­
actions between BHV 1 and the infected cattle, in a given epizootiological 
situation. 
This logical description has to be refined in the light of new expe­
rimental data: a special attention mut be given to a more detailed descrip­
tion of the immunological parameters (e.g. dissociation between humoral and 
cell-mediated immunity) and to the mechanism of reactivation (to assign 
experimental values to the time delays t and t-). Nevertheless, even in 
its present state, this logical description has already allowed us to use 
a more systematic approach in the analysis of BHV I latent infection, 
to propose solutions to some unanswered questions and to suggest new 
experiments. 
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ABSTRACT 
The most widely used test is the serum neutralization 
test, which is considered specific, sensitive and 
reproducible. Its drawback is the rather long time it takes 
to obtain the results. The next most frequently used 
technique is the ELISA, which takes only hours. Its 
disadvantage is a lower specificity which leads to a number 
of false positive results. Fast is also the radioimmunoassay, 
which can be conducted even with contaminated sera, but 
requires highly purified antigen preparations and the use of 
radioactive material. Other tests less frequently employed 
are the immunofluorescence, a passive hemagglutination and 
immunodiffusion test, a counter-immunoelectro-osmophoresis 
and a micro complement fixation test. 
INTRODUCTION 
BHV 1 infections were until the middle of this century 
confined to the genital tracts of male and females, where 
they caused the disease named coital exanthema. But little 
attention was given to the causative agent, which had been 
known to be a virus since 1928 (Reisinger and Reimann). When 
the etiological agent of the then new disease Infectious 
Bovine Rhinotracheitis (IBR) was discovered in the USA (Madin 
et al. , 1956) , the first serological method introduced was 
the serum neutralization test (McKercher et al., 1959a). This 
reliable test was the basis for the surprising finding that 
the etiological agents of coital exanthema and IBR were 
serologically identical (Gillespie et al., 1959; McKercher et 
al., 1959b). Since then serologically identical agents have 
been recovered from cases of encephalitis (French, 1962) , 
conjunctivitis (Abinanti and Plummer, 1961; McKercher et al., 
1959a),abortion (McKercher and Wada, 1964), mastitis (Greig 
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and Bannister, 1969; Straub and Kielwein, 1966) mostly 
overseas, but in recent years also in Europe (for review s. 
Straub, 1978, and Straub et al., 1982). These virus 
recoveries led to an enormous stimulus to establish 
laboratory methods for the serological diagnosis. 
THE SERUM NEUTRALIZATION TEST (SNT) 
The original components, serum and virus suspension, are 
still in use in 1984. Trials to improve test results by 
adding complement have not fulfilled the expectations. The 
test is conducted in manifold variations which have in common 
only the use of serial serum dilutions and a constant virus 
suspension for the determination of the antibody titres, or 
serial dilutions of virus suspensions and a constant serum 
dilution for the identification of viral isolates. The other 
parameters vary from laboratory to laboratory. Many different 
cells are used and in a comparative test conducted in EC 
laboratories these included fetal bovine kidney, bovine 
kidney, AUBEK, MDBK and GBK cells (Lorenz and Straub, 
unpublished data). The techniques employed included a tube 
test, a micro test, and in another trial the plaque reduction 
test. Other variables were the TCID^-s, growth and 
maintenance media, virus strains, temperature and time of 
incubation and finally the methods of estimation. Despite 
these variations there is general agreement that the test is 
(1) sensitive (2) reproducible (3) highly specific (4) easy 
to conduct (5) reacting with all classes of immunoglobulins 
(Matthaeus and Straub, 1977) but unable to differentiate 
between the causative agents of the various diseases which 
led to the antibody formation. 
THE ELISA 
In many antibody determinations this test has proven its 
superiority over other laboratory methods, especially the SNT 
as far as expenditures are concerned. In EC countries there 
are two commercial sets available which enable laboratories 
to conduct mass examinations in a relatively short period of 
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time. In comparative trials its sensitivity is highly rated, 
but in the doubtful range we could not confirm this 
advantage: on the contrary, its rather low specificity led to 
a number of false positive results. The reason for this, 
apparent discrepancy is based on the components of the 
reacting agents. If an animal has suffered from a BHV 1 
diseaseimmunoglobulins of the classes M, G and A are formed 
but only those of class IgG can be detected in the ELISA. If 
on the other hand an animal is only vaccinated parenterally 
then the ELISA and SNT titres should - provided the IgM class 
antibodies have already largely disappeared - give comparable 
results. In Table 1 an example is presented (Straub, 1984b). 
TABLE 1 A comparison between results obtained in the ELISA 
and SNT. 
Mode of Animals Titres in serum determinded by 
Vaccination no. ELISA ' SNT2' 
2 χ parenteral 174 10 240 2.85 
182 7 680 2.55 
412 480 2.10 
1 χ parenteral 
1 χ local 179 320 1.80 
185 160 1.95 
184 10 1.50 
field virus 
infection 158M 240 2.85 
1) - reciprocal values 
2) - in -log10 
THE PASSIVE HAEMAGGLUTINATION TEST 
This procedure was first described by Vengris and Mare 
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(1971) and recently by Dannacher et al. (1979). For 
references see Straub (1978). When we tried the first few 
tests described we could not confirm their efficiency and 
when the latest one was tried by the senior author in the 
comparative EC test it did not work either. At present there 
is obviously no passive haemagglutination test which can give 
reliable, reproducible results. 
THE IMMUNODIFFUSION TEST (IDT) 
Although a precipitation test has been described as 
early as 1967 (Estela) there is no recent report available 
that makes use of this test. There are, however, two 
publications in preparation (Spieck and Straub), were the IDT 
has been used. In our own work the IDT was compared with the 
results obtained by the SNT and the technique used was the 
same as for the serological diagnosis of enzootic bovine 
leukosis (EBL) (Straub 1984a). The test appears as highly 
specific and sensitive enough to detect antibody titres 
following an acute infection. 
THE RADIOIMMUNOASSAY (RIA) 
This test was found to be 320- to 150 000-fold more 
sensitive than the SNT in a comparative trial with swine 
herpes virus (Aujeszky) (Döller and Jakubik, 1980). 
Advantages are its rapidity and the possibility of using 
contaminated sera, but at present the necessity to use 
radioactive material appears to be an obstacle as is the 
requirement to have highly purified antigen available. 
THE IMMUNOFLUORESCENCE TEST (IFT) 
The IFT is most frequently used for the detection of 
antigen (Wellemans and Leunen, 1973), but it can also be used 
for the detection of antibodies as described by Bergmann and 
Hahnefeld (1967). Since it requires higher expenditures and 
skilful handling it has never been widely used. 
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OTHER METHODS 
There are some other methods described which, however, 
have never been widely used. These include counter-immuno-
electro-osmophoresis (Aguilar-Setién al. (1980), and a micro 
complement fixation test (Karadzhov and Khristova, 1980). 
DISCUSSION 
All the tests described can in the hands of experts lead 
to comparable results. The most widely used test appears to 
be the SNT. Its main drawback is certainly the period of time 
necessary to obtain the result, which as far as the ELISA is 
concerned is a major advantage. The higher sensitivity of the 
ELISA versa the SNT has led to the introduction of the ELISA 
for testing milk and even bulk milk samples, as now commonly 
used in Switzerland (de Meuron, 1982; Stuker et al., 1980). 
On the other hand the lower specificity of the ELISA results 
in a number of false positives. The use of monoclonal 
antibodies in the ELISA has improved the quality of the EBL 
diagnosis (Mammerickx et al., 1984) . Whether the same will be 
true for BHV 1 diagnosis remains to be determined. It would 
certainly improve the diagnostic horizon if it would be 
possible to establish an IgA ELISA. On the other hand the 
load of laboratory work already imposed on diagnostic centres 
may be lightened when the diagnosis can be based on a skin 
test. This is presently being tested on a large scale using a 
commercially produced antigen. 
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ABSTRACT 
Control of infectious bovine rhinotracheitis (IBR) can 
still not be achieved by vaccination. It is therefore impor­
tant to prevent introduction of IBR into uninfected areas and 
uninfected herds and to eradicate in infected herds. Relevant 
epidemiological features of the disease and principles of con­
trol and eradication are summarized. It is emphasized that 
tests used to disclose infected herds and infected animals and 
to secure freedom from infection should be both very sensitive 
and specific. The sensitive and specific tests used in Denmark 
are briefly described. 
INTRODUCTION 
It still seems to be generally accepted that it is impos­
sible to control infectious bovine rhinotracheitis (IBR) and 
Aujeszky's disease - two herpes virus infections - by use of 
vaccination. The best solution would therefore be to prevent 
introduction of such infections into uninfected areas and to 
eradicate in infected areas. This would presuppose exact know­
ledge of the epidemiology and the use of reliable tests to 
disclose infection or freedom from infection in herds as well 
as in individual animals. 
In Denmark, IBR has been subject to control in artificial 
insemination centres and progeny testing stations for many 
years (cf. Bitsch, 1984), but in February 1984 the farmers' 
organizations initiated a nation-wide voluntary eradication 
supported by legislation. A control program concerning Au­
jeszky's disease was introduced some years ago, and the final 
goal is now within sight (Andersen et al., 1984). 
In the following will be mentioned the most important 
epidemiological features of IBR with respect to infection con­
trol as well as aspects of serological control testing, includ­
ing requirements concerning serological tests. 
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RELEVANT EPIDEMIOLOGICAL FEATURES 
The intermittent release of virus from infected animals 
is of utmost importance. The amounts of virus shed during peri­
ods of recurrent excretion are generally much lower than during 
the acute phase of infection (Bitsch 1984). With regard to con­
trol and eradication, uninfected animals should therefore not 
be allowed to have contact with earlier infected ones. Never­
theless, on an infected premises eradication should have a rea­
sonable chance of success because of the low amounts of virus 
re-excreted, even when infected and uninfected animals are on 
the same farm, but separated from each other. 
It should be noted that in areas where artificial insemi­
nation is used, control is likely to be successful only when 
the semen used originates from centres free of IBR virus infec­
tion . 
Regarding eradication of Aujeszky's disease it is essen­
tial to eradicate region-wise (Bitsch and Andersen, 1982), but 
as with IBR no evidence of an airborne herd-to-herd transmis­
sion has been seen, eradication can be carried out in indivi­
dual herds irrespective of a possible presence of the infec­
tion in neighbouring herds. But co-ordinated, area-wise control 
will reduce the risk of a spreading between herds, for example 
by man. 
CONTROL AND ERADICATION 
In uninfected areas it is essential to establish surveil­
lance testings of herds and in infected areas to restrict move­
ment of animals, which should be allowed only after serological 
testing of the individual animals or the herds of origin. 
Test of bulk milk samples at regular intervals as perfor­
med in Switzerland (Kihm and Boriimeli, 1981) and now in Denmark 
will serve not only a surveillance purpose but also to disclose 
the infected herds, which is necessary in the initial phase of 
the eradication. Control testing of herds of beef cattle will 
have to be based on examination of blood samples. 
After a serological examination of all animals in infected 
herds, eradication can in principle be done in two ways, i.e., 
either by replacing the whole herd by animals from uninfected 
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herds, or by separating infected animals from uninfected ones 
and slaughtering of the infected animals when found appropriate. 
As it may be costly to replace a whole infected herd, it 
may be advantageous in such cases to rear instead t ne new calves 
isolated from the rest of the animals in order to establish a 
new herd on basis of such animals. 
If only a few animals are infected, they should of course 
be removed as soon as possible. 
If a somewhat higher proportion is infected, the infected 
animals should be kept apart from uninfected, preferably in se­
parate houses. In the course of a very few years such herds 
should have a very good chance to be free from infected animals. 
IBR ANTIBODY TESTS 
Virus-neutralizing antibody (VNA) tests and ELISA tests 
are most commonly used for demonstration of antibody to IBR 
virus. It is essential that the tests used in infection control 
are enough sensitive and specific. 
Unfortunately, VNA test modifications used at many labora­
tories have not demonstrated fulfilment of these requirements. 
The Danish P37/24 modification, however, being 16 times more 
sensitive than a conventional test, has proved to be sensitive 
enough for practical use, and its specificity is still as good 
0.999 when serum samples are tetsted undiluted (Bitsch, 1978). 
From examinations with ELISA tests based on enzyme-labelled 
anti-bovine immunoglobulin it was concluded that these tests 
were not as sensitive as the P37/24 VNA test. However, in work 
on Aujeszky's disease a blocking, direct ELISA test was develop­
ed, which fulfilled the above requirements (Bitsch and Meyling, 
unpublished; partly on basis of results obtained by Sørensen, 
unpublished), and an IBR blocking, direct ELISA test was elabo­
rated thereafter (Bitsch, Meyling and Abraham, unpublished). 
This ELISA test appeared to be just as sensitive and specific 
as the P37/24 VNA test, but was much easier to perform, faster 
and extremely inexpensive. It has been used routinely now for 
more than one year with excellent results. 
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AMcaci 
Goat herpesvirus isolates are reported from Norway and New Zealand. Five different isolates 
were neutralized and belong to one serogroup. An antibody survey with goat sera from European 
and Asian countries shows that goat herpesvirus infections seem to be widely spread and latent 
virus carriers must be present in these countries. 
INTRODUCTION 
Herpesviruses from goats heve been isolated in California (Saito et al., 1974) and Switzerland 
(Mettler et al,. 1979). The viruses isolated from severely diseased goat kids have been 
characterized and shown to be closely related to bovine herpesvirus type 1 (Engels et al., 
1983). In the past i t was shwon that goats can be infected by BHV-I exhibiting weak 
symptoms (McKercher et al., l959).The goat herpesvirus has been grouped as BHV-6 
(Ludwig, 1983). Since in a variety of countries in the world the goat is of economic 
importance we searched for other BHV-6 strains and specific antibodies. The date presented in 
this report show that goat herpesviruses are spread worldwide. 
MATERIALS AND MFTHOnS 
The E/CH and McK strains were used 3s references. Other strains obtained are listed in Table I. 
The viruses (including IBR- and IPV reference virus strains), were grown in GBK cells 
follwing standard conditions. Neutralization tests were performed using the plaque reduction 
assay (Peuli and Ludwig, 1977) in order to differentiate BHV-6 isolates from BHV- I. Aplaque 
immuno assay (Pauli et al., 1985) served to screen sera for the presence of anti-E/CH 
antibodies. Goat sera and a limited amount of information on disease problems in goats were 
received from co-workers in those countries listed in Table I and 3. 
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RESULTSAND DISCUSSION 
Several isolates obtained from adult goats with infections of the genital tract or even isolated 
from lymphocytes of healthy animals (Table 1) have been compared in neutralization tests 
with reference goat herpesvirus and BHV- 1. As shown in Table 2, these isolates could be 
classified es BHV-6 according to serological criteria. Hyperimmune serum as well as goat 
convalescent sera clearly show that no serological divergency exists between the goat 
herpesviruses. 
Jailflle Country 
1-McK/US California (1974) 
2-E/CH Switzerland (1979) 
3-CHV-9251-84 New Zealand ( 1984) 
4-CHV-44/N0R Norway (1984) 
5- CHV- 80/N0R Norway ( 1984) 


















Table 1: Goat herpesvirus (BHV-6) isolates identified by serology 
This group of viruses can readily be differentiated from IBR/IPV viruses (BHV-I) by 
neutralization . Goat herpesvirus specific goat antisera neutralize BHV- I considerably less 




























































Table 2: Cross-neutralization of BHV-6 isolates originating from different countries using 
cattle and goat antisera. 
Titres are expressed as the serum dilution neutralizing 80S of the plaques 
+ Serum after experimental infection. 
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Goat sera from a variety of countries were screened for the presence of antibodies (Table 3). It 
could be shown thai - although viruses were isolated in some of these countries and the sera 
derived from healthy animals - BHV-6 is latently oresent in animals of these countries. Some 
of the animals have relatively high neutralizing titres (up to 1.250) indicating that recurrent 
infections must have occurred. 
COUNTRY NEUTRALIZATION TEST 
NEUTRALIZING ANTIBODIES AGAINST 
BHV-1 BHV-6 
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Table 3 Serological survey on BHV- 6 antibodies 
+ Sera tested on BHV-6 ÍE/CH! infected GBK cells. 
♦ + No. sera positive/sera tested . 
N.T not tested 
A comparison of the neutralization and the ELISA titres from sera of seven countries where 
positive animals had been found is presented in Figure 1. The data indicate that ELISA titres 
were more than 10 fold higher than neutralization titres. All the neutralizing sera were 
clearly positive in the ELIJA, however, vice versa approx. 10$ of the sera showed ELISA 
reactions and had neutralization titres lower than 1:2 Positivity of a goat serum was in all 



















































Fig. Ι : Comparison of neutralzation and ELISA titres of goat sera obtained from European 
and Asian countries. The Swiss strain (E/CH) served as reference 
NO = Norway; TU = Turkey; SP=Spain; NI = Northern Ireland; IT = Italy; GR = Greece 
ELISA ti tre 
Neutralization titre 
Screening of several hundred goat sera hes brought valuable information on the spread of goat 
herpesviruses in several countries . The situation concerning this virus which is indigenious 
to the goat , seems to be reminiscent of BHV-1 infections in cattle (Straub, 1978). From the 
data presented it may be predicted that BHV-6 is spread in many countries and under immuno 
compromised conditions might be hazardous for its host leading to severe economic losses. 
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ABSTRACT 
The results of studies on the pathogenesis of bovid herpesvirus 2 
(BHV2) and the possibility that the virus remains as a latent infection in 
cattle, were reviewed. From those studies it seems reasonable to conclude 
that the pathogenesis of BHV2 infection in cattle might depend on the route 
of exposure to the virus, i.e., intravenous inoculation produces a systemic 
condition, whereas intradermal or intranasal exposure are followed by a lo­
calized disease. The study on latency of the virus supports the possibili­
ty that BHV2 induces a latent infection in cattle. This study suggested 
also that the skin, and probably the nervous system, are the host sites 
where the virus persists in the latent form. 
From the immunologic relationship study it was found that Herpes sim­
plex virus (HSV) partially protected calves against experimentally induced 
BHV2 infection. The most significant serologic finding was that the HSV­
preimmunized calves produced antibody to BHV2 challenge virus at earlier 
time than did the control calves. 
INTRODUCTION 
Bovid herpesvirus 2 (BHV2) is the etiologic agent of a trasmissibie 
disease of cattle and buffalo, characterized by the appearance of nodules, 
vesicles, ulcers and scabs on the skin and oral mucosa. Since a strain of 
BHV2 was isolated in Italy (Castrucci et al., 1972), some aspects on the 
pathogenesis of the infection have been investigated and also a program on 
the immunologic relationship between this virus and the Herpes simplex vi­
rus (HSV) was planned. The researches on the pathogenesis included the 
behavior of the virus in the target organs of the natural host and the la­
tency of the infection in experimentally infected cattle (Castrucci et a ] . , 
1977ï I9785 1979j I982). The study on the immunologic relationship between 
BHV2 and HSV, was undertaken with the purpose of verifying whether, because 
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of the common antigen, a viral envelope glycosylated protein (Norrild et 
al., I978), shared by the two viruses (Ludwig, I983), the HSV could pro­
tect calves against challenge with BHV2 (Castrucci et al., I984)· The 
present report summarizes the findings made. 
MATERIALS AND METHODS 
BHV2: the Italian strain 69/1LO (Castrucci et al., 1972) at its 2nd 
passage level in bovine embryo kidney (BEK) cell cultures was used. The 
6.50 titer was of 10 TCID /0.05 ml. 
HSV: strain 5007 of HSV1 and strain 224S of HSV2 were used at the 3rd 
passage level in BHK-21 line cells. The two strains were kindly supplied 
by Dr. G.R.B. Skinner, University of Birmingham, G.B., and the titers were 
8.50 7.50 . 10 or 10 /ml, respectively, for HSV1 and HSV2. For immunizing the 
calves the HSV1 and HSV2 antigens were inactivated by a 0.5% solution of 
Triton 100X. 
The behavior of BHV2 in the target organs of calves was studied in 38 
approximately 2 month-old Simmenthal calves, devoid of antibody to the 
virus, of which, 18 were infected intravenously (i.V.), 10 intradermally 
(i.d.) and 10 intranasal!}· (i.n.). In each group, calves were killed at 
predetermined intervals, each animal was necropsied and samples (Table 1) 
were obtained for histopathologic examinations and for culture of virus. 
The study on latency was conducted in 7 Simmenthal calves, approxima­
tely 6 months of age, which had recovered from experimental infection indu 
eed i.v. (3 calves) or i.d. (4 calves) with BHV2. The calves were given 
several i.v. inoculations of dexamethasone (DMS) and were killed at prede­
termined intervals subsequently. Attempts were made to isolate virus in 
tissue culture from nasal swabbings. nervous system tissues, lymph nodes 
and skin. Tissue were also examined for evidence of histopathological 
changes. 
The immunologic relationship between BHV2 and HSV was studied in 15 
Frisian calves, approximately 3 months of age and devoid of neutralizing 
antibody to either BHV2 or HSV'. Five calves were injected with HSV], fi-
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ve with HSV2 and the remaining five calves were kept separated from the 
others as uninoculated controls. Either HSV1 and HSV2 inactivated anti­
gens were inoculated to the calves in three times at intervals of 7 days. 
The first and the third inoculations were made intramuscularly with inocu­
lums of 5 and 2.5 ml, respectively. The second inoculation consisted of 
2.5 ml of antigen mixed with an equal volume of Freund's incomplete adju­
vant, given by the subcutaneous route. Thirty-two days after HSV was fir­
st inoculated, all calves were subjected to challenge exposure with BHV2. 
-1 -7 The virus, in dilutions of 10 - 10 , was inoculated i.d. in the skin of 
the left side of the thorax of two calves in each group and of two control 
calves. Each diluted preparation in a volume of 0.2 ml was inoculated in 
quintuplicate. The remaining three calves in each group, and the other 
three control calves, were inoculated i.v. with 5 ml of undiluted virus. 
The calves were observed for a period of 25 days. Nasal swabs for virus 
recovery and blood samples for serologic tests were obtained from each 
calf one day prior to challenge, and on 3, 8 and 21 post challenge day 
(PCD). 
RESULTS 
Pathogenesis of the 1ÌHV2 infection 
The results of the behavior of BHV2 in the target organs of the calf 
are shown in Table 1. Virus was first isolated, in the i.v. inoculated 
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NT not tested. 
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calves, on post inoculation day (PID) 2 from skin and adrenal gland, 24 
hours later it was detected in lymph nodes, blood and nervous system, and 
from the spinal fluid on PID 5· None of the calves killed through PID 5 
was clinically affected. However, all those killed after PID 5 were fe­
brile,had generalized skin lesions, enlargement of lymph nodes and were 
leukopenic. The i.n. exposed calves did not show any clinical signs of 
the disease. The virus was isolated from the nasal mucosa, the skin of 
the cheeks, and the trigeminal and glossopharyngeal nerves. In the case 
of the i.d. inoculated calves, virus was isolated from the skin of the i-
noculation site (left cheek) from PID 2-10 and from the trigeminal nerve, 
and the skin samples from the right cheek, perineum and scrotum, for a 
maximum of 6 days following infection. The scapular and precrural lymph 
nodes of these calves became enlarged, and a pruritus developed which was 
particularly intense in the skin of the scrotum and the thighs. The body 
temperature remained essentially within the normal range. Leukopenia was 
detected in some animals at PID 2-3; in others at PID 8-10. The histolo­
gical changes induced by the virus in the skin consisted initially in the 
hydropic degeneration of the epithelial cells of the stratum spinosum, 
then all layers of the epidermis were involved with extensive epithelial 
necrosis: at this time the virus reached its maximum titer in the lesion. 
The main changes in the nervous system were the presence of intranuclear 
inclusions in the neural and glial celts 
The results of the study on latency of BHV2 are reported in Table 2. 
The calves responded typically to BHV2 primary infection and all recovered 
in approximately three weeks time. Six months later, the calves were sub­
jected to treatment with DMS. After corticosteroid treatment, signs of 
disease including leukopenia and enlargement of lymph nodes, which are 
characteristic of IÎHV2 infection, were observed. Virus was isolated from 
nasal swabbings of all animals 11 days following the DMS treatment. Virus 
was also isolated from skin, nervous system and lymph nodes of 1 calf. 
Following DMS treatment, a piroplasmal infection was demonstrated in this 
calf. Histopathological changes observed in the tissues were similar to 
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those already described for the primary infection with the virus. 
TABLE 2 Reactivation in calves of BHV2 infection. 
Calves Infe­




Up to From PID After DMS 
PID 10 12­1 HO treatment 
Primary infection 
3 i.v. Present Present D 
4 i.d. Not present Present L 
After DMS treatment 
3 NA Not present Present I) 







PID = post infection day. DMS = dexamethasone. NA = not applicable. 
D = disseminated or L = localized lesions. i.v. = intravenously, 
i.d. = intradermally. 
Immunologic relationship between IÌHV2 and HSV 
The response of calves to BHV2 challenge infection is depicted in Ta­
ble 3. The evolution of the infection in the control calves was typical 
TABLE 3 Clinical response of calves immunized with HSV to challenge 
exposure with BHV2. 
BHV2 challenge exposure 
No. of calves/ Days of: Skin lesions: 





































:: Average. PCD = post challenge day. NA = not applicable.· + = few 
lesions on limited area of the body (muzzle and chin). +++ = widespre­
ad, covering most of the body. i.d. = intradermally. i.v. = intrave­
nously . 
of BHV2 (Castrucci et al., 1972). The HSV­immune calves responded to BHV2 
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infection with clinical signs which were much less severe that those ob­
served in the challenge control calves. The skin lesions in the calves 
exposed to i.v. inoculation of BHV2, were fewer in the calves in the HSV­
immune groups, whereas they were heavily disseminated, covering the skin 
of the entire body, in the control calves. In the case of calves which 
received BHV2 i.d., the titer of the virus, as is shown in Table 4, under­
went a reduction of more than one log unit in the pre­immunized calves. 
TABLE 4 Intradermal titration of BHV2 in calves previously inocula­
ted with HSV antigens. 
ID ■:■ of BHV2 calculated on 
Calves (No.) post­challenge day: 
3 7 11 
HSV­1 immune (2) 4­28 5­60 5­40 
HSV­2 immune (2) 4.00 5.55 5­62 
Controls (2) 5­37 6.60 6.71 
;i Infective doses, neg. log. 
BHV2 was recovered on PCD 3 and 8 from nasal swabbings of all HSV im­
munized or control calves. Samples obtained prior to challenge exposure 
or on PCD 21, were negative for virus. 
The serum samples from the calves were tested for neutralizing anti­
body to either BHV2 or HSV according to the method reported elsewhere 
(Castrucci et al., I984). 
Thirty one days after the initial injection of HSV antigen, the cal­
ves showed an average antibody titer of 1:4 to the homologous immunizing 
HSV (HSV­1 immune calves), or 1:6 (HSV­2 immune calves), whereas there was 
no serologic response to BHV2 at that time by any of the calves (Table 5)· 
Following challenge exposure with BHV2, the HSV antibody titer of the HSV­
immune calves underwent a progressive increase, reaching a value of 1:8 on 
PCD S and 1:16 on PCD 21. Antibody to BHV2 was first detected in these 
calves on PCD 8 with a titer of 1:5; on PCD 21 titers of 1:32 and 1:60 we­
re found in the calves immunized with HSV1 or HSV2, respectively. 
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In the control calves seroconversion to HSV was first detected on PCD 8. 
Seroconversion to BHV2 was evidenced in these calves only after 21 days of 
infection, at which time the titer was 1:20. 
TABLE 5 Serologie response to HSV and BHV2 of calves immunized 
with HSV and subjected to challenge with BHV2. 
Neutralizing antibody titers"' 
31 days after After challenge with BHV2, on day 
Calves (No.) 1st HSV inocu 3 8 21 
lation HSV BHV2 HSV BHV2 HSV BHV2 
HSV BHV2 
HSV-1 immune (5) 4 < 4 4 - 4 8 5 16 32 
HSV-2 immune (5) 6 < 4 6 ^ 4 8 5 16 60 
Controls (5) NA NA <4/<4°<4 4/4° <. 4 6/6° 20 
- Average of the reciprocal value. ° Titer to HSVl/titer to HSV2. 
NA = not applicable. 
DISCUSSION 
Studies of the behavior of BHV2 in the target organs of experimental­
ly infected calves suggest that the pathogenesis of the infection most li­
kely depends on the route of exposure to the virus. Thus, the i.v. inocu­
lation (Castrucci et al., 1978) of the virus into calves, it produces a 
systemic infection, with generalized skin lesions and persistence of the 
virus in the skin. By contrast, a localized infection develops when the 
calves are exposed to the virus i.d. or i.n. (Castrucci et al., 1979)· 
The study of the latency of BHV2 has confirmed that the virus, like other 
herpesviruses, can induce a latent infection in calves (Castrucci et al., 
I982). On the basis of the virologicai and the histopathological findin­
gs, it seems reasonable to suggest that the skin, and probably the nervous 
system, are the host sites where the BHV2 persists in the latent form. 
The immunologic relationship between BHV2 and HSV have been confirmed 
(Castrucci et al., I984)· Evidence of this is based on the clinical re­
sponse, and the virologie and serologic findings made in the experimental 
calves. As compared to the control calves, which underwent a clinical re-
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spouse typical of experimentally induced BHV2 infection, the HSV immunized 
calves showed a milder reaction to the challenge virus. The most signifi­
cant virologie finding was made in the calves exposed i.d. to BHV2 infec­
tion. In these calves BHV2 titer underwent a drop of more than 1 log unit 
in the HSV-immune calves. In view of the serologic findings, it is inte­
resting that HSV, while appearing to be unable to evoke antibody formation 
to BHV2, can reduce the latency period of the immune-competent system of 
the host in producing antibody to BHV2. This hypothesis seems to be sup­
ported by the finding that the antibody titer to BHV2 at the end of the 
experiment (PCD 21), is higher in the serums of the HSV-immune calves than 
in the challenge infection control calves. 
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Monoclonal antibodies against Bovine Herpesmammillitis 
Virus (BHV-2) and their cross reactivity with 
HSV-1 and - 2 
F. Conraths.G. Pauli, H. Ludwig and Jan C. Lewis' 
Freie Universität Berlin, Institut für Virologie, Nordufer 20. 
D- 1000 Berlin 65 
ábsir-acl 
Monxlonal antibodies were prepared against BHV-2 infected cells Some of their biological 
properties like neutralizing capacity and ability to recognize internal and external antigen 
structures of infected cells, were characterized. Based on the known cross reactivity of BHV-2, 
HSV-1 and -2 , the human herpesviruses were included in these studies. At least 3 different 
classes of epitopes were defined antigenic determinants common to BHV-2 . HSV- I and -2, 
antigens shared by BHV- I and one of the human herpesviruses and those antigens only present 
on BHV-2. 
INTRODUCTION 
The serological relationship of the herpes simplex virus types I and 2 (HSV- :, HSV-2) and the 
bovine herpesvirus type 2 (BHV-2, Sterz et al., 1973; Ludwig, et al . 1976, Nornld et al., 
1978; Yeo et al., 1980) offers a useful tool for the analysis of viral proteins. This is of 
particular interest since the common antigens induce cross-neutralising antibodies. Analysis of 
the cross-reacting antigens revealed that common antigenic determinants ere located on the 
viral glycoprotein gB of HSV (Norrild et al., l978;Ludwig, 1983) I! was shown that antisera 
directed against BHV-2 neutralize HSV much stronger than antisera directed 3gainst HSV 
do react with BHV-2 (Ludwig, 1983) The production of monxlonal antibodies directed against 
BHV-2 specific glycoproteins offers a possibility to study the expression of antigenic 
determinants on the cell surface of BHV-2 and HSV infected cells as well as on the viruses 
MATERIALS AND METHODS 
Production of monxlonal antibodies 
A31 cells, a permanent cell line derived from Balb/c mice were infected either with BHV-
' Jan C. Lewis was a Fulbright scholar 
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(strain TVA) or HSV-1 (strain F) and used for immunization of Balb/c mice. Clones designated 
"C" are derived from a mouse immunized with BHV-2 infected cells, clones named "E" originated 
from a mouse immunized with BHV-2 infected cells and boosted with HSV-1 infectedA31 cells. 
Clones were produced by fusion of NSI-Ag 4/1 myeloma cells with spleen cells of immunized 
mice following published procedures (Hybridoma technigues). After fusion the cells were 
suspended in medium and distributed in twenty 96-wel l microtitre plates 
Elisa 
Screening of specific antibodies in hybridoma supernatants was performed on formaldehyde or 
glutaraldehyde fixed Georgia bovine kidney (GBK) cells infected with BHV-2 and on HSV 
Infected African green monkey (Vero) cells grown in 96-wel l microtitre plates (NUNC, 
Denmark). Glutaraldehyde fixed infected cells were used to detxt surface antigens, 
formaledhyde fixed Triton x-100 treated cells to monitor for internal antigens (Pauli et al., 
1984). 
Vero cells were infected with BHV-2 (strain BMV). When the epe wes + + +, the cells were 
removed from the petri dishes with 2 mM EDTA in PBS, washed once with PBS 5$ fetal calf 
serum (FCS) and twice in PBS \% FCS (washing buffer), followed by incubation with the 
monxlonal antibody for 1 hour at room temperature and two additional washings. The cells were 
then incubated with fluorescein isothiocyanate labelled anti-mouse IgG for 1 hour at room 
temperature, washed twice and fixed with 95$ ethanol for 10 minutes, spun down and 
resuspended in 50% glycerol/PBS. 
For the preparation of nuclei we essentially followed the procedure given by Tsutsui et al. 
( 1983). BHV-2 infected cells were harvested, washed , suspended in 10 ml of RSB buffer 
(Tsutsui et al., 1983) and left for 5 minuteson ice. They were homogenized by lOstrokesina 
glass homogenizer. The nuclei were centrifuged through a sucrose cushion (0.5 M sucrose in 
RSB) at 70 x g for 5 minutesand the pellet was resuspended in RSB buffer. Nonidet P-40was 
added to a final concentration of 0.5SE and the mixture homogenized by 10 strokes with a glass 
homogenizer. The homogenate was layered on top of a cushion (0.5 M sucrose in RSB) and 
centrifuged for 5 minutes at 70 x g. The pellet was resuspended in PBS and this 
nuclei-preparation was used for the immunofluorescent assays 
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Neutralization test 
Monxlonal antibodies were serially diluted in medium supplemented with 58 fetal calf serum, 
0.5 ml of each antibody dilution were allowed to react with approx. 60-80 plaque forming units 
(pfu) of virus (BHV-2, strains BMV and TVA, HSV-1, strain F; HSV-2, strain Θ) for 10 min 
at 37°C. 2xlOb Vero cells in 100 μΐ of medium were added per well. 4 hours later the cells 
were overlaid with 0.5 ml medium containing 1.6B carboxymethylcellulose. After 36-48 
hours the cells were fixed with Z% formaldehyde and stained with GlEMSA-solution. 
To test the influence of complement the virus antibody mixtures were kept for 30 minutes at 
37UC. Then rabbit complement was added (final concentration 1:30) and allowed to react for 
further 30 min at 37°C. Control experiments were performed with heat inxtivated 
complement. 
RESULTS 
Monxlonal antibodies detecting antigenic sites in and on BHV-2 infected cells were selected for 
further studies. Such antibodies recognize antigens in the cytoplasm, on the nuclear membrane 
as well as in the cytoplasm (tables I and 2). Some of the antibodies crossreact with epitopes on 
HSV- 1 or HSV-2 infected cells. The rextion patterns obtained in or on HSV infected cells were 
comparable to those seen in BHV-2 infected cells (table 1 ). Two different antibodies (C2D8, 
E23F12) were tested on BHV-2 infected unfixed cells or isolated nuclei. Both antibodies bind 
to antigens on the cell surface, whereas only the antibody staining the nuclei in fixed cells, 
rexted with antigens on the nuclear membrane (table 2). 
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TABLE I: Recognition pattern of monxlonal antibodies on or infixed 
herpesvirus infected cells. 
Recognition of antigen on glutaraldehyde fixed infected cells ( s surface, + ■ positive 
reaction; -: no reaction detectable) and distribution of antigens in infected cells 
(¡ intracel lular) after treatment of formaldehyde fixed cells with detergent 
(c: cytoplasm stained; n: nucleus stained; -: no rext ion detectable). 
clone surfxe nuclei 
C2D8 + * 
E23FI2 + * 
Q8HI2 
TABLE 2: Detection of antigens on the surface of unfixed BHV 
infected cells or nuclei isolated from infected cells 
Uninfected cells or nuclei isolated from uninfected cells were not stained 
by the monxlonal antibodies. A monxlonal antibody ( 08H12 ) directed again·:, 
surface antigens of Pseudorabies virus infected cells servedas a control 
for the specificity of the reaction. 
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Neutralization tests performed with those monxlonal antibodies allowed a grouping in at leest 
three categories (table 3): those neutralizing BHV-2, HSV-1 and - 2 (C2D8), HSV-1 and 
BHV-2 (EI8E3) and only BHV-2 (E1D3). One monxlonal antibody E23F12 was shown to 
enhance the in fx t i v i t y of BHV-2 and HSV (up to twofold). In the presence of complement this 
antibody was able to inactivate BHV-2. This result implies that E23FI2 antibodies rex t with 
epitopes on the surface of the viruses 














TABLE 3: Reactivity of monxlonal antibodies with BHV-2, HSV- I and 
HSV-2 in neutralization test. 
+ + , + : neutralization of virus, - : noeffect.e: virus titres are increased 
compared to controls or, monxlonal antibodies without neutralizing 
x t i v i t y . Neutralization of BHV-2 was performed in the presence 
of rabbit complement ( C , last column); +: neutralization in the presence 
of complement, - : complement independent neutralization, n.t. not tested 
DISCUSSION 
Monxlonal antibodies directed against BHV-2 specific antigens were selected on glutaraldehyde 
fixed cells. Such antibodies define antigenic determinants on BHV-2 proteins f irst, epitopes 
which are conserved on BHV-2, HSV- 1 and - 2 , second which are shared by BHV-2 and one of the 
human herpesviruses and third which are specific for BHV-2. The differentiation of epitopes 
bases on neutralization tests. These data together with the results obtained in the ELISA tests 
implicate, that the determinants might be expressed differently on the viruses and in infected 
cells. The monxlonal antibody EID3, e.g., recognizes antigenic determinants in and on HSV-1 
infxted cells, but does not neutralize HSV- I , whereas the antibody reacts with BHV-2 antigens 
in fixed cells and inactivates BHV-2. Comparison of the biological activity of monxlonal 
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antibodies in neutralization tests and in the recognition of epitopes in or on the cell surface 
revealed that antibodies detecting antigen in the cytoplasm and on the cell surface can neutralize 
at least BHY-2, whereas an antibody recognizing also epitopes located on the nuclear membrane 
inxtivates BHV-2 only in the presence of complement. Without complement this antibody 
(E23F12) enhances infxtivity titres of the viruses. This effect might be due either to a 
stabilization of viral proteins or to a conformational change of the protein after antibody 
binding. 
Preliminary bixhemical analysis of the antigens recognized by the above described antibodies 
showed that the epitopes are localized on a BHV-2 spxific glycoprotein which is rxognized also 
by monxlonal antibody dirxted against gB ( HSV- 1 ) ( Perreira et al., 1981 ) 
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SUMMARY OF SESSION THREE. 
IMMUNE RESPONSE TO HERPESVIRUSES IN CATTLE. 
by G. CASTRUCCI and E. THIRY. 
In this session -four talks were given, the -first two on 
Bovine herpesvirus 1 (BHV 1) and the other two on Bovine 
herpesvirus 2 (BHV 2 ) . Two supplementary talks, given at the 
end o-f the seminar, were included in this session because their 
subjects were closely related to the other papers. One was 
consecrated to BHV 1, the other to Bovine herpesvirus 6 (BHV 
6) . 
The first paper on BHV 1 was presented by P.-P. PASTORET 
(Belgium) and his group. The interaction between the specific 
immune response o-f cattle and the virus was considered, with 
particular attention being paid to the latent infection status 
o-f the animal. The events that characterize either the primary 
infection or the reactivation of a latent infection were 
described. The behaviour of both the unifected and the latently 
infected animals to vaccination was also depicted. 
The author suggested an analytic method consisting of a 
series of equations the solution of which might give an answer 
of a reasonable reliability to the topic questions concerning 
the events mentioned above. 
The second paper was presented by D.C. STRAUB (West 
Germany). The author reviewed and discussed the common 
serological diagnostic methods of BHV 1 infections in Europe. 
It was pointed out that all classes of immunoglobulins are able 
to react in classical serum neutralization tests whereas other 
tests, such as the ELISA or the RIA, can only detect antibodies 
belonging to the IgB group. It was also stated that the common 
serological tests are unable to differentiate between the 
various diseases caused by BHV 1; whether or not monoclonal 
antibodies could improve the serological diagnosis remains to 
be determined. 
The paper of V. BITSCH (Denmark) dealt with control and 
eradication of infectious bovine rhinotracheitis which is under 
progress in Denmark. Specific and sensitive serological tests 
were developed by the author to allow the detection of infected 
herds and animals. Classical ELISA tests were considered to be 
as sensitive as the P37/24 virus neutralization test. However, 
an IBR blocking, direct ELISA test was also elaborated and 
found to be convenient by the author. 
H. LUDWIB (West Germany) presented the paper of M. KAO on 
the spreading of goat herpesvirus (BHV 6) infection in several 
countries. It appeared that this infection is widespread and 
the existence of latent virus carriers is postulated in 
European and Asian countries. 
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The next paper, presented by G. CASTRUCCI (Italy), 
described some aspects of the pathogenesis of the infection 
induced by BHV 2 and also considered the immunologic 
relationship between this virus and Hergessimgiex _yi.rys (HSV). 
Apparently, the pathogenesis of BHV 2 infection depends on the 
route of exposure to the virus: a systemic condition is 
produced when the virus is inoculated intravenously, whereas a 
localized disease is observed when the virus is inoculated 
through the intradermal or intranasal routes. From the 
immunologic relationship study it was proved that HSV partially 
protected calves against experimentally induced BHV 2 
infection. The most significant serologic finding in this study 
was that HSV—preimmuni zed calves produced antibody to BHV 2 
challenge virus at an earlier time than control calves. 
The last paper of the session was presented by F. CONRATHS 
(West Germany). Monoclonal antibodies used in serum 
neutralization tests revealed the possibility of defining on a 
BHV 2 glycoprotein (M.W. 130,000) at least 3 epitopes, one of 
which shows cross-reaction with HSV 1 and HSV 2 (gB); a second 
antigenic site is shared by HSV 1 and HSV 2, whereas the third 
determinant seems to be specific for BHV 2. 
Each presentation was followed by a stimulating discussion 
which proved very useful in giving a comprehensive meaning to 
the topic of the meeting. 
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HERPESVIRUS PATHOGENICITY AND THE IMMUNE RESPONSE 
Chairman : G. WITTMANN 
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IMMUNITY AND PATHOGENESIS OF MALIGNANT CATARRHAL FEVER 
H. W. Reid and D. Buxton 
Moredun Research Association, 408 Gilmerton Road, Edinburgh EH17 7JH, 
Scotland 
ABSTRACT 
The two distinct causes of malignant catarrhal fever (MCF), 
alcelaphine herpesvirus—l (AHV-1) and the as yet unidentified "sheep-
associated" agent, produce no disease in their respective natural hosts, 
wildebeest and sheep, but cause fatal lymphoproliferative disease 
following transmission to other species of ruminant. Only with AHV-1 is 
there any substantial information on the immune response of the natural 
host to infection. Epidemiological studies indicate that all wildebeest 
become infected by 9 months of age and virus can be isolated periodically 
from some animals particularly pregnant females and young calves. The 
presumptive agent of sheep probably follows a similar epidemiological 
pattern. 
The host immune mechanisms in wildebeest and sheep exquisitely ensure 
minimal detriment to the host yet exceptionally effective maintenance of 
the virus in even small animal communities. In complete contrast other 
species of ruminant infected by these viruses almost invariably die from 
catastrophic immunological dysfunction and virus does not normally spread 
to other animals. 
Current research into the pathogenesis of MCF suggests that the 
disease represents a highly specific lesion of a subset of T-lymphocytes. 
Data which is being generated from studies of the disease in cattle, deer, 
rabbits, rats and hamsters suggest that the fundamental lesion in all cases 
is the same. Evidence is presented to support the concept that in MCF the 
large granular lymphocyte (LGL) represents an important target cell for the 
virus although expression is normally incomplete. It is proposed that 
virus induced dysfunction of these LGL results in both a profound 
polyclonal expansion of T-lymphocytes and the extension of natural killer 
cell activity to normal tissues which results in the widespread lymphoid 
cell hyperplasia and tissue necrosis which characterise MCF. 
INTRODUCTION 
Malignant catarrhal fever (MCF) is a generalised disease of ruminants 
caused by infection with either of two recognised agents (Plowright, 1968). 
In areas of Africa and in Zoological Parks around the world the. disease 
occurs following transmission of alcelaphine herpesvirus-1 (AHV 1) 
(Plowright, Ferris and Scott, 1960) to cattle and certain other ruminant 
species from the natural host the wildebeest (Connochaetes spp.) (Reid and 
Buxton, 1984). The other agent, which has not yet been identified. 
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appears on circumstantial evidence to be a virus which normally infects 
sheep inapparently but which causes MCF on transmission to the other 
ruminants in particular cattle and deer (Reid, Buxton, Berrie, Pow and 
Finlayson, 1984). While neither agent produces any detectable clinical 
response in their respective natural hosts, in other species they both 
evoke the same dramatic reaction characterised by widespread necrosis 
particularly of the digestive and upper respiratory tracts and 
interstitial lymphoid cell accumulations in many tissues. 
Current understanding of the pathogenesis of AHV1 infection in its 
natural host which is largely based on epidemiological studies of free-
living populations and has recently been comprehensively reviewed 
(Plowright, 1984) will only be briefly summarised in this paper. The 
proposition that the "sheep-associated" agent behaves in sheep similarly 
to AHV1 in wildebeest is supported both by circumstantial evidence and by 
data suggesting that a virus sharing antigenic determinants with AHV1 is 
prevalent in sheep (Rossiter, 1981). Typical MCF caused by one or other 
agent has been reported in 11 species of Bovidae and 10 species of Cervidae 
as well as in laboratory rabbits, hamsters, rats and guinea pigs. 
Qualitatively the disease is the same in all species and is characterised 
by necrosis of the epithelia of the digestive and respiratory tracts as 
well as hyperplasia of lymph nodes and interstitial accumulations of 
lymphoid cells in many tissue. Although there are quantitative difference 
a common pathogenetic mechanism is assumed in this analysis. 
A. RESPONSE OF THE NATURAL HOSTS 
The recovery of virus from both fetal wildebeest spleen and from 
wildebeest calves under one week of age suggests that a proportion of 
wildebeest become infected in utero with AHV-1 (Plowright, 1965). Cell-
free virus shed in nasal secretions (Mushi, Rossiter, Karstad and Jessett, 
1980) would appear to be responsible for subsequent lateral spread - all 
wildebeest calves sero-convert by one year of age (Plowright, 1967). 
There is evidence that following infection, virus persists in the host and 
may be isolated intermittently from peripheral blood lymphocytes. Viraemia 
has been detected in 3/8 female wildebeest examined in the last months of 
pregnancy suggesting that recrudescence may occur at this time and allow 
spread of infection to the fetus. Although virus has generally been 
recovered from wildebeest leucocytes it should not be regarded as an 
obligate parasite of this cell type as it has been isolated from ocular and 
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nasal secretions, turbinate and corneal expiant cultures and trypsin-
dispersed kidney cell cultures (Mushi et al., 1980; Mushi, Rurangirwa and 
Karstad, 198 1 ; Reid, unpublished). 
No investigator has detected any clinical lesion attributable to 
infection and it is concluded that infection of wildebeest by AHV1 is 
normally benign. Antigenically related viruses would appear to behave in 
a similar fashion in two other species of antelope namely Coke's hartebeest 
(Alcelaphus buselaphus cokii) and topi (Damaliscus korrigum) although 
naturally occurring disease in other ruminants has never been attributed 
to these agents (Reid, Plowright and Rowe, 1975). 
Rossiter (1981a) examined 167 sheep sera for antibody to AHV-1 using 
an indirect immunofluorescent test and neutralising antibody test. He was 
able to confirm that neutralising antibody was not present in sheep serum 
whereas 162 of the sera were positive for immunofluorescent antibody and 
the titres recorded were of the same order as found in sera collected from 
wildebeest. From this he concluded that a virus is prevalent in sheep 
which is similar to AHV-1 but which has at least one antigenic difference. 
Recent observations in this laboratory using AHV-1 antigen in a Western 
blot test to detect antibody in serum from several species support these 
findings. We have found that wildebeest sera react with several major 
bands and that all sheep sera tested react with a proportion of the same 
bands. There is therefore increasing evidence that there is a herpesvirus 
prevalent in sheep, antigenically related to AHV-1 which is considered to 
be the likely cause of sheep-associated MCF. This form of MCF in cattle 
and deer generally occurs in animals that have had contact with 
periparturient sheep (Reid and Buxton, 1984; Selman, Wiseman, Wright and 
Murray, 1978), implying that excretion of infective virus might be 
associated with this period, and lending support to the idea that the 
pathogenesis of both viruses in their normal hosts is similar. 
B. RESPONSE OF OTHER RUMINANT SPECIES 
Generally disease follows a prolonged incubation period of up to 6 
months during which no obvious clinical signs can be detected. Onset of 
clinical disease is characterised by the abrupt development of fever with a 
generalised lymphadenopathy and inflammation and necrosis of the digestive 
and upper respiratory tracts and sometimes the skin. Conjunctivitis with 
corneal opacity progressing centripetally is frequently present and profuse 
lachrymal and nasal exudation rapidly becomes catarrhal. Meningo-
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encephalitis, diarrhoea and dysentery can also occur. The clinical signs 
in all species caused by either agent are essentially the same although 
their duration, which may be peracute, acute or chronic, dictates the 
extent and severity of the lesions. 
Virology and transmission 
It is an extraordinary feature of MCF that despite the dramatic 
pathological changes there is an absence of evidence of virus-induced 
cytological changes in affected tissues and even infectivity may be 
difficult or impossible to demonstrate. Virus can however be consistently 
recovered from the blood leuocyctes of cattle reacting to AHV-1 and 
viraemia may be present for as long as 15 days prior to the onset of fever 
(Plowright, 1968). AHV-1 antigen has been identified in fewer than 2 cells 
per 10 of lymphoid tissues taken from infected calves, although 
infectivity as identified by isolation in tissue culture appears to be 
present in approximately 100-fold more cells (Patel and Edington, 1981). 
Recovery of AHV-1 whether in tissue culture or by animal inoculation 
requires viable cells and infection never spreads from infected cattle to 
in-contact animals. However, experimental transmission of this form of the 
disease from affected cattle or other ruminants to susceptible animals can 
readily be achieved using cells derived from lymphoid organs or blood 
(Plowright, 1968). 
From cattle reacting with the sheep-associated agent no aetiological 
agent has been identified and even transmission from affected cattle to 
other cattle, with large volumes of blood and other tissues, cannot 
regularly be achieved (Plowright, 1968). In recent studies at our 
Institute large volumes of blood and lymphoid tissue suspensions were 
obtained from 18 individual clinical affected cattle cases of MCF and 
injected into calves, but on only two occasions was transmission 
successful. In marked contrast transmission from affected deer to other 
deer can be achieved with relative facility although to date, cattle 
inoculated with the same material have failed to react. Transmission of 
MCF to rabbits can also be readily achieved by inoculating tissue from 
affected deer (Buxton and Reid, 1980) but until recently all attempts to 
passage infectivity from cattle to laboratory animals had failed. 
However, at this laboratory each of two rabbits inoculated with a 
g suspension of 10 lymph node cells from an affected cow reacted after 12 
days with typical clinical and pathological signs of MCF while a calf given 
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10-fold more cells failed to react. It therefore appears likely that there 
are both quantitative and qualitative differences in the form of the sheep-
associated agent present in different species and individuals at the time 
when clinical signs develop. 
The immune response 
Cattle infected with AHV-1 do not normally develop neutralising 
antibody but a proportion do develop antibody which can be detected by 
indirect immunoflurescence and immunoperoxidase methods and complement 
fixation tests (Rossiter, 1981b; Rossiter and Jessett, 1980). There is 
also evidence to suggest that some cattle infected with the sheep-
associated agent may develop antibodies to AHV-1 which can be detected by 
fluorescence (Rossiter, 1983). However such antibodies do not appear to 
influence the fatal course of the disease. Furthermore, cattle 
hyperimmunised with tissue culture-propagated virus developed high titres 
of neutralising antibody but were still fully susceptible when challenged 
with virulent cell-associated virus (Plowright, Herniman, Jessett, Kalunda 
and Rampton, 1975). In an extensive study of AHV-1 in cattle 
approximately 6% survived experimental infection and 15/16 of the survivors 
were resistant to subsequent challenge (Plowright, 1968) suggesting that 
immunity to infection may develop in a few animals. 
C. RESPONSE OF RODENTS AND LAGOMORPHS 
Transmission of MCF caused by AHV-1 from affected cattle to rabbits was 
first reported in 1936 (Daubney and Hudson, 1936) and the resulting disease 
has subsequently been studied (Piercy, 1955; Edington, Patel, Russell and 
Plowright, 1979). Guinea-pigs, Syrian hamsters and rats also develop MCF 
following inoculation with AHV-1 and the disease can be transmitted through 
these laboratory species in series (unpublished data). Typical MCF can also 
be induced in rabbits and hamsters with the sheep-associated agent isolated 
from both affected deer and cattle. Following serial passage in rabbits 
AHV-1 and the sheep-associated agent may be transmitted to and passaged in 
rodent species but infectivity cannot apparently be passed back from 
rodents into rabbits. In addition AHV-1 which is readily recovered in 
tissue culture from affected rabbits cannot be recovered following passage 
in hamsters or rats suggesting that the virus may irreversibly adapt to 
these hosts. It is tempting to conclude that a similar adaptation might 
operate with the sheep-associated agent and explain some of the anomalous 
results of experimental attempts to transmit this agent from affected 
cattle and deer. 
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Virology 
Several attempts to identify AHV-1 antigen in infected rabbits by 
immunofluoresence indicate that, as is seen in cattle, few cells express 
viral antigen. Such cells are limited to lymphoid tissues where they 
represent 1 to 4 cells per 10 (Patel and Edington, 1980; Edington and 
Patel, 1981). However, following short term culture of lymph node cells 
from affected rabbits the proportion of cells carrying viral antigen 
increased to something in the order of 1 cell per 10 (Patel and 
Edington, 1980). Whether this arises through expression of viral antigen 
in previously infected cells or by infection of cells occurring in vitro 
is not clear. Limited attempts to identify viral antigen in the rodent 
species infected with AHV1 have so far proved negative. Similarly, in 
rabbits infected with the sheep-associated agent no viral antigen has been 
identified by immunofluorescence using serum from cattle affected with this 
agent which gave positive fluorescence with AHV-1 antigen. 
Immune response 
The humoral immune response to viral antigen has been studied only in 
rabbits infected with AHV-1 (Rossiter, Mushi and Plowright, 1977). 
Neutralising antibody was detected in rabbit serum from about one day 
before the onset of pyrexia whereas fluorescent antibody could be detected 
as early as 4 days after infection. No rabbit has ever been observed to 
survive infection hence as in cattle the antibody réponse does not appear 
to contribute to recovery from the disease. 
Both lymphocyte transformation tests and natural killer cell assays 
have been used to examine aspects of cellular immunity. The suggestion 
that the responsiveness of rabbit lymphocytes to Β and T-cell mitogens is 
reduced during the course of infection (Wilks and Rossiter, 1978) has not 
be confirmed by subsequent workers (Russell, 1980). Natural killer cell 
activity in rabbits inoculated with the sheep-associated agent was 
investigated in this laboratory (Reid and Buxton, 1984). Rabbits were 
infected with a standard inoculum and individuals were examined at 
intervals- Target cells consisted of Cr -labelled rabbit kidney cell 
line (RK13) and effector cells were prepared from mesenteric and popliteal 
lymph nodes and spleens. No NK activity was detected in any control rabbit 
nor in clinically normal rabbits incubating the disease. However, from the 
first day of reaction and increasingly on the second and third days of 
reaction, high NK activity was present in all cell suspensions tested. 
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D. CULTURE OF LYMPHOCYTE CELL LINES 
Until recently attempts to propagate lymphocytes from MCF-affected 
animals were unsuccessful. The first lymphoblastoid cell line to be 
described was designated MF 120 and was obtained from a rabbit reacting 
with the sheep-associated agent (Reid, Buxton, Pow, Finlayson and Berrie, 
1983). A suspension of mesenteric lymph node cells from the affected rabbit 
was mixed with fetal ovine kidney (FOK) cells and treated with polyethylene 
glycol before seeding in culture vessels. The resulting cultures had the 
appearance of normal monolayers of FOK cells and other cell types were not 
in evidence until day 21 in culture when the monolayer degenerated rapidly 
and numerous small round cells were observed in the supernatant fluid. 
These cells were maintained for several months in continuous culture by 
passaging them frequently to preformed monolayers of FOK cells as feeder 
cells. Recently they have been passaged on bovine turbinate feeder cells 
and it appears that they can be passaged indefinitely. 
The MF120 cells have the rabbit karyotype and morphologically resemble 
large granular lymphocytes (LGL) an assessment confirmed by histochemical 
and ultrastructural examination. They were also cytotoxic to a variety of 
cultured primary cells and cell lines, a characteristic of natural killer 
cells, and it was concluded that they were a sub-population of lymphocytes 
2 known as natural killer LGL. Inoculation of rabbits with as few as 10 
of these cells induced typical MCF indicating that they carry the agent 
although its identity remains obscure. 
Subsequent to this, cells with the characteristics of LGL have been 
isolated from tissues of cattle (Berrie, Reid, Buxton, Pow and Finlayson, 
1984) and deer (Reid, Buxton, Berrie, Pow and Finlayson, 1985) affected 
with the sheep-associated agent and from rats experimentally infected with 
AHV-1. They have been obtained from cultures of cerebrospinal fluid, 
cornea and lymph nodes. Typically a monolayer of fibro-epithelial cells 
forms which persists for days or weeks before suddenly degenerating, at 
which point numerous LGL can be detected in the supernatant fluid. 
Normally their continued culture is dependent on frequent passage to 
suitable feeder cell monolayers which are rapidly destroyed. Thé 
cytotoxicity displayed by these cells is characteristic of natural killer 
cells and it is apparent that like MF 120 they are natural killer LGL. 
However unlike the MF120 cell line none of those derived from cattle or 
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deer has caused disease following inoculation into cattle, deer or 
rabbits. It is interesting that simian lymphocyte cell lines induced by 
Herpesvirus saimirí, a lymphotropic virus similar to AHV-1, required less 
than 27% of the viral genome to be present to maintain transformation 
(Schirm, Muller, Desrosiers and Fleckenstein, 1984). By analogy it is 
possible that the cell lines derived from cattle and deer affected with the 
sheep-associated agent may carry only a proportion of the viral genome 
which is insufficient to establish infection in recipient animals. 
Cells characteristic of LGL with natural killer cell properties can 
also be obtained from both lymphoid and non-lymphoid organs of rats 
clinically reacting to AHV-1 (Reid, Jacoby, Pow and Buxton, 1984). These 
cell lines grow in clumps which appear in the supernatant fluid from the 
initiation of the culture and do not require feeder monolayers. Rats 
inoculated with these cells develop typical lymphoproliferative disease. 
However, it has not been possible to detect infective virus either by co-
cultivation with permissive cell systems or by inoculation of rabbits. 
Thus, by analogy with the lymphoblastoid cell lines transformed by 
Herpesvirus saimirí, these rat cells may have conserved only a proportion 
of the AHV-1 genome. 
Investigation of the possible role of interleukins in perpetuating the 
bovine and rat cell lines has been started. Pilot studies indicate that 
substances which significantly increase mitosis of normal bovine 
Concanavalin-A stimulated peripheral blood lymphocytes and an interleukin-2 
(IL-2)-dependent rat cell line are present in the supernatant fluids of 
both types of cell. These results suggest that the production of 
endogenous IL-2 or similar lymphokine may have a role in the propogation of 
these cell lines. 
E. PATHOGENESIS 
1) Experimental studies 
Critical studies of the pathogenesis of MCF have been confined largely 
to the experimental disease in rabbits (Edington e_t al·., 1979; Buxton, 
Reid, Finlayson and Pow, 1984). Following inoculation of either agent 
there is a variable incubation period during which no overt clinical signs 
are present. An abrupt febrile response indicates the onset of clinical 
disease which consists of anorexia, depression and ocular and nasal 
discharges with death generally occurring on the second or third day. 
Terminal changes are characterised by widespread lymphoid hyperplasia with 
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follicular necrosis in lymphoid organs and extensive damage to the liver, 
respiratory and gastrointestinal tracts. In a study with AHV-1, 
follicular necrosis was observed as soon as 2-4 days following inoculation 
with a massive dose of lymph node cells from affected rabbits (Edington et 
al., 1979). These changes were not detected in rabbits killed between days 
6-12 following inoculation although hyperplasia of the cortex of lymph 
nodes was observed. Severe lesions were seen in one of 2 rabbits killed on 
day 12 and in both killed on day 15. In a similar experiment using the 
sheep-associated agent (Buxton et al., 1984) the only early change observed 
was hyperplasia of lymphoid tissues which progressed throughout the 
incubation period while focal necrosis and degeneration were only observed 
in clinically affected animals (Figure 1). In these latter studies 5 χ 
10 lymph node cells from rabbits clinically affected with experimental 
MCF were used for inoculation. It is possible that the early necrotic 
lesions observed in the AHV-1 experiments could have arisen from a graft-
versus-host or similar reaction resulting from the large inoculum employed 
and was not an integral feature of the MCF response. In the sheep-
associated disease in rabbits the massive hyperplasia of lymphoid organs 
and lymphocyte accumulations in other tissues was shown to be due to an 
accumulation of T-lymphocytes. It is of interest that this T-lymphocyte 
hyperplasia was completely abrogated when cylosporin-A the potent T-
lymphocyte suppressor (Borei, Feurer, Gubler and Stahelin, 1976) was 
administered daily to rabbits from the day before challenge and throughout 
the incubation period. These treated rabbits, however, succumbed with MCF 
after a similar incubation period to infected but untreated animals but the 
pathological changes which they developed were dramatically modified. 
The characteristic marked lymphoid hyperplasia and T-lymphocyte 
infiltration of non-lyraphoid tissues was virtually ablated while necrosis 
in organs such as the liver was still present. 
2) Hypothesis 
A variety of pathogenetic pathways have been proposed to explain the 
dramatic changes seen in MCF. Plowright (1968) suggested that a 
hypersensitive response to viral or virus-induced antigens could be 
responsible. This concept was subsequently elaborated to include cell 
mediated responses to virus-infected vascular endothelium (Selman, Wiseman, 
Murray and Wright, 1974) or immune complex formation at membranes 
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Figure 1. Development of pathology in rabbits experimentally 
infected with MCF. The mean (± SE) thickness (pm) of the wall of 
the appendix of animals killed at given times after the 
administration of a standard inoculum (Buxton et al, 1984) is 
shown ( X — X ) . Each point represents the mean (± SE) of five 
measurements from each of two rabbits (three rabbits on day 13) 
made on formal fixed paraffin embedded sections stained by the 
Gordon and Sweet's method for reticulin. 
The presence of tissue necrosis in the mesenteric lymph node, 
appendix, ileal Peyer's patch and the liver from each of the 
rabbits above is also shown (· ·). No attempt has been made 
to assess the amount of necrosis in a particular organ, thus the 
presence of necrosis in one of the four tissues examined from a 
particular rabbit would be expressed as 25 per cent. 
Typical clinical signs of experimentally induced MCF in the 
rabbit were only seen on day 12 in the three rabbits killed on day 
13. 
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rejection (Liggitt and De Martini, 1980). Virus-induced lymphoid cell 
transformation has also been postulated to occur (Hunt and Billups, 1979) 
but none of these explanations has proved entirely satisfactory. Reid and 
Buxton (1981) proposed that a profound virus-induced immune regulatory 
dysfunction could be the fundamental lesion and Denholm and Westbury 
(1982) suggested that a mechanism involving depletion of T-suppressor 
cells accompanied by a B-lymphocyte cytolysis could have a central role in 
the pathogenesis. However, the subsequent isolation and propagation of 
LGL with natural killer cell properties from a variety of tissues collected 
from rabbits, cattle and deer infected with the sheep-associated agent and 
rats infected with AHV1 suggest that these cells may have a central role in 
the pathogenesis of MCF. 
We have suggested that LGL represent an important target cell for the 
viruses of MCF and that their subsequent dysfunction may have a central 
role in both the lymphoproliferative response and tissue destruction (Reid 
et al., 1985). We propose that IL-2 or similar lymphokine is produced in 
abundance by infected LGL and "drives" a T-lymphocyte hyperplasia, which is 
probably benign and polyclonal. The T-lymphocyte suppressor role that LGL 
are recognised to possess (Biron and Welsh, 1982; Trinchieri and Perussia, 
1984) may also malfunction and contribute to the hyperplasia, possibly in 
concert with exuberant IL-2 production. We further suggest that tissue 
destruction which appears to represent a terminal event in the disease may 
arise from unrestricted natural killer activity of infected LGL causing 
cytolisis of normal cells. 
The subtle variation in the distribution and severity of lesions in the 
different animal species affected with MCF and the widely varying 
incubation periods that are characteristic of the disease might thus be 
explained on the basis of the nature of the virus-induced, lesions in NK 
cells. It should be noted that simian lymphoblastoid cell lines derived 
from Herpesvirus ateies and Herpesvirus saimirí also have characteristics 
of LGL (Johnson and Jondal, 1981) and the similarity between the pathology 
induced by these viruses and MCF has previously been stressed (.Edinqton et 
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SUMMARY 
To obtain crude membrane extracts, thymic cells were harvested from 
thymus of 10 week­old SPF histocompatible chickens, and treated with 4 7, 
Tween 40 supplemented Tris HCl Buffer Saline (T.B.S.). Nuclei were discar­
ded. The supernatant was centrifuged and the pellet was purified by banding 
in discontinuous gradients of 10 to 48 % sucrose in 10 mM TBS. The highest 
major band was collected, pelleted and the protein content was measured by 
the Lowry technique. 
These membrane extracts were used : 
­ for immunization in Balb C mice by 3 injections of 60 micrograms of T 
purified membrane protein extracts ; 
­ for antibodies detection by ELISA test in the supernatants of clone 
culture. 
The fusion process was performed by contact between spleen cells of 
Balb C mice and SP2/0 Ag14 myeloma cells, at a ratio of 5:1 with polyethy­
lene glycol. Fourteen monoclonal antibodies were specifically positive for 
thymocyte membrane extracts by Elisa test. Five out of the fourteen have 
been studied and were tested by indirect immunofluorescence against lym­
phoid cells from different origins. Three monoclonal antibodies react only 
with cells in both the cortical and medullary areas of the thymus. Two 
reacted with certain subpopulations of thymocytes, peripheral blood T 
lymphocytes, Marek's disease lymphoblastoid cell lines (MDCC­MSB., MDCC 
HPRS2, MDCC RPLj, MDCC­PA5, MDCC­PA9) and cells originating from MD tumors. 
These results demonstrated that MD cell lines and MD tumoral cells posses­
sed a specific antigenic membrane determinant present only on mature T 
lymphoid cells. 
INTRODUCTION 
Marek's disease (MD) is a highly contagious disease of chickens caused 
by a herpes virus (MDV) (Churchill and Biggs, 1967). It is characterized by 
lymphoproliferation in the peripheral nerves and by the appearance of gross 
lymphomas in viscera, skin and other organs (Payne and Rennie, 1976). Tu­
mors are composed of a variety of cells with a predominance of thymus­
derived lymphoid cells (T cells). 
Many lymphoblastoid cell lines have been established from MD lymphomas 
and all bear T cell markers (Powell et al■, 1974 ; Nazerian and Sharma, 
1975 ; Calnek et al., 1978). T cells have a dual role : they act as target 
cells for MDV transformation in susceptible chickens and participate in 
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immune surveillance against MD. 
These functions could be carried out by different subclasses of Τ 
cells but our knowledge is much less documented in avian species than in 
mamma1s. 
The production of monoclonal antibodies would be very useful for the 
identification and separation of lymphocyte subsets (Pink and Rijnbeek, 
1983 ; Peault et al., 1982). 
This work describes the production of monoclonal antibodies against 
different Τ cell surface antigens. Antibodies obtained were used to charac­
terize different Τ cell subclasses and their distribution in some normal 
lymphoid tissues and in tumoral tissues from Marek's disease chicken tumors. 
MATERIALS AND METHODS 
Animals 
Specific Pathogen Free B13/B13 homozygote chickens and BALB/c ByJ 
mice (Jackson laboratories, U.S.A.) were used for this work. Chickens 
were reared under S.P.F. conditions. One day old chickens were surgically 
bursectomized and used 10 weeks later as donors of thymic cells. 
Preparation of thymic membranes 
All procedures were performed at 4°C. Thymic lobes were disrupted 
with a tissue homogenizer. Cells were suspended at 5.10 /ml in Tris/saline 
(T/s). They were crushed by magnetic stirring in 25 mM T/s added to an 
equal volume of 4 % Tween 40 in T/s. After centrifugation at 3,000 g for 
30 mn, the pellet was discarded and the supernatant centrifuged for 60 mn 
at 70,000 g in a SW27 rotor on a Beckman L5-65 ultracentrifuge. 
Membrane pellets were resuspended in 3 ml of 10 mM T/s layered on 
stepwise sucrose gradients. The steps used were 40,28 and 10 % sucrose 
(W/V). The gradients were centrifuged at 120,000 g for 16 hours. The 
lightest major band was collected, washed in 20 mM T/s to eliminate sucrose 
and concentrated by centrifugation at 120,000 g for 1 hour (Standring and 
Williams, 1978). 
The protein content of the pellets was estimated by the Lowry techni­
que (Lowry et al., 1951). 
Purified extracts were kept at - 70°C. 
Immunization of mice 
Mice were injected 3 times with antigen (60 jjg of purified membrane 
extracts) : the first of 30 yg IP and 30 ^g IV, the second of 60 pg IV 
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15 days later and the third of 60 ug IV 20 days later. Mice were sacrificed 
48 hours after the last injection and their spleen removed aseptically. 
Fusion 
Fusion was performed according to the general procedure (Köhler and 
Milstein, 1975) adapted by Grosclaude (personal communication). 
Minimum Eagle Medium (MEM) supplemented with essential amino-acids 
and vitamins at double concentration was used for fusion. For culture, 
L glutamine (1 % ) , sodium pyruvate (1 % ) , penicillin (100 Ul/ml), strep­
tomycin (100 yg/ml) and 10 % foetal calf serum were added. 
Spleen lymphocytes from mice were fused with myeloma cells SP2/0 Ag14, 
at a ratio of 5:1. After 24 hours, SP2-like living cells, were dispensed 
at 8-12.10^ cells/0,4 ml in each well of culture plates. 
One ml of selective medium (MEM with 10_¿lM hypoxanthine, 10~^M 
azaserin) containing 1.10 thymocytes from newly weaned mice added in the 
wells. 
After 14 to 15 days, supernatants of growing hydrids which were at 
least 20 % confluent were removed and tested for specific antibody produc­
tion. 
ELISA test (Engwall and Perlmann, 1972) 
ELISA test was used to detect hybrid cells secreting. 
Reagents : 
Alkaline phosphatase was used as enzyme-label for the antibodies and 
P-nitrophenyl disodium phosphate (PNPP, SIGMA) as substrate. 
According to preliminary assays, 2 micrograms of protein crude mem­
brane extracts were used as antigen for each well plastic plates (NUNC). 
The wells were dried in hot air and incubated with hybridoma super­
natants for 1 hour at 37°C. The supernatants were removed and the wells 
were washed 3 times with PBS containing 0,5 %. Tween 20. Rabbit anti-mouse 
IgG alkaline phosphatase conjugate (SIGMA) was added in each well at 
1:1000 and the plates were incubated for 1 hour at 37°C. After 3 washings 
the substrate (10 % PNPP in diethanolamine buffer) were added in each well 
and the plates were incubated for 1 hour at 37°C. The enzymatic reaction 
was stopped with 4N NaOH. The coloration was measured in a semi-automatic 
Titertek Multiskan ELISA plate analyser. 
When lymphoid cell suspension were used as antigen, the wells must be 
pretreated with L polylysine. Cells were fixed with glutaraldehyde at 
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0,025 % in PBS for 10 mn. 
After 5 or 6 washings, gelatin was added. The plates were sealed and 
stored at 4°C for weeks or months until use (Lansdorp et al., 1980). 
Marek's disease cell lines 
The chicken lymphoblastoid cell lines used were MDCC-MSB1, MDCC HPRS2, 
MDCC RPL1, MDCC PA5, MDCC PA9. The tissue culture medium was RPM1, 1640 
with 10 % inactived foetal calf serum and antibiotics. 
Indirect immunofluorescence test 
Suspensions of 4.10 cells were incubated with 0,4 ml of monoclonal 
positive undiluted supernatants for 40 mn, rinsed twice in PBS and put in 
contact with rabbit anti-mouse Ig (NORDIC) at 1:20 for 40 mn at 4°C. After 
two further rinse, sheep anti-rabbit Ig labelled with fluorescein isothio-
cyanate (I. Pasteur, Paris) at 1:40 was added for 40 mn at 4°C. Cells were 
rinsed again, mounted on slides in buffered glycerin and observed with a 
Leitz Ortholux fluorescence microscope (Hudson and Roitt, 1973). 
Immunoperoxydase test 
Cell suspensions were fixed in 1 % paraformaldehyde in 0,85 M NaCl and 
washed in PBS. Samples of fixed cells were dried on slides at 4°C. Cells 
were incubated with monoclonal antibodies for 40 mn at room temperature, 
washed, incubated for 30 mn with Rabbit anti-mouse Ig conjugated with 
horse radish Peroxydase and rinsed. Freshly prepared substrate (3'3' diami-
nobenzidine SIGMA) in phosphate buffer at pH 5 containing 0,02 ml/10 ml 
H^0^ was performed for 10 mn of contact. Slides were deshydrated and moun­
ted in synthetic medium for microscopic observation (Kurstak et al., 1972). 
RESULTS 
Screening and selection of monoclonal antibodies 
From initial 500 hybridomas proceeded, 60 were found to be positive 
by ELISA against purified T membrane extracts. Only 36 were selected for 
their stability and their competence upon passage and cloning. Some, also 
lost their capacity to secrete antibodies. 
Among the 36 selected hybridomas, 14 were positive against chicken T 
membrane extracts, 12 were reacting with chicken T and B membrane extracts 
and 10 were cross reactive with chicken, duck and guinea fowl T membrane 
extracts (Table I). 
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Table J_ SPECIFICITIES ANTITHYMOCYTES MONOCLONAL ANTIBODIES 
„ . . , __„ Clones positive in Elisa test Examinated clones : 500 , . , ,_ for antithymocytes : 60 
Selected clones : 36 
„,. , Chicken Chicken, duck .,. . . Chicken , , . ' , , Specificity against , thymocytes and guinea-fowl r ° thymocytes , , J .." and bursacytes thymocytes 
Positive clones 14 12 10 
Properties of some monoclonal antibodies 
Five out of the fourteen hybridomas specifically reacting with chicken 
thymocytes were tested against different lymphoid cells. 
Results are summarized in tables 2 and 3. 
Three monoclonal antibodies (8B6, 9B1, 24A3) belonging to the IgGI 
subclass, reacted only with cells in both the cortical and medullary areas 
of the thymus. They did not react with bursacyte membrane extracts and a 
low reactivity (< 10 %) was noted against whole cells from bursa. This 
may be due to the normal presence of a few T cells in the bursa (Toivanen 
et al. , 1981). They neither reacted against peripheral blood lymphocytes 
nor cells of Marek's disease cell lines or MD tumor cells from chickens. 
The two other monoclonal antibodies (8C4, 9A1) belonging to the IgG2a 
subclass, were positive with peripheral blood lymphocytes, and MD lymphoma 
cells. Whereas 8C4 reacted with all tested MD cell lines, 9A1 was only 
positive with certain MD cell lines. 
Table 2 SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST NORMAL 
LYMPHOID CELLS 
Antigens ^ - — i ^ ^ 8B6 9B1 24A3 8C4 9A1 
Thymocyte Membrane +++ +++ +++ + ++ 
(b) Extracts (a) 
Bursacyte Membrane 
(b) Extracts 
(c) Thymocytes +++ +++ +++ + ++ 
(c) Bursacytes + + + NT \' Τ 
y < io % < io % < io % N , i· Λ· χ· 
(b) Blood lymphocytes - - - ++ + 
(a)+,++,+++ Intensity of response (b) Elisa test (c) Im. Fluor, test 













Table 3 SPECIFICITIES OF MONOCLONAL ANTIBODIES AGAINST MD CELL LINES AND 
~" MD TUMO RAI CELLS 
MA 8B6 9B1 24A3 8C4 9A1 Antigens 
(a) MD cell lines 
MDCC RPL 1 
" MSB 1 
" HPRS 2 
" PA 9 
" PA5 
(b) MD Tumoral cells 
Liver - - - 100 % 100 Ζ 
Ovary - - - " " 
Kidney - - - " " 
Testis - - - " " 
(a) Immunofluorescence or Peroxydase test (b) Immunofluorescence test 
(c) % marked cells 
DISCUSSION 
This report studies the characterization of five monoclonal antibodies 
directed against thymic cells from chickens. Three of them 8B6, 9B1, 24A3 
did not bind to lymphocytes of peripheral blood. On the contrary 8C4 and 
9A1 recognized also certain lymphoid cells of blood. 
These results suggest the existence of, at least, one antigenic deter­
minant common to peripheral blood and thymic lymphocytes. This could 
correspond to an antigen appearing late in the maturation of Τ cells. 
On the other hand 8B6, 9B1, 24A3 reacted with epitopes present only 
on the majority of thymic lymphoid cells. This response was not related 
to a particular chicken line sex or age, which could mean that these 
antibodies are specific for Τ cells of the thymus. 
On tumoral cells authors have described the presence or the absence of 
different information on the MD cell line membranes (Ross et al., 1977 ; 
Coleman et al. , 1980 ; Powell et al., 1974 ; Witter et al.,1975 ; Schatetal., 1982). 
Our finding that SB6, 9B1, 24A3 tested by immunofluorescence did not 
label cells derived from tumors and MD cell lines, show that these 
specific thymic epitopes cannot be detected on tumoral cells. However, 
8C4 and 9A1 labelled both blood lymphoid cells and tumor derived cells. 
This result could suggest that the tumors are composed either of cells 
having reached a certain degree of maturity or of lymphoid cell lines 
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expressing early a specific membrane antigenic determinant characteristic 
of later stages of the differentiation process. 
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ABSTRACT 
A survey on the present knowledge of humoral and 
cell-mediated immunity to ADV is given on account of 
experimental datas. The following parameters of immunity have 
been investigated: Neutralizing antibodies (Ab), spontaneous 
cell-mediated cytotoxicity against non-infected (SCO and 
ADV-infected target cells (ADV-SCC), antibody-dependent 
cell-mediated cytotoxicity (ADV-ADCC), lymphocyte stimulation 
(ADV-LYST) and interferon production. No datas have been 
available with regard to T-cell cytotoxicity. 
The state of immunity before and after ADV infection is 
described with unvaccinated and vaccinated pigs without and 
with colostral antibodies and with latently infected pigs. 
The evaluation of the results has been rather difficult since 
no uniform reactivity of the animals existed and great 
individual variations occurred. 
Regardless of the pre-infectious immune state of the 
animals no enhanced immunological reactivity could be found 
during the first 4 days after infection. In the contrary, 
pigs with severe clinical symptoms showed depressed ADV-SCC. 
Enhanced ADV-SCC, ADV-LYST and Ab production occurred between 
DPI 7 and DPI 14. ADV-ADCC appeared in animals without 
pre-infectious Ab on DPI 14, when IgG-Ab were predominant. 
Discernible relations to the course of the disease did not 
exist with neutralizing Ab, ADV-ADCC, ADV-LYST and interferon 
production. 
No significant influence on SCC and ADV-SCC could be 
detected after vaccination, whereas ADV-ADCC, ADV-LYST and Ab 
production were initiated and increased after the second 
vaccination. Ab production after primary vaccination was 
inhibited by colostral Ab, but a booster effect occurred 
after the second vaccination. This was also reflected in 
ADV-ADCC. 
Latently infected pigs displayed SCC, ADV-SCC, ADV-ADCC 
and ADV-LYST. Neutralizing Ab could be demonstrated in all 
the animals tested between 3 and 22.5 months after ADV 
infection. After immunosuppression significant reduction of 
SCC and ADV-LYST occurred whereas neutralizing Ab titres 
generally were not reduced. In the contrary, an increase of 
ND., values occurred after 2-3 weeks. 
The results are discussed with regard to relations 
between the different immunological parameters and the course 
of ADV infection or protection, respectively. 
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ABBREVIATIONS 
Ab: antibodies, ADV: Aujeszky's disease virus, ADV-ADCC: 
ADV specific antibody-dependent cell-mediated cytotoxicity, 
ADV-SCC: ADV specific spontaneous cell-mediated cytotoxicity, 
ADV-LYST: ADV specific lymphocyte stimulation, CMI: 
cell-mediated immunity, cpm: counts per minute, CTL: 
cytotoxic Τ lymphocytes, N-ADCC: non-ADV specific ADCC, SCC: 
spontaneous non-specific cell-mediated cytotoxicity, WBC: 
White blood cells. 
INTRODUCTION 
Humoral immunity and CMI are considered as important 
factors in the immune defense mechanisms against ADV. Whereas 
humoral immunity is well known for years, CMI is being 
investigated only for a few years. It was shown that ADV 
induces reactions of CMI: ADV specific lymphocyte stimulation 
(Van Oirschot, 1978/1979; Wittmann et al., 1976), inhibition 
and enhancement of macrophage migration (Wittmann, 1976), 
enhancement of leukocyte migration (Gutekunst, 1979) , 
enhanced spontaneous cell-mediated cytotoxicity against ADV 
infected target cells (Martin and Wardley, 1984; Wittmann et 
al., 1983; Wittmann and Ohlinger, 1984) and reactivity of 
ADV-antibodies in ADCC (Ashworth et al., 1979; Wittmann et 
al., 1983; Wittmann and Ohlinger, 1984). In vivo, cutaneous 
hypersensitivity of the delayed type occurs (Skoda et al., 
1968; Smith and Mengeling, 1977). 
We are working on immunity against ADV for some years 
with priority to CMI. We investigated the immunological 
response of pigs after infection and after vaccination and 
infection, the response of colostral immune pigs to infection 
and to vaccination and infection, and the immunological state 
of latently ADV infected pigs. I want to present a survey of 
our results, a part of which has been published (Wittmann et 
al., 1983; Wittmann and Ohlinger, 1984) or is being published 
(Wittmann et al., 1985). 
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MATERIALS AND METHODS 
Details of the techniques used have been published. The 
neutralization test was done in the presence of guinea pig 
complement which enhances neutralization, especially with IgM 
antibodies (Jakubik and Wittmann, 1978). For LYST we used the 
macromethod with unpurified WBC and unpurified inactivated 
ADV and control antigen at the beginning (Wittmann et al., 
1976) . Later on we used the micromethod with Ficoll­purified 
lymphocytes and partly purified inactivated antigens 
(Wittmann and Ohlinger, 1984). The cell­mediated cytotoxicity 
tests (Wittmann and Ohlinger, 1984) were usually performed 
with WBC as effector cells and Cr labelled Vero cells as 
targets. The effector target cell ratio was 100:1 and the 
incubation time was 17 hrs at 37°C with all the tests. These 
conditions were found to be optimal. 
The tests were done in triplicates. The cytotoxicity 
indices were determined (in per cent) according to the 
formula 
cpm test­cpm spontaneous Cr release , n„ 
π 51„ . 51„ . 
cpm maximal Cr release­cpm spontaneous Cr release 
The following parameters of cell­mediated cytotoxicity 
were checked: 
Spontaneous cell­mediated cytotoxicity against non­ADV 
infected target cells (SCC) and against ADV infected target 
cells (ADV­SCC). By treatment of the effector cells with 
monoclonal Ab against porcine CTL (Jonjic and Koszinowski, 
1984) we could demonstrate that the SCC active lymphocyte 
population(s) were non­T lymphocytes which were non­adherent 
and very active against Κ 562 target cells. From this it can 
be concluded that they were NK­cells. The possibility that 
ADV­SCC reflected ADCC evoked by in vivo adsorbed Ab could be 
excluded since 37°C­treatment followed by repeated washings, 
procedures which cause elution of adsorbed Ab (Greenberg et 
al., 1977; Höh and Babiuk, 1979), did not reduce ADC­SCC 
activity. 
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For antibody-dependent cell-mediated cytotoxicity 
against ADV infected target cells (ADV-ADCC) Ab and effector 
cells from the same animal were used at the time of testing. 
As control for non-ADV specific ADCC (N-ADCC), e.g. ADCC 
evoked by Ab against non-viral vaccine constituents, non-ADV 
infected target cells were employed. 
It was found that the whole WBC fraction was essential 
for ADCC, since ADCC activity was significantly reduced when 
purified lymphocytes were used instead of WBC. However, no 
further reduction occurred, when the lymphocyte preparation 
was treated with monoclonal Ab against CTL. This indicates 
that the lymphocytes which participate in ADCC were non-T 
cells. These results correspond very well to the results of 
Ashworth et al. (1979), who found that neutrophilic 
granulocytes and monocytes/macrophages were the most active 
cell types in ADCC. 
We could not examine T-cell cytotoxicity since we did 
not have a syngenic system which seems to be necessary for 
detection of CTL. 
The statistical methods used for determination of the 
significance of positive results in the different tests have 
been described (Wittmann and Ohlinger, 1984). On account of 
multiple tests cytotoxicity values of =11% above cell 
controls in SCC were significant (p=0.01). ADV-SCC, that is 
enhanced SCC against ADV-infected targets, is considered as 
significant on account of the least significant differences 
between two individual index values when the ADV-SCC 
cytotoxicity value was =13.3% above the corresponding SCC 
cytotoxicity value. With the same calculation ADV-ADCC is 
significant when its cytotoxicity value exceeds that of SCC 
by 17.7%, that of ADV-SCC by 18.7% and that of N-ADCC by 
17.7%. In some cases the ADV-SCC intensity was so high that 
ADV-ADCC could not significantly exceed it. The significance 
of the comparison of the number of positive animals in 2 
groups was calculated on the 90% level by the fourfold table 
test. 
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TABLE 1 Immunological behaviour of non­immune pigs after infection. 
SCC 11/26 42.3% 
a) 
DPI 






















































a) Positive/number examined 
Underlined significant differences (p = 0.1) with regard to day 0 
b) Eight of 26 pigs with positive ND5ß (mean 1:5.6) on DPI 4 
c) 
d) 
Mean ND on DPI 6: 1:8 








Significance of ADV-LYST in comparison to the controls 
and to LYST by control antigen was determined by the t-test. 
The interferon assay of the sera was done in one 
experiment according to the method described earlier 
(Wittmann et al., 1980). 
RESULTS 
Before the results of the experiments are presented 
general remarks concerning the results are necessary. The 
animals did not show uniform reactivity since great 
individual variations occurred. For example, an animal had 
shown SCC, 3 weeks afterwards it was negative, and after 
further 2 weeks it was positive again. The same was true with 
ADV-SCC, ADV-LYST and to a considerably less degree with 
ADV-ADCC. This means, that when we get a ratio of positive 
animals on different days some animals which were positive on 
the one day were negative on the other day and vice versa. 
Therefore, it was impossible to interpret the results of CMI 
tests on the base of individual animals and rather difficult 
to do this with groups of animals. 
For determination of the cytotoxic potential of normal 
pigs we examined 4 9 animals between 11 days and 7 months old, 
but the majority was between 3 and 12 weeks old. In total, 
SCC by WBC was found with 49.0% of the animals and ADV-SCC 
with 24.5%. No ADV-ADCC, ADV-LYST and neutralizing ADV-Ab 
could be detected. 
Twenty-six of these animals were ADV infected when 12 
weeks or 7 months old. The immunological behaviour after 
infection is shown in Table 1. 
SCC was detected in 42.3% and ADV-SCC, in 23.1% of the 
animals on DPI 0. After infection an increase occurred from 
DPI 2 to DPI 4 onward, and 86.3% of the animals were positive 
in SCC and 44.4% in ADV-SCC on DPI 14. 
ADV-ADCC was regularly detected from DPI 14 onward. This 
corresponds to the results of Martin et al. (1983). But 
neutralizing Ab were already present in considerable amounts 
on DPI 7. These early Ab were of the IgM class and complement 
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* Significant reduction of cytotoxic activity of the WBC in comparison to SCC with a 
part of the negative animals 
IF: Inferieron titre 
a) Number of positive animals 
requiring. But ADCC is a function of IgG, which are the 
predominant Ab-class on DPI 14 and later. Since in the bovine 
system IgM react in ADCC in the presence of complement (Rouse 
et al. , 1977) we added in some instances guinea pig 
complement to ADCC-tests with early sera, however, no 
positive ADCC occurred. Pig complement was unsuitable because 
it was cytolytic for the target cells. But this does not 
exclude that IgM-ADCC in pigs might occur in vivo in the 
isogenic system. 
ADV-LYST was first detected on DPI 4 with a few animals. 
The number of positive pigs rose to 77.3% on DPI 6/DPI 7, and 
to 100% on DPI 14. 
Neutralizing Ab were demonstrated with 8 pigs in very 
low titres on DPI 4 and with most of the pigs on DPI 6. A 
significant rise of the titres appeared on DPI 7 and the 
maximal level was reached on DPI 14. Then the titres remained 
rather unaltered until DPI 84. 
In this connection I want to say that in other long term 
experiments we could never find that neutralizing Ab 
disappeared during the course of 2.5 years. In the contrary, 
the titres remained rather high with most of the animals. 
This may be due to reactivation of the latent virus. 
From the infection experiment the question arises 
whether relations existed between the clinical course of the 
disease and the immune response. This is difficult to answer 
and I have compiled the results in Table 2 with regard to 
this question. 
In all the three clinical groups no significant 
differences could be found in Ab production, SCC, ADV-SCC, 
ADV-ADCC and ADV-LYST with regard to the number of reacting 
animals. With ADV-SCC, however, differences existed with 
regard to the intensity of cytotoxicity on DPI 4. The mean 
cytotoxicity index, which is not given in the table, of group 
I was 2.9%, of group II 10.3% and of group III 43.5%. 
Further, it was observed that with 5 of the 6 animals of 
group I the ADV-SCC cytotoxicity index was significantly 
reduced in comparison with the SCC cytotoxicity index, and 
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* Significant reduction of cytotoxic activity of the WBC in comparison to SCC with a 
part of the negative animals 
Underlined significant differences (p = 0,1) with regard to day 0 
the cpm in ADV-SCC lay frequently beneath the cmp of the cell 
control. In group II 5 of the 16 animals reacted in the same 
way. This means that in some instances the NK-cells had 
completely lost their cytotoxic activity against ADV infected 
target cells. 
The reason for this depression is not known. One could 
argue that ADV multiplication had occurred in the cytotoxic 
effector cells and destroyed them, or that ADV infected Vero 
cells were unable to bind NK-cells as it has been described 
with herpes simplex virus (Welsh and Hallenbeck, 1980). 
However, these events would have occurred at every time and 
not only on DPI 4/DPI 6. A further possibility would be that 
target cells were rendered insusceptible against the 
cytotoxic activity of NK-cells by interferon (Trinchieri and 
Perussia, 1981/82). However, Vero cells do not produce 
interferon (Welsh and Hallenbeck, 1980), and if interferon 
producing effector cells were present, the depressor effect 
of interferon must also have been evoked in SCC. 
Thus, it might be that NK cell activity against ADV 
infected cells plays a role in the early phase of ADV 
infection. For the interpretation of the results it must be 
considered that the number of animals in group I and III was 
very small. Thus, our consideration with regard to ADV-SCC 
are statistically not secured. 
With regard to interferon type I (ß-IF) no differences 
existed between the pig groups on DPI 2 (not given in the 
Table) and DPI 4. However, 2 animals of group III showed 
prolonged IF titres on DPI 7 and one animal on DPI 9. 
The immunological behaviour of pigs after vaccination 
and infection is summarized in Table 3. At the time of 
vaccination with an inactivated vaccine the pigs were 11 
weeks old. Revaccination was done 21 days after the first 
vaccination and infection 14 days afterwards. 
SCC was detected in 66.7% and ADV-SCC in 11.1% of the 
animals on day 0. After vaccination SCC remained rather 
unaltered whereas ADV-SCC increased up to DPRV 14. A part of 
the animals showed reduced ADV-SCC cytotoxic activity of the 
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WBC after the first vaccination and 7 days after the second 
vaccination. Both SCC and ADV-SCC increased after infection, 
but the increase in SCC was not significant, whereas the 
increase of ADV-SCC was significant on DPI 7 but a decrease 
occurred on DPI 14. 
ADV-ADCC occurred with 44.4% of the pigs after the first 
vaccination and with 100% after the second vaccination. This 
level was maintained after infection. 
ADV-LYST was detected in about one third of the animals 
after vaccination. It did not increase after revaccination, 
however, after infection all the animals were positive during 
the first week and 77.8% after the second week p.inf. 
By means of ADCC with non-infected target cells and by 
LYST with control antigen we could demonstrate that 
immunological reactivity against non-viral vaccine 
constituents existed in the vaccinated animals. 
Neutralizing Ab were present with a mean titre of 1:43 
after the first vaccination and after the second vaccination 
the titre rose to about 1:200. Infection evoked a marked 
booster effect on DPI 4 (titre 1:540) and maximal values on 
DPI 7 and DPI 14 (titre about 1:1200). After 150 days the 
titre dropped to about 1:200. 
After infection the vaccinated animals did not show 
clinical signs of AD, but 77.8% of the pigs reacted with 
fever. However, no significant relations were found between 
the occurrence of fever and the immunological response. 
By comparing the immunological behaviour of 
non-vaccinated and vaccinated animals after infection it 
could be found: Both groups showed a tendency of increased 
SCC. ADV-SCC significantly increased only with the vaccinated 
animals during the first week p.inf., but decreased after the 
second week, reaching a level like with the non-vaccinated 
animals, ADV-ADCC was present in the vaccinated animals at 
the time of infection, but in the non-vaccinated pigs it 
lasted two weeks until ADV-ADCC was regularly detected. 
ADV-LYST was present in all the vaccinated pigs on DPI 4 and 







































Underlined significant reduction 
7 to reach this level. The production of neutralizing Ab was 
boostered in the vaccinated pigs on DPI 4, whereas low levels 
of Ab were detected in all the non-vaccinated pigs only on 
DPI 6 and the maximum level was reached on DPI 14. The Ab 
level in the vaccinated infected pigs were about 7-times 
higher than in the non-vaccinated pigs. 
Thus, protection against ADV infection seems to be 
predominantly a matter of neutralizing Ab and eventually of 
ADCC. However, the participation of enhanced spontaneous 
cell-mediated cytotoxicity against ADV-infected cells 
(ADV-SCC) during the first week of infection may act as a 
further defense mechanism. 
After the recovery phase the AD virions disappear and 
only virus DNA persists latently in certain parts of the 
body. The immunological state of latently infected pigs is 
shown in Table 4. The animals, most of them vaccinated, were 
tested between 3 and 22,5 months after ADV infection. The 
recovery of the virus was performed by co-cultivation of 
different tissues in MDBK cells. 
SCC was displayed by 65.2% of the pigs, ADV-SCC by 
30.4%, ADV-ADCC by 100% and ADV-LYST by 69.6%. Neutralization 
titres ranged from 1:14 to 1:512 without respect of time. 
Titres between 1:128 and 1:512 were even found after 22,5 
months. This might be an indication that spontaneous 
reactivation of the latent virus occurred during latency. 
The effect of immunosuppression on the immune response 
of the animals was mainly pronounced in SCC and ADV-LYST. The 
rate of SCC was significantly reduced from 63.3% of reacting 
animals before IS to 18.2% after this treatment, and that of 
ADV-LYST was significantly reduced from 72.7% to 9.1% of 
reacting animals. In contrast, IS did not alter ADV-ADCC. 
This may be in connection with the fact, that the 
neutralizing antibody titres in general remained unaltered 
after IS. A significant reduction only occurred in 2 of 13 
pigs, which were tested on day one after the end of IS. 
However, in other experiments it could be demonstrated that a 
significant increase of ND.. values occurred with most of the 
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TABLE 5 Immunological behaviour of piglets with colostral antibodies before and after 
infection. 
DPP WPP DPI 






































4/11 11/11 5/11 
36.7% 100% 45.5% 
4/11 4/11 10/11 
36.4% 36.4% 90.9% 
2/11 1/11 10/11 
18.2% 9.1% 90.9% 
0/4 4/4 5/11 
45.5% 
ND 50 77 112 106 62 67 166 181 
Symptoms Fever 
Underlined significant in comparison to WPP 7-9 
animals 2 to 3 weeks after immunosuppression (Wittmann et 
al., 1983) . 
It remains to be clarified whether the reduction of SCC 
and of sensitized lymphocytes ADV-LYST are in connection with 
the reactivation of the latent virus. Neutralizing serum Ab 
were apparently not involved in this process. This is not 
surprising, when the virus is distributed on neural pathways 
and in lymphocytes and macrophages. 
The next point examined was the immunological behaviour 
of pigs with colostral antibodies before and after infection 
(see Table 5). 
SCC and ADV-SCC were present in some of the piglets from 
DPP 1 to DPP 12. The number of positive animals increased at 
WPP 7 to 9, reaching the usual level of older animals. This 
may be an indication that SCC activity develops only after 
birth, what coincidents with results of other investigators 
(Kim et al., 1980; Cepica and Derbyshire, 1984), who did not 
detect NK-cell activity in pig fetuses. After infection SCC 
increased on DPI 7 and ADV-SCC on DPI 14, however, these 
increases were not significant with regard to DPI 0. 
ADV-ADCC was present in 87.5% of the animals on DPP 1 
and DPP 2. Thereafter, the number of positive animals 
decreased to 15.4% at WPP 7 to 9. This decrease is 
significant. After infection this state remains until DPI 7, 
afterwards the number of positive animals rose to 90.9%. 
Non-virus specific ADCC was shown by a few pigs between 
DPP 1 and DPP 5, indicating colostral transmission of Ab 
against non-viral vaccine constituents. Afterwards this 
activity disappeared. 
It is noteworthy that no correlation existed between 
ADCC and the titres of the colostral neutralizing Ab. Animals 
with ND.. titres of 1:12 were positive in ADCC, others with 
titres of 1:195 were not, and vice versa. This differs from 
the situation after active immunization, especially after 
revaccination. Furthermore, the ability of colostral Ab to 
evoke ADCC was rather high shortly after birth but decreased 
with rising age. Colostral Ab are composed of IgG, IgA and 
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TABLE 6 Distribution of cell-mediated cytotoxicity in the body of pigs with 
colostral immunity (DPP1-12). 





Spleen Liver Thymus 
SCC 13% 13% 0% 30% 43% 5% 
ADV-SCC 13% 9% 0% 0% 57% 0% 
ADV-ADCC 65% 0% 0% 22% 43% 0% 
ADV-LYST 0% 0% 0% 8% 0% 0% 
IgM. From these only IgG react in ADCC, at least in our test 
system. It might have been that IgA and IgM had hindered the 
adsorption of IgG on the effector cells. However, during the 
first days after birth, when ADCC was present, the 
IgG/IgM/IgA ratio is 7:1:5, whereas on DPP 30 it is 12:1:1 
(Jensen and Pedersen, 1979). Therefore, it is more likely 
that the colostral Ab have lost their cell affinity in the 
course of time. 
ADV-LYST with WBC could not be detected before infection 
and during the first 4 days afterwards. It appeared from DPI 
7 onward. 
Colostral neutralizing Ab were present from DPP 1 to WPP 
9. After infection active Ab production was first detected on 
DPI 7. Until this time, the ND. values after infection 
apparently reflected colostral Ab. 
Apart from the presence of colostral Ab the 
immunological response of colostral immune pigs after 
infection was very similar to that of non-immune infected 
pigs, which was shown before. Nevertheless, all the pigs with 
colostral Ab were protected against clinical AD . They only 
had elevated temperatures, which in some cases rose up to 
40.6 C. One can conclude that colostral Ab were probably 
predominantly responsible for protection. 
The 23 piglets which were examined between DPI 1 and DPI 
12 were killed at these times to investigate the cytotoxic 
activity in different organs. Table 6 shows this 
distribution. It can be seen that SCC was predominant in 
spleen and liver, ADV-SCC in liver, and ADV-ADCC in blood and 
liver. ADV-LYST was only found in 2 cases with spleen cells 
and, as it will be shown later, with WBC too. Since these 
animals did not have contact with ADV it can be assumed that 
ADV-sensitized lymphocytes or ADV-sensitizing mediators had 
probably been transmitted via colostrum. 
Vaccination of pigs having colostral Ab is a problem 
because active Ab production is inhibited by the colostral Ab 
and protection is not optimal. Therefore, the immunological 
behaviour of pigs with colostral Ab after vaccination and 
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* Thirteen pigs (a) vaccinated at WPP 3, five pigs (b) vaccinated at WPP 6 
Underlined significant (p = 0.1) with regard to WPP 3 
after infection is of interest. 
In Table 7 the results of 2 groups are summarized. The 
first group of 13 animals was vaccinated with an inactivated 
vaccine at WPP 3 and infected 4 to 6 weeks later. A second 
group of 5 animals was vaccinated at WPP 6 and infected 4 
weeks later. Since, apart from the colostral ND.n values, the 
results of both groups were very similar it is allowed to 
compile the results. 
SCC and ADV-SCC were only detected in a few animals 
before vaccination. After vaccination SCC as well as ADV-SCC 
significantly increased. Thereby, it cannot be decided, 
whether this was due to vaccination or due to the rising age 
of the animals. After infection the two cytotoxic activities 
further increased. 
ADV-ADCC was not present at WPP 3, despite of high ND__ 
titres. After vaccination some animals became positive. After 
infection ADV-ADCC was significantly enhanced. The fact that 
not all of the animals showed significant ADV-ADCC was due to 
very high ADV-SCC cytotoxicity indices, which could not be 
significantly exceeded by the cytotoxic indices of ADCC. 
ADV-LYST was detected with 2 animals at WPP 3, 
indicating colostrally induced sensitization of the 
lymphocytes. No significant indrease occurred after 
vaccination, but after infection the number of positive 
animals rose from DPI 7 onward. 
The titres of colostral Ab were in the mean 1:420 at WPP 
3 and 1:61 at WPP 6. When vaccination was done at 3 WPP, the 
Ab titres decreased afterwards down to 1:37. This means that 
no Ab production took place and the ND. values found were 
those of colostral Ab. When vaccination was done at 6 WPP, 
the Ab titres remained rather constant what may be caused by 
limited Ab production. However, the number of animals tested 
was too small to allow a definite statement. After infection 
no significant booster effect was found on DPI 2, but it was 
present from DPI 7 onward. 
In the last experiment we investigated the influence of 
revaccination on colostral immune pigs. The animals were 







































































Only lymphocyte fraction tested 
Underlined significant in comparison to WPP 3 
and infected 25 days afterwards. The results are given in 
Table 8. 
SCC and especially ADV-SCC were found with a part of the 
animals at WPP 3. The first vaccination did not alter the 
reactivity of the animals, but after revaccination an 
insignificant enhancement of SCC was seen. Infection evoked 
not significant enhancement of SCC, but the number of ADV-SCC 
positive animals increased. 
None of the animals showed ADV-ADCC on WPP 3, despite of 
high titres on neutralizing Ab. After the first vaccination 
positive animals were present and their number increased 
significantly after revaccination. After infection, no pig 
was positive on DPI 7, however, in this case we used purified 
lymphocytes for ADCC and thus the majority of reactive cells 
(monocytes and neutrophils) were not present. 
ADV-LYST was not detected at WPP 3 but it occurred after 
vaccination and revaccination with a part of the animals and 
it was enhanced after infection on DPI 7. 
The first vaccination did not evoke Ab production since 
the titres of colostral Ab fall from 1:904 before vaccination 
to 1:68 at WPV 3. Revaccination evoked in some of the animals 
a slight booster effect and on account of this the mean ND. 
values rose to 1:134 on DPRV 12. On account of the half-life 
time of neutralizing ADV-Ab, which is about 10 days (Wittmann 
and Jakubik, 1979), one can assume that the level of the 
colostral Ab still present would have been in the mean about 
1:34, however, the real ND value was 1:111. This indicates 
active Ab-production. After infection a moderate booster 
effect was found on DPI 7 and a very strong one on DPI 14. 
Thus, revaccination could obviously overcome the 
inhibitory effect of colostral Ab. This result coincidents 
with earlier investigations (Wittmann, 1983). 
All the vaccinated and revaccinated animals were 
protected against clinical AD when infected. They only showed 
fever of different intensity but no significant differences 
could be found between the 3 groups. However, differences 
existed with regard to the duration of nasal virus excretion. 
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This declined in succession non-vaccinated + vaccinated + 
revaccinated animals, but no group-significant differences in 
virus titres could be detected. 
CONCLUSIONS 
What general conlusions can be drawn from the results of 
the experiments? Since the animals did not show an uniform 
reactivity, but great individual variations, the number of 
animals used was too small to reflect the real situation. 
However, some tendencies can be noticed nevertheless. 
At infection the degree of spontaneous cell-mediated 
cytotoxicity against ADV infected cells with and without 
interferon participation may be of importance for the further 
course of infection and of clinical disease. This corresponds 
with results found with HSV and murine cytomegalo virus 
(Ching and Lopez, 1979; Quinnan et al., 1982). Nothing is 
known at present about the role of CTL in the early phase of 
infection. However, with other herpes virus infections about 
one week elapses until CTL are demonstrable (Quinnan et al., 
1978, 1980; Rouse and Babiuk, 1977). Ab production does not 
occur until the initiation of pathologic processes. Therefore 
direct Ab/virus interaction, complement-dependent cytolytic 
effects of Ab (Martin et al., 1983), ADCC and T-cell 
cytotoxicity might only be of influence in later phases of 
infection and in recovery. 
In vaccinated pigs neutralizing Ab seem to be the main 
factor of protection against ADV infection. They can act as 
described before. However, revaccination is necessary to 
evoke an optimal immunological Ab-dependent response. 
Besides, spontaneous cell-mediated cytotoxicity may limit 
local ADV multiplication. T-cell participation remains still 
open. The occurrence of fever without clinical signs of AD in 
vaccinated pigs might be an expression of immunological 
cytotoxic events in the body. However, protection against 
infection is apparently not only a matter of the immune 
state, but it is also influenced by different forms of the 
pathogenesis of ADV infection. For example, vaccinated cattle 
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with high serum Ab titres were not protected against ADV 
(Wittmann et al., 1983). Thus the virus must have multiplied 
on places and spread on ways which were not accessible to 
immune defense, e.g. neural tissue. The same is true when the 
virus is spread in lymphocytes and in macrophages. 
In colostral immune pigs the colostral Ab and their 
different reactions may be of main importance for protection 
against ADV infection, thereby ADCC apparently plays a 
secondary role. Besides sponataneous cell-mediated 
cytotoxicity may act immediately after infection. The 
inhibitory effect of colostral Ab on active Ab production 
after vaccination can be overcome by revaccination, and 
various Ab-dependent immunological events take place. 
However, these statements are theoretical considerations 
and, as with other herpes viruses (Rouse and Babiuk, 1978), 
nobody knows what really happens in the infected animal, 
especially with regard to cell-mediated immunity, because we 
have predominantly investigated the cytotoxic response of 
peripheral blood cells, and not the cytotoxic events in the 
organs. Besides, we have completely disregarded the local 
immunological responses taking place at the places of virus 
entry. 
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ABSTRACT 
The authors describe some virological, immunological and clinical 
aspects of BHV 4 infection in cattle under field conditions and after 
experimental inoculation. The virus was isolated in several cases of 
post parturient metritis up to several weeks after the onset of symptoms. 
The virus was evidenced in all the examined lymph nodes. With the direct 
immunofluorescence test only few isolated cells were fluorescing in 
uterine mucosa and lymph nodes slides. Important fluorescent plages 
were not demonstrated. 
After recovery of the animals, no neutralizing antibodies were 
evidenced. But with the indirect immunofluorescence test and the ELISA 
test, a clear seroconversion was demonstrated. 
The chronic nature of this affection was explained by the absence 
of neutralizing antibodies in most of the affected animals. The asso­
ciated symptoms, observed in the affected herds (diarrhoea, mortinatality, 
respiratory problems in cows and calves, mastitis) were obviously riot 
due to the direct action of the virus. This Herpesvirus could play an 
immunodepressive role favouring the development of secondary affec­
tions. 
VIROLOGICAL AND SEROLOGICAL STUDY 
During the winter 1982­1983, a cytopathogenic virus was isolated 
from the lochia of more than 20 cows affected with chronic metritis. 
This metritis appeared from the fifth postparturient day on, and was 
characterized by a slow evolution and repeated breeding problems. The 
vaginal discharge was not very abundant, sanguinolent till brownish, 
and continued for several months in some cases. 
In 4 farms the metritis was accompanied by a painful peritonitis, 
resulting in the death of the animal or emergency slaughter in most 
of the cases. 
Viral isolations were chiefly obtained from the mixture of uterine 
discharge and, in two cases, from the peritoneal liquid taken resp. 
3 weeks and 3 months after the onset of symptoms. 
The isolated viruses presented all the characteristics of the Herpes 
viruses : type A Cowdry intranuclear inclusions, sensitivity to chloroform 
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and to acid pH, morphology in electron microscope examination, etc... 
These viruses were not recognized in the direct immunofluorescence test 
nor neutralized by our anti-IBR (infectious bovine rhinotracheitis), 
Aujeszky and BHM (Bovine Herpes Mammitis) antisera. At the other hand 
our anti-Movar (Mohanty et al., 1971) and DN 599 (Potgieter and Mare, 
1974) antisera crossreacted with these viruses (see table 1). 
The cytopathogenic effect (CPE) appeared slowly after 1 to 2 weeks 
The first CPE appeared often only after 2 passages, whereas the presence 
of virus in the cell culture was very rapidly (2 to 3 days) detected 
with the direct immunofluorescence test. The following passages were 
faster ( 3 - 4 days). 
No typical fluorescent lesions were detected with the direct immuno-
fluoresence (DIF) test on ultrathin sections of genital organs. Only 
few disseminated positive cells were found in the affected mucosae. 
This absence of a clear cut infection localisation suggested a type 
Df infection different from the type usually induced by other viruses. 
Only two out of 66 recovered animals showed seroneutralizing anti­
bodies, and the observed titers were very low (1/2 and 1/4), though 
the indirect immunofluorescence (IIF) and ELISA titers were very high. 
The reduction of infected cells - test confirmed the lack of neutra­
lization of infectious particles by the convalescent sera (see table 2). 
This absence of neutralization could explain the chronicity of 
the infection, and the presence of infectious particles in samples till 
3 months after the onset of clinical symptoms. These findings corres­
pond with the statements made by other authors concerning BHV 4 infection 
in cattle (Osório and Reed, 1983; Mohanty et al., 1971; Parks and Hen-
drick, 1973). 
EXPERIMENTAL INOCULATION STUDY 
The firsL isolate (LVR 140) was inoculated intravenously in 6 cows 
in late pregnancy. Five cows were slaughtered one month after partu­
rition, one cow died one week after calving. 
The following conclusions were drawn from this experimental ino­
culation : 
1 . The 6 cows presented a metritis with vaginal discharge starting 
a few days after parturition. A tVR 140 virus was isolated. The 
inoculation was performed in some cases more than one month before 
parturition. 
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2. The same virus was isolated from the uterine mucosa of the animals 
slaughtered one month after parturition. Nevertheless, no charac­
teristic lesions were found with the DIF test, besides a few dissemi­
nated lesions. 
3. In all the examined lymphnodes (retromammary, prescapulary, pre-
cruraly, iliacal and mediastinal) and the liver (in 3 out of 6 
cows), LVR 140 virus was isolated. Here also disseminated fluores­
cent cells were detected with the DIF test. 
4. The evolution of 11F antibodies was situated on two levels as shown 
in fig.1. No neutralizing antibodies were detected in the sera 
obtained at slaughter. The viral reisolation and the evolution 
of antibodies show that no immunization was developed after ino­
culation and that the stress of delivery induced the genital patho­
logy. 
5. No IIP nor ELISA anLibodes were detected in the precolostral blood 
samples of the newborn calves. The virus seems thus not to pass 
the placental barrier. 
6. One cow presented nasal discharge after parturition and another 
cow died one week after delivery without showing clear morphological 
lesions at autopsy. 
FIELD STUDIES 
When studying the anamneses obtained in 21 affected farms ^see 
table 3) it became obvious that the postparturient metritis was not 
the only observed symptom. This genital pathology was often accompanied 
by other troubles affecting most of the organic systems. 
In 11 farms nasal discharge and coughing was noted in affected 
cows and their calves. Smith et al., 1972 and Bartha et al., 1976 des­
cribed the isolations of BHV 4 virus in similar cases. Neonatal diarrhoea 
was observed in 11 farms. Fecal material of calves form 4 farms con­
tained important quantities of Cryptosporidium oocysts whereas in 3 
other farms no valid diagnosis was established. 
In 8 farms mammitis symptoms were stated, characterized by an in­
duration of the mammary gland and a significant enhancement of the cell 
number. Bacteriological examination revealed only ordinary bacteria 
and high numbers of yeast cells. 
Frequent mortinatilities without apparent causes were observed 
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in 7 farms. No disease symptoms, explaining these sudden deaths, were 
found at autopsy. 
Although no LVR 140 virus was found, if cherched, in other than 
the genital organs, it seems not much probable in view of their frequent 
apparence that these symptoms were due to chance. 
In the numerous samples (fecal material, milk, nasal mucous, diffe­
rent samples at autopsy) only microbial or ordinary parasites (strepto­
coccus, Cryptosporidium, yeast cells), thus few or non pathogenic agents, 
were detected. 
One may consequently suppose that this Herpesvirus play an immuno-
depressive role or that the virus profits on a decreased general resis­
tance for its development in a herd (Van Opdenbosch et al., 1984). 
However, the experimental inoculations seem to be in favour of 
the first hypothesis although we did not succeed in inducing clearly 
an immunodepressive state in the animals kept in isolated stables. 
DISCUSSION 
The mean symptom of this BHV 4 associated symptomatology is the 
chronic metritis with or without peritonitis. The chronic nature of 
the affection was explained by the absence of neutralizing antibodies. 
This allows a persistent virus excretion as appeared from the virus 
isolation from peritoneal liquid 3 weeks and 3 months after the onset 
of symptoms. The virus could be isolated only from lochia, peritoneal 
liquid and lymphoid tissues. 
From other samples (fecal material, nasal discharge, milk samples) 
only ordinary bacteria and parasites were isolated (Cryptosporidium, 
Streptococcus and yeast cells). 
No fluorescent lesions were evidenced with the DIF test. So the 
replication place of the virus was not determined. The similarity of 
this virus with MOVAR 33/63 (Mohanty et al., 1971), DN 599 (Potgieter 
and Mare, 1974) and the virus isolated by Thiry (Thiry et al., 1981) 
was demonstrated. The lymphoid-associated persistent infection may have 
marked implications in immunological disorders in cattle (Osório and 
Reed, 1983). This could be an explanation of the great diversity of 
symptoms that we observed. 
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TABLE 1 Comparison between bovine Herpesvirus strains 
Serum LVR 140 
Strains Origine 





















* Calf serum before immunization 
** Calf serum after immunization 
NIVR : National Institute for Veterinary Research 




















































* Number of positives per number examined 
()** Titer (50 CCID.™) 
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TABLE 3 Symptoms in 21 problem herds in which the LVR 140 virus 
has been diagnosed (isolation + serology) 
S Y M P T O M S O B S E R V E D 
Herds Metritis Mastitis Resp.Dis.' Neo.Diarî* Sudden death 
1 + + + + + 
2 + 
3 + 
4 + + + + + 
5 + + + + 
6 + + + 
7 + + + 
8 + + 
9 + + 
10 + + + + 
11 + + + + 
12 + + -t- + + 
13 + + + 
14 + 
15 + + + 
16 + + 
17 + 
18 + + 
19 + 
20 + + 
21 + + 
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Studies in mice and in the animal model system tree shrew 
suggest that the gene functions responsible for the virulence 
of HSV-1 in vivo are located between the viral genome coordi­
nates of 0.71 and O.83 map units. Herpes simplex virus (HSV) 
type 1 strain HFEM whose genome contains a deletion of about 
Ί kilobasepairs (kbp) between 0.7 and 0.8 map units is patho­
genic in the tree shrew when the animals are inoculated intra­
venously, intraperitoneally and/or subcutaneously. Similar re­
sults were found using Balb/c mice. Studies of the state of 
viral latency in animals infected with HSV-1 strain HFEM re­
vealed that this strain was unable to colonize the ganglia of 
tree shrews. In contrast infectious virus could be recovered 
only from the spleens of latently infected tree shrews. Thus, 
this system offers new opportunities for investigating the ge­
ne functions responsible for the virulence of HSV-1. Marker 
rescue experiments were performed by the cotransfection tech­
nique using native DMA of HSV-1 strain HFEM and the Bam HI DNA 
fragment Β which was derived from the pathogenic HSV-1 strain F 
and cloned in a bacterial vector. A variety of intratypic re­
combinants was established in which the deleted genome region 
of HSV-1 strain HFEM was replaced. The pathogenicity of these 
recombinants was examined in vivo. Two out of nine recombinants 
caused generalized and lethal herpesvirus infection in the 
tree shrew. 
The exact map position of the deletion in the genome of HSV-1 
strain HFEM was determined using a recombinant plasmid con­
structed by insertion of the Bam HI DNA fragment Β of the HSV-1 
strains HFEM, F, and different recombinant viruses in the 
plasmid vector pAT153. The analysis of the insert of these re­
combinant plasmids using a variety of restriction enzymes and 
Southern blot hybridization revealed that the HpaI DNA frag­
ment Ρ of the intact viral genome of HSV-1 strain F is not 
present in the genome of HSV-1 strain HFEM,indicating that the 
deletion in HSV-1 strain HFEM corresponds to the Hpa I DNA 
fragment Ρ spanning the map coordinates 0.762 to 0.790 of the 
genome of HSV-1 strain F. The size of the deletion was found 
to be 4.1 kbp. 
INTRODUCTION 
The investigation of the pathophysiological mechanism of 
herpes simplex virus (HSV) infection is of special interest, 
since it focusses attention on the determination of the gene 
function responsible for tropism and virulence of HSV. Diffe­
rent animals, especially rodents, have been used in the last 
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decade to study tropism, pathogenicity and latency of HSV. The 
pathogenicity of the different HSV types 1 and 2 has been in­
vestigated in the animal model system tree shrew (Darai et al. 
1978, 1980, 1982, 1983, 1983a; Scholz et al. 1983; Darai & 
Scholz, 1984). These studies revealed that HSV-1 and HSV-2 are 
highly pathogenic in juvenile and adult tupaias. An infectious 
dose of less than 1.0x103PFU led to 100% lethality in juveni­
le animals. The clinical picture of the HSV infection was ma­
nifested as a state of herpetic hepatitis when the animals 
were inoculated intravenously, intraperitoneally and subcuta-
neously. The latent HSV was reactivated from the ganglia of 
those adult animals which survived an acute HSV infection and 
were sacrificed several months and/or years after inoculation. 
The genomic alterations at 0.1-0.22, 0.73-0.82 and 0.91-1.0 
map units of the HSV-1 genome were found to be associated with 
the avirulence and change of organotropism for latent HSV from 
the ganglia of the central nervous system (CNS) to the spleen 
in the reticular endothelial system (RES) in the tree shrew 
(Scholz et al. 1983; Darai & Scholz 1984). Thompson et al. 
(1983) recently reported that HSV-1 DNA region from 0.71-0.83 
map units was especially associated with the function respon­
sible for neurovirulence when tested in mice. Therefore it was 
of importance to prove the role of this gene region. 
The suspected gene region of the nonpathogenic HSV-1 can now 
be studied more closely by replacing it with the corresponding 
intact cloned DNA fragments of a pathogenic HSV strain using 
DNA cotransfection experiments and this is the subject of this 
report. 
MATERIAL AND METHODS 
The experimental approach for this investigation (e.g. vi­
rus, animals, cocultivation, preparation of viral DNA, molecu­
lar cloning, transfection procedure, restriction enzyme analy­
sis, Southern blot hybridization and nick translation) was 
carried out as described previously (Darai et al. 1978, 1980, 




Following a primary infection presenting with different 
clinical pictures HSV usually persists in a latent-state and 
remains lifelong in the animal. Spontaneously reactivated la­
tent virus can result in other clinical diseases. The mecha­
nism of this complex process is not completely clear. To under­
stand the mechanism many detailed biological and molecular-
biological investigations are necessary. A first step for 
achieving this goal is to determine the gene functions and the 
corresponding gene regions responsible for the biological pro­
perties of HSV in vivo, such as viral tropism, virulence and 
latency. Recently the genome regions at 0.72-0.83 map units 
(Scholz et al. 1983) and/or 0.71-0.83 map units (Thompson et 
al. 1983) of HSV-1 were suspected to be involved in the pro­
cess of pathogenicity and neurovirulence. The following stra­
tegy was chosen to investigate these observations in more de­
tail. 
Experimental approach 
HSV-1 strain HFEM with a deletion of 4 kbp between the 
coordinates at 0.7 and 0.8 map units of viral genome, which is 
known to be apathogenic in mice (Halliburton, personal commu­
nication), nas used for the experimental infection of tree 
shrews. For demonstrating that the deleted region in the ge­
nome of HSV-1 strain HFEM is indeed located in the Bam HI DMA 
fragment Β of the viral DMA it was analysed usir.s a variety of 
restriction endonucleases and the resulting cleavage patterns 
were compared to the intact viral genome of HSV-1 strain F. It 
was found that the deleted Bam HI DMA fragment Β of HSV-1 
strain HFEM is resistent to restriction endonucleases Eco RI, 
Hind III, BglII, PvuII, and Xbal. The homology of the DMA se­
quences of the deleted Bam HI DMA fragment Β of'HSV-1 strain 
HFEM to the intact Bam HI DMA fragment Β of HSV-1 strain F was 
32 conformed using Southern blot hybridization test. P-labelled 
DMA of the recombinant plasmid pHSHF-B-B harbouring the Bam HI 
DMA fragment E of HSV-1 strain HFEM was hybridised to Bam HI 
digested DNAs of HSV-1 strain F, HSV-1 strain HFEM, recombi-
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nant plasmid pHSF-B-B harbouring Bam HI DNA fragment Β of 
HSV-1 strain F, and pHSHF-B-B. The results of this analysis 
are shown in Figure 1. Positive hybridization was found to the 
DNA sequences of the Bam HI DNA fragments Β and E of HSV-1 
strain F (Figure IB, lane 3), to the corresponding Bam HI DNA 
fragments Β and E of HSV-1 strain HFEM (lane 5), and to the 
individual recombinant plasmids pHSF-B-B (lane 4) and pHSHF-B-B 
(lane 6). 
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Arrows mark the position of the deleted Bam HI DNA frag­
ment of HSV-1 strain HFEM. 
It is well documented that the tree shrew is highly susceptib­
le to wild-type HSV-1 and 2 which causes 100% lethality (Ta­
ble 1) in juvenile animals by generalized viral infection and 
predominantly herpetic hepatitis (Darai et al. 1978, 1980). 
TABLE 1 Pathogenicity of herpes simplex virus 1 and 2 
(wild type) in Tupaia belangeri (tree shrew). 
Wild type Route of Lethality 




Herpes Virus Infection 
-HERPETIC HEPATITIS-
Necrosis of 
Stomach, Intestine and 
Adrenal Gland 
Generalized 
72.3% Herpes Virus Infection 
-HERPETIC HEPATITIS-
Necrosis of 
Stomach, Intestine and 
Adrenal Gland 
s.o.: subcutaneously, i.m.: intramuscularly, i.p.: intraperitoneally, 
i.v.: intraveneously, p.o.: per os. 
If HSV-1 strain HFEM was not able to induce generalized herpes­
virus infection in the tree shrew this system could be applied 
to the second step of this investigation, in which the dele­
tion in the altered gene regions of the nonpathogenic HSV-1 
strain HFEM could be repaired by replacing it with the corre­
sponding intact cloned DMA fragment of a pathogenic HSV-1 
strain using DMA cotransfection experiments which allow the ge­
neration of intratypic recombinants. One can assume that gene­
tic information coded on the DNA sequence of the. Bam HI DMA 
fragment Β from HSV-1 strain F which is pathogenic for the ju­
venile tupaia could be transduced to the apathogenic HSV-1 
strain HFEM using this experimental approach (Table 2). There­
fore the recombinants generated should acquire new properties 
concerning their pheno- and/or genotype and could be virulent 
in vivo for juvenile tupaias. 
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TABLE 2 Transduction of virulence ir. herpes simplex vi­
rus type 1 from a pathogenic to an apathogenic 
strain by a cloned viral DNA fragment. 
PATHOGENIC STRAIN: HSV-1 strain F 
CLONED VIRAL DNA: Bam HI DNA fragment Β from HSV-1 F 
APATHOGENIC STRAIN: HSV-1 strain HFEM with adeletion* 
between 0.7 and 0.8 map units of 
viral genome. 
TRANSDUCTION METHOD: DMA-cotransfection on BHK-1 cells 
RECOMBINATION EVENT: Homologous, intratypic 
TEST ANIMAL: tree shrew 
* The size of the deletion was found to be 4.1 kilobase-
pairs corresponding to 2.7 megadalton; spanning the co­
ordinates 0.762 to 0.790 of the intact HSV-1 genome 
(Rosen & Darai 1985). 
Pathogenicity and state of viral latency of HSV-1 strain HFEM 
in tree shrew and mice. 
The susceptibility of juvenile tree shrews to HSV-1 
strain HFEM was investigated.The animals were inoculated by 
different routes (i.v., s.o., i.p., and i.e. with 1 χ 10 PFU / 
animal). The results of this study are shown in Table 3, part 1. 
It was found that HSV-1 strain HFEM was not pathogenic in the 
tree shrew when the animals were inoculated intravenously, 
subcutaneously and/or intraperitoneally. No clinical picture 
of illness was observed in these animals. As shown in earlier 
reports different strains of other HSV types 1 and 2 with in­
tact genomes are able to kill juvenile tree shrews within a 
few days (1 χ 10 PFU / animal) with the clinical picture of ge­
neralized herpetic hepatitis (Darai et al. 1978, 1980). In 
contrast it was found that after direct intracranial adminis­
tration of HSV-1 strain HFEM the animals developed a focal 
7 
encephalitis following an infection with 1 χ 10 PFU / animal. 
These animals showed the clinical picture of paresis and were 
sacrificed when moribund and autopsied immediately after death. 
The analysis of the different specimens from these animals for 
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TABLE 3 Sensitivity of juvenile tree shrews and Balb/c mice to infection with 
HSV-1 strain HFEM in comparison to the HSV-1 strain F. 
-vl 
CO 
Part HSV-1 PFU of virus/ No. of animal Time of Titre of HSV (PFU/g*tissue) 
animal dead/No. of death 





















































1(M) 1.0x10 (i.p.) 3­1 
plaque forming units/gram­1 issue ; the resulting titres of virus obtained from the plaque 
assay were normalised to 1.0 gram of the corresponding original tissue. 
virus isolated from the spleen of animal No.T13 which was inrected with HSV­1 strain HFEM. 
t
fnemanimaísdw:reSi^cul^:rwÍ¿h five virus stocxs of HSV­1­HFEM which were established from individual 
single plaques isolated after transfection of BHK­21 cell cultures with native DNA of HSV­1­HFEM. 
; Tupaia 
: Mouse 
Detailed necropsy and histopathology showed that the only af­
fected organ was the brain. The meninges were partially hemor­
rhagic and adhering to the skull only in the injection area. 
No specific alterations were found in other organs. The indi­
vidual viruses isolated from the brain tissue of the animals 
were identified by analysis of the viral genomes. Comparisons 
of the DNAs of these isolates and the DNA of the original in­
oculum by restriction enzyme analysis revealed no changes in 
the fragmentation patterns. 
For comparison, the data obtained in this study and the pat­
tern of virus spread and viral progeny in tree shrew after ge­
neralized herpesvirus infection with HSV-1 strain F are pre­
sented in Table 3, part 2. To demonstrate the lack of pathoge­
nicity of HSV-1 strain HFEM, additional experimental infec­
tions were performed using Balb/c mice. The results of these 
studies, as shown in Table 3, part 3 and 1 are completely si­
milar to data obtained from tree shrew. Taken together, this 
indicates that HSV-1 strain HFEM with a deletion of 1 kbp οΓ 
its genome located on the Bam HI DNA fragment Β is neither 
pathogenic in tree shrew nor in Balb/c mice under these condi­
tions . 
The state of viral latency was studied in those tree shrews 
which survived an infection with HSV-1 strain HFEM. The ani­
mals were sacrificed at different times after infection and 
specimens of blood, purified leukocytes, brain, cervical, tho­
racolumbar and sacral segments of spinal cord, thymus, spleen, 
and kidney were screened for recovery of infectious viruses by 
the cocui tiva tion technique using RC-37 cell cui tures.Al though 
a variety of specimens from the infected animals was used for 
recovery of latent virus, infectious HSV was recovered only 
from the spleen of the animals as shown in Table 3, indicating 
that the target organs responsible for the persistence of la­
tent HSV-1 strain HFEM in the tree shrew was the spleen of the 
reticulo-endothelial system and not the ganglia of the central 
nervous system as known for wild-type HSV. The analysis of the 
genomes of the various viruses isolated from the spleen of the 
animals, which were picked individually from single plaques, 
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was performed. The DNAs of each isolate were cleaved with dif­
ferent restriction endonucleases and the resulting DNA frag­
ments were separated by slab gel electrophoresis. A compara­
tive analysis of the DNAs from these isolates and the DNA from 
the original inoculum by restriction enzyme analysis revealed 
no changes in the fragmentation patterns (Rosen et al. 1984). 
Since the biological properties of the viruses isolated from 
the spleen were of special interest, some of these strains we­
re used to re-infect tree shrews. Juvenile tree shrews were 
inoculated as shown in Table 3, part 1, with such re-isolates 
under the same conditions as used for HSV-1 strain HFEM. As 
shown in Table 3, part 1, pathogenicity and latency of those 
isolates which were recovered from the spleens of tree shrews 
were similar to those of HSV-1 strain HFEM. 
The results obtained from experimental infection in tree 
shrews with HSV-1 strain HFEM demonstrate clearly that this 
strain cannot induce generalized herpesvirus infection in the 
tree shrew. Therefore this system is the model of choice for 
further molecularbiological studies. Ultimately these studies 
should prove whether or not a correlation exists between the 
presence of the deletion located on the Bam HI DNA fragment Β 
of the genome of this strain and the apathogenicity of this 
virus in tree shrew. 
Generation of intratypic recombinants for replacing the dele­
ted region. 
Three pmol of cloned Bam HI DNA fragment Β of HSV-1 
strain F which were derived from recombinant plasmid pHSF-B-B 
were coprecipitated with 0.01 pmol native intact DNA from 
HSV-1 strain HFEM and used for transfection of BHK-21 cell 
cultures. When generalized cytopathic effects occurred the to­
tal cultures were frozen, thawed and sonicated.and the cell 
free supernatant was used for single plaque isolation. The in-
32 dividual single plaques v/ere screened using P-labelled viral 
DNA and digestion with restriction endonucleases. As shown in 
Figure 2 one novel Bam HI DNA fragment appeared in the slab 
gel electrophoresis between the migration position of the 
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Bam HI DNA fragments A and C of HSV­1 strain HFEM DMA indica­
ting that intratypic recombination events in this specific re­
gion of the genome of HSV­1 strain HFEM must have taken place. 
Twelve out of nineteen single plaque isolates showed this new 
fragment. The size of this newly developed DMA fragment varied 
and reached a maximum size of 10.2 kbp in some of the recom­
binants. Further detailed analyses using different restriction 
endonucleases were carried out to identify the new DMA frag­
ment. It was found that the newly generated Ban HI DMA frag­
ment was resistant to Hind III (Figure 3), Eco RI and BglII, 
and Xba I (data not shown). 
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Fig.3 Autoradiograms of 3 P DNAs of two recombinants C 19 
(panel B) and C15 (panel C), and HSV­1 strain F (panel A) 
and HSV­1 strain HFEM (panel D ) . The DNAs were digested 
with Hind III (each lane 1), Bam HI (each lane 3), and 
double digestion with Bam HI and Hind III (each lane 2).The 
arrows mark the position of the novel generated Bam HI DNA 
fragment B. 
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In contrast, Hpa I (Figure U) cuts this novel generated Bam HI 
DNA fragment indicating that this DNA fragment originates from 
the Bam HI DNA fragment B. The different size of the newly ge­
nerated DNA fragment in different isolates is due to the 
slightly variable length of the DNA sequences which recombined 
from the cloned Bam HI DNA fragment Β of HSV­1 strain F into 
the corresponding genome region of HSV­1 strain HFEM. 
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32 Fig.4 Autoradiograms of Ρ DNAs of recombinant virus 
HSV­R­HFehx­C19 (panel B), HSV­1 strain F (panel A), and 
HSV­1 strain HFEM (panel C). The DNA samples were diges­
ted with restriction endonucleases Hpa I (each lane 1), 
Bam HI (each lane 3), and double digestion with Hpa I and 
Bam HI (each lane 2). The small arrow marks the position 
of the novel generated Bam HI DNA fragment B. 
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C h a r a c t e r i z a t i o n of r e c o m b i n a n t s : 
B i o l o g i c a l p r o p e r t i e s 
The c y t o p a t h i c e f f e c t (CPE), t he format ion of s y n c y t i a 
and the s i z e of p l aques produced by i n d i v i d u a l l y i s o l a t e d r e ­
combinants were s t u d i e d in comparison to the p a r e n t a l HSV­1 
s t r a i n HFEM and HSV­1 s t r a i n F from which the Bam HI DMA f r a g ­
ment Β vías c l o n e d . Some of the r ecombinan t s induced only round 
c e l l CPE and o t h e r s smal l s y n c y t i a on RC­37 c e l l c u l t u r e s . The 
b i o l o g i c a l p r o p e r t i e s of the i s o l a t e d r eco m b in an t s a r e summa­
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* VIRUS WAS PROPAGATED IN MONKEY KIDNEY CELL CULTURE (RC-37) 
** RC-37 CELL CULTURES WERE INFECTED WITH A MOI OF 0.01 PFU/CELL OF EACH VIRUS STRAIN 
AND INCUBATED AT 37°C FOR 24 HOURS. 
*** 100% LETHALITY IN JUVENILE TREE SHREW 
ND=N0T DONE 
RC=ROUND CELL CPE, SS=SMALL SYNCYTIAL PLAQUES, LS=LARGE SYNCYTIAL PLAQUES 
CPE= CYTOPATHIC EFFECT 
P a t h o g e n i c i t y 
To answer the c a r d i n a l q u e s t i o n in t h i s exper iment wheth­
er or not the r ep lacement of the d e l e t e d genome r e g i o n of the 
a p a t h o g e n i c HSV­1 s t r a i n HFEM with the c o r r e s p o n d i n g cloned 
DMA fragment from the p a t h o g e n i c HSV­1 s t r a i n F can l ead to 
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the generation of pathogenic HSV recombinants, the following 
experiments were done. The recombinant viruses HSV-R-HFehx-C3, 
15, 16, 19, 21, 25, 26, 34, and 39 were used for testing their 
virulence in the tree shrew. Juvenile tree shrews were inocu­
lated intraperitoneally with individual HSV recombinants by 
administration of 1x10 PFU / animal. Among the recombinant vi­
rus strains tested, the recombinants HSV-HFehx-C19 and C26 
were found to be pathogenic for tree shrews. The animals deve­
loped the clinical picture of generalized herpesvirus infec­
tion and died five days after inoculation. Histopathological 
studies of different organs revealed a generalized herpesvirus 
infection. The liver tissue showed several parenchymal changes 
with foci of hemorrhagic necrosis, a state of typical herpetic 
hepatitis. The electron microscopy showed herpesvirus nucleo-
capsids in different stages of maturation mainly within the 
nuclear portions of liver cells. For the determination of new 
viral progeny and virus spread a variety of specimens inclu­
ding blood, liver, spleen, kidney, adrenal gland and brain we­
re taken from the animals and tested by plaque assay. The re­
sults of these assays, which are shown in Table 5, demonstrate 
clearly the state of generalized herpesvirus infection in ju­
venile and adult tree shrews after intraperitoneal adminis­
tration of recombinant viruses HSV-R-HFehx-C19 and C26. Indi­
vidual viruses isolated from different tissues were identified 
by analysis of the viral genomes. A comparison of the DNAs 
from these isolates and the DNA of the originally inoculated 
virus by different restriction enzyme analyses revealed no 
changes in the fragmentation patterns, especially with respect 
to the novel replaced Bam HI DNA fragment B, thus indicating 
the genetic stability of the genomic arrangement of recombinant 
viruses HSV-R-HFehx-C19 and C26 after in vivo passage. 
The susceptibility of juvenile and adult tree shrews to infec­
tion with recombinant virus HSV-R-HFehx-C19 was investigated 
in more detail. The animals were inoculated with an infection 
dose of 1 χ 10 to 1 χ 10 PFU / animal intravenously, intraperi-U toneally and subcutaneously. It was found that 1 χ 10 PFU are 
still able to induce generalized herpesvirus infection in ju-
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TABLE 5 D i s t r i b u t i o n o f v i r a l p r o g e n y i n d i f f e r e n t o r ­
g a n s o f t r e e s h r e w s w i t h g e n e r a l i z e d h e r p e s v i ­
r u s i n f e c t i o n a f t e r i n j e c t i o n w i t h r e c o m b i n a n t 
v i r u s H3V-R-HFehx-C19 . 
Organs 
Blood 





Adrenal g lands 
T e s t i s 
Asc i t es 
T i t e r o f v i r u s 
A n 1 
J uven i l e 
7.56 x 1 o 3 
5.48 Χ ί ο ' ' 
1 . 2 0 X 1 0 1 
9.80 χ I O 1 
δ ^ χ Ι Ο 4 
2.86 χ IO 5 
2.24 χ IO 2 





3.47 χ 1 0 5 
8.68 χ ΙΟ 7 
IID 
I1D 
6.50 χ Ι Ο 3 
3.33 Χ 10^ 
(PFU/g* t i s s u e ) 
m a 1 
a d u l t 
6.25 χ IO 3 
5.63 χ IO 4 
1.13 χ IO 4 
4.60 χ IO 4 
7 . 0 0 X 1 0 5 
1.50 x 1 0 e 
2 . 7 2 x 1 0 ^ 
1 . 2 9 X 1 0 5 
4.18 x 1 o 3 
2.98 χ IO 4 
2 . 0 0 Χ 1 0 2 
3.92 χ IO 3 
2. 88 χ IO5 
1.41 χ IO 7 
1.53X IO 3 
2.55 χ IO 4 
ND 
HD 
'PLAQUE FURM1NG UNITS/GRAM TISSUE; THE RESULTING TITERS 
OF VIRUS OBTAINED TRON THE PLAQUE ASSAY WERE NORMALISED 
TO 1.0 GRAM OF THE CORRESPONDING ORIGINAL TISSUE. 
ND=NOT DONE 
venile tree shrews. In contrast those animals which were ino-
3 culated with 1 χ 10"PFU or less survived the infection, ι he 
possibility that the latent infection can occur in surviving 
animals was investigated by cocui tivating spinal cord, brain, 
spleen, and other organs. Surprisingly, infectious virus was 
recovered only from spinal cord of these animals, indicating 
that the target organ for viral latency for these animals is 
the ganglia of central nervous system in contrast to its pa­
rental virus strain (HSV-1 strain HFEM), which can only be re­
covered as a latent virus from the spleen of the tree shrews. 
Genome analysis of the isolated viruses from the spinal cord 
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of the animal was carried out using restriction enzyme analy­
sis. No changes in the DNA fragmentation patterns of these 
isolates were detected. 
Localization of the deletion 
For mapping the deleted genome region of HSV-1 strain HFEM 
which was apathogenic in mice and tree shrews the Bam HI DNA 
fragment Β of HSV-1 strain HFEM, HSV-1 strain F, and the re­
combinant HSV (HSV-R-HFehx-C19, C26, and C15) were analysed in 
detail. A variety of recombinant plasmids, as listed in Table 6, 
was established which harbour the Bam HI DNA fragment Β of 
HSV-1 strain HFEM (pHSHF-B-B), HSV-1 strain F (pHSF-B-B), and 
of the recombinant virus HSV-R-HFehx-C19 (pHSR19-B-B), HSV-R-
HFehx-C26 (pHSR26-B-B), and finally HSV-R-HFehx-C15 (pHSR15-B-
B). The DNAs of the recombinant plasmids were digested with the 
restriction endonuclease Bam HI and the resulting cleavage pat­
terns were compared to the corresponding Bam HI cleavage pat­
terns of individual donor HSV genomes. It was found that the 
insert of each recombinant plasmid migrated at the position of 
the Bam HI DNA fragment Β of the parental viral DNA. The iden­
tity of the inserts of the recombinant plasmids to its origi­
nal viral genome and its DNA sequence homology to each other 
32 was confirmed using Southern blot hybridization of P-label-
led pHSHF-B-E DNA to Bam HI digested DNAs of HSV-1 strain HFEM, 
HSV-1 strain F, and HSV-R-HFehx-C 19 as well as to the DNAs of 
pHSF-B-B and pHSR19-B-B. The results of this analysis are 
shown in Figure 1A. The data revealed that the DMA of the re­
combinant plasmid pHSHF-B-B harbouring Bam HI DNA fragment Β of 
HSV-1 strain HFEM hybridized to the Bam HI DMA fragment Β of 
HSV-1 strain F (lane 3), HSV-1 strain HFEM (lane 5), recombi­
nant virus HSV-R-HFehx-C19 (lane 8), and the Bam HI DMA frag­
ment Β of HSV-1 strain 17 (lane 1), which served as internal 
marker. Positive hybridization was found to the DNA sequences 
of the Bam HI insert of the recombinant plasmids pHSF-B-B 
(lane 4), pHSR19-B-B (lane 7), and to HSHF-B-B (lane 6). As 
shown in Figure IA the 32P-labelled DNA of the plasmid pHSHF-
B-B hybridized to the Bam HI DMA fragment E of HSV-1 strain 17 
(lane 1), HSV-1 strain F (lane 3), HSV-1 strain HFEM (lane 5) 
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Table 6 Properties of individual recombinant plasmids. 
co 
to 
Recombinant Corresponding Ho. 
Plasmid to panel C , F i g . 7 DNA fragment o f 
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Β (F) Κρη I deleted 
Β (F) Hpa I(P)deleted 
Β (F) Hpa KPWideleted 
B (F) Miu I deleted 
Β (HFEM) Miu I deleted 
B (R19) Miu I deleted 
B (F) Sal I deleted 
(F) ­, 
(HFEM) 
CR 19 ) 
CR 15) 




























7 3 8 - 0 . 7 8 6 
7 3 8 - 0 . 7 6 2 
7 3 8 - 0 . 7 5 1 
7 3 8 - 0 . 7 5 5 
7 3 8 - 0 . 7 5 5 
7 3 8 - 0 . 7 5 5 
4 0 . 8 0 2 
4 0 . 7 8 6 
4 0 . 7 8 6 
4 0 . 7 9 6 
4 0 . 7 9 6 
4 0 . 7 9 6 
■0 .809 
• 0 . 8 0 9 
• 0 . 8 0 9 
• 0 . 8 0 9 
■ 0 . 8 0 9 





derived from pathogenic recombinant viruses HSV­R­HFehx­C 19 and C26. 
derived from apathogenic recombinant virus HSV­R­HFehx­C 15. 
derived from apathogenic HSV­1 strains AK and F­BJAB which were kindly provided by Professor Kleinschmidt:, 
Department of Virology, University of Ulm, FRG . 
derived from apathogenic HSV­T­161B (Darai et al. 1982) 
exact position of the deletion not yet determined. 
p_X­CE­Mlu I vector which contains one Mlu I recognition site was constructed by insertion of phage lambda 
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In order to determine the position of the deletion in the vi­
ral genome a variety of restriction endonucleases was used. The 
results of these experiments are shown in Figure 5. 
The recombinant plasmids pHSF-B-B, pHSHF-B-B, pHSR19-B-B, 
pHSR26-B-B, and pHSR15-B-B were cleaved with restriction en­
zyme Hpa I and the resulting DNA fragments were separated by 
agarose slab gel electrophoresis. Three DNA fragments were ge­
nerated after cleavage of pHSF-B-B with Hpa I. In contrast, 
when the pHSHF-B-B plasmid was analysed under the same condi­
tions, only two DNA fragments were generated. The absence of 
the Hpa I DNA fragment Ρ revealed that the deletion in the 
Bam HI DNA fragment Β of HSV-1 strain HFEM maps in the Hpa I DNA 
fragment Ρ of the corresponding intact viral genome. The gene­
ration of the Hpa I DNA fragment W (0.751 to 0.762 viral map 
units) in the case of all recombinant plasmids after digestion 
with HpaI indicates that the recognition site of HpaI at the 
Ο.762 map units of the viral genome is intact. The restriction 
endonuclease Sal I recognizes two positions in the DNA of the 
insert of all five recombinant plasmids corresponding to the 
0.7^6 and 0.790 map units of the intact viral genome. This in­
dicates that the Sal I recognition site at the 0.790 map units 
is present in all DNA species. Further analysis revealed that 
the deleted DNA sequences in the genome of HSV-1 strain HFEM 
are spanning map coordinates 0.762 to 0.790 of the HSV-1 DNA 
(Rosen & Darai 1985). The size of the deletion was found to be 
1.1 kbp corresponding to 2.7 Md. The DNA of the pHSR19-B-B 
plasmid was analysed under the same conditions. It was found 
that the DNA of this plasmid has three recognition sites for 
Hpa I enzyme similar to the pHSF-B-B plasmid, but different 
from pHSHF-B-B which has only two cleavage sites for this en­
zyme. The presence of the HpaI DNA fragment Ρ of the pHSR19-B-B 
plasmid with the size of 3.15 kbp indicates that the deleted 
region in the genome of HSV-1 strain HFEM was substituted by 
about 3.I5 kbp of corresponding DNA sequences of the Bam HI 
DNA fragment Β of HSV-1 strain F. 
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Fig.5 Identification of the deletion in the genome of 
HSV­1 strain HFEM and its map location. DMA sequence ar­
rangements across the BamHI DNA fragment Β of HSV­1 
strain F, determined using recombinant plasmid pHSF­B­B. 
Panel A: Map of the genome of HSV­1 strain F for BamHI 
(Mocarski& Roizman 19 81) and for Hind III , Eco RI , and Hpa I 
(Morse et al. 1977). Panel Β: The location of the deletion 
in the genome of HSV­1 strain HFEM based on the results 
presented here, and the location of heterogenic!ty based 
­■ ". the results previously published by Locker & Freηkel 
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(1979). The position and direction of the arrows for re­
striction endonuclease SmaI show the external limitation 
of recognition sites. Between the two marked positions 
eight additional fragments exist, whose positions are not 
yet determined. The position and direction of the arrows 
for restriction endonuclease AluI show the internal limi­
tation of recognition sites. Beside these positions there 
is a variety of recognition sites for this enzyme.Panel C : 
Constructed recombinant plasmids (for detail see Tableó). 
The localization of the gC and syn phenotypes (panel A) is 
based on results described by Pogue­Geile et al. (1981) 
and the position of IEmRNAs and ICPOand 27 (panel B) are 
based on results described by Jacquemont et al. (1981). 
DISCUSSION 
The experimental approach and strategy for the determina­
tion of the genome region responsible for virulence of HSV­1 
in vivo used in this report and the results obtained demonstra­
te that the genetic information located on the DNA sequence 
region of Bam HI DNA fragment Β at the coordinates between 
0.738 and O.809 map units probably seem to be involved in the 
biological process which has influence on the HSV­1 virulence. 
The hypothesis based on the facts that the replacement of the 
deleted BamHI DNA fragment Β of the apathogenic HSV­1 strain 
HFEM with the corresponding cloned Bam HI DNA fragment Β of the 
pathogenic HSV­1 strain F led to the selection of pathogenic 
intratypic recombinants. The pathogenicity of the recombinant 
viruses HSV­R­HFehx­C19 and C26 is reflected in an induction of 
lethal generalized herpesvirus infection in tree shrew. An in­
fectious dose of 1 χ 10 PFU of recombinant C19 is still able to 
induce fatal viral infection in juvenile tree shrews. In con­7 trast, an infectious dose higher than 1 χ 10 PFU of HSV­1 strain 
HFEM, its subclones and/or clones derived after DNA transfec­
tion with native viral genome are still apathogenic in tree 
shrew. 
Furthermore it was observed that the ganglia of spinal cord is 
the target organ for persisting of latent recombinant virus 
HSV­R­HFehx­C19, a property known for wildtype HSV­1 and 2, but 
in contrast to the apathogenic HSV­1 strain HFEM, which can 
only be recovered as a latent virus from the spleen of the tree 
shrews. It is known that two of the five major alpha­genes, 
namely ICP 0 and ICP 27 and two immediate early mRNAs with a 
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molecular weight of 1.9 and 3 kb (Jacquemont et al. 1981) as 
well as the Cr and syn 1 and 2 loci are located at this region 
(Pogue-Geile et al. 1981). 
One other interesting aspect is that the deletion in the geno­
me of HSV-1 strain HFEM is not located at the region which is 
known for occurrence of variabilities. A heterogenicity within 
U. DNA sequences spanning map coordinates 0.71 to 0.76 of the 
HSV-1 genome has been reported (Locker & Frenkel 1979). 
Although the replacement of the deletion in the genome of the 
apathogenic HSV-1 strain HFEM using cloned viral DNA of the 
corresponding genome region of the pathogenic HSV-1 strain F 
led to isolation of recombinant viruses with an acquired viru­
lent Dhenotype, the molecular mechanisms and the functional 
activities of the viral genes at this genome region in the 
process of pathogenicity of HSV-1 in vivo are still unclear. 
Therefore further molecularbiological and biological studies, 
e.g. the genomic characterization of the BamHI DNA fragment Β 
of pathogenic and apathogenic recombinants and their parental 
viruses using heteroduplex mapping, the determination of the 
DNA sequences, the analysis of their transcripts and gene pro­
ducts are necessary for understanding the molecular mechanisms 
of tropism and virulence of HSV. 
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SUMMARY OF SESSIDN FOUR. 
HERPESVIRUS PATHOGENICITY AND THE IMMUNE SYSTEM. 
by G. WITTMANN, R.M. GASKELL and J.T. VAN OIRSCHOT. 
In this session dealing with herpesvirus pathogenicity and 
the immune response very different aspects were handled. REID 
investigated the pathogenesis and immunity of malignant 
catarrhal fever. The two distinct agents, alcelaphine 
herpesvirus 1 and the as yet unidentified "sheep-associated" 
agent have at least three antigens in common. These agents 
produce no disease in their natural hosts, wildebeest and 
sheep, but in other ruminants malignant catarrhal fever almost 
invariably runs a fatal course. Apart from ruminants the 
disease can be reproduced experimentally in rabbits, rats and 
hamsters. In all animals the large granular lymphocyte may 
represent an important target cell for the virus. It is 
hypothesized that a virus induced dysfunction of the large 
granular lymphocytes is primarily responsible for the specific 
lesions in malignant catarrhal fever, that is characterized by 
lymphoid accumulations in virtually every tissue, which are 
distant from areas of necrosis. 
CAUCHY, MAZZELLA, COUDERT and RICHARD gave a report on the 
characterization of Τ cells transformed by infection with 
Marek's disease (MD) virus by using monoclonal antibodies. The 
preparation of monoclonal antibodies against thymus cell 
membranes of chicken was described. Three clones have been 
found to react only with cells of the cortical and medullary 
areas of the thymus and two clones were reactive with certain 
subpopulations of thymocyte blood T-cells originating from MD 
tumors. Thus it was demonstrated that MD cell lines and MD 
tumor cells have a membrane determinant which is present only 
on mature chicken T—cells. 
Another paper presented by WITTMANN and OHLINGER surveyed 
the present knowledge on humoral and cell-mediated immunity 
(CMI) to Aujeszky's disease virus (ADV) in pigs. The following 
parameters were examined: neutralizing antibodies (Ab), 
spontaneous cell-mediated cytotoxicity against non-infected 
(SCC) and ADV-infected target cells (ADV-SCC), 
antibody—dependent ADV—specific eel1-mediated cytoxicity 
(ADV-ADCC), ADV-specific lymphocyte stimulation (ADV-LYST) and 
interferon production. The state of immunity before and after 
ADV infection is described with unvaccinated and vaccinated 
pigs without and with colostral Ab, and with latently infected 
pigs. It is concluded that ADV-SCC may be of importance for the 
initiation of infection. Nothing has been known with regards to 
T-cell participation during this phase. Direct Ab/virus 
interactions, complement—dependent cytotoxic effects of Ab and 
ADV-ADCC apparently may have some influence in the latter phase 
of infection and in recovery. In vaccinated pigs and in pigs 
with colostral Ab, Ab evoked reactions are primarily involved 
in protection; ADV-SCC may also play a role. 
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WELLEMANS, VAN OPDENBOSCH and ANTOINE reported on BHV-4 
isolation from cattle with post parturient metritis. The virus 
could be isolated several weeks after the onset of symptoms. 
The animals did not have neutralizing antibodies (Ab), but Ab 
could be demonstrated by the indirect immunofluorescence test 
and by ELISA and a distinct booster effect was found after 
parturition. The phase of replication of the virus is unknown 
and it is concluded that disturbed immunological functions 
exist in the animals. 
Studies of virulence genes of herpes simplex virus (HSV-1) 
were presented by DARAI and ROSEN. The location of the gene(s) 
responsible for the virulence of HSV-1 in tree shrews is known. 
Marker rescue experiments were performed by the co-transfection 
technique using native DNA of an avirulent HSV-1 strain and the 
Bam HI DNA fragment R which was derived from a pathogenic 
strain of HSV-1 and cloned in a bacterial vector. Two out of 
nine recombinants proved to be lethal for tree shrews. The 
recombinants proved to be stable. For use in vaccination it 
seems possible to produce genetechnologically virus which lacks 
the genome region coding for virulence but contains all the 
genes responsible for immunogenicity. 
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SESSION 5 
HERPESVIRUS IMMUNITY AND REACTIVATION 
Chairman : T . J . HILL 
Co-chairman : P . - P . PASTORET 
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MECHANISMS OF HERPES VIRUS LATENCY AND REACTIVATION 
WITH PARTICULAR REFERENCE TO THE IMMUNE RESPONSE 
T.J. Hill 
Department of Microbiology, Medical School, 
University of Bristol, Bristol BS8 1TD, U.K. 
ABSTRACT 
The mechanisms underlying establishment, maintenance and reactivation of 
latent infections with herpesviruses are considered, with herpes simplex virus (HSV) 
as the primary example. Particular attention is given to the role of the immune 
response at these different stages of latency. It is concluded that immune 
mechanisms may prevent access of the virus to the ' target ' cell in which latency can 
be established. However once established it seems unlikely that immune responses 
are important in maintaining the virus/cell interaction during latency. Following 
reactivation when infectious virus is produced immune mechanisms are again likely 
to be involved in clearance of virus from the tissues and thereby in determining 
whether or not recurrent disease is manifest. 
INTRODUCTION 
A number of recent reviews have dealt extensively with herpes latency, 
particularly with respect of EBV (Henle and Henle, 1982) and herpes simplex virus, 
HSV (Hill, 1984). Therefore in accord with the theme of this symposium, the present 
paper will focus particularly on the involvement of immunological mechanisms in 
the different stages of latent infection. Herpes simplex virus (HSV) will be 
discussed as the prime example but many of the general principles are applicable to 
other herpesviruses. 
Herpesviruses establish a latent infection in particular "target" cells - with 
alphaherpesviruses such as HSV the main "target" appears to be the sensory neuron 
but with gamma herpesvirus (CMV), the "target" cell is the lymphocyte. Evidence 
for latent infection in neurons is strongest for HSV (reviewed by Hill, 1984). 
However there are indications that extraneural latency may also occur with HSV in 
the footpad of the mouse or guinea pig (Al-Saadi et al., 1983; Scriba, 1977) and in 
mouse skin (Hill et al., 1980). Moreover in another neurotropic alphaherpesvirus, 
Pseudorabies, viral DNA has been detected in lymphoid as well as neural tissue 
(Gutekunst, 1979). It is important to determine whether such virus in extraneural 
tissues represents true latency or merely microfoci of productive infection fed from 
primary latency in the nervous system. 
The events that encompass the virus/"target" cell interactions in latency can 
be divided into three main phases: establishment of latency, maintenance and 
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reactivation (with or without recurrent clinical disease). At each of these phases 
the virus/"target" cell interaction might be affected by various "external" factors 
such as hormones or immune effectors. In any infection where virus persists for 
long periods (with herpes viruses this is usually for a lifetime), there might be 
expected to be varied degrees of continued or intermittent virus antigen expression. 
If such expression does occur immunological mechanisms might indeed be amongst 
the "external" factors which influence the latent s ta te . 
However in the face of the selection pressures of the immune system it is also 
likely that the virus will have evolved means of avoiding complete elimination by 
the host's defences. Knowledge of such mechanisms is clearly of importance in 
understanding the pathogenesis of herpetic disease and in designing rational ap-
proaches for immunological intervention in prophylaxis or therapy. 
ESTABLISHMENT OF LATENCY 
Under natural conditions when a herpesvirus first enters the host it will rarely 
interact directly with the target cell in which latency is to be established. For 
example with HSV it is probable that such interaction will follow a period of 
replication in cells of the skin or mucous membrane. Moreover in natural infections 
the infecting dose may be very small and therefore initial replication in the 
peripheral tissues will increase the chance of HSV entering the nerve endings. 
Therefore increasing the extent of this peripheral virus growth e.g. by immuno-
suppressive t reatments , will tend to increase the incidence of subsequent latent 
infection (Blyth et al., 1980). In contrast diminishing this growth by, for example, 
anti-viral t reatment or vaccination, will have the opposite effect (e.g., Walz et al., 
1976). However since the epithelium of mucous membranes and the skin contain 
many fine nerve endings HSV may have relatively rapid access to the cytoplasm of 
the sensory neuron. Hence in the non immune host the rapid, non-specific, defence 
mechanisms are likely to be of great importance in limiting the extent of virus entry 
into the neuron. Once inside the nerve ending, i.e. in the cytoplasm of the neuron, 
HSV will be inaccessble to immune effectors and will remain so during intra-axonal 
transport to the neuronal cell body in the ganglion. 
Little is known of the crucial interactions that must occur between HSV and 
neuron in the ganglion for latency to be established. Present evidence suggests that 
these interactions can occur quickly (within 1-2 days), that particular viral genes are 
important (Watson et al., 1980) and that productive infection is unnecessary. Indeed 
if productive neuronal infection does occur this is likely to result in cell death. 
Therefore t reatments which enhance such infection have been shown to diminish the 
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incidence of latency infection and vice versa (Price and Schmitz, 1979). Hence in 
the neuron itself latency may be established with limited expression of the viral 
genome. Under such circumstances the immune system would have little or no viral 
antigens to recognise. Therefore it seems unlikely that immune effectors are 
involved in "forcing" the virus into a latent s ta te . A more likely role for the 
immune system at this stage is clearance of virus and infected cells from the 
inoculation site, the p.n.s. and c.n.s. In the later phases of the primary infection 
(and perhaps in recurrent disease) an unwanted consequence of the immune response 
may be tissue damage. In the peripheral tissue, with the exception of stromal 
disease in the cornea, such damage may be of little significance since tissues such as 
skin are readily repaired. However immunopathological reactions following HSV 
infection in the c.n.s. may lead to demyelination (reviewed by Hill, 1983) and repair 
of such damage is much more limited. 
MANTENANCE OF LATENCY 
At present the weight of evidence for HSV favours the so-called stat ic s ta te of 
latency with limited expression of the viral genome (Roizman, 1965). Only one 
report, as yet unconfirmed, describes a viral antigen (the immediate early poly­
peptide ICP4) in the nuclei in latently infected neuron (Green et al., 1981). If viral 
antigens are truly absent particularly from the plasma membrane of latently 
infected neuron, there would be nothing for immune effectors to recognise. Hence 
such effectors are unlikely to be involved in maintenance of latency. A role for 
anti-HSV immunoglobulin has been suggested in maintaining latency (Stevens and 
Cook. 1974). However this seems unlikely since in mice latent infection with HSV 
can be maintained in the absence of serum neutralising antibodies (Sekizawa, 1980). 
These animals showed seroconversion when the infection was reactivated. Factors 
which may be involved in the maintenance (and establishment) of latency are 
expression of particular viral genes and the physiological s ta te of the "target" cell 
(highly differentiated and non dividing in the case of neurons). Moreover it has been 
suggested that the methylation of the viral and/or host DNA may also be involved in 
maintaining the latent s ta te (Hill, 1984). Preliminary evidence supports this concept 
since the rate and incidence of isolation of HSV from latently infected ganglia can 
be increased in vitro by treatment with 5 azacytidine or DMSO (Whitby, Blyth and 
Hill, unpublished results). Both these drugs cause hypomethylation of DNA. 
In the case of lymphotropic herpesviruses such as EBV, there is clear evidence 
that latently infected cells can express surface viral antigens (e.g. LYDMA) and 
thereby the cells are made susceptible to at tack by cytotoxic Τ cells (Henle and 
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Henle, 1982). However lymphocytes consist of a dynamic population of cells which 
is renewed from the bone marrow. Therefore there may be compensation for the 
latently infected cells that are lost through the action of immunological effectors. 
Mechanisms for the maintenance of the number of lymphocytes latently infected 
with EB virus have been proposed (Rickinson, 1983). Unlike lymphocytes, sensory 
neurons cannot be replaced. Therefore to avoid loss of latently infected neurons by 
immune surveillance, the genome expression of neurotropic viruses such as HSV may 
be more limited in neurons than EB virus expression in latently infected lympho-
cytes. 
REACTIVATION OF LATENT INFECTION 
Reactivation is the process by which infectious virus emerges from latent 
s ta te . A wide variety of stimuli have been shown to induce such reactivation in 
latently infected experimental animals (Hill, 1984). Some of these stimul e.g. nerve 
section are known to induce metabolic changes in the associated neuronal cell body 
and other reactivating stimuli e.g. trauma to the skin (Hill et al., 1978) may have 
similar effects. Nerve section itself is known to cause increased transcription of 
neuronal DNA (Watson, 1974) In these circumstances a close association between 
neuronal DNA and HSV DNA might result in reactivation of the viral genome. 
As mentioned above increased expression of the viral genome which is 
necessary for reactivation may involve changes in methylation of the DNA (Hill, 
1984). 
In mice latently infected with HSV very severe immunosuppressive treatments 
are required to induce reactivation in sensory ganglia. At such high doseages drugs 
such as cyclophosphamide may cause reactivation by acting directly on the latently 
infected neuron. However with some alphaherpesviruses e.g. bovine infectious 
bronchitis virus, moderate doses of immunosuppressive steroids can induce shedding 
of virus in respiratory secretions (reviewed by Ludwig, 1983). Such shedding may 
arise from reactivated infection in the nervous system and thereby may indicate a 
direct role for immune mechanisms in the reactivation process. Alternatively 
viruses such as IBR may show relatively frequent spontaneous reactivation of 
latency so that t reatment with steroids allows such such reactivation to be manifest 
as virus shedding in peripheral secretions. 
In latently infected mice, t reatment with cyclophosphamide prolonged the 
presence of infectious virus in latently infected superior cervical ganglia after 
induction of reactivation by nerve section (Price and Schmitz, 1979). Therefore 
although there is no clear evidence for direct involvement of immune effectors in 
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the reactivation process itself, once reactivation has occurred immune mechanisms 
are likely to play a crucial role in clearance of virus from the site of reactivation 
and the peripheral tissues. 
RECURRENT DISEASE 
In the case of HSV, reactivation of the latent infection may be followed by 
shedding of virus in the associated peripheral tissue with or without clinical disease. 
Experiments with HSV in the mouse ear model (reviewed by Hill, 1984) have 
confirmed the major sequence of events which lead up to recurrent herpes simplex: 
a variety of peripheral stimuli (all producing inflammatory responses in the skin) 
induce reactivation in the ganglion, one or two days later virus appears in the skin 
and in some cases clinical lesions develop (Harbour et al., 1983). Nerve section 
experiments have shown that virus travels from the ganglion to the skin via the 
nerve (probably by orthograde axonal flow) (Hill et al., 1983). 
Are immunological defects important in allowing recurrent disease to develop? 
A broad spectrum of such defects are produced by immunosuppressive t reatments 
and in man immunosuppression clearly produces increased severity and probably 
increased incidence of herpes simplex lesions (Ho, 1977). In the mouse it has proved 
difficult to induce recurrent disease by short term general immunosuppression alone 
but, as in man, recurrent lesions which occur during such t reatment take longer to 
heal (Blyth et al., 1980). 
Apart from these general effects of immunosuppressive t reatments , "natur­
ally" occurring minor defects in Τ cell surveillance may play a part in recurrent 
herpetic disease (reviewed in Rouse and Lopez, 1984). In particular reduced number 
of MIF producing lymphocytes have been found in the circulation at the time of 
recurrent disease. These changes are paralleled by an increase in the number of 
suppressor Τ cells. However it is difficult to be sure whether such changes are the 
cause or the effect of recurrent herpes simplex. Moreover caution is required when 
interpreting studies of human peripheral blood since the crucial changes in immuno-
regulation may be detectable only in the locality of the infected peripheral tissue 
and/or the draining lymph nodes. The importance of these more local changes have 
been stressed in the "skin trigger" theory of recurrent disease (Hill and Blyth, 1976; 
Hill, 1984). In this theory it is envisaged that the stimuli (such as U.V. light, or 
trauma) which induce recurrent herpes simplex, may themselves alter conditions in 
the skin so as to favour the development of a lesion. Such changes could occur 
either by direct effects on the susceptibility of skin cells to infection or by transient 
local immunosuppression. In either case it has been suggested that the release of 
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prostaglandins may be involved (Hill, 1984; Blyth and Hill, 1984). 
IMMUNOLOGICAL INTERVENTION 
From this brief review it seems that a t tempts to control latent herpes 
infection by immunological intervention may only be possible at two stages of the 
infection. Firstly at a very early stage so as to prevent interaction of the virus with 
the "target" cell (neuron in the case of HSV) i.e. to prevent establishment of 
latency. Secondly, after reactivation so as to remove infectious virus and thereby 
lessen the chance of virus shedding and recurrent disease. The lat ter is likely to 
prove more difficult since recurrent disease usually occurs in an already immune 
host. 
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ABSTRACT 
The conditions for reactivation of Bovine herpesvirus 1 were studied 
in different situations. The spontaneous reactivation of the thermosensiti· 
ve Cts) strain and of a conventionnally attenuated strain, both intra-
nasally administered, was examined in healthy young cattle: no spontaneous 
reactivation was demonstrated until 8 months after vaccination. Reactiva­
tion of ts strain during parturition was investigated and was shown to be 
a rare event: no nasal re-excretion occurred and only 1 out of 9 cows 
showed a rise in BHV 1 neutralising antibodies. Reactivation of ts strain 
by transport is not a constant feature, but nasal re-excretion was detec­
ted in 8 out of 19 animals, 1 to 3 days after transport. Dictyocaulus 
viviparus infestation is able to reactivate the ts strain 20 days after 
vaccination. This result implies that BHV 1 can be reactivated very soon 
after primary infection. 
INTRODUCTION 
The epidemiological significance of the persistence of Bovine herpes-
virus 1 (BHV 1) in a latent state is obviously linked with the possibility 
of viral reactivation followed by re-excretion of infectious particles. 
Several latent herpesviruses can be reactivated by injection of gluco­
corticoids: this procedure is extensively used in experimental work 
to reactivate BHV 1 in latent bovine carriers (Sheffy and Davies, 1972). 
It is also reported that therapeutic use of glucocorticoids provokes the 
reactivation of BHV 1 in treated cattle (Wellemans et al., !976). 
Several other stimuli can also provoke reactivation: superinfection with 
para-influenza 3 virus (Mensik et al., 1976), oral administration of 
3-methylindole (Espinasse et al., 1983), Dictyocaulus viviparus infestation 
(Msolla et al., 1983). 
It is usually assumed that stressful conditions can lead to BHV 1 
reactivation and this accounts, for example, for infectious bovine rhino­
tracheitis (IBR) outbreaks in recently assembled cattle, in which re-excre­
tion of infectious virus by a latent carrier propagates a virulent strain 
to uninfected cattle. 
Spontaneous reactivation of field virus occurs more frequently in the 
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genital tract than in the respiratory system. The term "spontaneous" must 
be cautiously interpreted: in this paper, spontaneous reactivation or re­
excretion will refer to reactivation with or without re­excretion induced 
without the aid of external identifiable stimuli such as those described 
above■ 
Spontaneous genital re­excretion of field virus is often demonstrated 
in both sexes, even more than one year after primary infection (Snowdon, 
1965; Bitsch, 1973), but the amount of virus is lower during re­excretion 
than after primary infection (Bitsch, 1975). Spontaneous nasal re­excre­
tion of wild­type strains is a rarer event (Snowdon, 1965; Bitsch, 1973), 
but, in dairy herds, seroconversion against BHV 1 and nasal isolation of 
field virus have been regularly demonstrated, indicating the circulation 
of virus in the herd, following its reactivation in one or more animal 
(Hyland et al., 1975; van Nieuwstadt and Verhoeff, 1983). 
Other circumstances that are theoretically able to induce BHV 1 
reactivation have received little or no attention. In addition, the condi­
tions of reactivation of vaccine virus in the field have not yet been 
extensively investigated. We therefore examined the spontaneous reactiva­
tion of the thermosensitive (ts) yaccine strain and of a conventionnally 
attenuated strain in healthy young cattle. Thereafter, parturition, 
transport and Dictyocaulus viviparus infestation were evaluated as possible 
causes of reactivation of the ts vaccine strain in the field. 
SPONTANEOUS REACTIVATION OF TWO BHV 1 VACCINE STRAINS ADMINISTERED 
INTRANASALLY (Thiry et al., 1983) 
In dairy herds, reactivation of virulent BHV 1 regularly occurs and 
provokes episodes of nasal re­excretion and seroconversion (Hyland et al., 
1975; van Nieuwstadt and Verhoeff, 1983). The possibility of spontaneous 
reactivation of vaccine strains administered intranasally was studied in a 
selection station where animals are kept under optimal conditions. 
Twenty­eight 3­months­old bullcalves were followed until their 
slaughter, at the age of I year. None of them excreted BHV 1 at day 0 
(day of vaccination); three calves had low titres of BHV 1 neutralising 
antibodies (2 or<2). They were divided into four groups and were vacci­
nated with two live vaccines, Tracherine (ts vaccine strain, Smith Kline, 
R.I.T.) and IBR­IPV (Bayer), following the procedures recommended by the 
manufacturers. 
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bulls n° day 0 day 27 
Group 1 1 to 7 Tracherine IBR-IPV 
Group 2 8 to 14 Tracherine Tracherine 
Group 3 15 to 21 IBR-IPV Tracherine 
Group 4 22 to 28 IBR-IPV IBR-IPV 
After the first vaccination, 13 out of 14 ts strain-vaccinated calves 
excreted the vaccine virus and 10 out of 14 IBR-IPV strain-vaccinated ani­
mals excreted BHV I, The excretion of ts strain was demonstrated by virus 
titration at 35°C and restriction of virus multiplication at 40°C. After 
the second vaccination, no bulls from groups I and 3 excreted the virus; 
in group 2, 3 out of 7 animals and in group 4, 4 out of 7 animals excreted 
the virus. Nasal swabs were taken monthly during eight months: no virus 
excretion was detected in any case (table I). 
TABLE 1.- Nasal excretion and re-excretion of vaccine viruses 
(number of animals which (re)excrete BHV 1) 
days: 0 to 7 27 to 34 77 112 167 216 244 
first second 































Seroneutralisation tests performed on samples taken after vaccination 
revealed that 10 out of 28 animals did not show any seroconversion; sero-
neutralisation was performed by a micromethod previously described (Thiry 
et al., 1983). 












































Only one animal was still seropositive at day 112 and, afterwards, 
all the animals were seronegative (table 2). 
No spontaneous reactivation of vaccine virus was demonstrated in these 
animals until 8 months after vaccination: neither nasal re-excretion nor 
a rise in BHV 1 neutralising antibodies were detected. This situation is in 
sharp contrast to what is observed in dairy herds, as indicated above. 
In our study, animals were not submitted to stressful conditions such as 
bad management or introduction of new animals; they had all the same age 
and did not develop any infectious pathology during the observation period. 
Under these conditions, spontaneous reactivation of BHV 1 vaccine virus 
administered intranasally is at least a rare event. 
REACTIVATION OF INTRANASALLY ADMINISTERED TS VACCINE STRAIN 
DURING PARTURITION (Thiry et al., 1984) 
Blood levels of glucocorticoids increase before and during parturition 
in the bovine species (Smith et al., 1973). The intensity of labour also 
influences the level of corticoids (Hudson et al., 1976). Parturition 
could thus represent a circumstance able to reactivate BHV 1 in a pregnant 
cow, latent carrier of the virus. This possibility was investigated in 9 
pregnant cows from a herd of 43 Holstein Friesian cows belonging to 
an agricultural Institute. These cattle had never been vaccinated against 
IBR. No respiratory disease had occurred on the farm during the last years 
and only a few animals possessed low titres of BHV 1 neutralising antibodies 
(titres: 35/43: 0; 7/43: 2; 1/43: 4 ) . All the animals were vaccinated with 
Tracherine (ts vaccine strain) following the recommended dosage. Nasal mucus 
samples were taken every 2 days, beginning 4 days before the theoretical 
date of parturition until the sixth day after parturition; sampling could 
not be continued for practical reasons. Plaque assay was performed in cell 
culture covered by Minimum Essential Medium (MEM) supplemented with 2.5% 
anti-BHV 1 bovine immuneserum (neutralising titre: 64). Either a field 
strain latently carried by cows at the time of vaccination or the vaccine 
strain could be reactivated in these animals. 
No infectious BHV 1 particles were detected in any swab by plaque assay 
at 35 and 40°C. Seroneutralisation was performed by a micromethod previously 
described (Thiry et al., 1983). Only one cow (17 1) presented a significant 
rise in BHV 1 neutralising antibodies after parturition (table 3), but 
without re-excretion of infectious particles, although its immune status 

























































Even if this seroconversion reveals BHV 1 reactivation without re­
excretion of infectious particles, it can therefore be concluded that 
reactivation of ts strain occurs only rarely during parturition. 
Parturition itself seems not to be a major cause of BHV 1 reactivation. 
REACTIVATION OF INTRANASALLY ADMINISTERED TS VACCINE STRAIN 
BY TRANSPORT 
Transport is generally considered as a possible cause of BHV 1 reac­
tivation. In fact, it is associated with an increase in corticoid blood 
levels in bovine and used to simulate stressful conditions in this species 
(Völker et al., 1973; Johnston and Buckland, 1976; Kent and Ewbank, 1983). 
The experiment was carried out in five parts, depending on the 
opportunities of transport of heifers belonging to an embryo transfer 
research unit. Fourty-six animals of this unit were vaccinated with a 
double dose of Tracherine, the ts vaccine strain. At the moment of vaccina­
tion, the distribution of BHV 1 neutralising antibody titres was: 
14/46:0; 25/46: 2; 2/46: 4; 2/46: 8; 1/46: 16; 1/46: 32; 1/46: 128. 
Two months after vaccination, two groups of animals (group 1: 5 ani­
mals; group 4: 6 animals) were transported over a distance of 170 km. 
Six months after vaccination, three groups of animals were transported: 
group 2 (6 animals, 90 km); group 3 (8 animals, 140 km); group 5 (8 ani­
mals, 200 km). Nasal swabs were taken the day of transport (just before 
or just after transport) and then regularly until the sixth or the ninth 
day. They were stored at -70°C. The presence of infectious particles was 
examined by plaque assay at 35 and 40°C in cell culture covered by MEM 
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supplemented with 2.5% anti-BHV 1 bovine antiserum. Serum samples were 
taken the day of transport, then I and 2 or 3 weeks later. BHV 1 neutrali­
sing antibodies were titrated by a micromethod (Thiry et al., 1983). 
In groups 4 and 5, only serum samples were collected. It must be emphasized 
that either the vaccine strain or a field strain latentlty carried by 
cattle at the time of vaccination could be reactivated. 
The results of this experiment are given in tables 4 to 8. In groups 
1 to 3, re-excretion of infectious particles was demonstrated in 8 out of 
19 animals from days 1 to 3 after transport; only low titres were observed 
and reactivated viruses multiplied only at 35°C. No significant rise in 
neutralising antibodies occurred, although each animal possessed BHV 1 
neutralising antibodies (tables 4 to 6 ) . In groups 4 and 5, in which 
sera were examined, 1 out of 14 animals (n°26) showed a significant rise in 
BHV 1 neutralising antibodies (tables 7 and 8 ) . 
TABLE 4.- Transport of group 1 animals. 
(170 km; 2 months after vaccination) 

























































day 0: day of transport. 
TABLE 5.- Transport of group 2 animals. 
(90 km; 6 months after vaccination) 

















































































TABLE 6.- Transport of group 3 animals. 
(140 km; 6 months after vaccination) 





























































































































day 0: day of transport 
TABLE 7.- Transport of group 4 animals; BHV 1 neutralising antibody titres. 
(170 km; 2 months after vaccination) 
0 0 0 
4 4 2 
4 4 2 
16 16 8 
2 2 2 
2 2 2 
TABLE 8.- Transport of group 5 animals; BHV 1 neutralising antibody titres. 







































Reactivation of BHV 1 by transport was not a constant feature, but 
occurred in 8 out of 19 cows, at least in our conditions of work:, cattle 
vaccinated with ts strain, young adult cattle kept under excellent hygienic 
conditions (embryo transfer research unit). When re-excretion occurred, 
a limited amount of infectious particles were excreted, over a short 
period ( 1 to 3 days): this is obviously not the best way to transmit the 
virus to in-contact cattle. 
REACTIVATION OF INTRANASALLY ADMINISTERED TS VACCINE STRAIN 
BY DICTYOCAULUS VIVIPARUS INFESTATION 
It has been recently reported that virulent BHV 1 can be reactivated 
in cattle experimentally infested with Dictyocaulus viviparus larvae 
(Msolla et al., 1983): BHV 1 was recovered from days 7 to 21 post-infesta­
tion. We have evaluated the possibility of early reactivation in animals 
vaccinated with ts strain one week before infestation with D. viviparus. 
Eighteen 3-months-old Friesian calves were vaccinated at day 0 
with a double dose of Tracherine (ts vaccine). At day 0, 5 calves possessed 
BHV 1 neutralising antibodies (table 10). At day 8, they were orally infes­
ted with D. viviparus L, larvae (30 L_/ kg body weight). At day 15, the 
animals were divided into 3 groups: the first group was treated once 
with levamisole (10 mg/kg; subcutaneous injection); the second was treated 
once with ivermectine (200 pg/kg; subcutaneous injection); the third was 
an untreated control group. Nasal swabs were taken twice a week during 
7 weeks and serum samples once a week. Infectious viral particles were 
titrated by plaque assay as described above, at 35 and 40°C. Either the 
ts strain or a field strain present in these calves in a latent stage 
could be reactivated. 
Excretion of vaccine virus was demonstrated in 13 out of 18 vaccina­
ted animals from days 2 to 13 (table 9). The 5 calves in which no excre­
tion was detected possessed BHV 1 neutralising antibodies at day 0. At day 
20, 12 days after experimental infestation, re-excretion of BHV 1 occurred 
in 13 animals at very low titres (table 9). Subsequently (day 44), one 
animal re-excreted virus at 35°C. Excretion and re-excretion of BHV 1 was 
demonstrated only at 35°C, indicating in each case that only the ts vaccine 
virus was present (table 9). Seroconversion was not detected in 3 animals 
(4, 9, 18). No ri.'e in specific neutralising antibodies was observed after 
day 20, except in 2 animals (3 and 15) (table 10). 
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TABLE 9.- Excretion and re-excretion of BHV 1 after vaccination and 
subsequent D. viviparus infestation.' 
days : 
animals : 




























































































































































































titres are given in PFU/ml of nasal swabs at 35°C; 
day 0: vaccination; day 8: infestation; day 15: treatment; 
group 1: treated with levamisole; group 2: treated with 
ivermectine; group 3: untreated. 
Whatever the treatment applied, re-excretion of ts vaccine strain was 
demonstrated in each group. We are not in a position to speculate on the 
differences between groups as far as the number of calves re-excreting 
virus is concerned: animals not shown to be re-excreting could have re-
excreted the virus out of the sampling days. In the same way, the fact that 
re-excretion was shown in 3 calves that did not excrete after vaccination 
is not surprising: they could have in fact excreted the vaccine virus out 
of the sampling days, over a very limited period. 
Treatment with ivermectine and levamisole sharply reduced the amount 
of larvae present in the faeces and the amount of worms in the lungs, as 
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compared to the control group, but they had not impede the migration of 
certain larvae through the alveolar wall; it is thus probable that these 
treatments did not prevent the injury of the respiratory epithelium caused 
by the passage of larvae. This could represent the stimulus inducing reac­
tivation, because re-excretion of BHV 1 was detected at day 20, 12 days 
after infestation: this is precisely the moment when larvae penetrate the 
alveolar walls and enter the lumen. 
TABLE 10.- BHV 1 neutralising antibody titres after vaccination and 
subsequent infestation with D. viviparus. 
days : 
animals : 























































































































































day 0: vaccination; day 8: infestation; day 15:treatment. 
Except in two cases (3 and 15), no seroconversion was detected after 
day 20. During reactivation, the animals were still in primary immune res­
ponse and the stimulus was probably not sufficient to increase the neutra­
lising antibody titres. Calves in which neutralising antibodies rose after 
day 20 did not shown any seroconversion before. During all the period of 
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examination, no neutralising antibody was detected in 3 animals, although 
the multiplication of the vaccine strain was proven in these calves 
(tables 9 and 10): vaccination with ts vaccine does not usually induce 
high levels of neutralising antibodies; moreover, certain animals do 
not show any serological response although they are protected against the 
clinical manifestations of the disease after challenge with virulent 
virus (Zygraïch et al., 1974; Nettleton and Sharp, 1980). 
Re-excretion is demonstrated very soon after the primary infection 
(day 20). It is reported elsewhere that reactivation can occur 28 days 
after primary infection with a virulent strain (Espinasse et al., 1983), 
or 40 days after primary infection with ts vaccine strain (Pastoret et al., 
1980). Attempts to reinfect cattle with virulent strain, four weeks after 
vaccination with ts strain, are successful, although the level of excretion 
is reduced (Zygraïch et al., 1974). We may therefore assume that BHV 1 
can be reactivated soon after primary infection. The level of re-excretion 
is decreased probably because the greater part of reactivated virus was 
neutralised and thereby not detectable as infectious particles. Bitsch 
(1975) observed that the level of virus excretion was usually lower 
after spontaneous reactivation than after primary infection. 
DISCUSSION AND CONCLUSIONS 
The results reported here show that certain conditions which could 
presumably reactivate BHV 1 in the field are effective reactivation 
stimuli, at least for the ts vaccine strain. When re-excretion occurs, the 
amount of re-excreted virus is low and the duration of re-excretion is 
short, so that transmission of the virus may be difficult even if a high 
percentage of animals re-excrete the virus, as after transport or infes­
tation with D. viviparus. On the contrary, parturition seems to be an 
inefficient reactivation stimulus for the ts vaccine strain. 
We postulate thet these stimuli, and others of the same nature, will 
induce full reactivation if their effects are combined on the same animal. 
In fact, if the stimulus is stronger, we reach a situation similar to that 
of experimental treatment with dexamethasone which, when correctly applied, 
provokes approximately 100% of reactivation and re-excretion with high 
virus titres (Pastoret et al., 1980). For example, the increase in blood 
corticosteroid levels in parturient cows is proportional to the duration 
and intensity of labour (Hudson et al., 1976). In Holstein-Friesian cows 
examined in this study, calving problems occur rarely and, except parturi-
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tion, these animals were not subjected to other objectivable stressful 
conditions. Transport is often associated in young calves with the so-
called "Shipping fever" syndrom, in which parainfluenza-3 virus is partly 
involved. Infection with this virus can provoke BHV 1 reactivation 
(Mensik et al., 1976) and the combination of these stimuli could lead to 
reactivate BHV 1 easier. In this study, 8 out of 19 animals re-excreted 
virus after transport: they were two-years-old heifers; no new animals 
were introduced and no respiratory illness was observed after transport. 
When speaking about BHV 1 reactivation, distinction should be made 
between infection by the nasal or the genital route. Genital infection was 
the natural situation in cattle before the fifties in U.S.A. and the 
seventies in European countries. Genital latency has thus been a naturally 
fixed situation since a long time ago (Bläschenausschlag was first descri­
bed in 1845) and the interactions between virus, host and environment have 
evolved to make easier genital reactivation followed by re-excretion, 
allowing the propagation of the infection in herds. On the contrary, res­
piratory infection by BHV 1 is a phenomenon of recent appearance in the 
history of the infection and, perhaps, virus-host-environment interactions 
have not yet reached the same degree of adaptation as in the case with 
genital infection. It is thus experimentally established that, following 
infection with a genital isolate, genital re-excretion is much more fre­
quent than nasal re-excretion (Snowdon, 1965; Bitsch, 1975). 
This hypothesis and the fact that we used an attenuated strain give 
some explanations of the reduction of the number of animals which re-excre­
ted in this study. 
In conclusion, the ts vaccine strain is not frequently re-excreted 
after vaccination in field conditions, although it shows the same nasal 
re-excretion pattern as virulent strains when dexamethasone treatment is 
applied on latent carriers (Pastoret et al., 1980; Nettleton et al., 1984). 
If an appropriate stimulus occurs, the ts strain is re-excreted at low 
titres, during a short time. The propagation of this vaccine strain is thus 
limited and probably restricted to the days following vaccination. 
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ABSTRACT 
3-Nethyl indole 13-HI) is ι powerful pul iomry toxic. After an expedients! infection χι th bovine 
herpesvirus-1 IBHV-1), 4 out of 4 adult bovines received various in t ra- runnal doses of 3-MI. No v i ra l 
excretion «as observed in tracheal or nasal lucus. l imnologica! response »as the only evidence of the BHV-1 
reactivation. Serie and local antibody levels increased after each dose of 3-MI. 
Froi the current knoniedqe on cel lu lar effects of 3-MI, soie hypotheses to explain BHV-1 reactivation 
are discussed. 
INTRODUCTION 
3 - M e t h y l i n d o l e (3 -MI ) i s a rumenal f e r m e n t a t i o n p r o d u c t o f 
L - t r y p t o p h a n . 3—MI i s i n v o l v e d i n n a t u r a l l y o c c u r r i n g a c u t e 
pu lmonary edema ( f o g f e v e r ) (Breeze e t a l . , 1975) and o r a l 
a d m i n i s t r a t i o n has been shown t o cause some l e s i o n s i n c a t t l e 
(Ca r l son e t a l . , 1975 ) , sheep, g o a t s (Bray and C a r l s o n , 1979) 
and p o n i e s (De rksen , 1 9 8 2 ) . -
Many h e r p e s v i r u s e s i n v a r i o u s s p e c i e s a r e l i a b l e t o 
p e r s i s t i n a l a t e n t f o r m i n t h e h o s t a f t e r p r i m a r y i n f e c t i o n . 
P a r t i c u l a r l y i n c a t t l e , i t has been d e m o n s t r a t e d t h a t l a t e n t 
b o v i n e h e r p e s v i rus—1 (BHV—1) can be r e a c t i v a t e d by 
c o r t i c o s t e r o i d a d m i n i s t r a t i o n (Dennet e t a l . , 1973 ; S h e f f y and 
D a v i e s , 1972 ; P a s t o r e t e t a l . , 1978 ) , e x p e r i m e n t a l i n f e c t i o n 
w i t h P a r a i n f l u e n z a 3 v i r u s (Mensick e t a l . , 1976) o r f o l l o w i n g 
D i c t y o c a u l u s v i v i p a r u s i n f e s t a t i o n ( M s o l l a e t a l . , 1983b) . I n 
o t h e r s p e c i e s , r e a c t i v a t i o n of l a t e n t h e r p e s v i r u s e s has been 
d e m o n s t r a t e d u s i n g v a r i o u s s t i m u l i : a p p l i c a t i o n o f d r y i c e on 
t h e l i p s of Herpes S imp lex V i r u s ( H S V ) - i n f e c t e d mice ( K l e i n , 
1982) , immunosuppress ion o f HSV human c a r r i e r a f t e r o rgan 
t r a n s p l a n t a t i o n ( A r m s t r o n g e t a l . , 1976) , e l e c t r i c a l e x c i t a t i o n 
of t r i g e m i n a l g a n g l i a o f i n f e c t e d r a b b i t (Green e t a l . , 1981 ) , 
c y t o t o x i c a g e n t s (Dpenshaw e t a l . , 1979) . 
The aim of t h i s s t u d y i s t o i n v e s t i g a t e t h e e f f e c t o f 
3 - M I , known t o be an i m p o r t a n t pu lmonary t o x i c , on l a t e n t BHV-1 
i n f e c t e d c a t t l e . 
MATERIALS AND METHODS 
Animals 
Six heifers, 15 ± 6 months old, of various breeds were 
raised in individual indoor stalls. They were fed with hay 
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twice a day. On day 0, each animal was inoculated with 10*·­,= 
tissue culture infectious dose 50 7. (TCID 50) of BHV­1 diluted 
in 5 ml of Eagles's minimum essential medium supplemented with 
2 7. foetal calf serum. On day 110, four heifers, A, B, C and D 
were given intrarumenally 3—MI* melted in 1—2 propanediol. A 
and Β received 25 mg/kg body weight and C and D 50 mg/kg. On 
day 131 Α, Β and C, D were given sub­toxic 3­MI doses, 
respectively 75 mg/kg and 100 mg/kg. 1—2 propanediol was only 
given on days 110 and 131 to two heifers, E and F. 
Cl^i_QÍca¿_examinatign_and_samg]i¿ng 
Each animal was examined daily in order to record 
respiratory and heart rates and rectal temperature. On days 1, 
2, 4, 7, 10, 14 and then once a week until the 5th week, 
animals were sampled by transtracheal aspiration. On days 49 
and 56, only nasal swabs were collected. Both transtracheal 
aspiration and nasal swabbing were undertaken on days 1, 2, 3, 
4, 6, 8, 10, 14, 20 after each 3­MI administration; heifers 
were bled on the same days. 
Vi_rgl.ggy 
Each swab was immediately pressed into a sterile, 
disposable syringe. Mucus was harvested in sterile tubes, 
centrifuged at 5000 rpm for half an hour. After serial 
dilution, 0.1 ml aliquots of supernatant fluid were used to 
infect 96­well microplates**, containing secondary or tertiary 
foetal calf kidney cells. Each dilution was tested in two 
wells. 
Starting with centrifugation, transtracheal aspirates 
(TTA) were processed in the same manner. 
Neutral_i_zatign_test 
BHV—1 serum neutralization tests were performed as 
described by Bitsch (1978). Serial 3 fold dilutions starting 
from the tenth were titrated in 96 wells plates on MDBK cells 
using a calculated 100 BHV­1 TCID 50 dose. 
ELISA_test 
ELISA plates*** were coated overnight with BHV­1 antigen 
prepared in the laboratory. Plates were washed three times with 
phosphate buffered saline pH 7.2 containing tween at a 
concentration of 0.05 "/. (PBS­Tw) . Then they were incubated with 
a PBS­Tw 1 7. gelatine solution for one hour in order to avoid 
attachment of non specific antibodies. Serial fout—fold 
dilutions of sera, starting from the twentieth were laid onto 
the plates for twenty minutes. Then they were washed again and 
incubated with peroxidase—labelled rabbit anti—bovine IgG****. 
After the last washing sequence, a 0.5 7. orthophenylenediamine 
solution in citrate­ phosphate buffer (w/v) added with H__.0­
(1/400 V/V) was distributed. The activity of the enzyme was 
stopped with H2SD« 2M. Plates were read on an ELISA 
spectrophotometer with a filter of 492 nm. 
!=gcal__an t i_bgdy__ti.tr at i gn 
Nasal swab exsudâtes were titrated for BHV­1 antibodies as 




All six infected heifers developed a transient rectal 
temperature elevation and a moderate nasal and ocular 
discharge. Ulcerative and fibrinous rhinitis occurred for C, E 
and F. A, Β and D only showed a congestion of the nasal mucous 
membrane and conjunctiva. By day 21 post infection (pi), all 
general and local clinical signs had disappeared. A, B, D, E 
and F excreted BHV­1 through the trachea from day 2 to 7 pi and 
C to day 10 pi, reached a maximum between the fourteenth and 
twentieth days pi, varied to day 70 pi and decreased for the 
six animals (Fig. 2 ) . ELISA results showed the same pattern as 
neutralizing antibodies (Fig. 3 ) . Local BHV­1 antibodies were 
irregularly observed from the tenth to the fiftieth days pi. 
3­Mi_adm__.n__s_tra__._mn 
Neutralizing and ELISA antibodies of A and Β increased 
after 3—MI administration. ELISA and neutralizing antibodies 
did not vary for the reference animals (Fig. 4 ) . The level of 
neutralizing antibodies also increased after the second 3­MI 
administration for A and B. ELISA for all animals and 
neutralizing antibodies for C, D, E and F remained stable (Fig. 
5 ) . Low levels of local . antibodies were irregularly found in 
the four tested animals after both 3­MI administrations. BHV­1 
was never recovered from nasal swabs from both 3­MI tested and 
reference animals. 
DISCUSSION 
The present results do not clarify previous data on the 
effect of 3­MI on BHV­1 latency (Espinasse et al., 1983). 
Bovines free of neutralizing and ELISA BHV­1 antibodies have 
shown usual clinical and immunological reaction after an 
experimental infection (Msolla et al., 1983a). A former 
experiment (Espinasse et al., 1983) and the present one give 
conflicting results. 
Viral excretion found previously with 150 mg/kg and 200 
mg/kg of 3­MI did not occur with lower doses varying from 25 to 
100 mg/kg. In contrast, the moderate increase in antibodies 
became more evident when lower doses of 3—MI were used. The 
increasing titers of serum neutralizing antibodies with two low 
doses (25 mg/kg and 75 mg/kg) was confirmed in five 
neutralization assays and never accompanied by any virus 
shedding. 
Two hypotheses could be suggested to explain the action of 
3­MI: 
i) 3­MI behaves as a non specific immune stimulant at lower 
rather than sub—toxic doses as i t was demonstrated with an 
immune modulator (Floe'h et al., 1983) 
ii) 3­MI allows BHV­1 release, which acts as a booster 
injection, either by destruction of BHV­1­containing cells 
or by direct activation. Failure to detect BHV—1 could be 
explained in this last hypothesis by the maintenance of the 
immune functions wich are not depleted as they could be, by 
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using corticosteroids. This remains consistent with some 
evidence that dexamethasone exerts a direct effect on 
latently infected cells to induce herpesvirus reactivation 
(Pastoret et al., 1982). 
Cornelius (1979) has established, and Hanafy and Bogan 
(1982) have confirmed, that 3-MI is not the direct cytotoxic 
product. Nine different metabolites of 3-MI degradation were 
described in the urine of goats administered with 3-MI 
(Potchoiba et al., 1982). Two of these were identified as main 
3-MI metabolites and no direct action of all of them was 
clearly demonstrated. The active unknown 3-MI derived toxic was 
recognized as acting on lung phospholipid synthesis (Kirkland 
and Bray, 1984) and on the mixed function oxidase system (Bray 
and Carlson, 1979). Individual susceptibility of cows has been 
found in various attempts at experimental non lethal 
reproduction of fog fever (unpublished data). However, in the 
present experiment, neutralizing antibody increase occurred in 
both cases in the same heifers. Further experiments could be 
carried out to amplify and improve our understanding of the 
described mild 3-MI effect. Nevertheless, in the absence of any 
inactivated reference antigen, to test possible lymphocytic 
non-specific activation, BHV-1 reactivation cannot be assumed 
from this experiment. However, BHV-1 excretion in the former 
experiment appeared to be spontaneous rather than induced 
reactivation. These results and the lack of accurate data on 
3-MI metabolism and its effect or the effect of related 
substances on immune functions, make it difficult to reliably 
evaluate the action of 3-MI on BHV-1 latency. 
I 3-Hethylindole (sitatole), Sigia Cheiical Coipany. 
It Falcon licrotest II 30-40, Becton Dickinson labonare. 
U t Liibro E.I.A, licrotitration plate, Flou Laboratories. 
tttt Anti-bovine 1.6 (Rb) Peroxidase, Miles Biocheiicali. 
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Bovine Herpesvirus 1 l i fe vaccine causes persistent infection of the genital 
tract with spontaneous shedding of virus in the semen. 
■j -P Gregersen ' and K. Wagner-
' Freie Universität Berlin, Institut für Virologie, Nordufer 20, D- 1000 Berlin 65 
^Staatliches Veterinäruntersuchungsamt, Druselstalstr 6 1 . D-3500 Kassel 
A_E_____I 
Bulls inoculated with PHV- ι life vaccine shed virus with semen up to several months after 
vaccination. Characterization of the viral DNA by restriction enzyme analysis revealed that 
DNAs of isolates were indistinguishable from DNA of the vaccine strain. These results emphasize 
the need for a safe efficacious and compatible BHV- I vaccine. 
The virus responsible for Infectious Bovine Phinotracheitis/lnfectious Pustular 
Vulvovaginitis (IBR/IPV) infections, classified as. Bovine Herpesvirus type l (BHV-1) is 
spread worldwide ( Ludwig. ¡933) Like other herpesviruses it cause? ¡aient infections, from 
which virus can be reactivated by natural or artif icial stress factors. Humoral antibodies do 
not prevent vir··-; latency bus have an infiucence on the frequency of recurrent infections and on 
'he amount of excreted virus ( Pastoret et al., 1980) 
Being aware of virus latency, inactivated BHV-1 vaccines have been tested for their ability 
to control the spreading of I BR-infect ions, but life virus vaccines appeared to be more 
efficacious (Straub, Ie*7?! During the last year? modified life BHV-1 vaccines have been 
iavoured speculating that vaccine virus would occupy places of viral latency and thus prevent 
the field virus to become latent ( t retschmar, 198 ! ). In contradiction excretion of vaccine 
virus and field virus after vaccination and subsequent challenge with field virus was observed 
( Sheffy and Rodman. : 973, Nettelton and Sharp, I960. Nettelton e t a t . 1984). 
We report on the excretion of BHV-1 identified as vaccine virus which occured in bulls of an 
artif icial insemination center 
MATERIALS AND METHODS 
Vaccination 
A commercial "IBR/IPV-Vakzine" was given to 25 breeding bulls in two artif icial 
insemination (Al) centers. One dose was applied intraprepucially, another dose was inoculated 
in equal quantities into the nostrils. 3 weeks later and in intervals of several months up to 
three booster inoculations were given. 
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Virus isolation 
Without prior immunosuppressive treatment of the animals semen of the bulls and washings 
from the inner wall of the artif icial vagina were taken and used for virus Isolation . After 
incubation of embryonal calf lung cells with the inoculum, cultures were observed for 
cytopathic changes during a maximum of three passages. Mock infected, parallel cultures did 
not contain BHV-1 specific antigen when assayed by immunofluorescence tests. Isolated virus 
was identified by virus neutralization using a defined BHV-1 antiserum from an 
hyperimmunized rabbit. 
Serum neutralization test 
Neutralization test were performed asmlcrotttre method in a constant virus ( 100 TCIDÇQ) 
varying serum system. Antibody titres are given as highest serum dilution causing total virus 
neturalization 
Restriction enzvme analyses 
Viral DNA was isolated according to a standard method (Pignatti etal . , l 979 ) f rom infected 
ueorgia bovine kidney cells after 2 -4 passages. DNA was digested with the following restriction 
endonucleases: BamHI, BstEII, EcoRI, Hindi 11. Hpal, Kpnl.Sstll according to the manufacturer's 
: BRL) instructions. Fragments were separated in 0.7$ agarose gels, stained with ethidlum 
oromioet Sigma, I rng/lOOOml H2O) andvisualized in UV-light (306 nm). 
RESULTS 
Virus could be isolated from the semen of 6 out of 25 bulls. Preputial washings of three of the 
6 animals contained virus, too. The intervals between the last vaccination and virus isolations 
were 60 or8 l days, respectively. Virus isolation was also successfully isolated from two 
nitrogen frozen semen samples of one of the virus shedding animals (Table I). 
BHV-1-isolation 






























TABLE 1 : Vaccination history and subsequent virus isolation from breeding bulls. 
BHV-1 -neutralizing antibodies before vaccination. 
BHV-1 -neutralizing antibodies at the time of viurs isolation/reciprocal serum dilution. 
L.N.: Liquid nitrogen frozen semen samples. 
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DISCUSSION 
Our finding of an uncontrolled shedding of BHV-1 vaccine virus several months after 
inoculation without any stimulation by corticosteroids should be considered for further 
vaccination strategies. Especially the excretion of vaccine virus with the semen of breeding 
bulls and the possibility of its wide spreading after conservation in liquid nitrogen causes 
serious problems. 
The genital excretion of virus suggests, that vaccine virus had established and replicated in 
the testicles or in the spermatic ducts without being inactivated by the immune response This 
interpretation is supported by the finding that from 6 animals excreting virus with the semen 
only 3 had virus on the preputial mucosa. Furthermore, the finding of of BHV- I antigen in the 
sperm heads by EHLAZHARY et al. ( 1980) becomes noteworthy in this context. 
Although our observations cover only a relatively short observation period the results show 
that major genome alterations are not detectable after animal passage. Presumably no infection 
with field virus had occurred. Before immunization all the animals were free of 
BHV- I -specific antibodies and there is little chance of a later infection under the conditions in 
an Al-center. 
There are good reasons to differentiate BHV- I life virus vaccine strains derived from isolates 
of IPV-cases and those descending from IBR infections. Abortions after life virus vaccination 
with strains causing the death of the fetuses or later on of the calves have been reported 
(McFeelyetal., I 960 , Kellinget al., 1973, Mitchell, 1974; Darcel leQ. and Dorward, 1975, 
Pastoret et a l . 1980). 
These reports came from North America, where IBR virus strains prevail and were commonly 
used as vaccine virus. There are no hints that similar events occurred in Germany where the 
vaccines are made of attenuated IPV-virus strains. Interestingly enough, however, virus of the 
IBR-type has been recovered on independent occasions from spleen and other tissues of healthy 
fetuses (Ludwig and Storz, 1973; Storz et al., 1980). From earlier investigations we know 
that abortogenic BHV-1 isolates represent IBR viruses whereas no abortogenic IPV-virus 
strain is known (Gregersen, 1983; Pauli et al., 1984). These findings are supported by the 
fact that abortion has never been described in connection with typical IPV-virus infections 
(Pauli, 1981, Ludwig, 1983). 
The choice of an IPV virusas vaccine strain obviously eliminates the risk of vaccine-induced 
abortion Nevertheless such a vaccine does not fu l f i l l the requirements for a safe vaccine 
because it leads to latent infections, can be excreted late after vaccination and can therefore be 
spread uncontrolled. These findings emphasize the urgent need for an efficacious, compatible and 
safe BHV- I vaccine. 
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After these results had been obtained , no further '.accinatio'"- way. perfcmed r.'<.~ .. ' ir 'a!?r 
virus isolation was tried again, Dui turned out lobe negative 
By restr iction enzyme analysis with six different enzymes we investigated the genome; of the 
isolates in order to identify them as vaccine or field virus strains. Furthermore we used the 
Hpal fragment pattern for the differentiation of IBR from IPV strains ι Pauli e: ai , 19S-J, 
Gregersen et al., in press). The results were as follow-· All isolates snowed identical DNA 
fragment patterns The genome profiles of the isolates were identical to those ν 'ne vaccine 
strain used, suggesting that all isolates represented re-isolates of the vaccine strami F>gure ! 
showsas an example the restriction enzyme patterns of isolates, caccine -.v,ì\~. '■ν·-'-- v.-.c 
one IBR-strain after EcoRI digestion 
Vaccine strain and isolates clearly differ from IBR virus strains and were identified as IPV 
/iruses according to their Hpal fragment pattern. 
Fig. 1 EcoRI restriction enzyme pattern of the DNA from isolates, vaccine virus. iPv arc ¡BR-
virus. 
Lane 1-8: DNA of the eight BHV-I isolates from vaccinated bulls. 
Lane 9: DNA of the virus used for vaccination. 
Lane IO: DNA of an IPV-virus and lane 11: DNA of an IBR-virus 
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ABSTRACT 
Felid herpesvirus 1 (FHV) causes a severe upper 
respiratory tract disease in cats. There are only 
limited reports of immunity during latent FHV infection and 
these mostly relate to serum neutralising antibody. The 
association of FHV-specific responses (serum neutralising 
antibody, cytotoxic antibody and lymphocyte transformation) 
and non-specific immune function (Con A lymphocyte 
transformation) with natural, "stress"-induced recurrence 
of latent FHV infection was investigated. Immuno­
suppression was not associated with induction of virus 
shedding, although the cats which shed had a lower base­
line cytotoxic antibody capacity, underwent a more severe 
"stress" response to a change of housing and had initially 
experienced a more severe primary disease episode than 
the cats which did not shed. A marked elevation in activity 
of specific immune function was associated with the 
occurrence of shedding. 
INTRODUCTION 
Felid herpesvirus 1 causes a severe upper respiratory 
tract disease of felidae. In common with specific herpes­
virus infections of many other species, the primary 
infection is followed by a latent infection in the host 
which may periodically reactivate with shedding of 
infectious virus. Following FHV 1 infection, at least 
82% of cats have been identified as carriers by induction 
of virus-shedding episodes (Gaskell and Povey, 1977). 
Such shedding was shown to occur spontaneously, following 
corticosteroid immunosuppression, or after the "natural" 
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physiological "stress" of a change of housing (up to 1%, 
69% and 18% of a group of cats respectively). The role of 
the immune system in the control of latent herpesvirus 
infections has been subject to much investigation prompted 
by observations of more frequent and/or more severe recrud­
escent disease in patients with immunodeficiency syndromes 
or undergoing immunosuppressive therapy (Reviewed by 
Babiuk and Rouse, 1979). Such studies have examined 
potential differences in immunity between individuals 
which were susceptible to frequent recurrent herpesvirus 
disease and non-susceptible individuals and have attempted 
to detect immune deficits associated with the induction 
of recrudescence. 
Studies on human patients, however, were confounded 
by clinical and ethical considerations, and this was 
further emphasised by studies of immune function during 
recrudescence, where sequential studies were severely 
limited by difficulty in prediction of such episodes. 
Experimental animal models of human herpesvirus 
recurrence involved physical trauma or pharmacological 
interference (Openshaw et al, 1981; Klein, 1982) , which 
did not represent "natural" stimuli. Similarly, studies 
of induced recurrence in domestic animals have utilised 
immunosuppression (Turner et al, 1970; Davies and 
Carmichael, 1973; Gaskell and Povey, 1977; Pastoret et al, 
1979; Wittman et al, 1983). For the study of immune 
events potentially involved in recurrence, a non-
immunologica1 inducer is obviously to be preferred, and 
the ability to provoke such episodes by rehousing "stress" 
in the cat provides a natural means of achieving this in 
the natural host-herpesvirus system. This paper describes 
immune events associated with susceptibility to, and 
induction of virus shedding. The study has been reported 
in detail elsewhere (Goddard, 1984; Goddard et al, 
manuscript in preparation). 
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MATERIALS AND METHODS 
Cats 
Seventeen specific pathogen free-derived cats were 
rehoused from communal controlled environment housing into 
individual external isolation pens. 
Cats were monitored daily for clinical signs and 
virus shedding for 7 days prior to and 21 days after 
rehousing. Prior to rehousing blood samples were assayed 
on five occasions for total and differential leukocyte 
counts, FHV-specific and Con A lymphocyte transformation 
(LT) response, and on two occasions for serum neutralising 
antibody titres (SNT) and antibody-complement lytic 
antibody capacity (CP). After rehousing blood was sampled 
on alternate days for 21 days and then at weekly intervals 
for 2 weeks. 
Virus Isolation 
Oropharyngeal and nasal swab samples were inoculated 
onto confluent monolayer cultures, using standard 
techniques, and exanined for FHV cytopathic effects. 
Clinical Scores 
Upper respiratory tract disease signs were scored from 
0 (normal) to 5 (severe) to give a total daily score. A 
"stress score" was recorded as clinical score for 
inappetance plus scores for behavioural disturbance 
(1 = nervous, 2 = overtly scared, 3 = physical withdrawal). 
Leukocyte Counts were estimated by standard laboratory 
techniques. 
Serum Neutralising Antibody Titres (SNT) 
A microassay adaptation of the method of Povey and 
Johnson (1969a and b) was used, and results expressed as 
reciprocal log serum dilution. Changes more than 2 log,, 
were regarded as significant. 
Antibody-Complement lytic capacity (CP) 
A standard Cr release microassay described previously 
(Goddard et al, 1984) was used. The % specific lysis of 
serum at log. dilutions of 1, 2 and 3 was recorded, 
arcsine transformed, and the area under the dilution curve 
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calculated to give the lytic capacity. 
Lymphocyte transformation (LT) 
FHV-specific LT and Con A induced LT were measured 
using the whole blood microassay system described previously 
(Goddard et al, 1984). Results were expressed as net 
(test-control) quench-corrected dpm. 
The pre-rehousing parameters of each cat were used to 
calculate upper and lower significance limits (P<0.05) 
for that cat to assess change after rehousing. Non-
parametric measurements were analysed by the Mann-Whitney 
U Test. 
RESULTS 
A detailed report of these results is given elsewhere 
(Goddard et al, manuscript in preparation). 
Virus isolation 
Three of 17 (17.65%) cats (1, 2 and 3) shed infectious 
FHV on post rehousing days 4-12, 7-14 and 8-10 respectively. 
These cats had undergone a significantly more severe 
primary disease episode than the cats which did not shed 
(P = 0.036) . 
The results of cat 3 were different to those of the 2 
other shedders and were considered to have been influenced 
by contact with another shedding cat 15 days before 
rehousing. This was 23 days before its own shedding period 
and was regarded as a separate episode. 
Immune Functions 
(1) The pre-rehousing Period. 
The mean resting CP of the three shedder cats was 
significantly lower (P<0.1) than that of the non-shedder 
cats. No other significant differences were observed. 
(2) The Post-rehousing Period. 
The three shedder cats had a significatly greater 
mean "stress" response to rehousing (P=0.025) than the 
non-shedder cats. No significant depression of any 
parameter was observed after rehousing in the shedder cats. 
However, isolated significant reductions were seen in some 
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of the non-shedder cats, particularly in one cat which had 
a selective lymphopoenia on post-rehousing day 1 associated 
with a significant depression in Con A LT and the most 
marked stress response in the experiment. 
(3) The Post Shedding Period. 
Shedder cats 1 and 2 showed marked boosting of SNT, CP 
and FHV-LT commencing during, and continuing after the 
virus shedding period. FHV-LT was still rising at 40 days 
post-rehousing, whereas SNT and CP responses reached a 
plateau at 20-30 days. Shedder cat 3 had much less 
marked responses at the time of shedding, and there was 
evidence of some specific boosting prior to rehousing, 
which could have resulted from the suspected contact 
infection. 
DISCUSSION 
In these studies, using a "natural" stimulus to induce 
recrudescence, no significant suppression of specific or 
non-specific immunity was associated with the induction of 
FHV shedding, and in fact the only significant reductions 
observed were in non-shedder cats, which may well argue 
against an absolute role for immunosuppression in induction 
of shedding. There have been few reports of immune events 
prior to natural herpesvirus recrudescence in other 
systems, but recently subtle changes in lymphokine 
production and suppressor lymphocytes have been reported 
(Sheridan et al, 1982). Thus in the present study such 
changes may have occurred undetected. 
The increase of FHV-specific parameters during the 
active shedding period observed in 2/3 shedders in the 
present study was consistent with reports of recrudescent 
human herpesvirus disease where most described either no 
change (Rasmussen et al, 1974; Sheridan et al, 1982) or an 
increase (Shillitoe et al, 1977 and 1978; Rattray et al, 
1980) in specific LT. While reports of LT were variable, 
the most consistent changes during this period related to 
raised lymphokine and interferon production (Rosenberg et 
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al, 1974; O'Reilly et al, 1977; Reichmann et al, 1977; 
Rattray et al, 1980; Sorrensen et al, 1980; Sheridan et al, 
1982). The discrepancies between parameters might be 
explained by the hypothesis that immune effector functions 
(e.g. cytotoxicity, lymphokines) are more important in 
herpesvirus control than memory functions (e.g. LT 
response) (Sheridan et al, 1982). 
The consequences of shedding in this study were 
boosting of FHV-specific responses. In other systems 
increases in serum antibody titres have been reported 
(Sorrensen et al, 1980; Sekizawa et al, 1980) although most 
workers reported no change (Rasmussen et al, 1974; Lopez 
and O'Reilly, 1977; Shillitoe et al, 1977 and 1978). 
However, the results were consistent with those reported 
after FHV recrudescence by Gaskell and Povey (1977). HSV-
specific LT has been observed to decline after recrudescent 
episodes (Shillitoe et al, 1977 and 1978; Rattray et al, 
1980) in contrast to the more persistent elevation of FHV-
specific LT seen in the present study. Again, in HSV 
systems it was lymphokine and interferon secretion which 
manifested marked change (increase) after recrudescence 
(Rasmussen et al, 1974; Shillitoe et al, 1977 and 1978; 
Cunningham and Merigan, 1983) and this is currently under 
investigation for FHV in the cat. 
The different response of shedder cat 3 was thought 
to have resulted from the contact infection experienced 
prior to rehousing. Such observations may be relevant to 
the effect of vaccination on carrier cats. 
The cats which shed virus had a significantly lower 
base-line cytotoxic antibody capacity, greater "stress" 
response to rehousing and had undergone a more severe 
primary disease episode than non-shedder cats. Reports 
of differences between herpes simplex virus (HSV) sero­
positive shedders and non-shedders in man have frequently 
given equivocal results. However, a rise of in vitro 
interferon secretion after recrudescent HSV infection has 
been found to correlate well with the time to the next 
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episode (Rasmussen et al, 1974; Cunningham and Merigan, 
1983). In addition to reduced lymphokine secretion (Wilton 
et al, 1972; Gange et al, 1975; Donnenberg et al, 1980; 
Sheridan et al, 1982), other "effector functions" -
specific direct lymphocyte cytotoxicity (Steele et al, 
1975; Thong et al, 1975; Fujimiya et al, 1978) and non­
specific cytotoxicity (Wilton et al, 1972) Antibody 
dependent cytotoxicity (Fujimiya et al, 1978) and 
neutrophil mobility (Rabson et al, 1977) have also been 
shown to be depressed in susceptible patients. In contrast 
most reports found that the susceptible individuals had 
higher serum antibody levels, although the results of work 
on herpes-specific LT is equivocal (Steele et al, 1975; 
Russell et al, 1976; O'Reilly et al, 1977; El Araby et al, 
1978). The interaction between stress and immune function 
is being increasingly studied (Kelley, 1980) and the"stress" 
response to rehousing may have affected the immune 
response of the cats, to facilitate overt virus shedding. 
Reductions in the immune functions measured did not 
appear to be fundamental in induction of recurrent FHV 
shedding, although some significant differences in para­
meters, behaviour and disease history of shedders and 
non-shedders were observed. However, regardless of the 
actual signal for reactivation of latent virus, it is the 
integrative activity of the immune system which controls 
the overt shedding of infectious virus and thus studies of 
herpesvirus immunity are crucial for the understanding of 
these diseases. This "natural" system provides a very 
useful means for the study of a herpesvirus in its natural 
host. Further studies with this system, which avoids 
pharmacological or physical interference with the host 
animal, may clarify the role of immunity in induction of, 
and susceptibility to herpesvirus shedding. 
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SUMMARY OF SESSION FIVE. 
HERPESVIRUS IMMUNITY AND REACTIVATION. 
by P.-P. PASTORET. 
The introductory paper given by T.J. HILL (United Kingdom) 
described the mechanisms underlying the establishment, 
maintenance and reactivation of latent herpesvirus infections. 
This paper deals mainly with the mouse model of infection with 
human herpesvirus (Herpes simple« virus). This model is 
relevant for natural herpesvirus infections of domestic 
animals, since it allows the carrying out of numerous 
experiments to clarify the underlying mechanisms. From these 
studies three main conclusions may be drawn: 
— immune mechanisms may prevent the access of the virus to the 
target cells in which latency is established; 
— when latency is established, the immune responses do not seem 
to be important for its maintenance; 
— following reactivation, immune mechanisms are likely to be 
involved in the clearance of the virus from the tissues. 
In the veterianry field, the phenomenon of re-e;<cretion is 
of great importance, from the epidemiological point of view. In 
this respect, it is important to better our understanding of 
the conditions necessary for herpesvirus reactivation. A paper 
presented by E. THIRY (Belgium) states that reactivation of 
Bg__ne hergesyirus 1 (BHV 1) is induced by several stimuli, 
such as transport or Dlc_yoc_u_us _ί__Ϊ_Ρ_#.___ infestation. 
Another paper from ESPINASSE and co-workers (France) indicates 
that, from immunological evidence, reactivation of BHV 1 seems 
to be induced also by the administration of 3-Methylindole, a 
powerful pulmonary toxic. 
The latency of attenuated vaccine strains used in the 
veterinary field is another aspect of the problem as seen from 
the practical side. A paper presented by BREGERSEN (West 
Germany) shows that bulls vaccinated with BHV 1 live vaccine 
shed virus in the semen for up to several months after 
vaccination. It is concluded that further studies are still 
required in order to produce new vaccines that will be as 
efficacious as the existing attenuated vaccines but completely 
devoid of side effects such as latency; such vaccines will help 
control vaccine virus dissemination. 
Finally, a paper presented by GODDARD (United Kingdom) 
deals with the immunological behaviour of cats latently 
infected by E_LÍEÍ h____________. The study shows a behaviour 
similar to that of other herpesviruses already studied. A 
marked elevation in specific immune function was associated 
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APPROACHES TO VACCINATION AGAINST HERPESVIRUSES: 
FROM ATTENUATION OF VIRUSES TO RECOMBINANT AND 
SYNTHETIC SUBUNIT VIRUS VACCINES 
Yechiel Becker, Tamir Ben-Hur, Eynat Tabor and Yael Asher 
Department of Molecular Virology 
Faculty of Medicine 
The Hebrew University of Jerusalem 
Jerusalem, Israel 
INTRODUCTION 
The herpesviruses constitute a virus group that, at the end of infec­
tion, take refuge in the host's nervous system and become latent. Reactiva­
tion of the latent herpesvirus leads to a new episode of disease, in spite 
of the previous exposure of the immune system to the virus, and in spite of 
the presence of neutralizing antibodies. In immune-compromised hosts, 
herpesvirus infections can become life-threatening. Thus, the immune system 
in its response to the viral antigens plays an important role in reducing 
the severity of the infection caused by the herpesvirus and probably en­
hances the defences against further recurrencies of the virus. However, 
this does not prevent the production of the virus in individuals who carry 
a reactivable latent herpesvirus and its spread to individuals who have not 
previously been exposed to the virus. 
Various approaches to the research and development of herpesvirus 
vaccines for humans and animals are summarized in Table 1. However, due to 
the unique properties of herpesviruses, it has been impossible to develop 
vaccines against this virus for use in man. The ability of herpes simplex 
virus (HSV) types 1 and 2 to transform cells under in-vitro conditions 
(Duff and Rapp, 1971. has so far prevented its use for the development of 
an attenuated live virus vaccine. 
The use of a live attenuated vaccine against a highly pathogenic tumor-
inducing herpesvirus of chickens (Marek's disease virus; MDV) was achieved 
by Churchill and his colleagues (Biggs et al., 1970). Today, chickens are 
immunized with a naturally occurring herpesvirus of turkeys (HVT) (Witter 
et al., 1970; Nazerian, 1979). The chickens are inoculated with a cell-
associated live virus which prevents the development of lymphoid tumors when 
infection with an oncogenic MDV occurs. Introduction of the HVT live virus 
vaccine markedly reduced economic losses for the chicken industry and proved 
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TABLE 1 Approaches to development of live and subunit 
herpesvirus vaccines 
1. Live attenuated viruses 
Selection of naturally occurring viral mutants; 
selection of virus mutants or mutants with a deletion in 
the virulence genes 
2. Subunit virus vaccines 
Cloning of viral glycoprotein genes in bacterial plasmids; 
expression and synthesis of HSV-1 gD (and other glycoproteins) 
in E. coli, yeast, or mammalian cells; 
purification of viral gD for use as a subunit virus vaccine 
3. Synthetic peptides 
Amino acid sequences of the antigenic epitopes can be 
synthesized and used as viral antigen in a vaccine 
4. Live recombinant viruses 
Gene(s) for the herpesvirus antigens can be cloned in an 
attenuated virus (poxvirus or another attenuated herpesvirus) 
which will be used as a live virus vaccine 
to be an effective way to prevent Marek's disease. However, the mechanism 
by which HVT protects chickens against MDV is still unknown. 
The use of attenuated Pseudorabies virus strains for the immunization 
of pigs against Aujeszky's disease is now a common practice (Wittmann and 
Hall, 1982). Immunized pigs do not develop the disease after infection with 
a virulent wild type Pseudorabies strain, but the virus can become latent 
in infected pigs and, when reactivated, the virulent virus can spread to, 
and infect, other pigs (Wittman et al., 1984). Studies on Pseudorabies 
vaccine strains revealed that the thymidine kinase-negative (TK") viruses 
had reduced virulence (Lomniczi et al., 1983). Extensive research on HSV-1 
has shown that the thymidine kinase (TK) gene plays an important role in 
the virulence of the virus (Field and Wildy, 1978; Tenser et al., 1981; 
Gordon et al., 1983; Ben-Hur et al., 1983, Becker et al., 1984a, b). 
Elimination of the viral TK gene from the virulent virus genome is not 
enough if a completely avirulent virus is needed; the neurovirulence gene 
(Table 2) must also be inactivated or deleted from the virus genome. It is 
also necessary to remove DNA sequences which might be involved in cell 
transformation (Jariwalla et al., 1980; Galloway et al., 1982). 
Cloning of genes for HSV-1 glycoproteins in bacterial plasmids and 
their expression in bacteria, yeast, or mammalian cells provide a new 
approach to the development of herpesvirus subunit vaccines. These pro-
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TABLE 2 Herpes simplex virus-1 genes involved in neurovirulence to mice 
Herpesvirus Map position in 
virulence genes virus genome 






and in the gene 
sequence 
Deletion 
Role in virus 
infection 
Replication in 
neurons and CNS 
Replication in 
brain (Thompson 
et al., 1983;Rosen 
et al., in press) 
cedures allow for large-scale industrial production of viral glycoproteins 
which, can be used for immunization of man or animals (Long et al., 1984). 
The viral antigens produced by this biotechnological approach, as well as 
synthetic peptides which contain the antigenic epitopes of the glycoprotein 
D of herpes simplex virus type 1 (Cohen et al., 1984) can be used to elicit 
antibody responses in the vertebrate host, which can neutralize both HSV-1 
and HSV-2. 
Another approach (Table 1) is the development of recombinant poxvirus 
vaccines into which the HSV-1 TK gene is introduced (Panicali and Paoletti, 
1982). Herpesvirus glycoprotein genes could also be introduced into such 
recombinant viruses,which would confer immunity against the poxvirus as 
well as the herpesvirus (Mackett et al., 1984). 
In this presentation, I will discuss some of the approaches used in 
my laboratory to study the attenuation of HSV-1 by selection of mutants, 
the analysis of viral glycoproteins of HSV-1 isolates, the cloning of the 
HSV-1 viral glycoprotein genes, and attempts to obtain their expression in 
E. coli and mammalian cells. 
MATERIALS AND METHODS 
Viruses and cell cultures 
The TK mutants used in this study were originally selected on the 
basis of plaque size from the NIH strain of HSV-1 that has a mixed plaque 
morphology of large and small plaques. The NIH wild type (wt) virus strain 
No. 11124 was propagated in BSC-1 cell monolayers grown in Dulbecco's 
modified Eagle's medium (DMEM; GIBC0) containing 10 per cent calf serum. 
From the wt virus that produced a heterogeneous population of large (2 mm 
diameter) and small (0.5 mm diameter) plaques, we obtained a large plaque 
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(LP) TK+ isolate, a small plaque (SP) TK!á mutant with 25 per cent of the 
thymidine kinase activity of the LP TK+ virus, and an LP TK" mutant that did 
not express TK at all (Gordon et al., 1983; Ben­Hur et al., 1983). 
Pathogenicity of virus mutants in mice 
Outbred albino mice of various ages were infected with the HSV­1 strains 
by inoculation onto scarified corneas (under ether anesthesia) at a concen­
tration of 10° or 10 pfu/ml. A drop (50­100 ul) of virus suspension was 
placed on each cornea, and the eyes were rubbed. The mice were observed 
for three weeks, and virus pathogenicity was determined by the number of 
mice that died. 
Four­week­old mice were susceptible to infection with the LP TK+ isolate 
of wt virus that replicated in the trigeminal ganglia and brain, and killed 
most of the mice. The TK" mutant virus with no TK activity did not infect 
the trigeminal ganglia or kill the mice. The SP TKÎs virus strain replicated 
in the eyes within 24 hr after inoculation and entered the trigeminal 
ganglia, establishing a latent infection in almost all the mice, but did 
not reach the brain or kill the mice (Gordon et al., 1983). 
Cloning of HSV­1 genes in pBR322 
The Q fragment (BamHI­BamHI) containing the TK gene from HSV­1 strain 
F was cloned in pBR322 to yield plasmid pBRTK. In plasmids pBY16 and 
pBY53­12, the TK gene was taken from the HSV­1 LP TK+ and SP TK¡s isolates, 
respectively (Becker et al., 1984a,b). In plasmid pBY40­2, the BglII/I 
DNA fragment of HSV­1 LP TK+ was cloned in the BamHI site of pBR322. 
Plasmid pBY718/pBY7(17) was derived from the Bglll­BamHI sequence of 
the Q fragment of HSV­1 strain F cloned in pBR322. This plasmid also con­
tained the BamHI J fragment of the viral DNA of LP TK+ (Becker et al., 
1984a,b) with the genes for glycoprotein D (gD) and part of gE. 
Plasmid pBY40­2 contained the BglII/I DNA fragment of the HSV­1 LP TK+ 
strain with the genes for the DNA binding protein (DNA BP), glycoprotein Β 
(gB) and glycoprotein A (gA). 
Plasmid pHABY119 contained the promoter left (P[_) and Ν gene (N) from 
phage λ DNA originally present in pHAlO (Honigman, 1981; Becker et al., 
1983). The Bglll­BamHI DNA fragment from HSV­1 LP TK+ containing the HSV­1 
TK gene was cloned in the BamHI site. Plasmid pHABY130 was derived from 
pHABY119 by cloning a Sacl­Sacl DNA fragment carrying the HSV­1 gD gene 
in the Saci site of the HSV­1 TK DNA. 
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Precipitation of HSV-1 glycoproteins from BSC-1 cells with monoclonal 
antibodies 
BSC-1 cells were infected with HSV-1, and after 6 hr the cells were 
labeled with "S-methionine (Sp, act.. 1400 C/mmol, Amersham Int., England). 
At 20 hr post-infection, the cells were rinsed three times with PBS and 
dispersed in 300 μΐ of extraction buffer consisting of 1% NP-40, 0.1 mM 
phenylmethyl sulphonylfluoride (PMSF) in PBS pH 8.0 at 4°C for 15 min. 
After centrifugation at 15,000g for 15 min, 20 μΐ of monoclonal antibodies 
were added to 100 μΐ of supernatant fluid. This was kept at 4°C overnight 
and then 50 yl of Protein A-Sepharose C1-4B beads (40% v/v, Pharmacia, 
Sweden) in extraction buffer was added for 1 hr at 4°C. The beads were 
washed three times with extraction buffer and 50 μΐ of electrophoresis 
buffer (2% SDS, 5% mercaptoethanol, 10 mM Tris-HCl, pH 7.0, 10% sucrose and 
2 mg/ml bromophenol blue) was added. After boiling for 2 min and centri­
fugation, the supernatant fluid (50 μΐ) was placed on 10% acrylamide gels. 
Neutralization of HSV by monoclonal antibodies directed against gB 
Virus suspensions were incubated with monoclonal antibody B5 (obtained 
from Prof. M. Levine, The University of Michigan, Ann Arbor, Michigan) for 
2 hr at room temperature. The virus was titrated on BSC-1 monolayers. 
Expression of HSV-1 gD gene in E. coli 
Plasmids pHABY119 and pHABY130 were transfected into E. coli strain 
157 (C600 AcI857) (obtained from Prof. H. Engelberg-Kulka, Dept. of 
Molecular Biology, our medical school) and grown overnight in LB medium 
containing ampicillin at 30°C. After dilution to 40 Klett units (blue 
filter) in medium M9 containing 1% casamino acids, the bacteria were grown 
at 30°C to 80 Klett units and then transferred to M9 medium containing an 
amino acid mixture without methionine and MgSO/). Each batch was divided 
into two and incubated for 2 hr at 30°C and 42°C, respectively. Then 0.1 
ml from each flask was transferred to an Eppendorf tube to which was added 
10 μΟί of 3->S-methionine (Sp, act. 1400 C/mmol; Amersham Int., England). 
The tubes underwent stationary incubation for 90 min at either 30°C or 
42°C. The bacteria were washed with PBS and 100 μΐ of a solution of 2 mg 
lysozyme,and 1 ml PBS was added for 10 min at 4°C. After centrifugation, 
100 μΐ supernatant fluid was mixed with 20 yl monoclonal antibodies to gD 
(supplied by Prof. Myron Levine, University of Michigan, Ann Arbor,Michigan), 
This was kept at 4°C overnight, mixed with Protein A-Sepharose beads and 
257 
prepared for electrophoresis in 10% acrylamide gels as described above. 
RESULTS 
Mutations in the HSV­1 TK gene lead to attenuation of virulence 
The relationship between the viral TK gene and virulence is presented 
in the following experiments (Ben­Hur et al., 1983). Infection of mice at 
different ages with the virulent virus strain (TK+) by inoculation onto 
scarified eyes resulted in the development of encephalitis and over 90% of 
the infected mice died (Fig. 1). Both virus mutants (TK" and TKI4) had lost 
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Fig. 1 Pathogenicity of HSV-1 virus strains in mice of different 
ages. The LP TK+, SP TK% and LP TK" isolates were inoculated onto 
scarified corneas at inoculum doses of 10° and 10? pfu/ml. 
(Reprinted with permission from Ben-Hur et al., 1983). 
most of their virulence for four-week-old mice. However, the infecting dose 
is also a determining factor: 10? pfu/ml of TK^ virus was virulent, whereas 
10 pfu/ml was not. An additional factor is the age of the mice: the TK" 
mutant was virulent for young mice during the first week of their life 
(Fig. 1), but 10-day-old mice infected with it were not killed. The TKÌs 
virus isolate, which is less pathogenic than the TK+ virus, demonstrates 
the development of gradual resistance to HSV-1 infection with increasing 
age. Mice were sensitive to the TK% virus up to ten days of age, after 
which their sensitivity gradually decreased. 
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TABLE 3 Possible sites for mutations in the HSV­1 TK gene leading to 
resistance of the virus to TK­activated antiviral drugs 
1. Mutations in the gene sequence 
a. Deletion of nucleotides 
b. Point mutations 
2. Mutations in the regulatory sequences of the TK gene 
a. Mutations in nucleotides in the RNA polymerase binding site 
b. Mutations in the CCCCGCCC or GGGGCGGC sequences in the 
α protein binding site (expression enhancer) 
c. Mutations in the TATA box 
d. Mutations in the palindromic sequence (attenuator sequence) 
centrally located between the mRNA start and the ATG codon 
of the TK gene 
Nature of mutations in the HSV­1 TK gene which lead to attenuation 
The promoter sequence of the HSV­1 TK gene with its functional domains 
is presented in Fig. 2 (Becker et al., 1984b). It is possible that a muta­
tion in one of the functional domains in the promoter (Table 3) will affect 
the level of gene expression in infected cells. Thus, a mutation in the TK 
gene at the active site will lead to synthesis of inactive TK enzyme mole­
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Fig. 2 A schematic organization of the HSV­1 TK gene promoter 
with its functional domains. (Reprinted with permission from 
Becker et al., 1984b). 
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TABLE 4 . Mutat ions in func t iona l domains o f HSV-1 TK promoter 
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NC 
NC = No c h a n g e 
3 pBRTK = The TK gene (BamHI-BamHI) from HSV-1 s t r a i n F cloned in pBR322 
b pBY16 = as in pBRTK, but TK gene cloned from HSV-1 IP TK+ s t r a i n 
c PBY53-12 = as in pBRTK, but TK gene cloned from HSV-1 SP TK'4 (Becker et a l . , 1984a,bl 
The EcoRI-Hpall fragment spanning the B g l l l s i t e was obtained f r on each TK gene, and the 
nuc leo t ide sequence was determined. The mutat ion of the Hpa 11 s i t e was a base chanqe 
(C + T ) . "Muta t ion" ind ica tes breakage of the DNA dur ino hydro lys is and ind icates a 
poss ib le change in nuc leot ides leading t o DNA f raamentat ion. 
Such TK" mutants can be s e l ec t ed by t r e a t i n g infec ted c e l l s with bromodeoxy-
u r i d i n e (BUdR). The v i ru s p a r t i c l e s t h a t survive are the TK" mutants , and 
t he se have been shown to have l o s t t h e i r pa thogen ic i ty for mice as descr ibed 
above. 
Another type of mutat ion i s the product ion of express ion mutants t ha t 
have a lower l eve l of TK express ion ( e . g . TK'Í mutan t ) . The mutat ion may 
have occurred in t he a t t e n u a t o r sequence in the promoter (Fig . 2; Becker et 
a l . , 1984b), most l i k e l y in the sequence for accura te t r a n s c r i p t i o n . As a 
r e s u l t of t h i s muta t ion , t he TKJj v i r u s produces TK at a level of 25% in 
infec ted LTK" mouse c e l l s , as compared with the TK+ v i r u s . Reduction in t he 
expression of the TK gene in t he TK!j mutant r e s u l t e d in a t t e n u a t i o n of the 
i n f e c t i v i t y of t h i s v i r u s s t r a i n in four-week-old mice (Fig. 1 ) . However, 
the TK'-ä mutant did not lose i t s pa thogen ic i t y for young mice. Sequencing 
of the EcoRI-Hpall fragments in the nuc l eo t i de sequence of the TK genes 
cloned from a number of HSV-1 i s o l a t e s revea led the ac tua l s i t e s of mutation 
(Table 4 ) . 
TK" mutants that can e a s i l y be i s o l a t e d may be d e f e c t i v e not only in 
the TK gene but a l s o in the func t iona l domains of t he TK promoter sequence. 
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Such mutants differ from each other in the degree of TK gene expression 
and, therefore, in their neurovirulence for young and for four-week-old mice. 
Plaque size of mutants and the TK gene 
An additional number of mutants was selected on the basis of plaque 
size from large plaques (2-4 mm in diameter) and from small plaques (0.2-
0.5 mm in diameter). From each isolate, we prepared a TK" mutant, using 
BUdR (the parent strain was TK+). The pathogenicity of these strains for 
mice was studied by inoculation of the virus onto scarified corneas of 
four-week-old mice. Table 5 shows that the small plaque (SP) mutant 11 
(designated SP11 TK+), which had an active TK gene, was less virulent 
(80.7% survivors) than either the LP TK+ isolate (2.8% survivors) or the 
SP18 TK+ isolate (5.4%). This result indicates that in the SP11 TK+ isolate 
an unknown gene was mutated which led to reduction in virus pathogenicity. 
A TK" mutant isolated from SP11 TK+ (designated SP11 TK") had lost its 
virulence completely and was not pathogenic for mice by the eye route even 
at 107 pfu/ml (T. Ben-Hur and Y. Becker, to be published). 
The virus isolate, SP18 TK+, was found to be highly virulent for mice, 
even after selection of a TK" mutant (SP18 TK"; Table 5). These observa­
tions indicate the presence of a neurovirulence gene in addition to the 
viral TK gene, as indicated in Table 2. 
The LP and SP isolates can be identified by restriction endonuclease 
analysis of the viral DNA (Fig. 3). LP isolates (lanes 3 and 5) have an 
additional band between the J(16Kb) and K(llKb) fragments. Another extra 
band is present between the K and L fragments. These extra bands are not 
present in the SP, F and Justine strains of HSV-1. 
TABLE 5 Virulence of HSV-1 isolates in mice inoculated in the eye 
Virus isolate Surviving mice % 
LP TK+ 1/36 2.8 
LP TK" 65/65 100.0 
SP11 TK+ 21/37 80.7 
SP11 TK" 10/10 100.0 
SP18 TK+ 2/37 5.4 
SP18 TK" 40/55 72.7 
Mice were infected by corneal scarification with 10 pfu/ml of virus, and 
their survival was determined over a three week period. 
261 
<- 4 . 4 Kb 
Fig. 3 Bglll restriction 
enzyme analysis of HSV-1 
strains: 
1) F, 2) SP TK1-«, 3) LP TK+, 
4) Justine, 5) LP TK" 
The DNA preparations were 
electrophoresed in 0.7% 
agarose containing ethidium 
bromide. 
1 2 3 4 5 
Analysis of viral glycoproteins in the plaque size mutants using mono­
clonal antibodies 
Glycoproteins gD and gB produced in BSC-1 cells infected with the four 
virus strains: LP TK+, SP TK%, and the two small plaque mutants SP11 TK+ 
and SP18 TK+ were compared (Fig. 4). The amounts of gD and gB glycoproteins 
precipitated by specific monoclonal antibodies (generously provided by Prof. 
M. Levine) were similar in the plaque size mutants tested. Glycoprotein C 
was also produced to the same extent by the four virus strains (not shown). 
Thus, no differences were found in glycoproteins among the various plaque 
size isolates. Nonetheless, it was of interest to determine whether mono­
clonal antibodies to gB can neutralize virus infectivity in these isolates. 
As shown in Table 6, infectivity was reduced by the anti-gB monoclonal 
antibodies in the LP TK+, SP TYh, and SP18 TK+ isolates, but SP11 TK+ was 
not affected at all. This result indicates that the antigenic epitope of 
gB on the outer membrane of SP11 TK+ virions was not detectable by the mono­
clonal antibody. It is not known if this particular missing gB epitope 
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Fig. 4 Precipitation of HSV­1 isolates with monoclonal antibodies 
to gD and gB. The virus strains were grown in BSC­1 cells and treated 
with monoclonal antibodies to gD and gB as described in Materials and 
Methods. Samples were electrophoresed in 10% acrylamide gels. 
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TABLE 6 Neutralization of HSV­1 mutants by plaque reduction with 































































Monoclonal antibodies to HSV­1 glycoprotein Β (monoclonal B5 obtained from 
Prof. M. Levine, The University of Michigan, Ann Arbor, Michigan) were 
diluted and added to each virus suspension. Bovine calf serum was used as 
control. The suspensions were incubated at room temperature for 2 hr before 
plating on BSC­1 plates. After a 2 hr adsorption period, the plates were 
covered with agar and incubated at 37°C for 3 days. The agar was removed, 
and the cells were stained with 0.1% gentian violet. The average number 





Promoter (TK gene) 
PBY40­2 
Fig. 5 A diagrammatic presentation of recombinant plasmid pBY40­2. 
The BglII/I DNA fragment of HSV­1 LP TK+ strain was cloned in the 
BamHI site of pBR322. The orientation of three HSV­1 genes is indicated: 
DNA binding protein (DNA BP), glycoprotein Β (gpB) and glycoprotein A 











4800 bp Saci / 100K 
gpE 
pBY718/pBY7(17) 
Fig. 6 A schematic representation of the recombinant plasmid 
pBY718/pBY7(17). This plasmid contains the Bglll-BamHI sequence 
with the HSV-1 TK gene. Two additional viral genes of HSV-1 strain F 
(gD and gE) were cloned in the BamHI site of pBY718. In the result­
ing recombinant plasmid, an unknown viral gene is present upstream 
to the viral gD gene. The viral gE gene is downstream to the gpD. 
The orientation of the viral genes is indicated by the arrows. 
Cloning and expression of HSV-1 glycoprotein genes in transfected L(TK") 
cells 
Two plasmids containing the gB/gA and the gD glycoprotein genes in 
pBR322, respectively (pBY40-2, Fig. 5; pBY718/pBY7(17), Fig. 6) were used 
to transfect LTK" cells using the HSV-1 TK gene for the selection of TK+ 
transformants. From the transfected LTK" cells (Becker et al., 1984b), 
individual colonies were obtained and propagated in HAT medium. The colonies 
which were designated with the number of the recombinant plasmid used for 
transformation were studied for the expression of the viral genes. The gB/ 
gA genes were not expressed in the cell colonies transformed by plasmid 
pBY40-2, as determined by the use of monoclonal antibodies to precipitate 
35s-methionine-labeled proteins. This might be due to the inability of the 
cellular RNA polymerase II to recognize and transcribe HSV-1 gamma genes 
which require the attachment of a beta gene protein product to its promoter 
(Roizman, 1983). 
Analysis of the JOS-labeled proteins of the colony transformed with 
plasmid pBY718/pBY7(17) revealed a 100K polypeptide which was precipitated 
by monoclonal antibodies to HSV-1 gD. The gD polypeptide has a molecular 
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weight of 55K (Morse et al., 1978; Lee et al., 1982). It is possible, how­
ever, that the 100K polypeptide recognized by the gD monoclonal antibodies 
is a fusion product, namely a polypeptide initiated in the gene which codes 
for a 42K polypeptide. This was described by Lee et al. (1982) and precedes 
the gD gene in the HSV­1 genome. The 42K gene is a beta gene which can be 
recognized by the cellular RNA polymerase II. Further studies are in pro­
gress to characterize this protein. 
Expression in E. coli 
The DNA fragment carrying the gD gene was cloned in the Sad site of 
the HSV­1 TK gene which was inserted downstream from the N gene of the λ 
phage left promoter under the control of the ci repressor (cI857). The 
resulting plasmid was designated pHABY130 (Fig. 7). This plasmid was 
introduced into E. coli strain 157 (C600ÀcI857) and the transfected bacteria 
were incubated at 30°C and 42°C. As a control, E. coli strain 157 was 
transfected with plasmid pHABY119 and incubated at 42°C. The bacterial 
homogenates were treated with monoclonal antibodies to gD and the antigen­
antibody complexes were precipitated and analyzed by Polyacrylamide gel 







Fig. 7 A schematic representation of plasmid pHABY130. Plasmid 
contains the left promoter (PrJ and Ν gene (N) from λ DNA. The 
Bglll­BamHI HSV­1 LP TK+ DNA fragment containing the HSV­1 TK gene 
was cloned at the BamHI site. A Sacl­Sacl DNA fragment which carries 




















Fig. 8 Expression of HSV-1 gD gene in E. coli. Plasmid pHABY130 
was incubated at 30 and 42°C and plasmid pHABY119 at 42°C, after 
which monoclonal antibodies to gD were added, as described in 
Materials and Methods. Samples with and without gD were electro-
phoresed in 10% acrylamide gels. 
only one polypeptide band (^ 66K) was obtained. In samples treated with gD 
monoclonal antibodies, proteins were precipitated from bacteria carrying 
plasmid pHABY130 at 30 and 42°C. The nature of these proteins is being 
studied, as is the question as to whether or not they are related to gD. 
It has been demonstrated that HSV-1 gD produced in E. coli is antigenic 
and can protect mice against challenge with a virulent strain of HSV-1 
(Weis et al., 1983). 
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DISCUSSION 
The development of new technologies of gene transfer has made it pos­
sible not only to identify viral genes involved in neurovirulence and 
malignancy, but also to use these genes for the production of viral antigens 
for vaccination purposes. Gene transfer technology has also made it feas­
ible to transfer genes from different viruses into poxviruses, which can 
then be used for vaccination of humans, animals and chickens against a 
number of diseases in addition to those caused by poxviruses. In this way, 
the naturally occurring attenuated poxvirus vaccine, which was introduced 
into medicine by Jenner in 1796, can be utilized as a carrier for the genes 
of hepatitis Β virus, influenza virus, or herpes simplex virus (Smith et 
al., 1983; Mackett et al., 1984). New and exciting possibilities thus 
exist for the use of engineered recombinant live virus vaccines for immuni­
zation of sensitive humans or animals against pathogenic viruses. 
The availability of recombinant live virus vaccines does not preclude 
the need for herpesvirus live attenuated vaccines. Immunization of the 
human eye against local infection with herpes simplex virus might reduce 
the incidence of herpes keratitis in humans. An attenuated live herpes 
simplex virus vaccine needs to be engineered in such a way that the genes 
coding for neurovirulence (TK and neurovirulence genes) will be mutated 
or deleted, in addition to deletion of the nucleotide sequences involved 
in cell transformation. 
Table 7 documents the response of cells in the reticuloendothelial 
system (RES) to live or killed viruses, as well as to viral proteins or 
peptides in synthetic and natural virus subunit vaccines. The attenuated 
live viruses involve the RES in immunizing the host and lead to life-long 
immunity against the virus. It is possible that the subunit virus vaccines 
will be useful in eliciting neutralizing antibodies to herpesvirus glyco­
proteins (Cohen et al., 1984). However, the live herpesvirus and recom­
binant poxvirus vaccines will also succeed in eliciting local tissue and 
RES immunity. Live attenuated vaccines like those used to protect chickens 
and pigs could be developed for herpesviruses of other domestic animals 
with the help of genetic engineering technologies. 
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Table 7 Involvement of the reticuloendothelial system in the immune 












































Virus replication leads 
to survival of Langer­
hans cells and presenta­
tion of antigens to the 
lymphocytes. 
Virus particles are taken 
up by the reticulo­
endothelial cells and 
viral antigens are pre­
sented to the lymphocytes. 
Low uptake? Low level of 
presentation of viral 
antigen to lymphocytes? 
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VACCINATION OF HUMANS AGAINST VARICELLA­ZOSTER VIRUS 
Lise THIRY 
Institut Pasteur du Brabant 
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1180 Bruxelles, Belgique 
ABSTRACT 
Clinical trials with live vaccines prepared with the attenuated Vari­
cella­Zoster Virus (VZV) OKA strain indicate that this vaccine induces hu­
moral and cell­mediated responses in healthy and in immunocompromised indi­
viduals. In a proportion of the latter individuals, the vaccine may cause 
mild varicella or zoster but it affords a 100% protection against severe 
disease after contact. There is no indication that vaccination of healthy 
adults harbouring latent VZV will protect against VZV reactivation and 
zoster symptoms. 
INTRODUCTION 
This paper tries to underline the principal features of the meeting 
which took place in Munchen on the 29th­30th November 1984. The author 
hopes that she did net inadvertently introduce some bias in the presenta­
tion of the lively discussions of the meeting. A full paper of this meeting 
will be published in a book. 
The need 
There is hardly any symptomless case of varicella. Chicken pox is as 
inevitable as death and taxes. Rates of encephalitis complications per 
100,000 cases are 1.7 and 15 in children and adults respectively, as well 
as 3.2 of Reye syndrome (N.B. The latter figure may vary with countries, 
since Belgian pediatricians refuted Reye syndrome association with chicken 
pox ; the highest rate of this syndrome is certainly registered during in­
fluenza epidemics). The world wide annual number of Zoster is estimated at 
5.2 χ 10 , with the cruciating pain which this disease involves, and the 
non negligable proportion of motor deficit sequellae. 
In immunocompromised patients, very severe varicella or Zoster were ob­
served in 11% of children with lymphoma, 30% of those with leukaemia (7 % 
of the leukemic children died of VZV infection) and in as much as 50% of 
bone marrow transplanted patients. In one german study of 109 children with 
acute lymphocytic leukaemia, there was a 2% mortality and 19% morbidity due 
to VZV (7 varicella, 11 Zoster, 1 encephalitis and 1 pneumonia). However, 
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these figures will be now strikingly reduced with the introduction of the 
highly effective acyclovir therapy. 
There are some discrepancies in the figures relating to the risk of con­
genital varicella. Gisela Enders in Germany followed women who did not 
possess VZV antibodies at the beginning of pregnancy ; among those with 
seroconversions, 4% only gave rise to abnormal infants. According to this 
author VZV intrauterine infection differs from rubella in that infection of 
the foetus does not lead to permanent virus production in the tissues, with 
no antibodies of the IgA and IgM class detected in the newborn. There is 
however a prolonged high titer of CF IgG. Distribution of the risks was 
quoted by Stanley Plotkin. Eighteen women with VZV symptoms during prenancy 
(15 with varicella, 3 with Zoster) gave birth to abnormal children. Nine of 
these women showed symptoms during the first trimester, 8 during the second 
and 1 during the third trimester. Ten infants had typical limb deformities, 
13 had ocular abnormalities, 9 suffered from central nervous system involv-
ment and 10 showed varicella cicatrices. 
The problem 
Varicella Zoster Virus (VZV) being a member of the herpesgroup, there is 
a theoretical risk that the vaccine might cause cancerous transformation. 
Most of us harbour wild VZV in a latent state but we do not know how much 
it contributes to our risk of cancer. Transformation might be more likely 
with an attenuated strain, if one refers to works with Herpes Simplex Virus 
which does not cause transformation when fully cytopathic, but only acqui­
res transforming properties after partial inactivation. VZV present in the 
attenuated vaccine is the OKA strain developed by doctor Takahashi and ex­
tensive research has shown that cells were not transformed by this strain. 
In Japan, there is already a ten year experience with the vaccine but one 
may argue that this delay is not yet sufficient, on the one hand, and that, 
on the other hand, negative attempts at in vitro transformation do not re­
flect the in vivo situation. In Japan, the complications of chicken pox 
have been estimated to heavily outweight the potential risk of remote can­
cer and generalization of the vaccination is recommended, although not with 
a rigid protocol. 
On the other hand, the risk that VZV vaccine strain may establish in the 
latent form is real and will be discussed below. 
From the point of view of the vaccine producer, VZV is uneasy to handle 
because it is cell associated with low yield in the supernatant and a low 
- 274 
ratio of intracellular virus to cell proteins. This implies tedious purifi­
cation procedures and high cost of vaccine. 
The immunogen 
Monoclonal antibodies to wild type VZV glycoprotein recognize three 
groups of epitopes. Site A migrates with a 105,000 MW protein and is a tar­
get for neutralizing activity of antibodies. Site Β epitope is found in 5 
distinct polypeptide bands of 98 to 45,000 MW, some of which are probably 
precursors of the others. These sites are targets for complement dependent 
neutralizing activity. (The actual total amount of neutralizing activity in 
an individual must be assayed in the presence of complement). 
Finally, epitopes of site C migrate with two proteins of 66 and 57,000 MW 
and are not targets for neutralizing activities. 
To our knowledge, the epitopes present in the vaccine strains are not yet 
well documented. 
The immune response 
Humoral antibodies are best evaluated by an immunofluorescence test 
(FAMA) which detects membrane associated viral antigens. It is recommended 
to introduce an internal control, i.e. to mix an excess of non infected 
cells with the VZV producing cells. This test equals in the evaluation of 
neutralizing antibodies. Elisa are somewhat less reliable but are prefered 
for large scale studies. 
In vitro evaluation of cell-mediated immunity by lymphocyte transforma­
tions assays is less reliable than an in vivo skin test. However, there is 
a great need for a standardized antigen. 
Frequent local reinfections do occur after the natural disease. This is re­
flected by frequent boosters at the level of secretory IgA antibodies. At 
long interval periods, some of the reinfections probably penetrate further 
within the organism, since boosters at the level of serum IgG antibodies 
and cell-mediated responses were noted after interval periods of decades. 
The importance of cell-mediated immunity for protection against the 
disease is proven. The issues of close contact which chicken pox cases were 
followed in individuals with a low titer of FAMA antibodies (1:8 and 1:16). 
Of those with a negative skin test, 6% contracted varicella symptoms, while 
no symptoms occurred in individuals with a positive skin test. Another stu­
dy showed that all of the individuals with a positive skin test have neu­
tralizing antibodies, while 6% of those with the antibodies do not show 
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positive skin tests. Vaccination of the latter individuals induced the 
appearance of cell-mediated response. 
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Fig. 1 Correlation between frequency of zoster and loss of cell-
mediated immunity to VZV. A : Proportion of individuals whith high 
(large diameter), low (small diameter) or no ( - ) skin reaction to 
VZV antigen. Β : Decrease with age of lymphocyte response to phyto-
haemagglutinin and to VZV. C : Proportion of individuals with Zoster 
symptoms according to age. 
276 
Figure 1 shows that the number of individuals with a positive skin test 
to VZV antigen strikingly decreased with age. In vitro, non specific lympho­
cyte response to phytohaemagglutinin decreases more slowly than that to VZV 
antigen. The age at which cell-mediated response to VZV wanes corresponds 
to the striking increase of Zoster incidence. If we live long enough, 15% 
of us will suffer from Zoster symptoms. 
Vaccination : efficacy and complications 
Inoculation of 5000 PFU of VZV vaccine will elicit antibody formation in 
90 to 100% of children, as well as cell-mediated response. Infants respond 
well but seronegative adults appear to be less receptive to the vaccine, 
and a higher dose than 5000 PFU may be needed. High degree of infant suscep­
tibility and relative resistance of adults remind of the situation with he­
patitis Β vaccine. 
After vaccination, humoral antibody level seems to decrease somewhat more 
rapidly than would be expected from a live vaccine, but positive skin tests 
are still observed many years after vaccination. Nevertheless, usefulnes 
of a booster dose of vaccine is envisaged. 
In contrast to natural disease, vaccination does not induce local secre­
tory IgA nor does it increase natural Κ cell activity. 
In immunocompromised patients, vaccination also provokes a high seroconver­
sion rate as well as good cell-mediated response. This is probably due to 
the fact that VZV vaccine strain is more invasive in these patients than in 
healthy individuals. The increased amount of viral antigens produced may 
compensate for the low level of immune response capacity. However, viral 
vaccine invasion results in the appearance of mild symptoms in some indivi­
duals of this group. Although it is recognized that VZV vaccine will afford 
a 100% protection efficacity against severe varicella, all the study groups 
showed a frequency of mild rash and/or Zoster within a short period after 
vaccination. The worst reactions are noted in leukemic children vaccinated 
during a relapse and without interruption of the antileukemic treatment. 
Up to 55% of these children developed a mild rash post vaccination and 7% 
suffered from a not severe zoster. This indicates that the vaccinal strains 
may establish within the neutral ganglia and there are a few examples that 
this can even occur in healthy individuals with no immunosuppression back­
ground. Post-vaccination mild rashes may be contagious to close contacts 
and thus vaccinated leukemic children must be kept away from other people 
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at risk. Figures for the post vaccinal complications are greatly lowered 
if the leukaemic patient is vaccinated while in remission or at a moment 
when lymphocyte counts reach at least 1200 per ml, or if antileukaemic 
treatment is suspended for at least one week before and one week after vac­
cination. 
In patients with lymphoma, solid tumours or steroid treatment, clinical 
symptoms are induced by the vaccine in 5%, 9.6% and 2.7%, respectively. 
Vaccination versus specific immunoglobulins or acyclovir treatment 
Before introduction of vaccination and active drugs, specific immuno­
globulins directed at VZV were efficiently used to prevent or decrease va­
ricella symptoms, if the immunoglobulins were injected within a few days 
after a contact. However, since contact risks are high among children, 
immunoglobulins often had to be injected as frequently as every 3 months. 
Moreover, many contacts occurred of course without notice. On the other 
hand, passive immunisation with immunoglobulin injections does not imply 
suspensions of antileukaemic treatments in contrast to acyclovir adminis­
tration or vaccination. Vaccination however presents the great advantage 
that the moment of treatment interruption may be appropriately chosen. 
Discomfort for the patient must also be taken into account. In this res­
pect, acyclovir treatment perhaps ranks the worst, since three daily per­
fusions of several hours each are necessary. 
Long term effects of the three treatments are being followed. Several 
studies indicate that anti VZV vaccination does not increase the risks of 
leukaemia relapses, and that this probably holds true for acyclovir admi­
nistration. As stated above, vaccine may cause mild Zoster early after vac­
cination,but does not increase the long term risk of Zoster due to wild type 
virus reactivation. Actually, some studies seem to indicate that vaccina­
tion has some beneficial influence on future natural zoster. Wild type and 
attenuated VZV isolated from Zoster vesicles can be readily differenciated 
by restriction enzymes (endonuclease) mapping. 
STRATEGIES 
A. Minimal 
A "coup par coup" policy will aim at identifying persons at risk and 
providing a vaccination at the least unfavourable moment. Decreasing prio-
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rit ies rank as follows : 
- Leukaemic children 
- Tumour patients, especially children 
-Children with cystic fibrosis (Pediatricians notice that varicella as well 
as measles not only are severe diseases in these patients, but that they 
can dramatically precipitate the course of cystic fibrosis) 
- Uremic patients (especially children) prior to kidney transplantation 
- Seronegative adults (or better, adults with a negative skin test) with a 
priority to health personal who represent a possible link for a chain of 
VZV transmission, as well as to child bearing age women,with contraindica­
tion of vaccination during pregnancy. Hazards of live VZV vaccinations 
for the foetus have however not been proven. 
B. Maximal (optimal ?) : the social barrier policy 
It is realised that the above scheme represents a heavy procedure not 
likely to be worlwidely applied. Attempts at long term eradication of VZV 
is thus envisaged. M. Just in Switzerland has applied the following vaccina­
tion scheme to 15 month old children. On the same day, these children re­
ceived 7 different vaccines 
1 - MMR (live measles, mumps, rubella) in one seringe 
2 - VZV vaccine in a second seringe 
3 - DT (diphteria, tétanos toxoids) in a third seringe 
4 - Sabin polio vaccine per os 
Post vaccination antibodies were of the same order of magnitude than in 
cases of separate vaccinations. However, mixing VZV with MMR seemed to re­
duce antibody response. Other workers obtained good results with a mixture 
of MMR-VZV. It was agreed that the appropriate optimal amounts of MMR-VZV 
antigens in a mixture have still to be defined. 
Cost benefit analysis of course demonstrated a striking benefit for 
this combined vaccination policy. In particular, generalization of VZV vac­
cination would decrease the cost per dose, since quality controls for lar­
ge batches are always more economical. 
If the above policy were applied with patience, tenacity and the will 
for win, a social barrier to the viruses would insure a double protection 
for the individuals at risk. No only would these individuals meet the wild 
viruses much more rarely, but the social barrier would enable the high risk 
groups to escape the hazards of vaccination : immunocompromised patients 
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might be spared VZV vaccination while whildren prone to convulsions would 
be spared measles vaccination and childbearing age women would receive 
booster rather than primary rubella vaccination. 
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ON THE IMMUNITY INDUCED IN PIGS BY CONVENTIONAL 
VACCINES AND DELETION MUTANTS OF AUJESZKY'S DISEASE VIRUS. 
J.T. van Oirschot*, W.G.V. Quint*, A.L.J. Gielkens*, P.W. de Leeuw* and A.J.M. Berns** 
* Department of Virology, Central Veterinary Institute, 
Houtribweg 39, 8221 RA Lelystad, the Netherlands 
* * Department of Biochemistry, University of Nijmegen, Geert Grooteplein N21 
6525 EZ Nijmegen, the Netherlands 
ABSTRACT 
Vaccination of pigs against Aujeszky's disease (AD) is common practice in 
many countries. In general, attenuated AD virus vaccines are more efficacious than 
inactivated vaccines. In addition, they can be given intranasally and this mode of 
vaccination induces better protection than parenteral vaccination(s). However, 
none of the present AD vaccines is capable of conferring complete protection 
against a challenge with a virulent virus. 
Attenuated AD viruses used as vaccines are usually obtained by numerous 
passages in cell culture. Consequently, (i) in these strains mutations are introduced 
in an uncontrolled way, and (ii) most attenuated strains contain several variants. 
The above observations indicate a need for more potent and better defined AD 
virus vaccines. 
Several approaches are possible for the development of new AD virus 
vaccines. Because (i) attenuated vaccines are basically more efficacious and (Π) the 
observation that pigs which survive an infection with virulent AD virus are fully 
protected against challenge 6 weeks later, we have chosen for bio-engineering a 
"l ive" AD virus vaccine, starting from a virulent and highly immunogenic AD wild-
type virus. We have constructed hybrid viruses of a virulent and an avirulent strain 
of AD virus and subsequently assayed for virulence in mice and pigs. A conclusion 
from this study was that the Us region comprises virulence genes. Subsequently, 
deletions were introduced in the Us region of the genome of the virulent strain. 
The deletion mutants generated were strongly reduced in virulence, and were 
highly immunogenic in pigs. 
INTRODUCTION 
Aujeszky's disease (AD) has a worldwide distribution. The pig is the natural 
host of AD virus and the only significant source of virus spread. In many countries 
vaccination of pigs is practised to reduce severe economical losses. Attenuated 
(live) as well as inactivated (killed) vaccines are available. Because comparative 
data on efficacy of AD vaccines are scarce, we have compared efficacy of the 
vaccines most frequently used in the Netherlands in sero-negative pigs under 
standardized laboratory conditions. In the Netherlands, most breeding pigs are 
vaccinated against AD twice a year and as a result young pigs acquire maternally 
derived antibody (MDA). It is diff icult to achieve an effective immunization of pigs 
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with MDA. The first results of intranasal (IN) vaccination of pigs with MDA were 
encouraging (De Leeuw et al., 1982) and subsequently we compared the efficacy of 
IN vaccination with an attenuated AD virus with parenteral vaccination(s) with 
inactivated vaccines. 
On several grounds the presently used attenuated AD virus vaccines are 
susceptible of improvement. In recent years, DNA recombinant technology has 
become available that may be employed to construct well-characterized, safe and 
effective "live" AD virus vaccines. 
The present report deals with the results of comparative studies on 
attenuated and inactivated AD virus vaccines, and with the construction and 
testing of deletion mutants of AD virus. 
Comparison of efficacy of AD virus vaccines in sero-neqative pigs 
We have compared 2 inactivated vaccines (A= Nobivac^, Intervet, the 
Netherlands, B= GeskyvacO, Roger Bellon, France) and 4 attenuated vaccines (C= 
MK-2rø(strain MK-25), Pharmachim, Bulgaria, D= Ay-vak® (strain B-KAL), Pliva, 
Yugoslavia, E= Delsuvac@(strain BUK/TK 650), Gist-Brocades, the Netherlands, F= 
an experimental vaccine (strain Bartha) provided by Duphar, the Netherlands). 
Two vaccines (C en D) were found to be excreted after vaccination. 
Table 1 summarizes the results on the efficacy of the 6 vaccines. Despite a 
maximum of standardization, considerable variation sti l l existed in mortality and 
growth arrest of control pigs after challenge. All vaccines, except vaccine E 
prevented mortality after challenge, but none conferred complete protection. Most 
vaccinated pigs stil l lost weight, developed fever and shed virus after challenge. 
The results of this comparative study indicate that 2 attenuated vaccines (D and F) 
conferred the best protection, that 1 attenuated vaccine (C) was of equal efficacy 
as the 2 inactivated vaccines (A and B) and the 4th attenuated vaccine (E) was the 
least effective. 
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* Fever = 40°C 
The experimental procedures have been reported previously (De Leeuw and 
Van Oirschot, 19B5). Briefly, 2 groups of sero-negative pigs were vaccinated 
intramuscularly at 10 weeks of age, one of them was revaccinated 3 or 4 weeks 
later. A 3rd group served as non-vaccinated control. Intranasal challenge with a 
virulent AD virus strain was done 3 months after the 1st vaccination. Evaluation of 
vaccine efficacy was based on mortality, growth arrest, fever and virus shedding 
periods after challenge. A maximum of standardization was exercised. 
Comparison of efficacy of an attenuated vaccine given intranasally with 2 
inactivated vaccines given parenterally in pigs with maternally derived antibody. 
In the Netherlands, over 90% of breeding pigs are vaccinated against AD, 
usually twice a year. In consequence, pigs possess MDA at' the start of the 
fattening period. Table 2 shows that pigs born to sows vaccinated in the field 
during each pregnancy (4 to 6 weeks before parturition) with an inactivated vaccine 
(NobivariB) Intervet, the Netherlands) can have rather high serum-neutralizing (SN) 
antibody titres around 10 weeks of age. In addition, considerable variation exists in 
individual SN-titres. 
- 283 
TABLE 2 Maternal antibody titres in pigs born to sows vaccinated under field 
conditions. 
Farm Age No. pigs Mean Variation 
(weeks) tested SN-titre SN-titre 
"Ã (ΓΊΟ 70 54 12-384" 
Β 10-12 19 35 12-128 
C 10-12 35 42 24-128 
D 10-12 24 18 6-48 
The neutralisation test was done with an incubation period of the serum-virus 
mixture of 24 hours. Titres were expressed as the reciprocal of the final serum 
dilution inhibiting epe in 50% of the cultures. An AD virus infection of these pigs 
could be excluded on the basis of supplementary serological investigations. 
Maternal immunity does not protect the pigs during the entire fattening 
period. Thus, in regions where AD is enzootic, vaccination of fattening pigs with 
MDA may be necessary. However, maternal immunity interferes with production of 
active immunity after parenteral vaccination. 
To overcome this, an IN vaccination with an attenuated virus has been 
developed (De Leeuw et al., 1982) and was subsequently compared with 2 
inactivated vaccines as to efficacy. The vaccines used were the attenuated Bartha 
strain for IN vaccination (vaccine A), and the inactivated vaccines GeskyvapB', 
(Roger Bellon, France) (vaccine B), and NobivacB; (Intervet, the Netherlands) 
(vaccine C). The results of 4 comparative experiments (Table 3) demonstrate that a 
single IN vaccination with the attenuated virus conferred a considerably better 
protection than parenteral vaccination with the 2 inactivated vaccines. 
However, the efficacy of IN as well as parenteral vaccination decreased with 
increasing levels of MDA at vaccination. More detailed results on IN vaccination 
have been published elsewhere (De Leeuw and Van Oirschot, 1985; Van Oirschot and 
De Leeuw, 1985). 
After IN vaccination the attenuated Bartha strain is excreted and this might 
result in transmission to susceptible pigs, and subsequently in serial passages over 
pigs. Passages over pigs may, theoretically, lead to reversion of virulence. We have 
made 6 passages with the non-plaque-purified Bartha strain in 2-day-old pigs and 
found no evidence for such a reversion. In another study, the Bartha strain could 
not be reactivated from pigs vaccinated intranasally at 10 weeks of age, suggesting 
that the strain does not induce latency (Van Oirschot and Gielkens, 1984). Thus, 
these often raised objections against the use of attenuated AD virus vaccines may 
not be justified, at least with respect to the Bartha strain. 
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TABLE 3 Summarized results of vaccination experiments in pigs with maternally 
derived antibody. 
Exp. Age at Vaccine 
No. vaccination 
(weeks) 
Mean SN t i tre 
at at No. 
Challenge results 
Mean days of 
vaccin- challenge dead Growth Fever Virus 






























































































Pigs (7 or 8 per group) with various levels of MDA were vaccinated between 4 
and 10 weeks of age and challenged 2 months after (the last) vaccination. The 
evaluation of vaccine efficacy was done as described previously (De Leeuw and Van 
Oirschot, 1985). 
The above and other studies (McFerran et al., 1982; Zuffa et al., 1982; 
Pensaert and Maes, 1984) indicate that attenuated AD virus vaccines are generally 
more effective than inactivated vaccines. However, even the best attenuated 
vaccines cannot prevent the development of mild illness, the shedding of virulent 
virus and the establishment of latency. Most attenuated vaccines are derived from 
virulent AD virus by numerous serial passages in heterologous cells and as a 
consequence random mutations are introduced into the viral genome. In addition, 
most vaccine preparations are heterogeneous, that is they contain a population of 
closely related genetic variants (Gielkens et al., 1984) of which some may have 
different biological properties (unpublished data). The above observations indicate 
a need for more potent and, in molecular-virological respect, better defined AD 
virus vaccines. 
Construction, virulence and immunoqenicity of deletion mutants from virulent AD 
virus 
As parent strain for the construction of a "live" bio-engineered AD virus 
vaccine a virulent and highly immunogenic virus (the Northern Ireland Aujeszky 3 
(NIA-3) strain, kindly provided by Dr. J.B. McFerran) was used. This strain 
conferred complete protection in pigs, as evidenced by the results of an experiment 
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in which the ¡mmunogenicity of a thymidine kinase negative (TK") mutant from the 
NIA-3 strain was tested (Table 4). 





































In this experiment a BUDR-induced TK" mutant of the NIA-3 strain was 
compared with a TK+ plaque-purified virus of the NIA-3 strain with regard to 
efficacy. Pigs were inoculated intranasally with 10' PFU of virus and challenged 
intranasally with 10' PFU of the NIA-3 strain at 6 weeks after inoculation. 
Evaluation of protection was done according to our standard procedures. 
After construction of hybrid viruses from the virulent NIA-3 strain and the 
avirulent NIA-4 strain and testing these for virulence in pigs it was concluded that 
genes mapping in the unigue short (Us) and/or repeat region are involved in the 
expression of virulence (Berns et al., 1985). In a recent paper, Lomniczi et al. 
(1984) reported that Us genes are necessary for virulence of AD virus as 
determined in young chickens. We therefore constructed mutants with deletions in 
the Us region, starting from the NIA-3 strain. 
The methods for the construction and characterization of deletion mutants 
wil l be described in detail elsewhere (Quint et al., submitted). Briefly, NIA-3 viral 
DNA was digested with endonucleases Bam HI or Hind III. Bam HI fragment 7 (Fig. 
1) was cloned in plasmid p8R 322. This plasmid was linearized by partial Bal 1 
digestion. Full-length DNA molecules were isolated, digested with exonuclease Bal 
31 and reclrculized. Two plasmids with deletions of 2.8 and 2.4 kbp in DNA 
fragment 7 were selected. From the molecularly cloned NIA-3 Hind III Β fragment 
the Mlul-Bgl II fragment was replaced by the Mlul-Bgl II fragment of the 2 plasmids 
bearing the deleted inserts. The viral inserts of the final recombinant plasmids 
(pHB 2.8 and pHB 2.4) were mixed with the Hind III A fragment of NIA-3 virus, and 
transfected into secondary porcine kidney cells (Fig. 2). 
Reconstituted viruses from transfections were plague-purified 3 times and 
their genomes characterized by Southern Blot analysis, using digestions with Bam 
H I , Sal 1, Bam HI + Kpnl, and Bam HI + Kpnl + Hind III, and probing with 3 2P-
labelled NIA-3 DNA or molecularly cloned subgenomic fragments. 
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Fig. 1. 
Physical map of the NIA-3 strain of AD virus. The sites for BamHI, Bgl II , Hind III 
and Kpnl are presented. The rectangles represent the inverted repeats. For each 
enzyme, fragments are given in alphabetical or numerical order according to size. 
Identical sized fragments are indicated by a "prime". 
090 ΟΘ5 Q80 
O B R 3 2 2 
1 κ 0 ρ 
j M U 088 087 0.86 Q85 
ρ BR 3 2 ! 
Fig. 2. 
A scheme of the procedure to construct deletion recombinant plasmids 
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The delet ion mutants were character ized as having a NIA-3 pa t te rn w i th 
delet ions of 2.8 kbp (2.8 N3A) and of 2.4 kbp (2.4 N3A) between map unit posit ion 
0.886 and the Bgl II site at posit ion 0.856, involv ing the loss of the Mlu l site at 
posit ion 0.876 (F ig. IB ) . The mutant 2.4 N3A had lost the SphI s i te , whereas the 
mutant 2.8 N3A had reta ined i t . In add i t ion , both mutants had a smal l delet ion 
(about 100 nucleotides) comprising the Hind I I I site in the inverted repeat region 
(Quint et a l . , submit ted) . 
The mean t ime to death (MTD) in mice upon inoculat ion w i th AD virus strains 
has been used to group strains according to virulence (Piat t et a l . , 1980). In 
general, v i ru lent AD virus k i l ls mice faster than at tenuated strains, but at least 
one vaccine virus stra in k i l ls mice in the same t ime as a v i ru lent stra in (Van 
Oirschot and Gielkens, 1984). The 2 delet ion mutants had s ign i f icant ly (Wilcoxon 
rank test , ρ < 0,05) longer MTD's than the parental NIA-3 stra in (Table 5), 
indicat ing that a marker for v irulence in mice is present in the Us and/or repeat 
region. The posit ion and/or length of the delet ion in the Us region may a f fec t 
v i ru lence, as shown by the s igni f icant (Wilcoxon rank tes t , ρ < 0,05) d i f ferences in 
MTD's of the 2 mutants (Table 5). 
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Groups of 8, 6 to 7-week old Balb/c mice were inoculated subcutaneously 
w i th 10^ PFU of virus in a 0.1 ml vo lume. The mice were moni tored at intervals of 
6 hours for 10 days. MTD (mean t ime to death) values are given w i th standard 
deviat ions. 
Groups of 5 pigs were inoculated intranasal ly w i th 10 ' PFU of v i rus. 
Evaluation of v irulence for pigs was done essential ly as described previously (De 
Leeuw and Van Oirschot , 1985). % pos = percentage of posi t ive oropharyngeal f lu id 
samples col lected the f i rs t 10 days a f ter inocu la t ion. Mean virus t i t re expressed as 
login. PFU of virus per gram of f l u i d . 
In the microneut ra l isat ion test a serum/vi rus incubat ion period of 24 hours at 
37°C was used. Ti t res were expressed as the rec iprocal of the f ina l serum di lu t ion 
inhib i t ing cy topath ic e f fec t in 50% of the cu l tures. Mean SN-t i t res at 3 weeks post 
' inoculation are given. 
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Both mutants had a strongly reduced virulence for pigs. Whereas the parental 
N IA-3 st ra in k i l led 2 of 5 pigs, the delet ion mutants induced no m o r t a l i t y . The pigs 
given the parenta l N IA-3 st ra in developed typ ica l signs of A D , whereas the pigs 
given the mutant 2.4 N3A or 2.8 N3A only showed very mi ld depression or fever , 
respect ive ly . The pigs inoculated w i t h the mutants showed no growth ar res t . The 
mutants were shed in oropharyngeal f lu id to a lower level than the parental stra in 
(Table 5). A t 3 weeks post inoculat ion the pigs surviv ing the N IA-3 in fec t ion had 
more than 10 t imes higher SN-t i t res than pigs given the mutants . However, the 
la t te r pigs were we l l p ro tec ted against a challenge w i t h v i ru lent AD virus 6 weeks 
post inoculat ion (Table 6). They developed no signs of disease, but did shed v i ru lent 
v i rus, although at a much lower level than non-vaccinated cont ro ls . Par t i cu la r ly , 
mutan t 2.4 N3A was able to considerably reduce v i ru lent virus shedding and in 2 
pigs given this mutant no virus shedding could be detected at a l l a f ter chal lenge. 
This aspect is of high signi f icance w i t h respect to e l iminaton of f ie ld-v i rus 
c i r cu la t i on . 
The pigs given the mutants 2.4 N3A or 2.8 N3A appeared to be bet ter 
p ro tec ted than pigs vaccinated IN w i th 10^ PFU (a 10 t imes higher dose than used 
in this study) of the Bartha st ra in (De Leeuw et a l . , 1982). 
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Pigs given the delet ion mutants and 2 sero-negative cont ro l pigs of the same 
age were 'inoculated intranasal ly w i th 10^ PFU of the v i ru lent N IA-3 s t ra in , 6 
weeks a f te r inoculat ion. The challenge and evaluat ion of p ro tec t ion was done 
according to our standard procedures. 
♦Percentage of v i rus-posi t ive oropharyngeal f lu id samples during the f i r s t 10 days 
a f t e r chal lenge. 
CONCLUSION 
The results demonstrate that 2 genet ical ly engineered delet ion mutants 
der ived f r o m a v i ru lent AD virus strain had a markedly reduced v i ru lence, and were 
highly immunogenic in pigs. Using the present approach more modi f ica t ions, i f 
necessary, can be introduced into the genome of these mutants , for instance to 
a f f ec t the v i ra l ab i l i t y to establish la tency, or to enhance immunogenic i ty . 
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Thus, the AD virus delet ion mutants are considered to provide a good base for 
the product ion of bio-engineered " l i ve " AD virus vaccines. 
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SUMMARY OF SESSION SIX. 
NOVEL APPROACH FOR THE PREVENTION OF HERPESVIRUS INFECTIONS. 
by H. LUDWIG and L. THIRY. 
Dr. BECKER reported on current developments in the field 
o-f vaccines. It was emphasized that a variety o-f live 
attenuated vaccines are known which induce a preventive immune 
response. As an example the yellow-fever virus vaccine was 
cited. Similar approaches have been made with herpesviruses. It 
is, however, neccessary to have more information on the genes 
coding for the immunogenic components, and more importantly, to 
know the genes responsible for virulence. Contributions of the 
STEVENS group and, in this meeting, of DARAI's group give 
promising insights into neurovirulence genes. The importance of 
the TK gene for a herpesvirus to go latent and/or pass the 
barrier to the brain was emphasized. TK~ viruses are known to 
reach the ganglion and cause latency. Furthermore, correlations 
of small and large plaque herpesviruses with virulence were 
presented. 
A further approach includes recombinant DNA vaccines which 
are currently produced using parts of the vaccinia genome and 
the glycoprotein regions of HSV like the gB and the gD region 
in expression vectors. Promising observations appear to come 
from the yeast-system rather than the E. coli system. 
A third attempt is chemical synthesis of immunogenic 
components (oligopeptides). This has successfully been done to 
synthesize gD products of HSV. These peptides are able to 
induce neutralizing antibodies and to protect mice. The problem 
with these experiments is that injection of virus and 
structural components does not reflect the natural way of a 
virus entering the organism. Dr. BECKER concluded that in 
current approaches to create save and efficacious herpesvirus 
vaccines it is of importance to present the immunogen in the 
right way for an effective activation of the immune response. 
Dr. L. THIRY's question concerning the TK gene(s) in human 
cells could not be answered, since such genes are more 
precisely investigated in the mouse system. Dr. LUDWIG raises 
the question whether attenuation of herpesviruses through 
passages in cell cultures or susceptible animals might be a 
helpful way to select avirulent viruses. Like in the 
pseudorabies virus system deletions seem to occur always at the 
same genome location. Dr. BASKELL points to an observation with 
feline herpesviruses where small plaque variants always occur 
after reisolation of virus from infected cats. There is, 
however, no obvious rearrangement in the DNA of such viruses. 
Is the cat naturally selecting the small plaque virus? Dr. 
LUDWIG does not agree with the opinion that a plaque phenotype 
in general correlates with virulence. Dr. SUBAK-SHARPE mentions 
that many genes influence plaque form and plaque size and there 
is not enough information about the gene functions yet. It is 
of importance that attenuated virus keep on going to mutate, 
which makes it essential to continuously control whether the 
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immunogenicity of these viruses is not lost. 
Dr. LUDWIG asks whether recombinations in nature might 
occur between wild type and attenuated or deleted viruses. Dr. 
SUBAK-SHARP mentions that recombination and reversion have to 
be kept apart. Reversion seldomly occurs. A recombination after 
superinfection with wild type virus is possible; the 
probability of its in vivo occurrence, however, is quite low. 
Dr. HILL asks whether one can regard latency as a good or a bad 
thing, since it is often established after immunization. Dr. 
BECKER states that it may be good in lymphocytes but 
deleterious in the nervous system. Dr. BECKER concludes with 
some suggestions on how to construct modern vaccines and 
emphasizes that a more rational approach (genetic engineering 
of vaccines) should be made, rather than producing vaccines on 
an empirical basis. 
The following report by Dr. L. THIRY covers the efficacy 
and the problems arising with the introduction of a new 
varicella zoster virus life vaccine into human populations. 
Questions concerning the effectiveness of the VZV vaccine 
against chicken ροκ cannot be fully answered. The vaccine 
strain has a clearly different restriction enzyme pattern from 
that of the wild type strain. The alterations on the genome 
have not been mapped. 
The last report by Dr. VAN OIRSCHOT deals with genetically 
engineered pseudorabies (PsR) virus vaccines. After it was 
detected that in vaccine strains, like the Bartha strain, 
deletions in the short unique region of PsV virus occur, Dr. 
VAN OIRSCHOT's group used this information to construct a new 
virus from two Northern Ireland strains. A virulent strain 
served for the part containing the unique long region and the 
non-virulent strain supplements the unique short region. The 
new virus has a characteristic deletion in the Bam HI fragment 
7 similar to that of the Bartha strain. The biological 
properties of the virus can be summarized as follows: infected 
mice die after a long incubation period, the virus does not 
kill pigs and does not lead to growth delay. Dr. CASTRUCCI 
raises the question, whether this virus is safe for cattle and 
other animals, and mentions that any vaccine that concentrates 
only on one species cannot be valuable. Dr. BECKER points to 
the information that TK - mutants should be used for 
constructing these vaccines, as well. Dr. VAN OIRSCHOT refers 
to further experiments, which still have to be done. 
In summary, this session presented information about two 
live-virus vaccines, one prepared from attenuated 
varicella—zoster virus, the other constructed from pseudorabies 
virus DNAs. These approaches show two extremes of current 
developments in vaccine production. First, creating vaccines on 
an empirical basis and secondly, engineering vaccines with, 
hopefully, less virulence. There is a general consensus that 
the control of herpesvirus infections by vaccination appears to 
be possible in some cases. In other cases we need more 
information on the viruses themselves and their interactions 
with their hosts. 
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SESSION 7 
PROTECTION OF ANIMALS AQAINST 
HERPESVIRUS INFECTIONS 
Chairman : O.C. STRAUB 
Co-chairman : J . T . VAN OIRSCHOT 
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ABSTRACT 
Intranasal vaccination with a cold-adapted strain of FHV-1 provides 
solid immunity against feline viral rhinotracheitis by 6 days post vacci­
nation. The onset of protection at this time appears to be specific and 
has all the characteristics of a conventional immune response. However at 
6 days post vaccination only low levels of FHV-1 specific IgA and IgM anti­
body can be found in serum and nasal secretions and no significant amounts 
of interferon are detectable. Also in lymphocyte transformation assays 
neither peripheral blood lymphocytes nor tonsil lymphocytes gave a signi­
ficant proliferative response in the presence of FHV antigen. 
Pathogenesis experiments demonstrated that the tonsil is an important 
primary site of virulent FHV-1 replication which was significantly reduced 
in the tonsils of vaccinated cats. This suggests that a local cell mediated 
immunity, possibly initiated within the tonsil, may play a more important 
role than local antibody in protection against FHV-1 infection. 
INTRODUCTION 
Feline viral rhinotracheitis virus, now known as Felid herpes-virus 1 
(FHV-1) is a major upper respiratory pathogen of cats and was first isolated 
in 1957 by Crandell & Maurer (1958). It causes an acute febrile syndrome 
characterised by sneezing, depression, and copious ocular and nasal dis­
charges. FHV-1 is also highly infectious and is a widespread problem in 
boarding catteries, breeding colonies and other situations where a large 
number of cats have been brought together. Infection is mainly by means of 
aerosols and the virus reproduces locally in the mucosae of the nasal turbi­
nates and conjunctival regions (Gaskell & Wardley 1978); soft palate, tonsil 
and trachea may also be involved (Gaskell, 1975). FHV-1 is relatively 
fragile in the environment and relies on survival by sequential spread and 
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setting up a carrier state in its host. As a result of this persistence 
in the animal, vaccines have only been moderately successful in controlling 
FHV-1 infection. 
Recently a live cold-adapted mucosal FVR vaccine (Duphar Veterinary) 
has been developed which is administered intranasally and so far evidence 
suggests that it prevents a carrier state when a cat is challenged with 
the field strain (Orr et al, 1980). This type of vaccination conforms to 
the natural route of infection and is thought to produce a localised 
response in the respiratory tract because protection is rapid and is 
reported to occur within 2 days post vaccination (Slater & York, 1976). 
However the protective mechanisms involved have not yet been established 
and have so far only been investigated in terms of serum antibody which 
remains undetectable until day 20 post vaccination (Orr et al, 1980). 
In this paper we have made use of another distinct upper respiratory 
condition of cats caused by feline calicivirus (FCV). This is a RNA virus 
unrelated to FHV and can therefore be used to study the specificity of the 
protection provided by FHV vaccine. Cats were challenged with either FHV 
or FCV at 2 or 4 days post vaccination with the cold adapted FHV vaccine. 
Clinical disease and virus shedding patterns were then monitored to 
determine the time of onset and specificity of early protection. 
Having established this pattern of development, the important sites of 
early resistance to field FHV replication in vaccinated cats were deter­
mined and compared with local and systemic antibody responses, IFN levels 
and FHV-specific lymphocyte transformation responses by peripheral blood 
and tonsillar lymphocytes. 
MATERIALS AND METHODS 
Experiment A 
An experiment was designed to determine the specificity of protection 
afforded by intranasal vaccination using a cold-adapted FHV-strain 
(login 6.9 TCID50 per cat, Duphar Veterinary). Sixteen cats of approxi­
mately 12 weeks old were placed in isolated groups of 4 (Gaskell & Povey 
1979) and designated A, B, C and D respectively. Groups Β and C were 
vaccinated and after 48 hours C was challenged intranasally with the viru­
lent strain of FHV-1 (B 927, loglO 7.1 TCID5o/cat) and Β with the un­
related virus FCV (69/1112 strain loglo 7 TCID5o/cat). Groups A and D 
served as challenge controls so that the pathogenicity of FHV and FCV 
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cells using Polyinosinic-polycytidylic acid (Richmond 1971) and its titre 
determined by the microplaque reduction technique using cowpox (Strain L97, 
Gaskell et al 1983) as an indicator virus. 
The sensitivity of FCV and FHV to the IFN produced in vitro was then 
examined using the same microplaque reduction technique as above. 
Blood samples for lymphocyte transformation assays were collected 6 
days post vaccination in syringes containing 20 units/ml preservative free 
heparin. Lymphocyte transformation assays were also carried out on lympho­
cytes isolated from tonsils (Goddard et al 1984). 
RESULTS 
Experiment A 
No clinical signs of disease were observed during the pretest period. 
No virus isolations were made from nasal specimens made at the time of 
grouping or on day 0. Vaccinating cats with FHV vaccine two days before 
challenge with virulent FCV provided no protection against clinical disease. 
The control group (A) had a total mean cumulative score per cat of 86 com­
pared to 84 for the vaccinated group (B) and this difference was not sig­
nificantly different (Wilcoxon's two sample rank test). Cats in both 
groups showed the same degree of disease which was typified by large 
inflamed mouth ulcers in all cases. 
The FHV-vaccine did however provide partial protection against virulent 
FHV. Within 5 - 6 days after challenge vaccinated cats (Group C) showed 
mild depression, reduced appetite, transient pyrexia and some sneezing and 
slight ocular/nasal discharge with a total mean cumulative clinical score/ 
cat of 26.9 ± 12.3. The unvaccinated cats (group D) showed marked pyrexia, 
reduced appetite, mild depression and marked ocular/nasal discharge. 
Sneezing, milk conjunctivitis and dyspnoea were also recorded. The total 
mean cumulative clinical score per cat for this group was 82 t 18.6 which 
was significantly different than the vaccinated/challenged cats (Wilcoxon's 
2 sample rank test Ρ < 0.01). 
However despite the reduction in symptoms virulent FHV was shed from 
vaccinated cats in group C and there was no significant reduction in 
shedding time compared to the control group D. 
The above experiment was repeated using FHV without FCV and the virus 
shedding patterns quantified. Both nasal and oropharyngeal titres of 
virulent FHV from vaccinated/challenged cats peaked at 3 days post chal-
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could be ascertained. The cats were examined daily for clinical signs of 
illness and the severity of the major signs assessed on a point scale from 
0 (normal) to 4 (severe) and expressed as a clinical score (Gaskell and 
Povey, 1979). Nasal and swab specimens for virus isolation (Wardley et al 
1974) were collected from all cats at the time they were first placed in 
isolation, on the day preceding day 0 and daily thereafter for 20 days. 
Where swabs contained both vaccine and virulent FHV-1 plaque size differ­
ences in feline embryo cells (FeA) were used to distinguish between them. 
Both viruses had been previously grown in FeA cells at 37°C with an over­
lay of methyl cellulose for 3 days and plaque diameters measured. This 
provided a standard size for each virus which could be compared with virus 
plaques from swab samples grown under similar conditions (Cocker et al 1984) 
Having established the specificity and degree of protection further chal­
lenge experiments were carried out using FHV only and cats were challenged 
at either 2 or 4 days post vaccination. One group was given the vaccine 
strain only. All cats were then monitored clinically and virologically 
for 20 days as described above. The nose and oropharynx were swabbed daily 
and virulent FHV-1 was quantified using a standard plaque assay system 
(Crandell et al, 1960). 
Experiment Β 
A second study was conducted to determine the primary sites of early 
replication and thereby ascertain in which tissues resistance to infection 
was taking place in vaccinated cats. Four cats were housed in two isolated 
pairs. One group was vaccinated with the FHV vaccine and after 6 days all 
four animals were challenged with virulent FHV. Euthanasia was performed 
on the cats after a further 48 hours and the viral content in nasal turbi­
nates, tonsil, soft palate, submandibular lymph nodes and conjunctiva 
analysed by tissue homogenisation (Gaskell & Povey, 1979). 
Experiment C 
A third study was undertaken to investigate the immune mechanism 
responsible for early protection following intranasal vaccination with the 
FHV vaccine. Sera and nasal washings were collected at day 0 and 6 days 
following vaccination. These were assayed for interferon (Campbell et al 
1975) and for anti-FHV antibodies using a plaque reduction assay (Gaskell 
et al 1983) and also an immunoglobulin class-specific ELISA (Voller et al 
1976). Cat interferon was produced in vitro from Crandell feline kidney 
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lenge (5-6 days post vaccination) then began to fall. (The peak titre 
recorded in nasal swabs was 10^ pfu/ul compared to 3 χ 10^ pfu/ul in oro­
pharyngeal swabs). 
The virulent titres from challenged only cats however reached higher 
levels (mean 5 χ 10^ pfu/nasal swab sample) and fell only after 7 - 8 days 
post challenge. 
The total amount of virus shed from the 4 vaccinated/challenged cats 
was 6.8 χ 10^ pfu/ul which was just significantly less than the total of 
9 χ 10^ pfu/ul recorded from unvaccinated challenged only cats (Wilcoxon's 
two sample rank test, (P < 0.05). 
The vaccine strain was isolated from both nasal and oropharyngeal 
swabs of the vaccinated only group for a period of 6 - 9 days and two out 
of four cats showed transient pyrexia ranging up to 40°C. and sneezing for 
1 - 2 days only. 
When cats were challenged 4 days after vaccination instead of 2 days 
no clinical disease was evident and virulent FHV was isolated at a very low 
level, 5 χ 10^ pfu per swab on one day from the nasal swab of one animal 
only. Four unvaccinated controls inoculated with virulent virus showed 
similar clinical signs and shed virus as before. 
Experiment Β 
In unvaccinated cats challenged with virulent FHV significant levels of 
the virus were only found in the tonsils and nasal turbinates at 48 hours 
post challenge. The mean titr. irulent FHV in nasal turbinates was 10^ 
pfu/mg wet tissue weight, and . tonsil 7.5 χ 10 pfu/mg wet tissue 
weight. 
However in nasal turbinates and tonsils of cats that had been vacci­
nated 6 days prior to challenge with virulent FHV the levels of virus were 
significantly reduced. A mean of 15 pfu/ug wet tissue weight was recorded 
for nasal turbinates and 0.5 pfu/ug wet tissue weight for tonsillar tissue. 
Experiment C 
Interferon results 
Using a microplaque reduction technique and cowpox as an indicator 
virus, only very low levels of interferon were recorded 6 days post vacci­
nation. Out of 5 cats examined the highest titre recorded was 1:30 for 
nasal washings and 1:10 for serum. 
Cat interferon was produced in vitro using polyinosinic-polycytidylic 
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acid. This antiviral activity was confirmed by demonstrating that its 
ability to cause a 50% reduction in cowpox plaques was relatively unaffec­
ted by ultracentrifugation and overnight dialysis at pH2, but severely 
reduced by trypsin treatment. Using a standard in vitro cat interferon 
preparation FHV and FCV showed a 50% plaque reduction with a 1:175 and a 
1:100 IFN dilution respectively. At 6 days post vaccination, anti-FHV 
neutralising activity could hot be detected in either serum or nasal 
washings by a plaque reduction assay. However, using the more sensitive 
ELISA system, low levels of IgM and IgA antibody were found in nasal 
washings. This low level antibody response was also evident in serum but 
was restricted to the IgM class. 
Lymphocytes from blood and tonsils of vaccinated cats showed a good 
proliferative response to the non-specific T-cell mitogens concanavalin A 
and phytohaemagglutinin in an in vitro lymphocyte transformation assay. 
However no FHV-specific response was evident when these lymphocyte popu­
lations were cultured for 6 days with an inactivated preparation of FVR 
infected FEA cells. In contrast, blood lymphocytes from cats recently 
recovered from a natural FVR infection consistently responded to this 
same antigen preparation when cultured under similar conditions. 
DISCUSSION 
Vaccination of cats with a cold adapted FHV-1 strain four days before 
exposure to the virulent virus will protect against clinical disease. 
Since the incubation period of experimental FHV in this study was one to 
two days it is concluded that cats show resistance to infection by five 
to six days after vaccination (i.e. four days between vaccination and 
challenge plus the one to two day incubation period). The onset of 
protection therefore has all the characteristics of a conventional immune 
response and appears to be specific for FHV-1 because no protection was 
afforded against FCV. Only very low levels of interferon were detected 
in nasal and serum samples six days post vaccination. These levels are 
probably unimportant in early protection because FCV replication, which we 
have shown to be sensitive to interferon in vitro, was not affected by 
vaccination. 
However, despite the evidence for a solid immunity providing specific 
protection by six days post vaccination, only very low levels of anti-FHV 
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neutralising activity were found in nasal washings and serum. Similarly 
blood and tonsil lymphocytes showed no proliferative response to FHV anti­
gen. In the unvaccinated cat challenged with virulent FHV, the tonsil 
appears to be an important primary site of virus replication (Gaskell & 
Povey 1979). Therefore the very significant reduction in replication seen 
in vaccinated cats suggests that a local cell cytotoxicity response plays 
an important role in protection against FHV disease. 
The importance of the tonsil in protection against disease has been 
demonstrated by several workers studying human tonsil cells. Recently 
Drucker et al (1979) have detected cell-mediated immune responses in human 
tonsils, and Ogra et al 1971 demonstrated that children undergoing tonsil­
lectomy before vaccination respond less well to a primary local immuni­
sation with live, attenuated polio than do control subjects. 
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ABSTRACT 
Bacterially produced human interferon ( Hu­IFNou ), which has a weak 
antiviral effect on the multiplication of Bovine Herpesvirus 1 ( BHV 1 ) 
in vitro, was intramuscularly administered ( 10 IU/kg body weight ) 
daily during 6 days to young heifers, beginning one day prior to intra­
nasal infection with 5 10 PFU of BHV 1. Treatment with Hu­IFNau did not 
reduce the virus excretion nor the nasal discharge. Moreover,establishment 
of BHV 1 latency was not prevented, as demonstrated by viral reactivation 
following dexamethasone treatment. However, the injected interferon was 
biologically active. Indeed, in the treated animals, IFN induced the 
2'­5' oligoadenylate synthetase activity and blocked the production of 
endogenous interferon. 
INTRODUCTION 
Bacterially produced human interferon Hu­IFNoL ( Nagata et al., 1980 ) 
was shown to be clearly active in vivo against experimental vaccinia virus 
infection in young calves ( Goossens et al., 1982 ; Wérenne et al., 1983, 
c 
1985 ). A daily treatment schedule at a dose of 10 IU/kg body weight pro­
vided complete protection in some animals. Although this experimental sys­
tem was particularly convenient to quantify the protection conferred by 
interferon treatment, it remained to be determined if human interferon 
might be useful for the treatment of some important viral diseases of cat­
tle. We have already shown that Rotavirus induced newborn calf diarrhoea 
is totally inhibited by exogenous Hu­TENt*. ( Schwere et al., 1985 ). 
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The fully successful protection against this important viral disease we 
have obtained confirmed the role of endogenous interferon in the control 
of pathogenicity of Rotavirus we had demonstrated before ( Vanden Broecke 
et al., 1984 ). We had shown indeed that in conditions where endogenous 
interferon is produced very early after infection with Rotavirus ( using 
a very high dose of virus ) no sign of pathogenicity was observed. On 
the contrary, in conditions where an identical level of interferon is 
produced but much later on ( using a small dose of virus ), pathogenic 
symptoms fully developed. The time of establishment of the antiviral sta­
te is therefore more essential than the level of circulating interferon 
produced. A similar situation could therefore be expected by analogy in 
other viral infections. 
Infectious bovine rhinotracheitis is economically among the most impor­
tant infections in cattle. In fact, the pathology of infection is largely-
due to respiratory infection. Other symptoms can also be observed : 
infectious pustular vulvovaginitis, enteritis, conjunctivitis, abortion, 
encephalitis in young calves. Newborn calves like foetuses suffer from an 
acute and systemic fatal infection, but present also, sometimes, the res­
piratory disease ( Pastoret and Thiry, 1984 ). 
With BHV 1, known to be a good interferon inducer ( Ahl and Straub, 1971 ; 
Rosenquist and Loan, 1969 ), a temporal relationship between interferon 
in respiratory tract secretions after avirulent 1ER treatment and onset 
of protection against virulent BHV 1 challenge was described in some stu­
dies ( Todd et al., 1972 ) but not in other ( Savan et al., 1979 ). As we 
showed that BHV 1 is inhibited in vitro by recombinant Hu-IFNoC ( Gcossens 
et al, 1983a ) even if it is less susceptible than was VSV or Rotavirus 
( Goossens et al., 1983b ), we decided to undertake an in vivo study also. 
We tested the antiviral effect of bacterially produced human interferonia 
on the primary infection of cattle by BHV 1 as well as the effect on the 
treatment on the establishment of BHV 1 latency. For this purpose, we u-
sed Hu-IFN<<„ Arg supplied by Boehringer Ingelheim. 
MATERIAL 
Interferon : Lyophilized bacter ia l ly produced human interferon Hu-
IFNtf. Arg ( specific ac t iv i ty of 3 10 IU/mg protein ) was supplied by 
Boehringer Ingelheim Vetmedica. The interferon preparation contains hu-
man serum albumin ( 15 mg HSA/ 5 10 IU ) . The in vi t ro ac t iv i ty cf IFN 
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preparation was tested against the LA strain of BHV 1 by a plaque reduc­
tion assay in GBK cells. 
Virus : The strain IBR/Cu 5 of Bovine Herpesvirus 1 ( BHV 1 ) which 
was isolated in Belgium from a respiratory case ( Pastoret et al., 1979 ) 
was used for cattle infection. The strain IBR/LA was used for seroneutrali-
zation procedure. 
Experimental animals : Eight Holstein friesan heifers 6-8 months of 
age and devoid of serum neutralizing antibodies against BKV 1 virus were 
obtained from a single source. 
METHODS 
Titration of nasal virus excretion : Ten fold dilution of virus sus­
pensions were adsorbed to monolayers of Georgia Bovine Kidney ( GBK ) 
ce l l s grown in microplates. Plaques were obtained under MEM supplemented 
with 5% specific bovine an t i BHV 1 serum ( neutralization antibody recipro­
cal t i t r e : 64 ). After three days of incubation, ce l ls were fixed and 
stained with an hydro-alcoholic solution of crystal violet . Plaques were 
counted. 
Interferon t i t r a t i o n : Circulating ant iv i ra l ac t iv i ty was determined 
in the plasma by the c lass ical technique of reduction of cytoparhic effect 
( Stewart, 1979 ) in GBK c e l l s , using as challenge Vesicular Stomatitis 
Virus ( VSV ). 
Determination of the lymphocytic 2 ' -5 ' oligoadenylate synthetase 
ac t iv i ty : Lymphocytes were isolated from blood by Ficoll-Hypaque density 
centrifugation, divided into aliquots ( 4 10 cel ls / tubes ) and stored at 
-70°C. Cell extracts were prepared by Ncnidet P-40 lys is ( Williams et a l , 
1981 ) and 2'-5'A synthetase ac t iv i ty was measured in solution assays 
containing ΙΟ/ol of ext ract , 20 mM Hepes buffer pH 7.5, 25 mM Mg(OAc) , 5 
mM ATP, 1 mM DTT, 4 mM Fru-P„, 20,kg/ml Poly IC, 0.SJU.1 (3H) ATP ( NEN, 
47 Ci/mmol ) in a f inal volume of 25/ί,Ι. The 2 ' -5 ' oligoA synthesized we­
re isolated by DEAE-cellulose chromatography as described by Minks et a l . 
( 1979 ) . 
Determination of antibodies against BHV 1 : Two-fold serum dilution 
were reacted with 100 plaque forming unit ( PFU ) of BHV 1 and tested by a 
micromethod using GBK ce l l s maintained in MEM supplemented with 5% foetal 
calf serum ( FCS ) . Titres represented the reciprocal of the highest serum 
dilution which inhibited 50% of cytopathic effect. 
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Experimental schedule and procedures : 
1. Grouping of animals : 8 BHV 1 seronegative animals were divided 
into three groups. Group I. Three heifers ( 305, 460, 785 ), maintained 
outside, were infected with BHV 1. 
Group II. Three heifers ( 307, 461, 781 ), maintained 
outside and separated from the 3 first animals 
were infected with BHV 1 and treated with Hu-
IFN<<2. 
Group III. Two heifers were kept together in a stable : 
heifer 457 was considered as a " negative con­
trol " , heifer 409 only received HU-IFNDC 
( IFN control ). ~ 
2. Primary infection with BHV 1 : On day 0, animals of the two 
first groups ( I, II ) were infected with 5.10 PFU of IBR/Cu5 strain of 
BHV 1. Nasal swabs were taken daily during 15 days. Swabs were weighed be­
fore and after sampling. After sampling, they were eluted in 2 ml MEM. 
Virus titration was performed as soon as possible and virus excretion was 
expressed in PFU/ 100 mg of nasal exsudate. Serum samples were regularly 
( 7 days interval ) collected for neutralization and were heat-inactivated. 
Hu-IFN oc ( 10 IU/kg ) was intramuscularly injected daily, from day - 1 to 
day 4 ( 6 injections ) to the animals of group II and one animal of group 
III ( 409 ). The other animal of group III ( 457 ) as well as the animals 
of group I were intramuscularly ( i.m. ) with physiological serum, follo­
wing the same schedule. To measure the circulating antiviral activity and 
the level of 2'-5'A synthetase activity in lymphocytes, blood samples 
( 20 ml ) were collected in heparinized tubes at different times : at t=0h, 
lh, 8h on day -1 and at t=0h on days 0,1,2,3,4,5,6,8,10,16 ( t=0h corres­
ponding to the time of IFN injection ). Body temperature was taken daily. 
3. BHV 1 reactivation with dexamethasone treatment: Reactivation as­
say started after three months ( day 84 ) by giving to all the animals 
five consecutive daily intravenous injections of dexamethasone ( Fortecor-
tine Bayer : 0.1 mg/ kg body weight ). Body temperature was taken daily. 
Nasal swabs were collected daily during 15 days and treated as previously 
described. Serum was taken regularly for neutralization. Blood samples 
were collected ( 20 ml ) daily until day 11 days after the beginning of 
reactivation to measure the circulating antiviral activity and the lympho­
cytic 2'-5'A synthetase activity. 
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RESULTS 
1. Effect of Hu-IFNat, Arg on BHV 1 replication in vitro 
BHV 1 replication in GBK cells is weakly sensitive to the antiviral 3 effect of Hu-IFNo( Arg. Indeed, even with 10 IU/ml of interferon, only a 
reduction of 50% of BHV 1 plaque formation can be observed ( Figure 1 ). 
Fig. 1. In vitro effect of Hu-IFN« 
on the formation of BHV 1 plaques 
in bovine GBK cells. 
2. Primary BHV 1 infection 
All the animals infected with BHV 1, treated or not with interferon 
excreted BHV 1 virus from day 1 to day 9, day 0 being the day of virus ino­
culation. The maximum of nasal virus excretion was localized between days 
2 and 4. Ten days after the virus inoculation, none of the animals excre­
ted virus anymore ( Figure 2 ). 
Although the disease symptoms seemed somewhat less important in the trea­
ted animals ( nasal discharge, red nose ... ), replication of BHV 1 was 
not inhibited in the nasal tractus after intramuscular injection of Hu-
IFNc(2 Arg. All the 6 animals inoculated with BHV 1 had. f ever. Temperature 
increase measured every 24 hours ( before IFN injection in the treated a-
nimals ) reached a maximum of 1.2°C on day 4. This increase corresponded 
to the development of the disease ; indeed, on the same day, the symptoms 
were clearly observable. 
After a single injection in the control animal, circulating antiviral ac­
tivity was already detectable 60 minutes after injection and was complete-
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Fig. 2. Profile of nasal virus excretion during the 
primary infect ion with BHV 1, start ing on day 0 
ly cleared out from the circulation after 24 hours. Hyperthermia, which is 
now described as a classical effect of interferon, was maximum ( + 1.5°C ) 
after 8 hours and disappeared after 24 hours. A two fold increase of the 
lymphocytic 2'­5'A synthetase level could be observed already after this 
single injection ( data not shown ). 
Kinetics of circulating antiviral activity apparition was studied on day 
­ 1 in the three treated animals ( BHV 1/ IFN ). It was similar to what 
has been observed in heifer 409 ( IFN control ) : the maximal IFN level 
obtained after one hour was 10 IU/ml. No more interferon could be detected 
24 hours after the injection. No IFN accumulation was detectable at the end 
of the daily treatment.( Figure 3 ). In the plasma of the 3 infected hei­
fers, not treated with interferons peak of antiviral activity could be 
detected by the classical test of reduction of VSV cytopathic effect in 
bovine GBK cells ( Figure 4 ). This peak localized between day 2 and 4 in­
dicates that relatively high level of circulating interferon ( 200 to 
3 10 U/ml ) resulted from viral infection. This peak was not present in the 
plasma of IFN/ BHV 1 heifers. 
Modifications of the lymphocytic 2'­5'A synthetase activity : 
During this Hu­IFNc(­ Arg repeated treatment ( a total of 6 i.m. injections) 
the maximal level of 2'­5'A synthetase activity in the lymphocytes ( 4 
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Fig. 3. Antiviral activity detected in the plasma 
of the animals of group II, infected with BHV 1 
and treated i.m. with Hu-IFNe^ Arg ( 10 IU/kg body 
weight ). 
Fig. 4. Antiviral activity detected in the plasma 
of the animals of group I, during the primary in­
fection with BHV 1. 
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fold increase ) was reached af ter two injections ( Fieure 5 ). This level 
was maintained unt i l the end of the treatment ( day 4 ). Twelve days after 
the l a s t injection ( day 16 ) , the lymphocytic level of 2'­5'A synthetase 
was identical to the basal level exis i t ing before the beginning of the 
experiment. The increase in act ivi ty of 2'­5'A synthetase was related to 
the level of circulat ing interferon ; the maximal increase of the 2'­5'A 
synthetase ac t iv i ty was observed in the lymphocytes of the heifer 461 
which had the highest plasmatic interferon level one hour af ter injection 
( data not shown ). A single IFN injection was not sufficient to reach 
the maximal level of the enzyme act iv i ty : as mentionned above, a two 
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Fig.5. Induction in the 2'­5'A synthetase actvity 
in lymhocytes of the heifers infected with BHV 1 
treated or not with Hu­IFN«. ( Mean of the results 
obtained on 3 animals in each group ). 
Without interferon treatment, in the three infected animals, the 2'­5'A 
synthetase activity remained constantly low during the first 4 days of 
BHV 1 infection. The enzyme level was however slightly increased on day 6, 
two days after the maximal level of endogenous antiviral activity was rea­
ched ( see the mean values in figure 5 ). 
Production of anti BHV 1 antibodies : Production of anti BHV 1 anti­
bodies occured already two weeks after BHV 1 inoculation : it was identi­
cal in the two groups of animals. This level remained constant until the 
beginning of the dexamethasone treatment. 
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3. BHV 1 nasal reexcretion by dexamethasone treatment. 
Daily injections ( for 5 days ) of dexamethasone to the heifers, 
previously infected with BHV 1, reactivated BHV 1 nasal secretions. This 
reexcretion was maximal from day 4 till day 8 after the first dexamethaso­
ne injection and stopped 14 days after the beginning of the treatment 
( Figure 6 ). Again , no difference in the clinical symptoms was observed 
between the two groups of animals. After dexamethasone treatment, no endo­
genous IFN production could be detected by the CPE test on GBK cells nei­
ther in the plasma of heifèr 409 ( LTN control ) nor of the 6 heifers re­
excreting BHV 1 virus particles. A very slight increase of the 2'­5'A 
synthetase activity was however observed in the lymphocytes of the animals 




Fig.6. Profile of BHV 1 reexcretion following 
dexame­thasone treatment ( 5 daily consecutive 
i.v. injections of dexamethasone at a dose of 
0.1 mg/kg ). 
Nine days after the beginning of virus reexcretion, production of anti­BHV, 
bodies was enhanced in all animals : the titre obtained varied at the 
time between 32 and 128 ( Table 1 ). 
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Fig.7. Level of the 2'­5'A synthetase acti­
vity in lymphocytes after dexamethasone treatment. 
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Table 1. Evolution of the anti BHVl antibodies 
level during all the experimentation ( day 0 : 
primary infection ; day 83 : beginning of the 
dexamethasone treatment. 
DISCUSSION 
Intramuscular injection ( i.m.) cf bacter ia l ly produced human in ter ­
feron ( Hu­IFN<*7 Arg ) in the bovine species did not suppress vira l r ep l i ­
cation in heifers intranasally infected with BHV 1. On the basis of the 
data obtained with the small group of animals studied, we may not conclu­
de for a s t a t i s t i c a l l y significant reduction in any part icular symptoms 
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( temperature, nasal discharge ) resulting from the viral infection, after 
IFN treatment. Further study using a lower viral infectious dose, closer 
to what occurs generally in natural infection, would be necessary to clari­
fy the situation. Moreover, the establishment of viral latency ( as revea­
led by virus reactivation with dexamethasone treatment ) was not suppressed 
either. Viral multiplication in the nasal tractus being not affected by 
interferon, we would conclude, if the site of latency establishment is the 
same as the site of primary infection, that IFN has no specific effect 
on the critical step involved in the process. However·, it is not excluded 
that latency results from viral infection at a secondary site. Lymphocy­
tes could be good candidates. Again we could infer that such process is 
not affected by interferon treatment in the present conditions. 
On the other hand, biological activity of Hu-IFN0(? Arg in cattle was 
nevertheless clearly demonstrated in the present study : 
- 2'-5'A synthetase activity was induced in lymphocytes of 
the animals treated with interferon 
- no endogenous antiviral activity was induced, in contrary 
to what was observed in the infected untreated animals. 
The biological events responsible for the induction of this endogenous 
activity were therefore inhibited by interferon. 
Whether the absence of effect of interferon on the disease is due to 
the fact that, as we have shown in vitro, BHV 1 is relatively weakly 
susceptible to interferon or to the fact that the type of interferon ad­
ministration used did not result in an appropriate biodisponihility of 
IFN can not be deducted on the basis of our present data. If it is the 
first possibility,we may have more chances to observe a protective anti­
viral effect with a lower viral infectious dose. If the second possibility 
holds, a local treatment with interferon, using an airspray system might 
give perhaps better results. Therefore before excluding the usefulness of 
interferon treatment for protecting cattle against infectious bovine 
rhinotracheitis , further studies are necessary. 
Even, combined therapeutics, using other antiviral agents, including 
other interferon subtypes known to have other antiviral patterns, might be 
worthwhile to test, if appropriate conditions for a therapeutic action 
with Hu-IFNi<„ Arg can not be established. 
The total success we have obtained ( Schwere et al., 1985 ) in protecting 
newborn calves against rotavirus induced diarrhoea encourages us to pursue 
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( temperature, nasal discharge ) resulting from the viral infection, after 
IFN treatment. Further study using a lower viral infectious dose, closer 
to what occurs generally in natural infection, would be necessary to clari­
fy the situation. Moreover, the establishment of viral latency ( as revea­
led by virus reactivation with cexamethasone treatment ) was not suppressed 
either. Viral multiplication in the nasal tractus being not affected by 
interferon, we would conclude, if the site of latency establishment is the 
same as the site of primary infection, that IFN has no specific effect 
on the critical step involved in the process. However·, it is not excluded 
that latency results from viral infection at a secondary site. Lymphocy­
tes could be good candidates. Again we could infer that such process is 
not affected by interferon treatment in the present conditions. 
On the other hand, biological activity of Hu-IFN0(7 Arg in cattle was 
nevertheless clearly demonstrated in the present study : 
- 2'-5'A synthetase activity was induced in lymphocytes of 
the animals treated with interferon 
- no endogenous antiviral activity was induced, in contrary 
to what was observed in the infected untreated animals. 
lhe biological events responsible for the induction of this endogenous 
activity were therefore inhibited by interferon. 
Whether the absence of effect of interferon en the disease is due to 
the fact that, as we have shown in vitro, BHV 1 is relatively weakly 
susceptible to interferon or to the fact that the type of interferon ad­
ministration used did not result in an appropriate biodisponihility of' 
IFN can not be deducted on the basis of our present data. If it is the 
first possibility,we may have more chances to observe a protective anti­
viral effect with a lower viral infectious dose. If the second possibility 
holds, a local treatment with interferon, using an airspray system might 
give perhaps better results. Therefore before excluding the usefulness of 
interferon treatment for protecting cattle against infectious bovine 
rhinotracheitis , further studies are necessary. 
Even, combined therapeutics, using other antiviral agents, including 
other interferon subtypes known to have other antiviral patterns, might be 
worthwhile to test, if appropriate conditions for a therapeutic action 
with Hu-lFNiC Arg can net be established. 
The total success we have obtained ( Schwere et al., 1985 ) in protecting 
newborn calves against rotavirus induced diarrhoea encourages us to pursue 
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i n t o t h i s d i r e c t i o n . Moreover, i n t e r e s t i n g da t a could be generated by 
such s t u d i e s . The obse rva t ions we have a l r eady made, showing some b i o ­
l o g i c a l e f f e c t s of i n t e r f e r o n in BHV 1 in fec t ed h e i f e r s , i n d i c a t e t h a t 
i n t e r f e r o n may be a f a s c i n a t i n g t o o l t o c l a r i f y some a s p e c t s of pathoge­
n e s i s due t o t h i s v i r u s , inc lud ing l a t e n c y . 
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SUMMARY OF SESSION SEVEN. 
PROTECTION OF ANIMALS AGAINST HERPESVIRUS INFECTIONS. 
by O.C. STRAUB and J.T. VAN OIRSCHOT. 
The two presentations o-f this session dealt with 
protection against herpesvirus infections. COCKER (United 
Kingdom) studied the mechanisms underlying the early protection 
after intranasal vaccination o-f cats with a cold adapted -felid 
herpesvirus 1 strain. 
Τα determine whether non-specific immune mechanisms were 
involved cats were infected with felid calicivirus. Four to six 
days after intranasal vaccination cats are well protected 
against challenge. At six days after vaccination low or no 
levels of interferon, neutralizing antibody and specific IgM, 
IgG and IgA were detected in serum and nasal washings. 
Peripheral blood lymphocytes and tonsillar lymphocytes were 
poorly stimulated by antigen at that time. Virus replication is 
markedly reduced in the tonsils of vaccinated cats. It is 
therefore suggested that local cell-mediated immune mechanisms 
are mare important than local humoral immune responses in 
protecting cats against felid herpesvirus 1 infection. 
Although intramuscularly administered, bacterially 
produced human interferon cx2 was biologically active in young 
heifers, it was not able to reduce the severity of clinical 
signs, or to curtail viral excretion after intranasal infection 
of young heifers with bovine herpesvirus 1. In addition, this 
product was not able to prevent the establishment of bovine 







IMMUNITY TO HERPESVIRUS INFECTIONS IN DOMESTIC ANIMALS 
SUMMARY AND CONCLUSIONS 
Y. Becker 
Department of Molecular Virology 
The Hebrew University 
Jerusalem, Israel 
The subject of this seminar has been the immune response of domestic 
animals to infections by herpesviruses. However, the discussions focussed 
mainly on new approaches for the development of live virus vaccines based 
on genetic engineering technologies. Live virus vaccines, such as herpes­
virus of turkeys (HVT) or attenuated Marek's disease virus (MDV), that are 
used to immunize chickens against Marek's disease and pseudorabies virus 
used in pigs against Aujeszky's disease are derived from naturally occuring 
virus isolates. It became clear, as the seminar progressed, that it is 
essential to understand how the animal responds immunologically to infection 
by a pathogenic wild type virus, and how infection with a live attenuated 
virus leads to protection and immunity. I will try to summarize the major 
points raised in the contributions detailed in this book as an integrated 
subject, without citing all the individual contributors. 
Viruses dealt with in the seminar 
The viruses dealt with are listed in Scheme 1. Most are herpesviruses 
causing diseases in domestic animals (bovine, goat, pig, cat) and birds 
(chicken, pigeon). Studies on the human herpes simplex virus were presented 
as a molecular model, since existing knowledge on this virus is far more 
advanced than on any herpesvirus of animals. Varicella-zoster virus was 
discussed as an example of the use of an attenuated, non-engineered, 
vaccine for immune-depressed cancer patients. 
Virus vaccines 
The different types of virus vaccines which were discussed in the 
seminar are presented in Scheme 2. Live attenuated pseudorabies viruses 
are currently used to immunize pigs against Aujeszky's disease. Studies on 
the Bartha strain of Aujeszky's disease virus revealed that a mutation in 
the viral thymidine kinase (TK) gene leads to lack of TK expression (TK" 
mutants) and to complete attenuation of the virulence of the virus. This is 
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Scheme 1 Viruses discussed in seminar 
Bovine herpesvirus 1 
Bovine herpesvirus 2 
Bovine herpesvirus 4 
Goat herpesvirus 
Aujeszky's disease virus 
Feline herpesvirus 
Pigeon herpesvirus 
Marek's disease virus 
B. Herpes simplex virus 
Varicella-zoster virus 
Scheme 2 Virus vaccines 
A. Attenuated virus 
B. Inactivated virus 
C. Subunit virus vaccine 




D. Recombinant poxvirus 
Transfer of GP genes from 
herpesvirus to a poxvirus 
similar to herpes simplex virus type 1 (HSV-1) in which a TK" mutation, or 
deletion of the TK gene, causes attenuation of the virulence for mice. It 
was indicated that HSV-1 TK" mutants can replicate in the nervous system 
of young mice (during the first 20 days after birth), when the nervous 
system thymidine kinase gene is still expressed and the immune system is 
not yet fully developed. Genetic engineering technologies make it possible 
to delete the TK gene from HSV-1, and thus to construct attenuated virus 
strains. 
In addition to the HSV-1 TK gene which is involved in pathogenicity 
and allows the virus to invade the ganglia and brain stem of infected mice, 
an additional neurovirulence gene was discovered. This gene controls the 
ability of HSV-1 to replicate in the central nervous system (CNS). It was 
demonstrated that a deletion in the DNA in a naturally occurring HFEM 
strain of HSV-1 markedly reduced the pathogenicity of the virus. Recom­
bination between HFEM DNA and a DNA fragment isolated from a pathogenic 
(F) strain of HSV-1 during transfection of cells in-vitro, led to transfer 
of the gene for virulence to the avirulent strain HFEM (Rosen and Darai, 
this volume; R.L. Thompson, E.K. Wagner and J.G. Stevens, Virology 131: 
180, 1983). 
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Modifications of the DNA genome of Aujeszky's disease virus, using 
genetic engineering techniques, will, it is hoped, lead to the development 
of an engineered live vaccine strain for vaccination of pigs (Van Dirschot, 
this volume). 
The use of inactivated herpesvirus vaccines for the immunization of 
domestic animals was also discussed. It was felt that live attenuated 
vaccine strains will be safe to use in domestic animals only when other 
animal species living around the vaccinated animals will not be endangered. 
Attenuated live virus vaccines can induce an immune response at the same 
site of entry as the wild-type virulent virus in the infected animal. In 
this context, the possible use of viral glycoproteins derived from cloned 
viral genes which can be expressed in E. coli, yeast, or mammalian cells, 
was discussed. All these procedures are based on the cloning of the rele­
vant herpesvirus glycoprotein genes in a variety of expression vectors 
(plasmids). The viral glycoproteins can be isolated by passing cellular 
homogenates through columns with the specific monoclonal antibodies. The 
usefulness of these viral antigens for immunization of domestic animals 
will ultimately be dependent on the cost and availability of recombinant 
live attenuated herpesvirus vaccines. 
Another possibility for the development of a recombinant virus vaccine 
was briefly discussed, namely the insertion of herpesvirus glycoprotein 
genes into poxviruses,as reported by B. Moss and collaborators (M. Mackett, 
G.L. Smith, B. Moss., J. Virol. 49:857, 1984). The use of such a recombinant 
vaccinia virus also depends on the removal of pathogenic viral genes from 
the poxvirus DNA genome. 
Some of the problems arising from the immunization of domestic animals 
with a live virus vaccine were discussed. It will be necessary to consider 
the age of the animals to be immunized, the site of virus inoculation, the 
ability of the live herpesvirus to become latent, the ability of the 
immunized animal to shed the virus, and the ability of the virus to infect 
othe1" animal species on the farm. 
Infection with herpesviruses and the immune response 
Scheme 3 depicts the sites of herpesvirus infection in domestic animals 
and in experimental animals discussed in the seminar. The initial step of 
the infection process (as summarized in Scheme 4-1) , is the adsorption of 
the herpesvirus to cells at the port of entry, most probably the epithelial 
cells (keratinocytes). The skin-associated macrophages, Langerhans cells, 
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Scheme 3 Site of virus infection 





may also be involved. Replication of the virus in the infected cells leads 
to the release of the virus progeny to further infect neighboring cells. 
The viral glycoproteins are inserted into the outer membranes of the in­
fected cells; the gE of HSV-1, for example, serves as an Fc receptor on the 
surface of the infected cell (M.F. Para, R.B. Baucke, P.G. Spear, J. Virol. 
34:512, 1980). At this stage of infection, the herpesvirus can be isolated 
for diagnosis of the disease-causing virus. 
The immune system responds to the virus infection (Scheme 4-2): viral 
antigens in the lesion are presented to subsets of Τ and Β lymphocytes, 
antibodies are produced and released locally into the blood. At this stage, 
the disease can be diagnosed serologically. Macrophages enter the lesion, 
and eventually a healing process will start. 
After the destruction of infected cells in the epidermis, the virus 
finds nerve endings and becomes attached to them (Scheme 4-5). Entry into 
the neurites signals the escape of the virus from the inhibitory effects of 
the immune system. With the axonic flow, the virus reaches the nucleus of 
the nerve cell in the corresponding ganglion. In the nucleus, the virus 
replicates, infects other ganglia and supporting nerve cells, and eventually 
continues its way through the axons to the brain stem and the CNS. A TK" 
mutant of HSV-1 is unable to infect the ganglion. Under conditions which 
prevent the herpesvirus from entering the CNS, the virus remains latent in 
the ganglion and can be reactivated at this site (Scheme 4-4). Reactivated 
virus returns through the axons to the skin and replicates in epithelial 
cells, causing a recurrent lesion. It is assumed that interferon made 
locally in the ganglion leads to inhibition of virus infection and to virus 
latency. Processes leading to virus reactivation in neurons of the ganglia 
were discussed (Hill, this volume). 
At the site of the virus lesion, herpesviruses might have the ability 
to infect lymphocytes (Scheme 4-5) , in which the virus can remain dormant 
until the cells are stimulated to synthesize DNA. At this stage, virus 
replication is reactivated, and virus infection is possible. The immune 
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Scheme 4 Cellular and immunological 
infection in animals 
1. Infection 
Adsorption of virions to cells 
Epithelial cells 
Langerhans cells (Fc 
receptors) 
Replication of virus 
Expression of viral genes 
Viral glycoproteins on 
cell membranes: 
HSV-1 gE is the Fc receptor 
gD on cell surface 
Diagnosis: Virus isolation 
2. Immune system responds 
Viral antigens are presented 
to Τ and Β lymphocytes 
Antibodies are made 
Macrophages enter lesion 
Diagnosis: Serological tests; 
neutralization test 
Infected cells shed virus 
3. Virus attaches to nerve 
endings and enters neurons 
Infection of neurons 
in ganglia 
Interferon produced locally 
Virus latency in neurons 
responses to herpesvirus 
4. Reactivation of virus 
Lesion on epithelium 
Virus shedding 
Rise in virus antibody titer 
Spread of virus 
5. Lesion develops further 
Virus particles in fluid 
Lymphocytes adsorb virus 
Virus latency in lymphocytes 
Virus replicates when lymphocytes 
are stimulated to divide 
6. Immune response necessary to 
limit the lesion 
Failing immune system leads to 
further increase in size of 
lesion 
Active immune response leads to 
healing processes 
Scar formation 
7. Generalized disease 
Virus infects RES cells 
(Kupffer cells in liver, etc.) 
Virus enters spinal cord 
Virus enters brain 
Encephalitis 
responses are needed to limit the development of the lesion at the site of 
virus infection (Scheme 4-6). A depressed immune system fails to limit the 
development of the lesion, whereas an active immune response leads to heal­
ing of the lesion. In immune-deficient patients, the herpesvirus can cause 
a generalized disease, most probably by infecting reticuloendothelial cells 
(e.g. Kupffer cells in the liver, etc.; Scheme 4-7). Such an infection 
can lead to the entry of the virus into the spinal cord, and eventually 
into the CNS, leading to brain damage and death. 
The events described in Scheme 4 apply to all the animal herpesviruses 
discussed in the seminar (Scheme 1). It is hoped that the impact of the 
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seminar will be felt as work continues on the immune responses to herpes­
viruses, and new data will be provided on the mechanisms of infection and 
immunity in domestic animals. 
Conclusions 
The practical conclusions have been summarized by Dr. P.P. Pastoret, 
to whom we are indebted for organizing this seminar (together with Dr. E. 
Thiry). The need for live attenuated vaccine strains for effective and 
inexpensive immunization of domestic animals became obvious during the 
seminar. It seems that the genetic engineering approaches for the develop­
ment of such vaccines were clearly pointed out.Many aspects of the sequence 
of events in infection and the responses of the immune system to herpes­
viruses are still unknown and require further investigation. 
It was felt that the seminar has not only added further information 
on the role of the immune response in animals in the defense against 
herpesvirus infections, but has also added to our understanding of the 
nature of new biotechnological possibilities for future research. 
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RECOMMENDATIONS FOR FURTHER RESEARCH. 
P.-P. PASTORET, J. SALIKI and E. THIRY. 
As was painted out during the opening session of the 
meeting, latent herpesvirus infections are of great importance 
for domestic animal health and production and the phenomena of 
latency, reactivation and re-excretion impede their control, 
because of their crucial epidemiological significance. 
Therefore studies on immunity to herpesvirus infections of 
domestic animals should lay more emphasis not only on the 
mechanisms that can play against the deleterious effects of a 
primary or secondary infection but also on those that can 
control viral re-excretion and, consequently, viral 
dissemination. The same is true of the next generation of 
vaccines. Their conception should take into account both the 
prevention of the effects of an infection and the control of 
viral excretion and dissemination by the animal. For this 
purpose, more basic knowledge is needed to upgrade our 
understanding of the precise role played by the various 
immunogenic components of the different herpesviruses that 
infect domestic animals, making use of what is already known on 
human herpesviruses. 
The new data presented during this meeting were in favour 
of attenuated live vaccines which offer to the animal the most 
complete range of immunogenic components necessary for a 
wel 1—balanced immune response. The attenuated live vaccines now 
available were produced rather empirically. Prospects of 
producing such vaccines by genetic engineering techniques 
appear nowadays to be more rewarding than the now classical 
approach of producing sub-unit vaccines. New horizons are now 
open for the construction of attenuated strains at will; 
attempts should be made to localize and delete "unwanted" viral 
genes, such as virulence genes, without altering the panoply of 
necessary genes. Efforts should also be directed towards the 
localization and eventual deletion of latency genes, in order 
to produce strains devoid of the side—effect of latency, if it 
is considered to be an undesirable effect. The attenuated 
strains now available remain in the organism in a latent state 
and the virus can be disseminated later on, virtually 
indi seriminatel y. 
Since the pattern of the immune response, and especially 
of the immune control of re—excretion, changes with time, 
further research work should also be done on vaccination 
procedures. Furthermore, the consequences of latency are so 
complex that we need a new conceptual approach that may help to 
better our understanding of the interactions between immune 
mechanisms and the herpesviruses; such an approach may also be 
useful in evaluating a Qriç>ri_ the impact of vaccination 
procedures. In this context, logical analysis appears to be of 
great help for the overall epidemiological understanding of 
latent herpesvirus infections of domestic animals. 
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It is now obvious that emphasis should be laid more on 
improved prophylactic methods than on hygienic measures, for 
the control of herpesvirus infections of domestic animals; this 
is true not only for economical and ethical reasons but also 
because the features of latent infections are too often a cause 
of failure of hygienic measures. It must be stressed however 
that improved prophylactic methods do not discard the need for 
good therapeutic tools in the case of clinical disease 
outbreaks. Among the available drugs, interferon seems to be 
one of the most promising, even if parenterally administered 
human interferon α 2 (Hulfnoíz) failed to protect cattle against 
IBR infection. Further research is still needed in the field of 
antiviral drugs for veterinary use. 
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